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As the incidence of gastro -oesophageal cancer continues to increase accurate staging 
remains challenging and the general outlook for these patients is poor. As well as improving 
prognostic accuracy, investigation of systemic inflammation and cachexia in these patients 
may enable the identification of much needed novel therapeutic targets. 
Aims 
The aims of this thesis were to describe the genesis, mediators and clinical sequelae of 
systemic inflammation in patients with gastro -oesophageal cancer. The usefulness of 
systemic inflammation as a prognostic indicator and the role of cachexia as a factor in the 
adverse prognosis associated with systemic inflammation were expanded in detail. The key 
hypothesis being that tumour cells produce mediators (eg cytokines), which can either directly 
or indirectly (via systemic inflammation) induce a catabolic state in the peripheral tissues of 
the host. Such wasting may be one of the mechanisms linking systemic inflammation with 
adverse prognosis in patients with cancer. 
Materials and Methods 
A consecutive series of 220 patients with gastric or oesophageal cancer were studied. Data 
were collected prospectively and a nutritional assessment and performance status were 
determined for each patient and survival duration was recorded. Samples of blood, urine and 
tumour tissue were collected for determination of cytokine and acute phase protein 
concentrations. The expression of other potential tumour -derived mediators, parathyroid 
hormone -related peptide (PTHrP) and proteolysis- inducing factor (PIF), were also studied. 
Results 
Systemic inflammation (CRP >10 mg /I) was present in 43% of patients with gastro- 
oesophageal cancer. Serum acute phase protein concentrations (especially CRP), but not 
serum cytokine concentrations, were robust measures of systemic inflammatory activity. 
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However, concentrations of pro -inflammatory cytokines within tumour tissue were significantly 
elevated and were linked with markers of systemic inflammation. IL-18 in particular was over - 
expressed in tumour tissue and may be a key determinant of systemic inflammation in 
patients with gastro -oesophageal malignancy. A chronic inflammatory cell infiltrate into the 
tumour tissue was present in 75% of tumours and was also linked with markers of systemic 
inflammation. Tumour cells or host immune cells or a combination of the two may be the main 
source of these mediators. The presence of systemic inflammation was also influenced by 
host cytokine genotype. Other potential tumour -derived mediators, such as PIF and PTHrP, 
may also play a (minor) role in the generation of systemic inflammation. These factors may 
also have additional effects on the host, such as potentiating weight loss. CRP concentrations 
were identified as the best marker of prognosis and the magnitude of serum CRP 
concentrations were negatively linked with survival duration. 
83% of patients had lost weight at the time of diagnosis and within 3 months this had 
increased to 92 %. Increasing weight loss was positively associated with serum markers of 
systemic inflammation. Weight loss among patients with gastro -oesophageal cancer was not 
accounted for entirely by reduced food intake or mechanical obstruction secondary to the 
tumour. Alternatively, the presence of systemic inflammation contributed to nutritional decline 
(estimate of effect 34 %). Weight loss was associated with adverse outcome and cachexia 
may be an aetiological factor involved in the link between systemic inflammation and adverse 
prognosis. 
Conclusions 
Systemic inflammation, weight loss, performance status, and stage of disease were the main 
determinants of outcome in patients with gastro -oesophageal cancer. These factors were 
used to devise a novel model to improve prognostic accuracy to aid clinical decision -making 
for these patients. These studies identify systemic inflammation as both an important 
prognostic indicator and a potential therapeutic target for patients with gastro -oesophageal 
malignancy. 
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SUMMARY OF THESIS 
Introduction 
The incidence of gastro -oesophageal cancer continues to increase at an alarming rate in the 
UK. Accurate clinical staging remains challenging and the general outlook for these patients is 
poor. Surgery offers the only real prospect of cure but carries significant risks in terms of 
morbidity and mortality. A number of alternative palliative treatment options are available, but 
are generally limited in their effectiveness. Current staging practices are failing to identify 
prospectively which patients will truly benefit from surgical resection in terms of survival 
benefit and quality of life. In addition, novel therapeutic strategies, both with curative and 
palliative intent, are much needed for these patients. Elevated markers of systemic 
inflammation are commonly found in patients with cancer and have been linked with survival 
duration, cachexia and outcome. As well as improving prognostic accuracy, investigation of 
systemic inflammation and cachexia in these patients may enable the identification of much 
needed novel therapeutic targets. Therefore, the aims of this thesis were to describe the 
genesis, mediators and clinical sequelae of systemic inflammation in patients with gastro- 
oesophageal cancer. The usefulness of systemic inflammation as a prognostic indicator and 
the role of cachexia as a factor in the adverse prognosis associated with systemic 
inflammation was also examined. The key hypothesis being that tumour cells produce 
mediators (for example, cytokines), which can either directly or indirectly (via systemic 
inflammation) induce a catabolic state in the peripheral tissues of the host. Such wasting may 
be one of the mechanisms linking systemic inflammation with adverse prognosis in patients 
with cancer. 
In order to address the aetiology of systemic inflammation and the mechanisms linking it to 
adverse prognosis, a consecutive series of patients with newly diagnosed gastric or 
oesophageal cancer in the Lothian and Borders regions between March 2002 and June 2004 
were studied. Following diagnosis patients were staged with a combination of computerised 
tomography (CT), endoscopic ultrasound (EUS) and laparoscopy /laparoscopic ultrasound 
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(LUS) and treatments were decided following discussion at the multi -disciplinary team 
meeting (MDT). Clinical and pathological data were collected prospectively and a nutritional 
assessment and performance status were determined for each patient and survival duration 
was recorded. Samples of blood, urine and tumour tissue were collected for determination of 
cytokine and acute phase protein concentrations. The expression of other potential tumour - 
derived mediators, parathyroid hormone -related peptide (PTHrP) and proteolysis- inducing 
factor (PIF), were also studied. 
Prevalence of systemic inflammation in patients with gastro -oesophageal cancer 
Serum concentrations of positive acute phase proteins were elevated significantly in patients 
with gastro -oesophageal cancer (Chapter IV). Systemic inflammation (serum CRP 
concentration >10 mg /I) was present in 43% of patients at the time of diagnosis. In contrast, 
serum cytokine concentrations (with the exception of sTNF -R concentrations) were not 
significantly different to those measured in healthy controls. Subsequent CRP measurements 
were influenced by treatment modality: surgical resection was associated with a transitory 
increase in CRP concentrations. In contrast, pre- operative chemotherapy was associated with 
a reduction in serial serum CRP concentrations. These findings suggest that at the time of 
diagnosis a substantial majority of patients have tumour -associated systemic inflammation, 
which may be reduced by chemotherapy or enhanced by surgical intervention. 
Role of cytokines in the genesis of systemic inflammation in patients with gastro- 
oesophageal cancer 
Cytokine concentrations were measured in tumour tissue and levels of expression compared 
with concentrations measured in tissue from healthy controls and with markers of systemic 
inflammation (Chapter V). Pro -inflammatory cytokine concentrations (mRNA and protein) 
were significantly elevated in tumour tissue when compared with concentrations measured in 
tissue samples from healthy controls. Moreover, tumour tissue IL-113 was highly expressed 
and concentrations correlated with markers of systemic inflammation (CRP). The degree of 
chronic inflammatory cell infiltrate into the tumour tissue was also assessed and compared 
with tissue cytokine concentrations and with markers of systemic inflammation (also Chapter 
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V). A chronic inflammatory cell infiltrate was identified in 75% of tumours and was associated 
with markers of systemic inflammation (CRP), but not with elevated tissue cytokine 
concentrations. Although circulating levels of cytokines did not correlate with the presence of 
systemic inflammation, tumour tissue cytokine concentrations were related to markers of 
systemic inflammation. These findings suggest that the tumour tissue itself may be an 
important primary source of the pro -inflammatory response. The latter may be generated both 
by tumour cell cytokine production and host inflammatory cell infiltrate or a combination of the 
two. 
The influence of cytokine genotype on the ability of the host to mount a systemic 
inflammatory response is described in Chapter VI. Genotype polymorphism expression 
patterns were compared with markers of systemic inflammation, tissue inflammation and 
outcome. IL -6 -174 CC and IL -10 -1082 GG genotypes were associated with elevated 
markers of systemic inflammation (serum CRP and sTNF -R concentrations) and the IL -6 - 
174 CC genotype was also associated with elevated tumour tissue cytokine concentrations. 
These two genotypes were also linked with adverse prognosis. In addition, the TNFa -308 AA 
genotype was linked with adverse outcome and was identified as an independent prognostic 
indicator, but was not associated with markers of systemic inflammation. These findings 
suggest that host cytokine genotype may modify the generation of systemic inflammation in 
patients with gastro -oesophageal cancer and may partly explain the link between genotype 
and adverse prognosis. 
Role of other mediators in the genesis of systemic inflammation in patients with 
gastro -oesophageal cancer 
The potential role of mediators other than pro -inflammatory cytokines in the aetiology of 
systemic inflammation in patients with cancer is described in Chapters VII and VIII. Serum 
concentrations of parathyroid hormone -related peptide (PTHrP) were compared with markers 
of systemic inflammation, adverse nutritional status, and survival duration (Chapter VII). At 
the time of diagnosis, elevated serum PTHrP concentrations were detected in 17% of patients 
with gastro -oesophageal malignancy without hypercalcaemia. An elevated serum PTHrP 
concentration was associated with markers of systemic inflammation and demonstrated a 
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trend toward adverse prognosis. Subsequently, an elevated serum PTHrP concentration was 
detected in 49% of patients approximately three months following diagnosis (again without 
evidence of hypercalcaemia). These follow -up measurements were not influenced by 
treatment modality and were positively linked with markers of adverse nutritional status. 
Studies on proteolysis- inducing factor (PIF) expression are described in Chapter VIII. 
Tumour tissue mRNA expression and urinary protein levels were compared with markers of 
systemic inflammation, cachexia and prognosis. PIF protein was detected in 51% of patients' 
urine and was associated with adverse nutritional variables and there was a trend between 
PIF detected in patients' urine and elevated markers of systemic inflammation. PIF mRNA 
expression was detected in tissue from healthy controls and at significantly elevated 
concentrations in tumour tissue from patients with gastro -oesophageal malignancy. However, 
levels of PIF mRNA were not associated with systemic inflammation, nutritional status or the 
presence of urinary PIF. This may reflect the lack of correlation between measured mRNA 
concentrations and translated protein concentrations in vivo. 
The link between systemic inflammation, nutritional status and prognosis in patients 
with gastro- oesophagea! cancer 
The association between systemic inflammation and survival duration is described in Chapter 
IX. Concentrations of serum acute phase proteins and sTNF -R, but not concentrations of 
serum cytokines, were associated with survival duration. CRP concentrations were identified 
as the best marker of prognosis and the magnitude of serum CRP concentrations were 
negatively linked with survival duration. An increase in serum CRP concentration from a value 
of 1 mg /I to 10 mg /I was associated with an almost 50% increase in likelihood of death within 
two years of diagnosis. However, CRP lost its prognostic value after initiation of treatment. 
The effect of treatments and disease progression clouds the value of systemic inflammation 
(CRP) as a prognostic marker. 
The changes in nutritional status and the association between nutritional variables 
and markers of systemic inflammation and prognosis for patients with gastro -oesophageal 
cancer are described in Chapter X. Eighty -three percent of patients had lost weight at the time 
of diagnosis (median weight loss 7 %) and within three months this had increased to 92% 
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(median weight loss 10 %). Increasing weight loss was associated with elevated serum 
markers of systemic inflammation (serum acute phase protein concentrations). Multiple 
regression analysis estimated that 38% of weight loss was due to level of dietary intake, 34% 
was due to the presence of systemic inflammation (serum CRP concentrations), and 28% due 
to stage of disease. These data suggest that processes in addition to reduced dietary intake 
and mechanical obstruction by the tumour are important in the generation of cachexia and the 
presence of systemic inflammation appears to play a key role. 
Weight loss was linked with adverse prognosis and cachexia may be an aetiological 
factor involved in the link between systemic inflammation and adverse prognosis in patients 
with gastro -oesophageal cancer. 
Finally, a novel risk prediction model for gastro -oesophageal cancer was constructed 
from various clinical and investigative factors, including markers of systemic inflammation and 
cachexia (Chapter XI). Systemic inflammation, weight loss, performance status, and stage of 
disease were the main determinants of outcome. These factors were used to devise a novel 
model with improved prognostic accuracy to aid clinical decision -making. 
Conclusions 
Systemic inflammation is common in patients with gastro -oesophageal cancer. Serum acute 
phase protein concentrations (especially CRP), but not serum cytokine concentrations, are 
robust measures of systemic inflammatory activity. However, concentrations of pro - 
inflammatory cytokines within tumour tissue are significantly elevated and linked with markers 
of systemic inflammation. IL-1I3 in particular is over -expressed in tumour tissue and may be a 
key determinant of systemic inflammation in patients with gastro -oesophageal malignancy. 
Tumour cells or host immune cells or a combination of the two may be the main source of 
these mediators. The presence of systemic inflammation is also influenced by host cytokine 
genotype. Other potential tumour -derived mediators, such as PIF and PTHrP, may play a role 
in the generation of systemic inflammation. These factors may have additional effects on the 
host, outwith the context of systemic inflammation, such as potentiating weight loss and 
cachexia. 
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Weight loss is common among patients with gastro -oesophageal cancer and is not entirely 
due to reduced food intake secondary to mechanical obstruction by the tumour. Indeed, the 
presence of systemic inflammation appears to contribute to nutritional decline. Weight loss 
and systemic inflammation are associated with adverse outcome and cachexia may be an 
aetiological factor involved in this association. 
Systemic inflammation, weight loss, performance status, and stage of disease are the 
main determinants of outcome in patients with gastro -oesophageal cancer. These factors can 
be combined in a novel model to improve prognostic accuracy to aid clinical decision -making 
for these patients. Overall, this thesis identifies systemic inflammation as both an important 




HYPOTHESES AND AIMS 
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The incidence of gastro -oesophageal cancer continues to increase at an alarming rate and is 
the third leading cause of cancer -related death in the UK. Accurate clinical staging remains 
challenging, particularly with regard to tumours located around the gastro -oesophageal 
junction. Surgery offers the only real prospect of cure but carries significant risks in terms of 
morbidity and mortality. A number of alternative palliative treatment options are available, but 
are generally disappointing. Current staging practices are unable to identify prospectively 
which patients will truly benefit from surgical resection in terms of survival benefit and quality 
of life. Many novel prognostic factors have been proposed including the presence of systemic 
inflammation. Previous work has also suggested an association between markers of systemic 
inflammation and cancer cachexia, which is commonly associated with gastro -oesophageal 
cancer and has also been linked with poor outcome. As well as improving prognostic 
accuracy, investigation of systemic inflammation and cachexia in these patients may enable 
the identification of much needed potential novel therapeutic targets. 
The overall aim of this thesis is to describe the genesis, mediators and clinical 
sequelae of systemic inflammation in patients with gastro -oesophageal cancer (Figure 1.1). 
The usefulness of systemic inflammation as a prognostic indicator and the role of cachexia as 
a factor in the adverse prognosis associated with systemic inflammation are expanded in 
detail. 
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Figure 1.1 Overview of thesis aims and objectives 
Gastro -oesophageal cancer 
- increasing incidence 
- difficult to stage accurately 
Overall poor prognosis 
Multiple treatment options with limited 
imnart nn niitrnma 
Need for more accurate staging and 
new therapeutic targets 
Systemic inflammation as a prognostic 
tool /therapeutic target 
Examine the prevalence of 
systemic inflammation in gastro- 
oesophageal cancer patients 
Describe the genesis of systemic 
inflammation in gastro- 
oesophageal cancer patients 
Use systemic inflammation as a 
tool to refine prognosis 
Describe the clinical sequelae of 
systemic inflammation in cancer 
patients (eg cachexie and prognosis) 
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Hypotheses and Aims 
1. Markers of systemic inflammation are elevated in patients with gastro- 
oesophageal cancer and are associated with adverse prognosis. 
The prevalence of systemic inflammation at the time of diagnosis and following treatment is 
described in patients with gastro -oesophageal cancer. Markers of systemic inflammation 
(serum cytokine and serum acute phase protein concentrations) will be measured at the time 
of diagnosis and later in the course of the disease in a cohort of consecutive patients newly 
diagnosed with gastric or oesophageal cancer. The association between elevated serum 
markers of systemic inflammation and adverse prognosis was examined (Chapters IV and 
IX). 
2. Tumour cells produce mediators (such as pro -inflammatory cytokines, 
proteolysis- inducing factor, and parathyroid hormone -related peptide), which 
can stimulate a systemic inflammatory response in the host and may induce a 
catabolic state in the peripheral tissues. Such wasting (cachexia) may be one of 
the mechanisms linking systemic inflammation with adverse prognosis in 
patients with cancer. 
The role of tumour tissue in the generation of the systemic inflammatory response was 
investigated by measuring cytokine protein and mRNA concentrations within the tumour 
tissue and relating these values to systemic concentrations (Chapter V). Proteolysis- inducing 
factor (PIF) and parathyroid hormone -related peptide (PTHrP) are tumour -derived mediators 
that may contribute to the systemic inflammatory response and tissue wasting and may be 
related to adverse prognosis. The expression of these mediators in the host was investigated 
and their association with systemic inflammation, nutritional status and prognosis was 
examined (Chapters VII and VIII). The role of cachexia in explaining the link between 
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systemic inflammation and adverse prognosis was investigated by examining the relationship 
between markers of systemic inflammation and nutritional variables in the patient cohort 
(Chapter X). 
3. Cytokine genotype may influence the ability of the host to generate a systemic 
inflammatory response via alterations in tumour tissue cytokine concentrations 
which, in turn, may influence survival duration. 
Cytokine genotypes were determined for the study population and individual polymorphisms 
were studied with relation to tumour tissue cytokine concentrations, the magnitude of markers 
of systemic inflammation, and prognosis (Chapter VI). 
4. The development of a prognostic model for gastro -oesophageal cancer. 
The usefulness of systemic inflammation and cachexia as prognostic indicators was 
investigated in Chapter XI. Various clinical and investigative factors, including markers of 
systemic inflammation and cachexia, predictive of death from gastro -oesophageal cancer 
were determined with the aim of constructing a novel risk prediction model. This model may 
then be used to assist in the prospective prognostic evaluation of patients with gastro- 
oesophageal malignancy and assist in the clinical decision making for these patients. 
It is hoped that this work will advance the understanding of tumour -associated inflammation 
with particular reference to the clinical sequelae and impact on nutritional status and 
prognosis. This may, in turn, lead to the identification of potential new therapeutic targets for 
this devastating disease and allow the development of individually tailored therapeutic options 





This chapter outlines the increasing incidence of gastric and oesophageal cancer in the UK 
and describes current staging modalities and therapeutic options available. The need for 
improved prognostic accuracy and therapeutic strategies for these patients is emphasised. 
Previous studies suggest that markers of systemic inflammation may have a prognostic role in 
gastro -oesophageal cancer and, as such, may also provide novel therapeutic targets. The 
overall aim of this thesis is to describe the genesis, mediators and sequelae of systemic 
inflammation in patients with gastro -oesophageal cancer. The mechanisms involved in the 
generation of acute and chronic systemic inflammation are described in detail in this chapter 
with particular emphasis on key cytokines and acute phase proteins. The clinical sequelae of 
these acute and chronic inflammatory syndromes are also described and their contribution to 
wasting and prognosis in cancer patients is explored. The usefulness of systemic 
inflammation as a prognostic indicator and the role of cachexia as a factor in the adverse 
prognosis associated with systemic inflammation are expanded in detail. 
1. GASTRO -OESOPHAGEAL CANCER 
a) Epidemiology of gastric and oesophageal cancer 
Oesophageal cancer 
The incidence of oesophageal cancer has risen steadily in the UK and throughout Western 
Europe and North America over the past few decades (NHS Scotland, 2004; Office for 
National Statistics, 2004). The incidence of adenocarcinoma of the oesophagus is increasing 
at the fastest rate of any solid tumour in Europe and North America (Blot el al, 1991). The 
incidence rates for oesophageal cancer have increased substantially in Scotland which now 
has the highest incidence rates in the UK (Figure 2.1.1) (NHS Scotland, 2004). Scottish 
female adenocarcinoma rates have been reported as among the highest in the world (Parkin 
et al, 1997). In 2004 there were 7531 new diagnoses of oesophageal cancer in the UK (783 in 
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Scotland) making oesophageal cancer the 
7th most common malignancy in men and the 11th 
most common cancer diagnosed in females in the UK (Cancer Research UK, 2004). 
Figure 2.1.1 Trends in incidence rates of oesophageal cancer in the UK (1975- 2002). 
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The increasing incidence of oesophageal malignancy has been attributed largely to an 
increase in adenocarcinoma arising in the distal oesophagus and at the oesophago -gastric 
junction [OGJ] (Jankowski et al, 2000). These are now the most common sites for tumour 
occurrence and the incidence of such tumours is increasing at 2% per year in Scotland 
(Reed, 1991; McKinney et al, 1995). These tumours may arise from areas of Barrett's 
metaplasia affecting the distal oesophagus and the increasing incidence of OGJ cancers has 
been matched by a similar increase in the rates of Barrett's oesophagus (Jankowski et al, 
2000). Metaplastic changes predispose the oesophagus to dysplasia and malignant 
transformation and around 62% of oesophageal tumours have histological evidence of 
Barrett's metaplasia within the specimen (Jankowski et al, 1999; Cameron et al, 2000). In 
addition, while the total number of squamous cell carcinomas has remained relatively 
constant, the incidence of adenocarcinoma has risen considerably throughout the past three 
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decades and approximately 73% of oesophageal malignancies in the UK are now 
adenocarcinoma in type (AUGIS database report, 2004; Pera et al, 2001; Cameron, 1997). 
Prognosis remains generally poor for patients with oesophageal cancer with most 
patients presenting late in the UK with locally advanced or metastatic disease at the time of 
diagnosis (NHS Scotland, 2004; Cancer Research UK, 2004). Oesophageal cancer is the 4th 
leading cause of cancer -related death in males in the UK (behind lung, prostate, and 
colorectal) (Figure 2.1.2). 
Figure 2.1.2 Causes of male cancer deaths UK (2004). [Adapted from Cancer Research 
UK cancer statistics online] 
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The trends in mortality follow closely those for incidence due to the very poor survival rates 
from this disease. As such, mortality rates have risen despite advances in staging, 
chemo /radiotherapeutics and surgical techniques, although there has been a modest 
improvement in median survival (Office for National Statistics, 2004). Overall 5 -year survival 
remains extremely poor at 6 -8 %. 
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Gastric cancer 
Fifty years ago stomach cancer was the leading cause of cancer -related death in the UK. 
Since then the incidence has declined, but gastric cancer still accounts for almost 9000 new 
cases per year in the UK and the surgical workload in Lothian has not declined (NHS 
Scotland, 2004; Office for National Statistics, 2004; Cancer Research UK, 2004; Sedgwick et 
al, 1991) (Figure 2.1.3). In 2004 the incidence of gastric cancer in males in Scotland was 19.5 
per 100,000 population and 8.6 per 100,000 for females, making stomach cancer the 5th 
commonest cancer diagnosed in UK men and the 9th most common cancer in UK women 
(Cancer Research UK, 2004). 
Despite an overall decrease in the incidence of stomach cancer, there is evidence to 
suggest increasing numbers of tumours arising in the proximal stomach and gastric cardia 
(Dolan et al, 1999; Wayman et al, 2001). These tumours have been associated with more 
advanced disease stage at the time of presentation and with overall stage -related poorer 
long -term survival (Rohde et al, 1991). Some authors have suggested that these tumours 
have a different biological behaviour compared with tumours located more distally in the 
stomach and should therefore be addressed separately (Webb etal, 1978). 
Figure 2.1.3 Age standardised incidence of, and mortality from, stomach cancer in 
England and Wales (1950- 1999). [Adapted from Cancer Research UK cancer statistics 
online] 
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Gastric cancer is the 5th leading cause of cancer -related death in UK males. An overall 
decline in incidence has been matched by a fall in mortality rates (Figure 2.1.3) and survival 
rates have improved by 2% every five years from 1970 (Office for National Statistics, 2004). 
Some of these improvements in survival have resulted from better survival rates following 
surgical resection (Akoh and Macintyre, 1992). Despite these improvements in survival, many 
patients present with advanced stage disease in the UK and as such overall survival rates 
remain very disappointing. Current 1 -year survival rates are 28% and 5 -year survival rates are 
10% (NHS Scotland, 2004; Cancer Research UK, 2004). 
b) Current Staging Modalities and Treatment Options 
Currently, treatment decisions for patients with gastro -oesophageal cancer are based on the 
clinical stage of disease, patient co- morbidity and patient preferences. Accurate pre- operative 
assessment and staging of patients with oesophageal and gastric cancer is essential in order 
to determine the most appropriate management option for each patient. With the introduction 
of new therapeutic strategies and as neoadjuvant regimens are designed and tested, 
accurate staging is essential not only in terms of patient selection, but also in assessing 
outcome. it is now clear that surgical resection is no longer the best form of palliation for the 
majority of patients with gastro -oesophageal cancer whose tumour is not curable by resection 
(Blazeby et al, 2000). These patients are better served by alternative palliative treatments 
directed at improving symptoms. 
Clinical staging is based on estimating the anatomical extent and distribution of the 
disease, principally using imaging modalities such as computerised tomography (CT) and 
endoscopic ultrasound (EUS). The TNM staging systems for gastric and oesophageal cancer 
are used in the UK (Sobin et al, 2003). The TNM system is based on an anatomical 
classification of disease involvement, where T represents the extent of the primary tumour, N 
the presence or absence and extent of regional lymph node metastases, and M the presence 
or absence of distant metastases. The addition of numbers to these groups indicates the 
progression of the disease (Table 2.1.1). 
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T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
NO No regional lymph node metastasis 
N1 Regional lymph node metastasis 
MO No distant metastasis 
M1 Distant metastasis 
For tumours of the lower thoracic oesophagus M1 a Metastasis in coelic lymph nodes 
M1 b Other distant metastases 
For tumours of the upper thoracic oesophagus M1 a Metastasis in cervical lymph nodes 
M1 b Other distant metastases 
(B) 
T stage T1 Tumour invades lamina propria or submucosa 
T2A Tumour invades muscularis propria 
T2B Tumour invades the subserosa 
T3 Tumour penetrates serosa (visceral 
peritoneum) without invasion of adjacent 
structures 
T4 Tumour invades adjacent structures 
N stage NO No regional lymph node metastasis 
N1 Metastasis in 1 to 6 regional lymph nodes 
N2 Metastasis in 7 to 15 regional lymph nodes 
N3 Metastasis in more than 15 regional lymph 
nodes 
M stage MO No distant metastasis 
M1 Distant metastasis 
Once a TNM category has been decided, a stage grouping is assigned (Table 2.1.2). This 
simplifies the staging analysis allowing easier comparison of outcomes. The groupings are 
chosen to ensure that each group is similar in terms of prognosis, while at the same time 
maintaining differences between groups. 
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Table 2.1.2 Internationally unified TNM stage groupings for (A) oesophageal cancer and 
(B) gastric cancer 
(A) 
Stage group T stage N stage M stage 
Stage 0 Tis NO MO 
Stage I T1 NO MO 
Stage IIA T2, T3 NO MO 
Stage IIB T1, T2 N1 MO 
Stage III 
T3 N1 MO 
T4 Any N MO 
Stage IVA Any T Any N M1a 
Stage IVB Any T Any N M1b 
(B) 
Stage group T stage N stage M stage 
Stage 0 Tis NO MO 
Stage la T1 NO MO 
Stage lb 
T1 N1 MO 
T2A or B NO MO 
Stage II 
T1 N2 MO 
T2A or B N1 MO 
T3 NO MO 
Stage Illa 
T2A or B N2 MO 
T3 N1 MO 
T4 NO MO 
Stage Illb T3 N2 MO 
Stage IV 







Some authors have also proposed a separate additional staging method for tumours arising 
from the gastro -oesophageal junction (Hardwick and Williams, 2002). These tumours are 
rapidly increasing in incidence and are defined as those that are centred within 5cm proximal 
or distal of the anatomical cardia. The International Society for Diseases of the Oesophagus 
has endorsed a classification of junctional tumours which is based on the likely origin of the 
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tumour (Siewert and Stein, 1998). Type I represents adenocarcinoma of the distal 
oesophagus with the centre of the tumour lying 2 -5cm above the anatomical cardia. Type Ill 
cancer is a gastric carcinoma with its centre 2 -5 cm below the anatomical cardia. Type II 
lesions are true junctional tumours with centres 2cm above or below the anatomical cardia. 
Adenocarcinoma arising in the region of the oesophago -gastric junction pose a 
problem for staging with the main difficulty lying in the identification of regional lymph nodes. 
Due to their anatomical location, these tumours may metastasise to lymph nodes above or 
below the diaphragm. Involvement of these nodes may therefore be classified as regional 
nodal involvement (N) or metastatic (M) both of which may have repercusions on 
management decisions and prognosis. At the present time, Type I tumours are staged as 
oesophageal cancers and Type III lesions are staged as gastric tumours but debate still exists 
as to the best staging system for Type II tumours and some authors have proposed the need 
for a separate staging system in order to address these particular problems (Hardwick and 
Williams, 2002; Wijnhoven et al, 1999). 
Staging algorithm 
Clinical staging includes physical examination, laboratory studies and imaging. An algorithm 
for the investigation and clinical staging of a patient presenting with gastro -oesophageal 
cancer in the Lothian and Borders regions is shown in Figure 2.1.4. Initially an endoscopy and 
biopsy are performed on any patient in whom the disease is suspected. Once the disease is 
confirmed histologically, the patient undergoes clinical staging to assess the extent of 
disease. In our region, patients are generally assessed by computerised tomography (CT) 
and endoscopic ultrasound (EUS). A laparoscopy is also undertaken in patients who are 
thought to be suitable for surgery to exclude peritoneal disease. The result of each 
investigation is documented and patients are discussed at regular multi -disciplinary team 
(MDT) meetings. Following this meeting an overall clinical stage is agreed for each patient, 
individual patient characteristics and preferences are considered, and treatment options are 
decided. The clinical stage also provides information on prognosis. Estimations of prognosis 
as well as management decisions are, therefore, largely based on the clinical (anatomical) 
stage of disease. 
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Figure 2.1.4 An algorithm for the investigation and clinical staging of a patient presenting 
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The only real prospect of cure lies in surgical resection, with or without pre- operative 
chemo /radiation, although comparable survival rates among patients with squamous cell 
carcinoma of the oesophagus treated with radical chemoradiotherapy have been documented 
(Toh et al, 2006). Patients without evidence of metastatic disease and who are medically fit 
are offered surgery. It is practice in our region for patients with local disease (T1/2 NO) to go 
directly for surgery. Patients with more advanced disease (T2 N1 or T3 NO or T3 N1) are 
considered for pre- operative (neo- adjuvant) chemotherapy. Surgery carries significant risks 
both in terms of morbidity (40 -50 %) and mortality, which is in the region of 5 -10% (Stephens 
et al, 2006). 
Patients with metastatic disease may receive a number of palliative treatments, such 
as palliative chemotherapy, radiotherapy, or endoscopic procedures, such as placement of an 
oesophageal stent or endoscopic laser therapy to improve swallowing or reduce tumour 
bleeding. These procedures attempt to alleviate symptoms and improve quality of life, but are 
overall disappointing. 
c) The clinical problem - accurate prognosis and novel therapeutic 
targets 
Despite advances in surgical techniques, critical care and chemo- therapeutics overall survival 
rates remain dismal as most patients present with locally advanced disease in the UK (NHS 
Scotland, 2004; Cancer Research UK, 2004). Treatment decisions are based on clinical stage 
and overall patient fitness. Improvements in staging techniques have lead to improved staging 
accuracy and better patient selection for surgery, which has resulted in improvements in 
survival duration (Hofstetter et al, 2002). However, despite advances in these staging 
techniques, 5- year -survival rarely exceeds 30% (Dresner and Griffin, 2000). This figure, 
however, represents all patients undergoing resection and those patients with locally 
advanced disease (stage IIB and III) achieve 5- year -survival post- resection survival rates of 
less than 10% (Dresner and Griffin, 2000). Indeed in this group, which represents 
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approximately two- thirds of all patients who are suitable for curative resection, around 50% do 
not survive more than 18 months, even though these patients have undergone 'curative' (RO) 
resection. Data from Bristol has shown that those patients who failed to live 2 years following 
surgery do not regain pre- operative quality of life (QOL) levels compared with those who live 
greater than 2 years, whose QOL measurements returned to normal by 9 months (Blazeby et 
al, 2000). These results provide strong support for the increasingly held view that patients in 
whom a potentially curative resection is not possible should not undergo surgery for 
oesophageal cancer. The problem lies in identifying prospectively such patients. Clearly 
improvements in pre- operative staging techniques (for example, CT and EUS) are likely to 
help, but additional factors which influence survival and can be used to refine prognosis are 
required. Tumours located at the OGJ are particularly difficult to stage accurately (Department 
of Health, 2001). 
If clinicians could identify prospectively patients unlikely to live more than 12 -18 
months following radical oesophagectomy /gastrectomy then these patients could be offered 
more appropriate non -surgical palliative therapy. More rigorous selection of patients would 
avoid surgery in those who gain no survival benefit, may suffer considerable morbidity, a 
chance of procedure related death, and greatly reduced quality of life. 
In addition to better prognostic accuracy, improved understanding of tumour biology 
may provide much needed novel therapeutic targets for this devastating disease (such as 
targeting mediators involved in the generation of systemic inflammation) and also novel 
palliative therapy targets, such as anti -cachexia treatments. A better knowledge of these 
factors may also offer individually tailored therapeutic options and selective interventions. 
d) Potential novel prognostic markers (and therapeutic targets) for 
gastro -oesophageal cancer 
Biological staging attempts to analyse tumour behaviour, assessing the likelihood for 
metastatic spread, disease recurrence and responsiveness to various chemotherapeutic 
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agents. There have been many different molecules that have been investigated as potential 
prognostic markers in gastric and oesophageal cancer, some of these are novel molecules 
whereas others have demonstrated previous prognostic value in other diseases. Most of 
these potential prognostic markers may be grouped as tumour markers, tumour suppressor 
genes /proto- oncogenes, adhesion molecules, heat shock proteins, growth factors, and 
markers of systemic inflammation (Table 2.1.3). 
Tumour markers do not offer any diagnostic aid to gastro -oesophageal cancer and 
their use as prognostic markers remains unclear. Some studies have reported a correlation 
between carcino- embryonic antigen (CEA), CA19 -9 and CA72 -4 and increased stage of 
gastric cancer (Gaspar et al, 2001; Lai et al, 2002; Kim et al, 2000; Lundin et al, 1995; Kodera 
et al, 1996). They also found that CA72 -4 was an independent prognostic indicator on 
multivariate analysis and elevated levels were associated with over four times increased 
chance of recurrence. However, other researchers have failed to identify any association 
between tumour markers and stage or survival (Duraker and Celik, 2001). 
The important consequences of mutations of the tumour suppressor gene p53 in 
tumour genesis is well known and up to 90% of adenocarcinomas of the oesophagus possess 
a p53 mutation (Younes et al, 1993). There is some evidence that p53 expression is 
associated with an adverse prognosis in gastric and oesophageal cancers (Liu et al, 2001; 
Ogawa et al, 2001; Diez et al, 2000) and elevated levels have been associated with a poorer 
outcome in node negative oesophageal cancer patients treated by surgical resection (Aloia et 
al, 2001; Shimada et al, 2000). In contrast, the frequency of proto -oncogene activation is very 
low in gastric and oesophageal cancers. 
Impaired adhesion molecule expression is thought to favour cancer invasion and 
metastases. Abnormal expression of E- cadherin has been associated with advanced stage in 
gastric cancer and has been related with early disease recurrence (Chan et al, 2001; Chan et 
al, 2003; Liu et al, 2002; Tanaka et al, 2003). Matrix metalloproteinases (MMPs) are a family 
of peptidases capable of degrading the extracellular matrix and play important roles in 
allowing tumor invasion. MMP expression has also been associated with adverse outcome in 
early stage oesophageal cancer (Gu et al, 2005). 
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Table 2.1.3 Value of novel prognostic factors for gastro -oesophageal cancer 
Marker Negative survival effect Prognostic impact 
Tumour markers 
CEA Elevated expression Weak 
CA19 -9 Elevated expression Weak 
CA72 -4 Elevated expression Weak 
Tumour suppressor genes 
p53 Mutation Strong 
Adhesion molecules 
E- cadherin Reduced expression Strong 
MMP -1 Elevated expression Moderate 
Heat shock proteins 
HSP 27 Reduced expression Weak 
Growth factors 
VEGF Elevated expression Weak 
FGF Elevated expression Weak 
EGF Elevated expression Weak 
Systemic inflammation 
CRP Elevated expression Strong 
IL -113 Elevated expression Weak 
IL -6 Elevated expression Weak 
IL -10 Elevated expression Weak 
TNF -a Elevated expression Weak 
Heat shock proteins are a family of protective proteins produced in response to stress. Recent 
work has associated some of these proteins with prognosis in gastric cancer and reduced 
HSP 27 tumour expression has been associated with adverse outcome on mutivariate 
analysis among patients with oesophageal cancer who had undergone surgical resection 
(Kapranos et al, 2002; Kawanishi et al, 1999). 
Growth factors, such as the angiogenic factor vascular endothelial growth factor 
(VEGF), have been linked with adverse out come in gastric cancer, but it's prognostic value in 
oesophageal cancer is less clear (Shida et al, 2005; Kleespies et al, 2004). Fibroblast growth 
factor (FGF) has been associated with early recurrence and poorer outcome in surgically 
treated oesophageal cancer (Barclay et al, 2005). 
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The role of systemic inflammation as a prognostic aid to cancer patients will be described 
separately in the following Section (e). Many other potential prognostic markers have been 
investigated in relation to gastro -oesophageal cancer and novel candidates are continually 
proposed, especially following the introduction of DNA microarray systems (Yamabuki et al, 
2006). The prognostic role of many of these remains unclear and require prospective 
evaluation (see Lagarde et al, 2007 for a current review). 
e) Role of systemic inflammation in cancer prognosis 
Elevated serum pro -inflammatory cytokine concentrations have been found in association 
with most epithelial malignancies, but the relationship between serum cytokine concentrations 
and prognosis in cancer patients remains unclear (Table 2.1.3) (Ashizawa et al, 2005; Galizia 
et al, 2002; Forones et al, 2001; De Vita et al, 1999, De Vita et al, 2001; Wang et al, 1999; 
Wu et al, 1998). Elevated serum cytokine concentrations are generally regarded as markers 
of poor prognosis, but conflicting results have been found in pancreatic cancer, lung cancer 
and many other malignancies (Tas et al, 2005; Songur et al, 2004; Martignoni et al, 2005; 
Falconer et al, 1994). The prognostic value of serum cytokine concentrations in gastric and 
oesophageal cancer remains equally contradictory. Elevated serum concentrations of 
interleukin -6 (IL -6), IL -10 and tumour necrosis factor -a (TNFa) have been associated with 
poor and favourable outcomes in equal measure. These inconsistent findings may be partly 
explained by the difficulty in reliably measuring serum cytokine concentrations. Short half - 
lives, molecular lability and fluctuating levels of circulating cytokines contribute to the 
difficulties in measuring circulating cytokine concentrations (Gabay and Kushner, 1999). In 
addition, the relevance of circulating cytokine concentrations may not be as functionally 
important as the local concentrations within target tissues and those produced by peripheral 
blood mononuclear cells (PBMC's) (see later Sections). 
In contrast to circulating cytokine concentrations, serum acute phase protein 
concentrations demonstrate more stability within the systemic compartment and may be a 
more reliable measure of systemic inflammatory activity (Gabay and Kushner, 1999). Serum 
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acute phase protein concentrations have been linked with outcome in benign disease, for 
example ischaemic heart disease and acute pancreatitis, as well as in malignant disease 
(Shah, 2000; Puolakkainen et al, 1987). An acute phase protein response (APPR) has been 
shown to be an independent adverse prognostic indicator in the majority of types of cancer, 
including pancreatic, lung, breast, melanoma, lymphoma, ovarian, renal, and gastrointestinal 
tumours (Rashid et al, 1982; Nozoe et al, 2001; Shimada et al, 2003; Crumley et al, 2006; 
Alexandrakis et al, 2003; Falconer et al, 1995; Cooper, 1988; Caspers et al, 1984; Forrest et 
al, 2003; McMillan et al, 2001; Masuda et al, 1998; Kodama et al, 1999; Elahi et al, 2005; 
McMillan et al, 2003; Fujita et al, 1999; Jamieson et al, 2005). In patients with gastric cancer 
the presence of an APPR has been associated with a markedly reduced median survival (9 
versus 53 weeks, p <0.001) (Rashid et al, 1982). Similarly, two Japanese studies have 
identified a shortened survival in oesophageal cancer patients with an elevated serum C- 
reactive protein (CRP) at the time of diagnosis (Nozoe et al, 2001; Shimada et al, 2003). More 
recently a group from the UK has similarly identified elevated serum CRP and reduced serum 
albumin concentrations as independent prognostic indicators among patients with inoperable 
gastro -oesophageal cancer (Crumley et al, 2006). In addition, a large study of patients with 
colorectal, breast, gastric and bronchogenic cancers demonstrated a negative relationship 
between the magnitude of the systemic inflammatory response and survival duration 
(McMillan et al, 2001). Despite this apparent strong association little is known about the 
mechanism initiating systemic inflammation and the factors that link systemic inflammation to 
adverse outcome. 
Serum concentrations of acute phase proteins have also been linked with disease 
progression and the development of recurrent disease. Patients with irresectable pancreatic 
cancer demonstrate increasing serum CRP concentrations as the disease progresses and the 
proportion of patients with an elevated serum CRP concentration increases from 43% at the 
time of diagnosis to 78% as patients approach the final stages of their disease (Falconer et al, 
1995; Barber et al, 1999). An elevated serum CRP concentration following potentially curative 
surgery for colorectal, pancreatic and gastric cancers has also been associated with earlier 
disease recurrence (McMillan et al, 2003; Fujita et al, 1999; Jamieson et al, 2005). 
37 
Therefore, serum markers of systemic inflammation, such as acute phase protein 
concentrations, appear to be linked with survival duration in patients with cancer. Moreover, 
these concentrations may alter as the disease progresses and responds to treatment. The 
association between systemic inflammation and prognosis in patients with gastro- 
oesophageal cancer will be explored in this thesis along with the origin of the systemic 
inflammatory response. The potential mechanisms involved in the generation of such 
inflammation will now be described in the following Section. 
2. THE GENERATION OF AN INFLAMMATORY RESPONSE - AN OVERVIEW 
The inflammatory response is a reaction of the body to tissue injury and immune system 
activation. It functions principally as a defense mechanism designed to destroy or reduce an 
injurous agent, limit tissue damage, and promote tissue healing. Initiation and propagation of 
the inflammatory response is mediated through a complex interaction of chemical mediators 
derived from host tissues and immune cells as well as the injurous agent itself. Such chemical 
mediators, acting together or in sequence, then influence the evolution and magnitude of the 
inflammatory response. The inflammatory response is not limited to the site of tissue injury 
and inflammatory cells and chemical mediators are free to circulate in the plasma and tissue 
fluid exerting effects on distant target tissues (see Figure 2.2.1). The effect of such systemic 
inflammation has consequences on the host distant from the site of injury. These systemic 
effects, such as tissue wasting and altered metabolism (cachexia), will be explored later in 
this chapter. The mechanisms underlying the generation of the inflammatory response will 
now be described. 
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a) Cellular events 
Initial cellular events in the generation of inflammation involve the influx (emigration) of 
neutrophils to the site of injury. Neutrophils function primarily to aid the destruction of the 
injurous agent (Figure 2.2.1). This may be achieved by phagocytosis or release of enzymes 
and metabolites (degranulation). These metabolites, for example, oxygen free radicals, may 
serve to amplify the inflammatory stimulus and further recruitment of inflammatory cells may 
occur. Peripheral blood mononuclear cells (PBMC's), macrophages and lymphocytes (T and 
B cell) are the main cell types attracted to the site of inflammation. These cells also fight the 
injurous agent through mechanisms such as phagocytosis, degranulation and activation of 
adaptive immunity. A key role is also in the release of the chemical mediators of inflammation. 
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Figure 2.2.1 A schematic overview of the processes involved in the generation of an 
inflammatory response. Tissue injury leads to the release of local metabolites, such as free 
radicals, which recruit inflammatory cells to the site of injury. Initially neutrophils are attracted, 
then macrophages and lymphocytes. These cells secrete cytokines and other chemical 
mediators, which interact to control the inflammatory process. These mediators act locally at 
the site of tissue inflammation, but are also free to circulate throughout the body and exert 
systemic effects (eg IL -6 stimulates acute phase protein production in the liver). 
Tissue injury/Cancer 
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b) Chemical mediators of inflammation 
Cytokines 
Cytokines are a group of polypeptides produced predominantly by macrophages and 
lymphocytes in response to inflammation. They modulate the function of other cell types 
through autocrine, paracrine and endocrine pathways. Cytokines may be grouped into 
interleukins, tumour necrosis factors and interferons. There are many cytokines described, 
however, the key mediators and their principal actions are listed in Table 2.2.1. Interleukin -16 
(IL -1(3), interleukin -6 (IL -6), interleukin -8 (IL -8), and tumour necrosis factor-ci (TNFa) are 
generally regarded as key pro -inflammatory cytokines. Interleukin -10 (IL -10) is thought to act 
predominantly as a counter -inflammatory cytokine. 
Table 2.2.1 Key cytokines involved in the regulation of inflammation and their systemic 
effects. 
Cytokine Main sources Inflammatory effects Systemic effects 
IL-16 Macrophages Pro -inflammatory Fever 
Endothelial cells Induces IL-16, TNFa, and IL -6 production Muscle protein loss 
Up- regulates adhesion molecule Elevated blood glucose 
expression Changes in trace element 
Induces COX 2 expression concentrations 
IL -6 Macrophages Pro -inflammatory Fever 
T lymphocytes Up- regulated by IL-16 and TNFa Weight loss 
Stimulates acute phase protein Increased energy expenditure 
production in the liver Increased cortisol /glucagon 
IL -8 Macrophages Pro -inflammatory Unknown direct effect 
Induced by IL-16 and TNFa Contributes via maintenance of 
Principally a chemokine inflammatory response 
TNFa Macrophages Pro -inflammatory Fever 
Induces IL -16 and TNFa production Muscle protein loss 
Stimulates apoptosis Anorexia 
Promotes release of oxygen species Altered serum lipid and trace 
element concentrations 
IL -10 Macrophages 
T lymphocytes 
Inhibits pro- inflammatory cytokine 
production 
Sheds TNF receptors into the circulation 
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IL -1p is a key pro -inflammatory cytokine in humans. It is released principally from 
macrophages during the inflammatory process, but may also be produced by a number of 
other cell types, such as endothelial cells. IL-1p up- regulates the inflammatory response by 
inducing its own synthesis and also by increasing TNFa, IL -6, and IL -8 production (Yasumoto 
et al, 1995). IL-1p can act directly by increasing adhesion molecule expression, especially 
intercellular adhesion molecule (ICAM), which promotes leucocyte sticking to endothelial cells 
to aid chemotaxis. IL-1(3 also stimulates the production of acute phase proteins by the liver 
indirectly through increased stimulation of IL -6 and promotes leucocyte recruitment via IL -8 
(Gershenwald et al, 1990; Hellerstein et al, 1989). The systemic effects of IL-113 include fever, 
anorexia, weight loss, alterations in glucose metabolism, and loss of muscle protein 
(Moldawer et al, 1988). Loss of muscle mass is due to increased rates of skeletal muscle 
breakdown and decreased rates of muscle synthesis, principally through activation of the 
cyclo -oxygenase pathway (Baracos et al, 1983). 
TNFa is also an important pro -inflammatory cytokine, capable of stimulating its own 
synthesis as well as IL -113, among others. TNFa and IL -1p work together as the key 
conductors of the generation of the inflammatory response. TNFa is produced principally by 
macrophages and promotes macrophage apoptosis and release of oxygen free radicals at the 
site of inflammation. TNFa also has widespread metabolic effects upon the body, some of 
which are similar to IL-1P and include fever, anorexia, weight loss, and muscle protein loss 
(Mahony and Tisdale, 1988; Charters and Grimble, 1989; Starnes et al, 1988). In addition, 
TNFa is associated with increased lipolysis, insulin resistance and elevated energy 
expenditure in both animals and humans (Selbey et al, 1987). Circulating TNFa 
concentrations appear to exhibit circadian changes and concentrations are not reliably 
detected in the circulation (Muc- Wierzgon et al, 1996). TNFa binds to two receptors of 
differing molecular weight: 55 kDa and 75 kDa (Brockhaus et al, 1990) and these two 
receptors are shed from cells into the circulation in response to TNFa release and may 
therefore provide an indirect measure of TNFa activity (Spinas et al, 1992). Plasma soluble 
TNF receptor (sTNF -R) levels are, therefore, a more robust indirect index of TNFa production 
in tissue compartments and are not subject to the diurnal variation of cytokine release (Muc- 
Wierzgon et al, 2003). 
42 
IL -6 is released from macrophages and activated T lymphocytes mainly in response to 
stimulus by TNFa and IL-1f3. The main inflammatory function of IL -6 is the induction of the 
acute phase response by the liver (O'Riordain et al, 1999). The acute phase response is a 
component of innate immunity and will be described in detail in the following section (Section 
2 (c)). Administration of IL -6 to human subjects produces weight loss, fever, increased energy 
expenditure, and increased serum cortisol and glucagon concentrations (Stouthard et al, 
1995). IL -6 is generally regarded as a pro -inflammatory cytokine, however, infusion of IL -6 
into human subjects has been shown to increase the release of anti -inflammatory mediators 
(IL -1 receptor antagonist and soluble TNF receptors) leading some groups to postulate that 
IL -6 may also function as an anti -inflammatory cytokine (Tilg et al, 1994). It is equally possible 
that the release of these anti- inflammatory mediators is simply a counter -response to the pro - 
inflammatory activity of IL -6. 
IL -8 is also stimulated by TNFa and IL-18 and is released by macrophages. IL -8 acts 
locally at the site of inflammation promoting neutrophil degranulation and recruitment of 
leucocytes (chemotaxis) (Ward and Westwick, 1998). The direct systemic effects of IL -8 
remain unclear, however, IL -8 contributes to the overall effects of systemic inflammation 
through maintenance of the inflammatory response. 
In contrast to the previously described cytokines, IL -10 acts as an anti -inflammatory 
cytokine via inhibition of TNFa and IL -18 production. IL -10 suppresses synthesis of TNFa and 
IL-113 mainly through accelerated degradation of TNFa and IL-18 mRNA (Adib -Conquy et al, 
1999). IL -10 also promotes the shedding of soluble TNF receptors into the circulation thus 
binding biologically active TNFa. As such, IL -10 acts as a powerful counter -inflammatory 
cytokine. 
There are many other cytokines as well as other chemical mediators (such as prostaglandins, 
leukotrienes, complement factors, and kinin products) that contribute to the inflammatory 
process. Their interactions are complex and poorly understood. The inflammatory process will 
be influenced not only by the interaction of these multiple mediators, but also by the 
concentrations of specific binding proteins and the levels of receptor expression and affinity. 
This overview has highlighted some of the key mediators involved in the regulation of 
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systemic inflammation and it is these mediators - namely IL-113, IL -6, IL -8, TNFa and IL -10 - 
that will be studied in this thesis. 
c) The acute phase protein response 
The acute phase protein response (APPR) is a component of innate immunity and is also a 
systemic manifestation of tissue inflammation. It is characterised by re- prioritisation of liver 
protein synthesis leading to alterations in serum protein concentrations. There is a fall in the 
concentration of negative acute phase proteins, such as albumin and transferrin, and a rise in 
the concentrations of positive acute phase proteins, such as C- reactive protein (CRP), 
haptoglobin, al- antichymotripsin, and fibrinogen (Table 2.2.2) (Morley and Kushner, 1982). 
The function of the APPR is to destroy harmful agents, prevent on -going tissue injury and 
promote tissue healing (Figure 2.2.2). 
Table 2.2.2 Some examples of acute phase proteins produced by the liver, their functions 
and changes in serum concentrations during an acute phase response. 
Protein Principal Function Serum concentrations during acute 
phase response 
C- reactive protein 
Haptoglobin 
Pro -inflammatory (eg activation of 
complement) 
Increase 
Binding of free haemoglobin 
Antioxidant 
a1-antichymotripsin 




Binding and carrier protein 
Osmotic regulator 






IL -6 is the chief inducer of the APPR (Gauldie et al, 1987). IL -6 is stimulated principally by IL- 
113 and administration of anti -IL -113 antibodies attenuates IL -6 production and the magnitude 
of the APPR (Gershenwald et al, 1990; Yasumoto et al, 1995). However, an APPR may still 
be mounted in IL -6 knockout mice, suggesting that other cytokines are capable of inducing 
the APPR via alternative pathways (Fattori et al, 1994). There is some evidence that IL -8 can 
also induce an APPR in the liver and novel tumour -derived mediators, such as proteolysis - 
inducing factor and parathyroid hormone -related peptide, may similarly be capable of 
activating the APPR (Wigmore et al, 1997; Ogata, 2000; Takahashi et al, 2003; Watchorn et 
al, 2001). 
The re- prioritisation of proteins that characterises the APPR has systemic 
consequences on the host. There are altered demands for amino acids that may not be met 
through dietary intake in the anorexic cancer patient and alternative amino acid stores in the 
body may be sacrificed in preference for the APPR. Such stores include skeletal muscle and 
increased rates of skeletal muscle proteolysis and reduced rates of protein synthesis have 
been associated with pro -inflammatory cytokines involved in the generation of the APPR 
(Baracos et al, 1983). In addition, the alteration in circulating protein concentrations may lead 
to impaired function, especially for the negative acute phase proteins whose concentrations 
decline during the APPR. For example, reduced concentrations of transferrin may lead to 
anaemia that is associated with chronic (inflammatory) disease. The systemic effects of 
inflammation will be discussed in detail in Section 3. 
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Figure 2.2.2 Diagramatic representation of the mechanisms involved in the generation of 
the acute phase protein response and associated changes in protein metabolism. 









T Nitrogen loss 
The APPR occurs in association with inflammation at any site in the body and may occur 
secondary to any stimulus, for example, infection or trauma. An APPR may also be found in a 
significant proportion of patients with cancer (Rashid et al, 1982; Nozoe et al, 2001; Shimada 
et al, 2003; Crumley et al, 2006; Alexandrakis et al, 2003; Falconer et al, 1995; Cooper, 1988; 
Caspers et al, 1984; Forrest et al, 2003; McMillan et al, 2001; Masuda et al, 1998; Kodama et 
al, 1999; Elahi et al, 2005; McMillan et al, 2003; Fujita et al, 1999; Jamieson et al, 2005). The 
pattern of acute phase protein expression varies depending on the underlying stimulus for the 
inflammatory response and may also demonstrate individual variation (Gabay and Kushner, 
1999). This thesis will, therefore, investigate the expression of a range of positive and 
negative acute phase proteins in order to determine the most relevant among patients with 
gastro -oesophageal cancer. The acute phase proteins listed in Table 2.2.2 will be 
investigated; namely CRP, haptoglobin, a1- antichymotripsin, albumin, and transferrin. 
APPR 
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This section has outlined an overview of the key processes involved in the generation of an 
inflammatory response. The main cell types and the key cytokines involved have been 
described along with the important role of the acute phase protein response. The systemic 
effects of tissue inflammation on the host ('systemic inflammation') will now be described in 
the following section. 
3. SYSTEMIC EFFECTS OF INFLAMMATION 
The consequences of the inflammatory response are not confined to the site of tissue 
inflammation, but the activated inflammatory cells and mediators may circulate and act on 
target tissues distinct from the site of tissue injury resulting in systemic sequelae of 
inflammation. As such, systemic inflammation may affect the host in a number of ways, 
including alterations in protein and fat metabolism, changes in endocrine function, and 
increased energy expenditure. These clinical sequelae may be broadly classified into acute 
and chronic systemic inflammatory syndromes. 
a) Acute systemic inflammatory response syndrome (SIRS) 
The early consequences of systemic inflammation are better known as systemic inflammatory 
response syndrome (SIRS). The definition of SIRS was outlined by the American Society of 
Critical Care Medicine and is shown in Table 2.3.1 (Bone et al, 1992). SIRS may be induced 
by any insult to the body, including infection, trauma, hypoxia, burns and surgery and is 
associated with poor outcomes. SIRS is generated, in part, by the complex network of 
cytokines involved in the generation of inflammation as previously described. Circulating 
concentrations of several cytokines, including TNFa, IL -18, IL -6, IL -8 and IL -10 have been 
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linked with morbidity and mortality in patients with SIRS (Casey et al, 1993; Pinsky et al, 
1993; Hack et al, 1997). 
Table 2.3.1 Definition of systemic inflammatory response syndrome (SIRS). 
Two or more of 
Temperature <36 °C or >38 °C 
Pulse > 90 beats /minute 
Respiratory rate > 20 breaths /minute or PaCO2 < 4.3 kPa 
White blood count > 12 x 109/1 or < 4 x 109/1 or > 10% immature (band) forms 
The circulating inflammatory mediators affect the function of several organ systems, which 
may lead to organ dysfunction and even organ failure. Increased endothelial permeability in 
response to pro -inflammatory cytokines leads to interstitial and alveolar oedema that may 
progress to acute lung injury and acute respiratory distress syndrome (ARDS) and 
concentrations of IL -8 in lung broncheoalveolar lavage fluid in patients with ARDS has been 
shown to correlate with mortality (Donnelly et al, 1993). Nitric oxide is synthesised in vascular 
endothelium in response to cytokine release. Nitric oxide is a powerful vasodilator and 
consequently there is a fall in peripheral vascular resistance, which in turn leads to reduced 
cardiac output, hypotension and shock (Rees et al, 1995). Cytokines can also induce 
myocardial depression directly. Renal dysfunction is common affecting up to 50% of patients 
with SIRS. This may be partly as a consequence of the hypoperfusion of the kidney 
accompanying the relative hypotension, but also may be linked with direct tissue injury 
secondary to the release of free radicals and other cell- mediated inflammatory toxins. SIRS 
may also be associated with coagulation disorders secondary to the cytokine- mediated 
activation of the coagulation pathways. IL -6 and IL -8 induce tissue factor expression and 
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activation by monocytes and endothelial cells leading to activation of the clotting cascade 
(Neumann et al, 1997). Dysfunction in the control of the clotting cascade may lead to 
disseminated intravascular coagulation (DIC), characterised by both bleeding and micro - 
thrombi within the circulation. This in turn may contribute to further organ dysfunction. 
In contrast, over- expression of counter -inflammatory cytokines, such as IL -10, may 
lead to a loss of balance between pro -inflammatory and anti- inflammatory mediators. This 
may lead to relative immunosuppression, which has been linked with organ failure following 
major surgery (Bone, 1996). This condition has been termed compensatory anti -inflammatory 
response syndrome (CARS) and elevated serum anti -inflammatory cytokine concentrations 
have been linked with increased complications following major surgery (Mokart et al, 2002). 
Localised tissue inflammation, therefore, results in the systemic release of 
inflammatory mediators, which act on target organs throughout the body. In the acute setting, 
an imbalance between pro -inflammatory and anti -inflammatory cytokines may lead to serious 
and life- threatening sequelae. 
b) Chronic systemic inflammatory response syndrome 
The chronic sequelae of systemic inflammation occur more insidiously and are more relevant 
to the cancer patient, but may accompany any chronic inflammatory condition. The effects are 
characterised by changes in metabolism, including alterations in lipid and protein synthesis, 
elevated resting energy expenditure, and changes in patterns of endocrine secretion (Table 
2.2.1 and Figure 2.3.1). These metabolic changes result in a number of physiological changes 
in the host and patients may experience several symptoms as a consequence. The symptoms 
may include fatigue, weakness, nausea, anorexia, early satiety, and weight loss and these 
symptoms are associated with reduced performance scores and prognosis in cancer patients 
(Deans and Wigmore, 2005). The symptoms share a similar pathophysiologic background 
and some authors have labelled the cluster of symptoms as 'systemic immune- metabolic 
syndrome' (SIMS) (Cerchetti et al, 2004). The widespread metabolic effects of systemic 
inflammation that may lead to SIMS are mediated through the direct and indirect effects of 
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pro -inflammatory cytokines and changes in the neuro- endocrine network. The systemic 
effects of individual cytokines have already been described in Section 2 (b). This section will 
outline the metabolic effects of chronic systemic inflammation on the host. 





Acute phase response Anorexia 
Loss lean body 
mass and fat 
Catecholamine release, 
insulin resistance 





Changes in protein metabolism 
Muscle protein is catabolised to provide the amino acids required to synthesise the proteins 
and cells necessary for the immune response. This is largely mediated through IL-13 and 
TNFa acting via the cyco -oxygenase pathway to increase the rate of skeletal muscle 
proteolysis and reduce the rate of muscle synthesis (Baracos et al, 1983). More recently, 
TNFa (and y- interferon) have been shown to selectively down -regulate myosin heavy chain 
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expression through an RNA -dependent mechanism (Acharyya et al, 2004). This group also 
demonstrated the selective breakdown of myosin heavy chain protein in a mouse model of 
cachexia via up- regulation of the ubiquitin -proteolytic pathway. Cytokines may, therefore, 
stimulate skeletal muscle proteolysis through a more targeted approach that is as yet unclear. 
The acute phase protein response stimulated by IL -6 and generated by the liver is a 
main consumer of many of these amino acids (see Figure 2.2.2). Fibrinogen (a positive acute 
phase reactant) synthesis rates are significantly elevated among cancer patients 
demonstrating a systemic inflammatory response when compared with controls (Barber et al, 
2000). In addition, amino acids are converted to glucose as a preferential energy source to 
help fuel the inflammatory process and there is increased urinary nitrogen loss. 
Other groups have also suggested that muscle protein may be lost through cytokine- 
generated muscle apoptosis (Carbo et al, 2002). Mice bearing a cachexia- inducing tumour 
demonstrated marked DNA fragmentation in skeletal muscle (suggesting muscle apoptosis) 
compared with mice bearing the same tumour but gene- deficient for TNF receptor protein 1. 
These findings suggest that TNFa may play a role in skeletal muscle apoptosis. 
As a consequence of these changes in protein metabolism there is a net loss of lean 
body mass, which may contribute to weakness, fatigue, weight loss and reduced activity 
levels, commonly experienced in patients with SIMS. 
Changes in fat metabolism 
Fat catabolism is increased to provide the additional energy sources required by the immune 
response. This is driven mainly by TNFa acting on the liver to stimulate lipolysis (Selby et al, 
1987). Rates of lipogenesis are also reduced and this may be due to reduced levels of 
lipoprotein lipase expression (Jeevanandam et al, 1986; Vlassara et al, 1986). These 
changes in fat metabolism may also contribute to the weight loss commonly identified in these 
patients. 
Changes in energy expenditure 
Resting energy expenditure (REE) is elevated among patients demonstrating a systemic 
inflammatory response, particularly in those patients with burns, sepsis or trauma. In patients 
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with cancer the pattern is less clear. Longitudinal animal studies suggest that there may be an 
initial hypermetabolic period, followed by a slowing in energy comsumption as subjects 
approach death (Zylicz et al, 1990). Elevated resting energy expenditure has been 
documented in pancreatic cancer patients when compared with healthy controls and, 
moreover, levels of resting energy consumption were significantly higher in those cancer 
patients with elevated markers of systemic inflammation (Falconer et al, 1994). Both IL -6 and 
TNFa have been implicated in the pathophysiology of elevated REE, possibly mediated by 
induction of mitochondrial uncoupling proteins, however, changes in patterns of 
neuroendocrine activation are also important determinants of this catabolic syndrome (Selby 
et al, 1987; Stouthard et al, 1995). 
Altered patterns of endocrine expression 
As previously described, pro -inflammatory cytokines may affect concentrations of insulin, 
cortisol and glucagon leading to metabolic consequences for the patient. Elevated 
concentrations of cortisol and glucagon result in increased rates of gluconeogeneis and 
raised blood glucose concentrations to help fuel the energy demands of the immune 
response. In addition, these elevated hormone concentrations may amplify the magnitude of 
the acute phase response (Baumann and Gauldie, 1994). The insulin resistance associated 
with systemic inflammation also contributes to elevated serum glucose concentrations with an 
associated reduction in anabolic growth in the tissues. Alterations in serum insulin -cortisol 
ratios may also contribute to tissue catabolism (Fearon et al, 1998). Therefore, pro - 
inflammatory cytokines may indirectly exert a wide range of metabolic effects through 
alterations in hormonal secretion patterns. 
Other metabolic consequences of systemic inflammation include reduced plasma trace 
element concentrations (for example, zinc and iron). These changes are mediated through IL- 
16 and TNFa and are partly due to redistribution of the trace elements in the body to aid 
immune cellular function and also due to depletion through tissue healing. Anorexia is also 
commonly associated with SIMS. Reduction in food intake is common among patients with 
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cancer and TNFa concentrations have been linked with reduced rates of food intake in animal 
studies (Darling et al, 1990). 
The chronic sequelae of systemic inflammation are characterised by changes in 
protein and fat metabolism, elevated energy expenditure and other metabolic changes, 
mediated by pro -inflammatory cytokines and changes in hormonal expression. These 
changes exert a high metabolic and nutritional cost upon the body and induce a catabolic 
state. Such metabolic alterations result in a cluster of common symptoms, such as anorexia, 
fatigue and weakness, collectively known as systemic immune -metabolic syndrome (SIMS). 
These symptoms and the underlying metabolic consequences are commonly identified in 
patients with cancer. They are important due to their negative impact on quality of life, 
performance status, and overall prognosis among these patients (Deans and Wigmore, 
2005). 
The next section (Section 4) will describe the incidence of systemic inflammation 
among patients with cancer, outline possible mechanisms involved in its genesis, and 
describe the clinical sequelae of systemic inflammation in cancer patients, with particular 
emphasis on changes in nutritional status (cachexia). 
4. TUMOUR -ASSOCIATED TISSUE INFLAMMATION 
Tumour -associated inflammation has been implicated in carcinogenesis, tumour growth and 
progression, and the development and spread of metastatic disease. Tumour tissue 
inflammation may also be associated with the development of systemic inflammation and 
cancer patients are therefore exposed to the systemic sequelae of inflammation. Previous 
studies have also suggested that the presence of tumour -associated inflammation may also 
have a role in improving prognostic accuracy. Increased understanding of the mechanisms 
underlying the aetiology of tumour -associated inflammation may, therefore, provide insights 
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into the origins of systemic inflammation in cancer patients, improve prognostic accuracy, 
and, in turn, may lead to the identification of novel inflammation -based therapeutic targets. 
a) Innate and adaptive immunity 
The immune system may be considered to have two components; innate and adaptive 
immunity. The innate immune response is a non -specific, stereotyped, rapid response to the 
presence of a foreign antigen or tissue injury. Innate defences include mechanical (for 
example, skin), chemical (for example, gastric acid) and the acute phase protein response. 
The key cells of the innate response are macrophages and natural killer (NK) cells. 
Macrophages are a mobile population of cells that circulate throughout the body 
compartments and tissues ready to respond to environmental stimuli. Macrophages become 
activated in response to local stimulation from cytokines (such as interleukins and y- 
interferon), tissue injury or complement receptors (Duffield, 2003). Once activated, 
macrophages fulfil their immunological role; namely release antimicrobial molecules and 
enzymes, produce cytokines, and undertake phagocytosis. Exposure of macrophages to 
different environmental stimuli, in particular to cytokines such as IL -10 and IL -4, results in a 
different macrophage response characterised by tissue repair and growth rather than the 
tissue destruction that typifies the classical activation pathway (Duffield, 2003). This creates a 
local environment that favours angiogenesis and growth and this may actually contribute to 
carcinogenesis and tumour progression (see later section) (O'Byrne and Dalgleish, 2001; 
Sharma et al, 2003). 
Natural killer (NK) cells are lymphocytes lacking receptors typical of T and B cells. 
The main role of NK cells is in the recognition and destruction of 'non -self' cells, including 
cells that do not express HLA antigens correctly on the cell surface, such as some cancer 
cells, and, therefore, NK cells play an important role in tumour immunosurveillance (also see 
following section) (Moretta et al, 1996). 
The adaptive immune response, in contrast, is a delayed response that is specific for 
an antigen, characterised by antibody formation and demonstrates memory. The adaptive 
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response consists of humoral and cell- mediated components (Figure 2.4.1). B cells produce 
antibodies and develop into memory cells, conferring future immunity to a particular antigen. 
B cells depend upon T cell subsets (T helper cells, CD4 +ve) to develop and function 
correctly. T helper cells are responsible for the regulation of the adaptive immune response 
and macrophage response. T helper cells may differentiate into type 1 or type 2 cells and the 
path of differentiation is principally controlled by local cytokines. Type 1 cell differentiation is 
stimulated by IL -12 and y -IFN and favours macrophage cell activation. Type 2 maturation is 
controlled by IL -4 and IL -10 and promotes B cell activation. Another T cell subset, cytotoxic T 
cells (CD8 +ve) undertake the cell- mediated immune response. Cytotoxic T cells are the 
effector cells and are key orchestrators of the immune reponse. They are directly involved in 
targetted cell death through TNFa and Fas ligand receptor binding resulting in triggering of 
apoptosis and are the main secretors of chemical mediators of inflammation, such as pro - 
inflammatory cytokines. The T cells of the adaptive immune response can only recognise 
antigens expressed in the correct form on cell surfaces. So called antigen presenting cells, 
such as macrophages and dendritic cells, endocytose antigen molecules and express the 
antigen on their cell surface in the correct form in association with a major histocompatability 
complex (MHC) molecule. This allows T cell receptor binding and correct activation of the T 
cell (Steinmann, 2003). Another subset of T cells, regulatory T cells, regulate the adaptive 
immune response by exerting inhibition on T cell effector mechanisms. 
Both the innate and adaptive immune responses are inter -related and dependent 
upon each other for an effective immune response. Each component has also been 
implicated in the generation of tumour -associated inflammation. 
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b) Tumour immunosurveillance 
Host antigens are recognised as 'self' by the immune system and in normal circumstances no 
immune reaction is generated. Such immune tolerance is attained early in development. 'Non - 
self' or foreign antigens are detected by immune surveillance and destroyed by the host 
immune response. In addition to recognising foreign antigens, the immune system may react 
to abnormally expressed 'self' antigens. Abnormal expression of host antigens may arise due 
to over -expression, point mutation or re- arrangement of tumour chromosomal transcripts, or 
following re- expression of developmental or embryonic genes as may occur in certain tumour 
phenotypes. These abnormally expressed host antigens are termed tumour -associated 
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antigens (TAAg's) (Lagarkova et al, 2000; Akervall et al, 2002; Benchimol et al, 1989). Anti - 
tumour immunity directed towards these TAAg's may be mediated through several processes, 
including humoral (B cell mediated), cell- mediated T cell cytotoxic killing, and innate cell 
responses (macrophage and NK cell activation). These processes serve to recognise 
abnormal host cells which are then destroyed by the immune response and consequently 
reduce the likelihood of tumour development. 
c) Tumour escape of immunosurveillance 
Immunosurveillance may fail and tumour development may occur. Failure of 
immunosurveillance may occur due to tumour escape mechanisms or through host 
immunosuppression (Figure 2.4.2). The tumour may fail to produce TAAg's, which is more 
common among poorly differentiated tumours, or abnormal HLA/MHC expression may 
prevent effective T cell receptor binding resulting in failure of T cell activation (Seliger et al, 
2001; Garrido and Algarra, 2001). Such lack of immunogenecity may account for the little 
inflammatory infiltrate noted in some tumours. Tumours may also produce mediators, 
including cytokines and growth factors, which act locally within the tumour mass and may 
influence immune cell function. Variations in cytokine concentrations and receptor expression 
within the tumour tissue may create a local environment which favours the tumour and 
dampens down the local immune response. IL -10 and transforming growth factor -beta (TGF- 
13) are produced by some tumour types and promote activation of type 2 T helper cell 
activation (Logullo et al, 2003). This favours humoral rather than cell- mediated activity and 
reduces tumour cell destruction. In addition, IL -10 also appears to have the ability to protect 
tumour cells from lysis by cytotoxic T cells (Gatsl et al, 1993). Other tumour -derived mediators 
may induce local immunosuppression. Increased concentrations of soluble Fas ligand have 
been measured in tumour cell lines and these elevated concentrations have been associated 
with increased rates of apoptosis of T cells and DC's in patients with cancer (Liu et al, 1998; 
Nat et al, 2002). In addition, dendritic cells (DC's) have been shown to be immature and 
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dysfunctional in gastric cancer and this is thought to be mediated through tumour -derived 
VEGF production (Saito et al, 1998). DC's are important antigen presenting cells as well as 
key cells involved in cell- mediated killing and therefore impaired DC function leads to local 
immune suppression. Several other tumour -derived cytokines and growth factors have been 
implicated in creating a milieu within the tumour tissue that induces immunosuppression and 
favours tumour escape, including granulocyte /macrophage -colony stimulating factor (GM- 
CSF) (Almand et al, 2001). 
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d) Role of immunology in carcinogenesis 
Some chronic inflammatory conditions are associated with increased risk of cancer 
development; for example, ulcerative colitis and colon cancer, and viral hepatitis and 
hepatocellular carcinoma. In upper gastrointestinal cancer, infection with Helicobacter pylori 
(H pylori) induces chronic gastritis, which has been linked with increased risk of development 
of gastric cancer (Forman et al, 1991). Similarly, Barrett's metaplasia is associated with an 
inflammatory cell infiltrate into the oesophagus and is now recognised as a pre -malignant 
condition (Jankowski et al, 2000). Such close association between inflammatory conditions 
and the development of cancer suggests that tissue inflammation may play a role in 
neoplastic progression. Mice deficient in TNFa (TNFa knockout) are protected from epithelial 
damage and carcinogenesis from environmental agents, implicating a role for TNFa in cancer 
development (Moore et al, 1999). In patients with gastro -oesophageal cancer, an 
inflammatory cell infiltrate into the stomach is associated with increased generation of reactive 
oxygen species (Naya et al, 1997). These mediators may accumulate in the cell and induce 
DNA damage, including mutations in oncogenes, such as p53, predisposing to the 
development of gastric cancer (Farinati et al, 1998). Alternative activation of 
monocytes /macrophages, principally through stimulation by IL -10 and IL -4, creates a local 
tissue environment in which cell- mediated immune responses and apoptosis are reduced 
while angiogenesis is promoted (Dalgleish and O'Byrne, 2002; O'Byrne and Dalgleish, 2001; 
Sharma et al, 2003). Alternatively activated innate immune cells may therefore actually 
contribute to carcinogenesis within these tissues (Figure 2.4.2). Furthermore, immune cells 
may secrete cytokines, growth factors and other active mediators into local tissues promoting 
malignant transformation. TNFa has been implicated in the progression along the metaplasia- 
dysplasia- carcinoma sequence in Barrett's oesophagus and IL -16, IL -6 and IL -10 have been 
measured at significantly elevated concentrations within Barrett's segments (Tselepis et al, 
2002; Fitzgerald et al, 2002; Dvorkova et al, 2004). In addition, possession of an IL-113 
polymorphism that is associated with increased tissue IL -16 production is linked with an 
increased risk of H pylori associated gastric cancer, presumably through acid suppression 
and stomach atrophy (EI -Omar et al, 2000). Cytokines can also regulate matrix -degrading 
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enzymes, such as metalloproteinases, and reduce adhesion molecule expression, for 
example, E- cadherin, both of which affect the ability of cells to become invasive (Kim et al, 
2000). 
Cyclo -oxygenase -2 (COX -2) is an inducible form of cyclo -oxygenase that is involved 
in the rapid production of prostaglandins during inflammation. COX -2 is over -expressed in a 
variety of malignant tumours. Increased concentrations of COX -2 have also been measured 
in gastric and oesophageal cancers and have been associated with adverse outcome (Mobius 
et al, 2005). Non -steroidal anti -inflammatory agents (NSAIDs), which reduce levels of COX -2 
expression, have been associated with lower rates of malignant transformation in Barrett's 
metaplasia and with lower risk of developing oesophageal and gastric cancers in the general 
population (Jankowski et al, 1999; Lindblad et al, 2005). 
Hypoxia inducible factors (HIF) are key proteins regulating cellular response to 
hypoxia. Increased HIF expression is observed after exposure of cancer cells to hypoxia and, 
although increased expression may occur due to oncogene activation, over -expression of HIF 
in tumours is likely to represent tumour hypoxia (Feldser et al, 1999; Wiesener et al, 1998). 
Pro -inflammatory cytokines, including IL-18, IL -6 and TNFa, have also been shown to 
increase levels of HIF expression (Westra et al, 2007). It is postulated that exposure of cells 
to cytokine stimulation promotes cellular HIF expression which prepares the cell for the 
relative tissue hypoxia that is associated with tissue inflammation ( Frede et al, 2007). 
Prolonged activation of HIF under conditions of inflammation, however, may contribute to the 
survival of damaged tissue and cells, thus promoting the development of tumours. Cytokine 
induced HIF expression may also provide some resistance of tumour cells to hypoxia and 
promote tumour survival and growth. 
Increasing expression of HIF proteins have been measured in the Barrett's 
metaplasia -dysplasia -adenocarcinoma sequence and similarly in the gastric carcinogenesis 
sequence (Griffiths et al, 2007a; Griffiths et al, 2007b). Elevated levels of expression have 
also been correlated with advanced disease stage and reduced survival duration (Kurokawa T 
et al, 2003; Griffiths et al, 2007b). Cytokine- induced expression of HIF may be one of the 
mechanisms linking tumour inflammation with poor outcome. 
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In contrast to immunosurveillance, immune cells may, therefore, contribute to and 
facilitate tumour development directly through local immune suppression and secretion of 
active mediators, such as cytokines and growth factors, which create a local environment 
favouring carcinogenesis. 
e) Role of immunology in tumour progression and spread 
Established tumours are commonly infiltrated by immune cells, including macrophages, 
dendritic cells, NK cells, and T and B lymphocytes. These cells may mount an immune 
response to the tumour, through mechanisms such as cell- mediated cytotoxic killing in 
response to TAAg's. Alternatively, these immune cells may be subverted into promoting 
tumour growth and progression by mediators and cytokines produced locally by the tumour 
creating a milieu leading to local immune suppression and favouring growth factor production, 
angiogenesis, and matrix degradation. Two immune cell sub -populations have been primarily 
investigated for their role in tumour -associated inflammation. These are tumour -associated 
macrophages (TAM's) and tumour -infiltrating lymphocytes (TIL's). 
Up to 60% of the tumour mass may be accounted for by TAM's, which may vary by 
tumour type but tend to remain constant for a particular individual tumour (van Ravenswaay et 
al, 1992; Toomey et al, 1999; Evans, 1972). Factors derived from tumour cells themselves 
appear to play an important role in the regulation of macrophage levels within the tumour 
(Mantovani et al, 1992). Monocyte chemotactic protein -1 (MCP -1) is a factor produced by 
tumour cells and concentrations of this mediator have been found to correlate with 
concentrations of TAM's in oesophageal cancer (Koide et al, 2004). MCP -1 has also been 
shown to induce IL -p and IL -6 production in monocytes (Jiang et al, 1992). TAM's also 
demonstrate an increased life -span and proliferative capacity, processes which may 
contribute to the maintenance of a constant macrophage population within the tumour 
(Bottazzi et al, 1990). Activated macrophages within the tumour mass have a wide range of 
biological functions depending on their mode of activation. These functions may promote or 
inhibit tumour growth depending on the balance of these opposing actions (Figure 2.4.3). 
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Actions inhibiting tumourigenesis include facilitating T cell- mediated cytotoxic killing of tumour 
cells by antigen presentation and direct lytic effects through release of toxic mediators, such 
as oxygen free radicals. Alternatively, macrophage functions favouring the tumour include the 
production of growth factors (for example, TGF -ß and VEGF), release of lytic enzymes 
facilitating invasion and dissemination (for example, matrix metalloproteinases), and inducing 
local immunosuppression (for example, secretion of IL -10). The mechanisms controlling of 
these opposing functions are poorly understood, but local cytokine concentrations are likely to 
play a key role; for example, alternative monocyte activation by IL -10 and IL -4 favours the 
tumour through increased production of angiogenic factors, secretion of growth factors and 
suppression of cell- mediated cytotoxicity (O'Byrne and Dalgleish, 2001). 
Figure 2.4.3 Potential actions of tumour -associated macrophages (TAM's). These 
functions may promote or inhibit tumour growth depending on the balance of these opposing 
actions. 
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Lymphocytes (TIL's) are also commonly found within tumour tissue. These cells appear to be 
functionally compromised by local (tumour tissue) production of mediators and as a 
consequence there is a failure of immunosurveillance and the tumour attains a position of 
immune privilege (Chiou et al, 2005). There is down -regulation of cell- mediated killing due to 
preferential type 2 T helper cell activation secondary to tumour IL -10 production (Ferguson et 
al, 2003). Signalling defects have been identified in TIL's resulting in impaired immune 
functioning (Nakagomi et al, 1993). Regulatory T cells may also play a vital role in the failure 
of anti -tumour immune activity. Tumour cells may influence regulatory T cells, which in turn 
produce cytokines and other mediators that inhibit the adaptive immune response towards the 
tumour (Curie) et al, 2004). 
The clinical relevance of TAM's and TIL's to patients with cancer remains unclear, 
especially among patients with gastro -oesophageal malignancy. An increased macrophage 
infiltrate is associated with more advanced disease stage in patients with gastric cancer in 
one study, whereas other studies have suggested a more favourable prognosis associated 
with a more pronounced macrophage infiltration (Heidi et al, 1987; Ohno et al, 2003; Tsujitani 
et al, 1987). Similarly, increasing tumour -infiltrating lymphocyte count has been linked with 
decreased risk of death from gastric cancer in one study, but associated with an adverse 
prognosis in another (Grogg et al, 2003; Setala et al, 1996). Studies relating to oesophageal 
cancer are equally contradictory (Koide et al, 2004; Ma et al, 1999). This topic is further 
explored in Chapter V. 
f) Summary 
The immune system and tumour biology are intimately associated. Failure of 
immunosurveillence, either through tumour escape mechanisms or host immunosuppression, 
allows tumour development. Alternatively, there is evidence that the presence of chronic 
inflammation may have a direct role in carcinogenesis. An inflammatory cell infiltrate is 
commonly identified once tumours are established and may include cells of the innate 
immune system (TAM's) and cells from adaptive immunity (TIL's). The tumour is able to 
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subvert the normal anti -tumour functions of these cells through the local production of 
cytokines and other mediators that creates a local environment within the tumour tissue 
favouring tumour growth and dissemination. The clinical significance of an inflammatory cell 
infiltrate into the tumour tissue is unclear, especially among patients with gastro -oesophageal 
cancer. This thesis will investigate the influence of an inflammatory cell infiltrate on prognosis 
for patients with gastro -oesophageal cancer and compare the magnitude of the inflammatory 
infiltrate with cytokine concentrations measured in both the tumour tissue and the systemic 
compartment. Additional studies will attempt to determine whether the aetiology of systemic 
inflammation in cancer patients is derived from host immune cells or is driven by tumour - 
derived mediators. 
Local tumour -associated inflammation is also associated with systemic inflammation and, as 
such, cancer patients are exposed to the systemic sequelae of inflammation. This may have 
an impact on patients' function, quality of life, nutritional status, response to treatment, and 
prognosis. This is discussed in the following section. 
5. TUMOUR -ASSOCIATED SYSTEMIC INFLAMMATION 
The presence of cancer within the host may trigger an immune response and lead to the 
generation of tissue and systemic inflammation. Patients with cancer are, therefore, exposed 
to the local and systemic sequelae of tumour -associated inflammation. The clinical sequelae 
of systemic inflammation has already been described in Section 3, however, this Section will 
describe the sequelae among patients with cancer, with particular emphasis on the effects of 
systemic inflammation on patients' nutritional status and function (cachexia). Firstly, the 
incidence of systemic inflammation among patients with cancer will be described and then a 
discussion on the possible causes of systemic inflammation in cancer patients will follow. 
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a) The incidence of cancer -associated systemic inflammation 
Elevated markers of systemic inflammation have been measured in patients with most types 
of cancer. Increased pro -inflammatory cytokine concentrations have been measured in sera 
from patients with cancer and elevated concentrations of IL-113, IL -6, IL -8 and TNFa have 
repeatedly been measured in blood collected from patients with gastro -intestinal malignancy, 
including pancreatic, gastric and oesophageal cancers (Barber et al, 1999; Wang et al, 1999; 
Kabir and Daar, 1995; Ebrahimi et al, 2004). However, reliable measurement of serum 
cytokine concentrations is difficult, partly because of short half -lives and the presence of 
blocking factors, but also due to circadian variations in plasma concentrations (May et al, 
1992). The difficulties in reliably measuring serum TNFa concentrations has already been 
aluded to (Muc- Wierzgon et al, 1996). In addition, the end -organ effects of these systemic 
cytokines will depend upon binding to transport proteins, receptor expression and receptor 
affinity. These findings have raised doubt as to the significance of circulating concentrations 
of pro -inflammatory cytokines as markers of systemic inflammatory activity. It is possible that 
the local release of pro -inflammatory cytokines into target tissues by peripheral blood 
mononuclear cells (PBMC) is a more accurate determinant of pro -inflammatory activity in the 
tissues. Such PBMC's become 'activated' by local cytokine production as the cells pass 
through the tumour tissue, circulate in the bloodstream, and release cytokines in target 
tissues thereby increasing local tissue concentrations. PBMC's from patients with pancreatic 
cancer with an elevated serum acute phase protein response demonstrate greater rates of 
pro -inflammatory cytokine (IL -6 and TNFa) production when compared with those without a 
systemic inflammatory response (O'Riordain et al, 1999). These cells are then capable of 
stimulating increased rates of C- reactive protein (CRP) production by hepatocytes in co- 
culture systems (O'Riordain et al, 1999). 
Serum concentrations of acute phase proteins (APPR) demonstrate more stability 
within the systemic compartment and may be a more reliable marker for the presence of 
systemic inflammation in patients (Gabay and Kushner, 1999). Up to 50% of patients with 
cancer have an APPR at the time of diagnosis, including patients with upper gastro -intestinal 
malignancy (Chen et al, 1999; Alexandrakis et al, 2003; Barber et al, 1999; Falconer et al, 
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1994; Falconer et al, 1995). In cancer patients circulating concentrations of IL -6 have been 
shown to correlate with markers of systemic inflammation such as CRP (Barber et al, 1999). 
The presence of such an acute phase reaction may then be used as an indirect marker of 
increased pro -inflammatory cytokine activity and serum concentrations of acute phase 
proteins may, therefore, be used to confirm the presence of systemic inflammation. 
b) The aetiology of systemic inflammation in patients with cancer 
The origins of systemic inflammation in patients with cancer remain unclear. The close 
relationship between tumourigenesis and host immunology has already been described in 
Section 4(a). The cellular interactions between host immune cells and tumour cells are 
controlled by locally produced cytokines and other mediators that serve to create a local 
environment favouring the tumour. Little is known of the systemic relevance of these locally 
produced mediators. Studies comparing tissue cytokine concentrations with systemic 
concentrations have mainly involved chronic inflammatory conditions. In Crohn's disease 
tissue cytokine concentrations correlate with serum CRP concentrations (Raddatz et al, 
2005). Similarly, tissue production of inflammatory cytokines (IL -16, TNFa and IL -6) correlates 
with the intensity of the systemic inflammatory response in giant -cell arteritis (Hernandez - 
Rodriguez et al, 2004). Conversely, other groups investigating inflammatory joint disease 
have failed to demonstrate an association between tissue cytokine concentrations and 
systemic markers of inflammation (Rioja et al, 2004). In patients with cancer this relationship 
is equally unclear. Tumour tissue from patients with head and neck cancer demonstrate 
elevated concentrations of pro -inflammatory cytokines and elevated serum acute phase 
protein concentrations, but not elevated serum cytokine concentrations (Chen et al, 1999). It 
is likely that tumour tissue cytokine concentrations have little correlation with serum cytokine 
concentrations. However, immune cells may become activated as they pass through the 
inflamed tumour tissue and become exposed to the locally produced cytokines and other 
inflammatory mediators. These cells are then free to circulate in the systemic circulation and 
act on target tissues exerting their pro -inflammatory effects. For example, by inducing an 
66 
acute phase protein response from the liver (Figure 2.5.1). In support of this, peripheral blood 
mononuclear cells (PBMC's) from cancer patients with an elevated serum APPR demonstrate 
greater rates of pro -inflammatory cytokine (IL -6 and TNFa) production when compared with 
those without a systemic inflammatory response ( O'Riordain et al, 1999). These cells are then 
capable of stimulating increased CRP production by hepatocytes in co- culture systems 
(O'Riordain et al, 1999). Other groups have also identified the ability of certain tumours to 
sensitise PBMC's and induce IL -6 expression from these cells (Martignoni et al, 2005). 
Whether the main stimulus for the systemic inflammatory response in patients with 
cancer arises from the tumour cells or the host immune cells remains unknown. Either the 
tumour cells or the host cells or a combination of the two are responsible for the production of 
the pro -inflammatory cytokines that induce the APPR. It may simply follow that the host 
immune system mounts a response secondary to the tumour burden or in response to a 
necrotic tumour that is behaving like an 'abscess' with associated release of cytokines. 
Elevated serum CRP concentrations have been linked with increased tumour volume in 
patients with oesophageal malignancy (Nozoe et al, 2001). However, the complexities of 
tumour immunology have already been outlined in Section 4(a) and this explanation is likely 
too simplistic. The interactions between host and tumour cells appear to be crucial to the 
development of tumour -associated inflammation and, therefore, also crucial to the 
development of systemic inflammation. Furthermore, the extent of leucocyte infiltration into 
tumour tissue (TAM's and TIL's) does not reliably correlate with either tumour tissue cytokine 
concentrations or with markers of systemic inflammation (Chen et al, 1999). Local immune 
cell immunosuppression and alternative activation of monocytes (type 2 activation) within the 
tumour tissue has already been aluded to and it is possible that these host immune cells do 
not contribute to the generation of systemic inflammation. Alternatively, tumour cells are 
capable of constitutive production of pro -inflammatory cytokines. Oesophageal cancer cells 
have been shown capable of producing increased pro -inflammatory cytokine mRNA and 
protein concentrations (Yuan et al, 2000; Martignoni et al, 2005; Nozoe et al, 2003). Gastric 
cancer cells are also capable of producing a range of pro -inflammatory cytokines (Yasumoto 
et al, 1992). The main stimulus for systemic inflammation in patients with cancer may 
therefore be driven by the tumour cells. This topic will be further explored in Chapter V. 
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Figure 2.5.1 An overview of the possible mechanisms underlying the generation of a 
systemic inflammatory response in patients with cancer. The cellular interactions between 
host immune cells and cancer cells within the tumour mass and the inflammatory mediators 
produced by these cells appear to be crucial in the development of systemic inflammation. 
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c) The clinical sequelae of systemic inflammation in patients with 
cancer 
The clinical sequelae of systemic inflammation have already been described in detail in 
Section 3. The chronic sequelae are of particular relevance to patients with cancer and these 
effects are characterised by changes in protein and fat metabolism, elevated energy 
expenditure and other metabolic changes, mediated by pro -inflammatory cytokines and 
changes in hormonal expression. These metabolic alterations are commonly identified in 
patients with cancer and lead to a cluster of common symptoms, such as anorexia, fatigue 
and weakness, collectively known as systemic immune -metabolic syndrome (SIMS). These 
symptoms and the metabolic changes underlying are important due to their negative impact 
on quality of life, performance status, response to treatment and overall prognosis among 
these patients (Deans and Wigmore, 2005). This section will describe the effects of systemic 
inflammation on nutritional status (cachexia). The role of systemic inflammation in determining 
prognosis in patients with cancer has already been discussed in Section 1(e). 
Cachexia 
Cachexia is a syndrome characterised by a group of symptoms including anorexia, early 
satiety, weight loss, weakness and anaemia (Fearon, 1992). The syndrome is associated with 
alterations in metabolism and also changes in patient functioning and performance status. 
More recently a definition of cachexia has evolved to encompass these two aspects of 
cachexia (Fearon et al, 2006). A 3- factor profile incorporating weight loss (greater or equal to 
10 %), low food intake (less than or equal to 1500 kcal /d), and systemic inflammation (CRP 
greater or equal to 10 mg /L) identifies patients with both adverse function and prognosis. 
Cachexia is not exclusive to cancer, but is also seen in chronic illness, such as rheumatoid 
arthritis and AIDS. The syndrome of cachexia is, however, common among patients with 
cancer, especially among patients with malignancy affecting the gastrointestinal tract (DeWys 
et al, 1980). Up to 85% of patients with pancreatic cancer have symptoms relating to cachexia 
at the time of diagnosis and almost all of these patients develop symptoms close to the time 
of death (Wigmore et al, 1997). 
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The clinical sequelae of cachexia may have significant detrimental effects on the host and 
cachexia remains an important cause of morbidity and mortality among cancer patients. 
Cachexia is associated with reduced quality of life scores, reduced performance status, lower 
response rates to chemotherapy, and overall poorer outcomes in patients with cancer 
(DeWys et al, 1980; Barber et al, 1999). Weight loss has been associated with adverse 
outcome in cancer patients and it has been suggested that around 20% of deaths from cancer 
are directly related to cachexia (Studley, 1936; Inagaki et al, 1974). 
The metabolic changes underlying cachexia are similar to those seen in SIMS 
(section 3(b)). There is weight loss secondary to reduction in lean body mass and fat mass. 
There is preferential loss of skeletal muscle protein with relative sparing of visceral protein, 
which contrasts with the pattern of protein loss seen through starvation (Fearon and Preston, 
1990). Skeletal muscle is depleted through reduced rates of protein synthesis and increased 
rates of proteolysis (Baracos et al, 1983; Acharyya et al, 2004). Some authors have also 
suggested muscle cells may undergo apoptosis during cachexia also contributing to loss of 
muscle mass ( Garbo et al, 2002). Fat is lost through reduced dietary intake, increased rates 
of lipolysis, and reduced rates of lipogenesis (Jeevanandam et al, 1986). Cachexia is also 
associated with hypermetabolism. Rates of resting energy expenditure are significantly 
elevated in patients with pancreatic cancer, and higher still in those patients with evidence of 
an acute phase response (Falconer et al, 1994). There is a reduction in food intake due to 
anorexia, early satiety and alterations in taste that are associated with the syndrome (Fearon, 
1992). There are also alterations in endocrine function that may contribute to overall tissue 
catabolism (Fearon et al, 1998). 
The metabolic similarities underlying SIMS and cancer cachexia suggest that pro - 
inflammatory cytokines also play a role in the mechanisms of cachexia. Animal studies initially 
suggested a role for pro -inflammatory cytokines in the generation of cancer -associated 
cachexia. IL -18, IL -6 and TNFa among others have been associated with anorexia and weight 
loss in rodent tumour models (Ghelin et al, 1991; Strassman et al, 1993). These pro - 
inflammatory cytokines have also been implicated in cachexia among human subjects, where 
elevated serum cytokine concentrations have been linked with weight loss in cancer patients 
(Martignoni et al, 2005). Martignoni and co- workers identified IL -6 over -expression in the 
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serum and also in the tumour specimens of cachectic patients with pancreatic cancer. They 
identified IL -6 mRNA expression to be significantly increased in tumour samples of cachectic 
patients compared with non -cachectic patients or pancreas samples from normal controls. 
These authors have suggested that IL -6 over -expression in cachectic pancreatic cancer 
patients is related to the ability of certain IL -6 producing tumours to sensitise PBMC and 
induce IL -6 expression in PBMCs. In patients with inoperable oesophageal cancer treatment 
with thalidomide, an inhibitor of TNFa synthesis, was associated with weight gain and 
increased muscle mass after only two weeks (Khan et al, 2003). 
The acute phase response has also been linked with cachexia. Serum CRP 
concentrations have been correlated positively with weight loss in cancer subjects (Falconer 
et al, 1995; Wigmore et al, 1997; O'Gorman et al, 1999). Resting energy expenditure (REE) in 
patients with pancreatic cancer and evidence of an APPR have greater rates of REE 
compared with cancer patients without an APPR (Falconer et al, 1994). Cancer patients with 
an APPR have elevated fibrinogen synthesis rates in both the fed and fasting states (Preston 
et al, 1998; Barber et al, 2000). The protein substrate to fuel this APPR is thought to be 
mainly derived from muscle stores and it is this reprioritisation of protein metabolism that 
accompanies the APPR that may also contribute to the wasting observed in cancer cachexia 
(Fearon et al, 1999). 
The aetiology of cancer cachexia is almost certainly mutifactorial, although elevated 
pro -inflammatory cytokines and the presence of systemic inflammation are likely to play a 
role. Additional potential mediators of cachexia are tumour -derived products, such as 
parathyroid hormone -related peptide (PTHrP) and proteolysis- inducing factor (PIF) (Figure 
2.5.2). Parathyroid hormone -related peptide (PTHrP) is a tumour -derived circulating factor 
that has been associated with hypercalcaemia of malignancy, affecting up to 20% of patients 
during the advanced stages of cancer (Twycross, 1997; Suva et al, 1987). PTHrP expression 
has been found in association with both gastric and oesophageal malignancy (Jais et al, 
1997; Tachimori et al, 1991; Abdeen et al, 1995; Engelich et al, 2000; Alipov et al, 1997). 
PTHrP may contribute to the pro -inflammatory cytokine cascade and several studies have 
identified elevated serum PTHrP concentrations in association with elevated serum cytokine 
concentrations in cancer patients (Ogata, 2000; Takahashi et al, 2003). PTHrP has been 
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shown to stimulate IL -6 production from osteoblasts in vivo and administration of PTHrP to 
mice increased serum acute phase protein levels (Pollock et al, 1996; Funk et al, 1998). 
PTHrP has also been linked with cachexia. PTHrP is produced by a human lung cancer 
model (HARA -B) and, when implanted into mice, results in a significant reduction in body 
weight and tissue mass, an effect that is reversed by addition of an antibody to PTHrP (Iguchi 
et al, 2001). The relevance on PTHrP in the generation of systemic inflammation, weight loss 
and prognosis will be explored in Chapter VII. 
Figure 2.5.2 Tumour -derived mediators, such as proteolysis- inducing factor (PIF) and 
parathyroid hormone -related peptide (PTHrP), may also be involved in the aetiology of 
cachexia and systemic inflammation in patients with cancer. 
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PIF is a tumour -derived mediator that may be linked with systemic inflammation, weight loss 
and prognosis in cancer patients. Initially isolated from a murine cachexia tumour model 
(MAC16), a human homologue of PIF was subsequently identified in human urine from weight 
losing cancer patients, but not from weight -stable cancer patients or patients with weight loss 
secondary to benign disease (Todorov et al, 1996; Wigmore et al, 2000; Cariuk et al, 1997). 
PIF has been named as such because it has been shown to induce skeletal muscle 
proteolysis through activation of the ubiquitin proteolytic pathway (Lorite et al, 1997; Lorite et 
al, 2001; Todorov et al, 1997). PIF has been identified within gastrointestinal cancer cells and 
its presence was associated with increased weight loss among these patients (Cabal - 
Manzano et al, 2001). PIF has also been shown to stimulate production of IL -6, IL -8 and CRP 
in hepatocytes via induction of transcription factors NF -kB and STAT3 (Watchorn et al, 2001). 
PIF may, therefore, contribute to the inflammatory state observed in conjunction with cancer 
cachexia in addition to its proteolytic function. The role of PIF in the generation of systemic 
inflammation, weight loss and prognosis in patients with gastro -oesophageal cancer will be 
investigated in Chapter VIII. 
In summary, cancer cachexia is commonly associated with malignancy of the 
gastrointestinal tract and is an important cause of morbidity and mortality among patients with 
cancer. Metabolic and clinical similarities with SIMS suggest that pro -inflammatory cytokines 
are linked with cachexia, although other mediators, such as PIF and PTHrP may be involved. 
Markers of systemic inflammation may therefore be linked with markers of cachexia, which in 
turn may be linked with reduced prognosis. Examining the link between systemic 
inflammation and cachexia may lead to improved estimations of prognosis among patients 
with gastro -oesophageal cancer, allow earlier identification of patients at risk of cachexia, and 
lead to the identification of novel therapeutic targets. This topic will be explored in Chapter X. 
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6. SUMMARY 
This chapter has highlighted the increasing incidence of gastric and oesophageal cancer in 
the UK and outlined the current staging modalities and therapeutic strategies available. 
Current practices are failing to stage accurately these patients and treatment modalties are 
ultimately of a palliative nature. Improved staging accuracy would enable better treatment 
selections for individual patients, moreover, novel therapeutic strategies are much needed. 
Markers of systemic inflammation may have a prognostic role in gastro -oesophageal cancer 
and improved understanding of the mechanisms involved in the generation of systemic 
inflammation in cancer patients may provide insights into novel therapeutic targets and enable 
individualised patient care. The important cells and mediators involved in the generation of 
inflammation have been described, including key cytokines and the acute phase response. 
The role of immunology in carcinogenesis, tumour progression and spread has been 
described and possible mechanisms underlying the aetiology of systemic inflammation in 
patients with cancer have been discussed. The adverse clinical sequelae of systemic 
inflammation on the host have been outlined with particular relevance to alterations in 
metabolism, nutritional status (cachexia), and prognosis. 
Therefore, the overall aim of this thesis is to describe the genesis, mediators and 
sequelae of systemic inflammation in patients with gastro -oesophageal cancer. The 
usefulness of systemic inflammation as a prognostic indicator and the role of cachexia as a 
factor in the adverse prognosis associated with systemic inflammation are expanded in detail. 
The key hypothesis being that tumour cells produce mediators (such as cytokines, PIF and 
PTHrP), which can either directly or indirectly (via systemic inflammation) induce a catabolic 
state in the peripheral tissues of the host. Such wasting may be one of the mechanisms 
linking systemic inflammation with adverse prognosis in patients with cancer. Potential novel 
therapeutic targets may also be identified. 
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CHAPTER III 
MATERIALS AND METHODS 
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This thesis aims to describe the genesis, mediators and sequelae of systemic inflammation in 
patients with gastro -oesophageal cancer. The usefulness of systemic inflammation as a 
prognostic indicator, and the associated role of cachexia, are explored in more detail. This 
Chapter outlines the main methods undertaken to fulfil these tasks. 
The Chapter describes a prospective cohort study to characterise the natural history 
of patients with gastro -oesophageal malignancy, documents the prevalence of elevated 
serum markers of systemic inflammation, examines the role of tumour tissue in the generation 
of systemic inflammation, explores various hypotheses related to novel mediators /factors 
giving rise to systemic inflammation, and provides data for the development of a prognostic 
model involving markers of systemic inflammation and cachexia. 
Firstly, an overview of the study protocol is outlined, including details on patient 
recruitment to the study and subsequent episodes of patient contact, timings of sample 
collection, and follow -up data collection. A detailed description of assays performed on blood 
samples will be described, including measurements of serum cytokine concentrations, serum 
acute phase protein concentrations, and routine clinical chemistry. The contribution of tumour 
tissue to the generation of systemic inflammation was investigated by measuring 
concentrations of cytokine mRNA and protein within tissue homogenates, using real -time 
polymerase chain reaction (PCR) and cytometric bead array analysis. Cytokine genotyping 
was undertaken to examine the potential influence of host genotype on the generation of a 
systemic inflammatory response. Finally, the potential roles of tumour -derived mediators (PIF 
and PTHrP) on systemic inflammation and cachexia were investigated. Western blotting and 
mass spectroscopy were used to detect urinary PIF. Tumour tissue PIF mRNA was measured 
by real -time PCR and systemic PTHrP was determined by radio -immunoassay. 
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1. STUDY PROTOCOL 
a) Ethical approval 
All aspects of this study received full ethical permission from the Lothian Research Ethics 
Committee (reference LREC /2002/5/9). In every instance patients provided written informed 
consent and patients were issued with appropriate information sheets (see Appendix A). 
b) Statistics and Power Estimation 
Prior to commencing the prospective collection of patient data /samples a power calculation 
was performed. In addition to investigating the origin of systemic inflammation in gastro- 
oesophageal cancer, the latter part of this thesis is to examine the prognostic role of systemic 
inflammation and to develop a novel prognostic model. Therefore, a nomogram was used to 
estimate the sample size for this study, which is specifically designed for calculating patient 
numbers for studies using survival as an end point (Schoenfeld and Richter, 1982). Previous 
studies in pancreatic cancer patients have suggested a 50% survival difference between 
patients with systemic inflammation and those without (Falconer et al, 1995). Assuming this to 
be true for patients with gastro -oesophageal cancer, and based on a two -sided test with a 
significance level equal to 0.05 and a power of 0.9, a 2 -year study with a mean follow -up 
period of 6 months would require two hundred patients to demonstrate a 50% survival 
difference. Therefore, over two hundred patients were recruited to the study. 
Statistical analyses are described in detail within context in each Chapter. In general, 
data were considered not to be normally distributed and non -parametric tests were applied. 
Log -rank analysis was used to determine prognostic value for univariate analysis and Cox's 
proportional hazard's model was used to test for multivariate analysis. A p value <_ 0.05 was 
considered statistically significant in each case. Analysis was performed using SPSS® 
software (SPSS, Chicago, Illinois, USA). 
77 
c) Patient recruitment and follow -up 
An overview of the study protocol is shown in Figure 3.1.1. 
Figure 3.1.1 An overview of the study protocol and the patient journey following diagnosis 
of gastro -oesophageal cancer. 
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Patients were recruited to the study between 25 March 2002 and 25 June 2004. All patients 
were enrolled before any treatment had been initiated and within 1 -2 weeks from the time of 
diagnosis. Newly diagnosed patients were identified principally from the multi -disciplinary 
team meetings. The Lothian and Borders Oesophago- Gastric Cancer Group is a multi- 
disciplinary team (MDT) comprising specialist oesophago -gastric surgeons, 
gastroenterologists, medical and radiation oncologists, radiologists, pathologists, dieticians, 
clinical nurse specialists, data collectors, researchers and trainee medical /surgical staff. This 
team provides a regional referral service for patients with oesophageal and gastric cancer 
from the Lothian and Borders regions (population approximately 1 million). Patients newly 
diagnosed with gastric or oesophageal cancer within these regions are referred to the MDT, 
which meets on a weekly basis to discuss all new referrals and to decide on individual patient 
management strategies. Alternatively, suitable patients were identified in outpatients, on the 
wards (when admitted as emergencies), and from the clinical nurse specialists. It is estimated 
that through these methods most patients newly diagnosed with gastro -oesophageal 
malignancy in these regions would have been identified (approximately 150 patients per 
year). There were a few known cases where patients were diagnosed in hospitals out -with 
Edinburgh Royal Infirmary and were not referred to the MDT due to extreme frailty of the 
patient and these patients were not recruited to the study. No patients refused entry into the 
study. 
Once identified, suitable patients were interviewed and, following written informed 
consent, numerous demographic, clinical and pathological data were recorded using a 
standard data collection sheet (see Section 1(d) and Appendix B). The timings of data 
recording and sample collection are shown in Figure 3.1.2. 
After the initial interview at the time of recruitment to the study patients were followed - 
up when possible and repeat information was collected on the data sheet. Patients who 
underwent surgical treatment were reviewed approximately three months following surgery, 
and those patients who received pre- operative chemotherapy were additionally reviewed at 
the completion of neoadjuvant therapy and prior to surgery (Figure 3.1.2). Where possible 
patients who received palliative treatments were similarly reassessed a various time points 
during their disease progression. Dates and cause of death were identified from the upper GI 
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cancer data manager, the patients' General Practitioners, and the National Registry of Births, 
Deaths and Marriages. 
Figure 3.1.2 Approximate timing of data recording and sample collection during the study. 
Further information of the type of data collected and samples collected is described in the text 
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The various timings of data collection and the type of information gathered are shown in 
Figure 3.1.2. Demographic data was recorded and included age and sex for each patient. Co- 
morbidity was documented for each patient as well as current health and medications taken 
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(including over the counter preparations), which may modify the systemic inflammatory 
response. Duration of symptoms and the date of diagnosis, defined as the date of histological 
confirmation of disease, were also recorded in all instances. 
All patients underwent endoscopic investigation and histological analysis of tissue 
prior to entry into the study. Following histopathological confirmation of disease patients 
followed a staging protocol devised by the MDT, which included investigation by 
computerised tomography (CT) and, provided there was no metastatic disease, endoscopic 
ultrasound (EUS). In addition, patients with tumours involving the distal oesophagus and 
stomach also underwent laparoscopic assessment including laparoscopic ultrasound (LUS) to 
identify potential peritoneal disease. Patients considered too frail for interventional treatment 
may not have progressed further than a tissue diagnosis. Each patient was staged according 
to the International Union Against Cancer (UICC) (Sobin and Wittekind, 2003). Final 
histopathological stage (pTNM) was used where available, but was only available for those 
patients who underwent surgical resection. In all other cases the final clinical stage (cTNM), 
as agreed at the unit MDT meeting, was recorded. Tumours around the oesophago -gastric 
junction were classified according to Siewert and Stein and those classified as type I and II 
were staged as oesophageal tumours and type Ill as gastric cancers (Siewert and Stein, 
1998). 
In addition to staging information, the anatomical position of the tumour was recorded 
as well as the histological type, the degree of differentiation, and any other relevant features 
on histological analysis (including the presence of signet ring cells, tumour necrosis, 
Helicobacter pylori, and peri- neural or vascular tumour invasion). Treatment modality 
undertaken by each patient was recorded as well as intent (palliative versus curative). 
Survival duration, defined as time from histological diagnosis until death, was documented 
and where possible the cause of death was confirmed as either disease related or due to 
another cause. 
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2. NUTRITIONAL ASSESSMENT 
Patients underwent a nutritional assessment to record changes in body composition and 
dietary intake at the time of diagnosis and later in the course of the disease. This was to 
document changes in nutritional status in a cohort of patients with gastro -oesophageal cancer 
from the time of diagnosis, through the advancement of disease and, in some cases, up to the 
time of death. These findings could then be used to explore any association between adverse 
nutritional status (cachexia) and the presence of systemic inflammation and, in turn, examine 
the role of cachexia in explaining the adverse prognosis associated with systemic 
inflammation in patients with gastro -oesophageal cancer. This topic is further explored in 
Chapter X. 
The assessment of nutritional status included calculation of body mass index (BMI) 
and anthropometry in all patients. In a subgroup of patient's body composition analysis was 
also undertaken using electrical impedance. Dietary intake was recorded in dietary diaries 
and also estimated by patients. The severity of dysphagia was also assessed and 
documented. 
Calculation of body mass index (BMI) and rate of weight -loss 
Height was measured using a wall- mounted stadiometer without shoes. Patients were 
weighed on spring balance scales without shoes and wearing light clothing. Body mass index 
(BMI) was calculated following height and weight measurements. Pre -morbid patient weight 
was recalled by the patient and verified where possible from the medical notes. Individual 
weight loss was calculated and expressed as percentage of pre -illness body weight lost per 
month of symptoms. 
Anthropometry 
Anthropometry was undertaken on each patient and included measurement of mid -arm 
circumference (MAC) and triceps skinfold thickness. MAC was measured at the mid -point 
between the acromion and the olecranon processes. Triceps skinfold thickness was 
measured with Harpenden skin callipers (Holtain, Byberian, UK) and mid -arm muscle 
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circumference (AMC) was calculated by means of Jelliffe's equation (Jelliffe, 1966). Values 
were normalised using standardised reference tables (Bishop et al, 1981). 
Body composition analysis 
Body composition analysis was performed on a randomly selected patient sub -group 
attending the outpatient clinic. Bioelectrical impedance analysis was performed using a four - 
terminal multi- frequency bioelectrical impedance analyser (Xitron 4000 MFBIA, Xitron 
Technologies, San Diego, USA), operated at a current of 200pA root mean square. All values 
were recorded with the subject supine with limbs apart. Values for total body water were 
obtained using equations validated in a similar patient group (Hannan et al, 1995). Lean body 
mass was calculated from total body water assuming a hydration coefficient of 0.732. 
Estimation of dietary intake 
Dietary intake was estimated by all patients and scored as 1 = normal, 2 = reduced and 3 = 
poor /minimal. The smaller group of randomly selected patients provided detailed 3 -day food 
diaries for comparison. Patients were instructed to record all food and drink consumed over a 
3 -day period, which included a weekend day and the data were analysed by a senior dietician 
who provided information on the level of intake of macronutrients using computer software 
(CompEat®, Nutrition Systems, Grantham, UK). Comparisons were made to dietary reference 
values issued by the Department of Health (Department of Health, 1991). 
Dysphagia score 
The severity of dysphagia was assessed at each interview and was scored according to 






able to eat normal diet / no dysphagia. 
able to swallow some solid foods 
able to swallow only semi solid foods 
able to swallow liquids only 
unable to swallow anything / total dysphagia 
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3. ASSESSMENT OF PERFORMANCE STATUS 
Patient performance status was scored at each assessment using the scoring system devised 
by Karnofsky (Karnofsky and Burchenal, 1949): 
Normal, no complaints 100 
Able to carry out normal activities, minor signs of disease 90 
Normal activity but with effort 80 
Self- caring but unable to carry out normal activity or work 70 
Requires occasional assistance but able to care for most needs 60 
Requires considerable assistance and frequent medical care 50 
Disabled, requires special care and assistance 40 
Severely disabled, hospitalisation indicated although death not imminent 30 
Very sick, requires hospitalisation. Active supportive treatment necessary 20 
Moribund 10 
Dead 0 
4. COLLECTION OF BIOLOGICAL SAMPLES 
Biological samples were collected at different time points during the disease process (see 
Figure 3.1.2). At the time of recruitment (diagnosis) whole blood was collected for 
determination of serum concentrations of acute phase proteins, cytokines, albumin, alkaline 
phosphatase, urate, parathyroid hormone -related peptide (cPTHrP), and calcium. The cellular 
component was separated and used for extraction of DNA for cytokine genotyping. Patients 
also provided a sample of urine for proteolysis- inducing factor (PIF) determination. 
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At each follow -up interview an additional blood sample was collected for determination of 
serum concentrations of C- reactive protein (CRP), albumin, alkaline phosphatase, urate, 
cPTHrP, and calcium. Additional urine samples were also collected. 
Paired samples of tumour tissue and adjacent normal mucosa were collected from 
patients at the time of surgery for measurement of tissue cytokine mRNA and protein 
concentrations and for PIF mRNA analysis. In order to preserve as much pathological staging 
information as possible the resected specimens were transferred fresh from the operating 
theatre to the pathology department where representative tissue samples were cut by a 
Consultant Pathologist before the samples were snap frozen in liquid nitrogen prior to storage 
at -80 °C. 
5. BLOOD ASSAYS 
As part of the investigation into the genesis and mediators of systemic inflammation in 
patients with cancer, concentrations of serum cytokine and acute phase proteins were 
measured. 
a) Serum acute phase protein measurement 
C- reactive protein (CRP), haptoglobin, a,- antichymotrysin (ACT), albumin, and transferrin 
were selected as the acute phase proteins for investigation. CRP, haptoglobin, and ACT 
represent positive acute phase proteins and albumin and transferrin represent negative acute 
phase reactants (see Chapter II, Section 2 (c) for further details). 
C- reactive protein (CRP) 
Serum CRP concentration was measured using an automated immuno -turbidimetric assay 
within the Clinical Biochemistry Department, Edinburgh Royal Infirmary, UK. Using this assay 
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a concentration of 10mg /I represents the upper limit of the normal range with most healthy 
individuals having a serum concentration <2mg /I (Gabay and Kushner, 1999). The coefficient 
of variation was less than 3 %. 
Serum concentrations of CRP begin to rise within 24 hours of the onset of the 
inflammatory stimulus and continue to rise for 3 -4 days. Elevated serum concentrations 
continue until the systemic inflammatory stimulus resolves (Gabay and Kushner, 1999). 
Haptoglobin 
Serum haptoglobin concentrations were determined by sandwich enzyme- linked 
immunosorbent assay (ELISA). Whole blood was collected into lithium -heparinised tubes and 
samples were centrifuged at 1500g for 5 minutes at 4 °C. The serum was stored at -80 °C until 
batch analysis. Samples were diluted to 1 in 15,000 in dilution buffer (see Appendix C for 
reagent recipes) prior to analysis. 96 -well plates (Costar) were coated with 100p1 primary 
antibody (polyclonal rabbit anti -human, Dako, Ely, UK) at a concentration of 10 mg /I, covered 
in aluminium foil, and incubated overnight at 4 °C. The plates were washed with dilution buffer 
3 times using an automated washing device. 100p1 of diluted sera was added to the coated 
wells and incubated at room temperature for 2 hours. Standards were prepared in a similar 
manner. All reactions were performed in duplicate. Plates were washed as before and 100p1 
of peroxidase- conjugated secondary antibody diluted 1 in 5,000 (polyclonal goat anti -rabbit, 
Dako) was added to each well and incubated for 1 hour at room temperature. Plates were 
washed again before 100p1 of chromogenic substrate was added. The substrate used was 
OPD (o- Phenylenediamine dihydrochloride, Dako) in substrate buffer and the reaction was 
stopped after 15 minutes with 100p1 of 0.5M sulphuric acid. Plates were read at 490 nm using 
a Dynatech MR5000 automated plate reader (Billinghurst, UK). Standard curves were 
generated using standards of known concentration supplied by the manufacturer (Dako, UK). 
Taking into account the sample dilutions the lower limit of sensitivity for the assay was 100 
pg /ml. The coefficient of variation was less than 10 %. 
Serum haptoglobin concentrations start to rise with 24 -48 hours of stimulus and 
continue to increase steadiliy for 7 -10 days (Gabay and Kushner, 1999). Elevated 
concentrations may continue for as long as the inflammatory stimulus is maintained. 
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a,- antichymotrysin (ACT) 
Serum concentrations of ACT were determined by sandwich ELISA using the same 
methodology described for haptoglobin measurement. Serum samples were diluted 1 in 
4,000. The primary antibody was a polyclonal rabbit anti -human (Dako, Ely, UK) used at a 
concentration of 10 mg /I. The secondary antibody was diluted 1 in 2,000 and was the same 
as that used for haptoglobin. The lower limit of sensitivity for this assay was 50 pg /ml. The 
coefficient of variation was less than 10 %. 
Albumin 
Serum albumin concentration was measured by the automated bromocresol green dye - 
binding technique in the Clinical Biochemistry Department, Edinburgh Royal Infirmary, UK. 
Normal serum concentrations are 35 -50 g /I. The coefficient of variation was less than 3 %. 
Albumin is a negative acute phase reactant and serum concentrations decline after 
24 hours of an inflammatory stimulus and continue to decline for several days or weeks 
depending on the duration of inflammation (Gabay and Kushner, 1999). 
Transferrin 
Serum transferrin measurement was performed by ELISA in the same manner to that 
described for haptoglobin and ACT. Serum samples were diluted 1 in 17,000. The primary 
antibody was a polyclonal rabbit anti -human (Dako, Ely, UK) used at a concentration of 10 
mg /I. The secondary antibody was diluted 1 in 5,000 and was the same as that used for 
haptoglobin. The lower limit of sensitivity for this assay was 30 pg /ml. The coefficient of 
variation was less than 10 %. Transferrin is also a negative acute phase protein and serum 
concentrations follow the same pattern as albumin (Gabay and Kushner, 1999). 
b) Serum cytokine measurement 
Serum interleukin -16 (IL -16), IL -6, IL -8, IL -10 and soluble tumour necrosis factor receptor 55 
kDa (sTNF -R) were chosen for analysis. IL-113, IL -6 and IL -8 are key pro -inflammatory 
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cytokines and IL -10 is an important anti -inflammatory cytokine (see Chapter II). Serum TNFa 
concentrations are not reliably detected within the circulation, however, TNF receptors are 
shed into the circulation in response to TNFa release, and concentrations of TNF receptors 
are more reliably detected in the circulation (Muc- Wierzgon et al, 2003). Therefore, serum 
TNF receptors provide a more robust indirect measure of TNFa production and consequently 
this study measured TNF receptor (sTNF -R) concentrations instead of TNFa concentrations 
(Spinas et al, 1992). Serum cytokine concentrations were determined by ELISA using module 
kits and were performed according to the manufacturers instructions (Caltag, Bender 
MedSystems, Towcester, UK). 
96 -well plates (Costar) were coated with 100p1 of the primary antibody. The primary 
antibody concentrations were; IL-1p 1 pg /ml, IL -6 2.5 pg /ml, IL -8 5 pg /ml, IL -10 0.5 pg /ml, and 
sTNF -R 3 pg /ml. Plates were covered and stored at 4 °C overnight. The wells were then 
washed 3 times with buffer (0.5ml Tween 20 in 1 litre of phosphate buffered saline) using an 
automated washer. The wells were then blocked with the addition of 250 pl of assay buffer 
(see Appendix C) and kept at room temperature for 2 hours. The plates were washed as 
described previously before the addition of 100 pl of the test sample into each well. Patients' 
serum was diluted 1 in 2 in all cases except for sTNF -R where the samples were diluted 1 in 
10. Standards were prepared by serial dilutions of a lyophilised standard protein provided by 
the manufacturer. All samples were prepared in duplicate. 50 pl of biotin -conjugate (diluted 1 
in 1000 with the assay buffer) was added to each well before incubation at room temperature 
for a further 2 hours on a plate shaker set at 200 rpm. Following another wash, 100 pl of 
streptavidin -HRP (diluted 1 in 10,000 with the assay buffer) was added to each well for 1 hour 
on a microplate shaker (200 rpm) at room temperature. The plates were washed again and 
100 pl of substrate solution (1 in 2 mixture of H2O2 and tetramethylbenzidine) was added to 
each well. The plates were incubated in the dark at room temperature for a further 15 minutes 
before the reaction was stopped by the addition of 100 pl of 4N sulphuric acid. Plates were 
then read at 450 nm using an automated plate reader (Dynatech MR5000, Billinghurst, UK). 
The lower limit of sensitivity for each assay was; IL-113 <1 pg /ml, IL -6 1.4 pg /ml, IL -8 11 pg /ml, 
IL -10 0.8 pg /ml, and sTNF -R 5.8 pg /ml. The coefficient of variation for each assay was: L-1 I3 
5.1 %, IL -6 5.2 %, IL -8 8.7 %, IL -10 5.6 %, and sTNF -R 8.6 %. 
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c) Clinical chemistry 
Routine serum clinical chemistry (CRP, albumin, alkaline phosphatase, and calcium) was 
kindly performed by the Clinical Biochemistry Department, Edinburgh Royal Infirmary. Serum 
total calcium was measured by an automated analyser. Calcium levels were adjusted for 
serum albumin concentration using the following formula (Truong et al, 2003): 
40 - albumin concentration 
4 
x 0.1 + measured serum calcium concentration 
The normal range for corrected calcium is 2.12 - 2.62 mmol /I. The normal range for alkaline 
phosphatase is 40 -125 units /I and normal ranges for serum urate concentrations are 0.12- 
0.42 mmol /I for males and 0.12 -0.36 mmol /l for females. The coefficient of variation of all 
automated assays was 3% or less. 
d) Serum Parathyroid hormone -related peptide (PTHrP) 
measurement 
Parathyroid hormone -related peptide (PTHrP) is a tumour -derived product that is postulated 
to play a role in the generation of systemic inflammation and cachexia in patients with cancer 
(Ogata, 2000; Takahashi et al, 2003). To investigate this potential role in patients with gastro- 
oesophageal cancer serum concentrations of PTHrP were measured in the study population. 
This topic is explored in Chapter VIII. 
Whole blood was collected into lithium -heparinised tubes and samples were 
centrifuged at 1500g for 5 minutes at 4 °C. The serum was stored at -80 °C until batch 
analysis when all samples were analysed at the same time. PTHrP has a very short half -life 
and is unstable unless stored in plasma with esterase inhibition. However, its breakdown 
products include a c- terminal region, which is stable when stored in serum and demonstrates 
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direct correlation to circulating intact serum PTHrP concentrations (Suehiro et al, 1994). This 
is a direct breakdown product of PTHrP and, therefore, its presence indicates PTHrP in 
plasma. In this thesis the c- terminal fragment (cPTHrP) was measured by radio -immunoassay 
(Daiichi, Tokyo, Japan). 
The assay was performed according to the manufacturers instructions and followed 
national safety guidelines on the use and handling of radioactive substances. 200p1 of each 
standard (0 pmol /l, 10 pmol /1, 30 pmol /1, 100 pmol /l, 300 pmol /1, and 1000 pmol /I) was pipetted 
into a clean test tube. Similarly, 200pl of a positive control provided in the kit was also 
prepared in addition to 200pl of dH2O as an additional negative control. Patient serum 
samples were thawed and diluted by a factor of ten by adding 180pl of dilution reagent to 20p1 
of serum. 100p1 of iodinated (1125) cPTHrP was then added to 200p1 of each of the test 
samples and to each standard. In addition, 100p1 of 1125 cPTHrP was added to an empty test 
tube, which was used to provide the total count measurement. All standards and test samples 
were prepared in duplicate. 100p1 of cPTHrP antibody (sheep antiserum) was added to each 
tube, shaken well, and then stored at room temperature for 24 hours. The following day 500p1 
of B/F reagent (sheep IgG donkey antiserum) was added to each tube, mixed well and 
incubated at room temperature for a further 1 hour. Tubes were then centrifuged at 2000g at 
4 °C for 30 minutes and the supernatants were removed by careful aspiration. Counting rates 
were measured by a gamma -ray counter and a standard curve was generated using the 
counts obtained from the standards. cPTHrP concentrations for each patient sample were 
then read from the standard curve and multiplied by the dilutional factor of 10. Samples were 
re- analysed if there were any count discrepancies and results were obtained for all patient 
samples. 
This assay has no demonstrable cross -reactivity with parathyroid hormone (PTH). 
The sensitivity of this test is 10 pmol /l and the intra -assay variability is 4.1% and the inter - 
assay variability is 3.3% (Daiichi, Tokyo, Japan). Using this assay, serum cPTHrP levels in 
healthy volunteers were ( ±2 SD from the mean) 13.8 - 55.3 pmol /l for males and 13.9 - 54.0 
pmol /l for females (Fukunaga, 1992). No female patients had a cPTHrP serum concentration 
between 54.0 - 55.3 pmol /1, and therefore for simplicity serum levels above 55.3 pmol /l were 
considered above the normal range for both sexes. 
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6. CYTOKINE GENE POLYMORPHISM GENOTYPING 
As part of the investigation into the aetiology of systemic inflammation in cancer, the influence 
of host cytokine genotype was examined. Comparisons between host genotype, tissue 
cytokine concentrations and systemic markers of inflammation are investigated in Chapter VI. 
a) Isolation of genomic DNA from whole blood 
Blood was collected from every patient for genotyping. Genomic DNA was extracted from 
samples of lithium -heparinised blood using the Wizard® Genomic DNA purification kit 
(Promega, Southampton, UK). Whole blood was centrifuged at 1,500g for 5 minutes at 4 °C. 
300 pl of the cellular layer was added to 900 pl of cell lysis solution in a 1.5 ml microcentifuge 
tube and mixed thoroughly by inverting the tubes several times. The mixture was incubated 
for 10 minutes at room temperature followed by centrifugation at 15,000g for 20 seconds also 
at room temperature. The supernatant was discarded and the process of adding cell lysis 
solution, incubation and centrifugation was repeated once more. 300 pl of nuclei lysis solution 
was added to the pellet and the tube was vortexed to resuspend the white cells. The solution 
was pipetted gently several times to lyse the white cells. 1.5 pl of RNase solution (Promega) 
was added to each tube, mixed and incubated at 37 °C for 15 minutes. After allowing the 
tubes to cool to room temperature, 100 pl of protein precipitation solution was added and 
mixed by vortex for 15 seconds. Samples were then centrifuged at 15,000g for 3 minutes at 
room temperature. The supernatants were then transferred to a clean 1.5 ml microcentrifuge 
tube and mixed with 300 pl of pure isopropanol. Gentle mixing reveals the appearance of the 
DNA as white thread -like strands. Further centrifugation at 15,000g for 1 minute at room 
temperature allows the DNA to be collected as a pellet at the bottom of the tube. The 
supernatant is then decanted and 300 pl of ethanol 70% is added to wash the pellet. The 
samples were then centrifuged again for a further minute at 15,000g and the ethanol was 
carefully aspirated away. 100 pl of DNA rehydration solution (10mM Tris -HCI and 1mM 
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EDTA) was added to each tube and samples were incubated at 65 °C for 1 hour. DNA 
samples were then stored at 4 °C. 
The quality and quantity of the isolated DNA was assessed by optical density (OD) 
readings of the samples taken at 260 nm and 280 nm using a spectrophotometer (Ultrospec 
2000, Pharmacia Biotech, Bucks, UK) employing Beer -Lambert's law. Typical yields were 
between 20 -80 pg (in 100 pl total volume) with OD260/0D280 ratios between 1.5 -2.0. In 
addition, the quality of the DNA was confirmed by conventional polymerise chain reaction 
(PCR) prior to shipment to Southampton for genotyping. 2 µl of DNA was mixed with 1 pl 
MgCl2 (25mM), 2.5 µl 10x Taq DNA polymerase buffer with added MgCl2, 2.5 µl dNTP 
(10mM), 5 pl forward and reverse primers (10 µM), 11 µl DEPC treated water and 1µl Taq 
DNA polymerase (5u /µ1) (all reagents Promega, Southampton, UK). Primers for Cytochrome 
b were used to confirm adequate quality DNA. The forward primer sequence was 
GGTTCTGGAATAAGAATATAGG and the reverse primer sequence 
GACAACACAGTAAGAACCAGG, giving a product of 367 bp if adequate DNA was present. 
b) Cytokine genotyping 
Single nucleotide polymorphism (SNP) genotyping was performed by TaqMan® allelic 
discrimination genotyping in collaboration with Professor Robert Grimble, Dr Martin Howell, 
and Dr Matthew Rose -Zerilli (Histocompatibility and Immunogenetics Laboratory and Institute 
of Human Nutrition, School of Medicine, University of Southampton, UK). The following single 
nucleotide polymorphisms were selected for genotyping due to their documented but variable 
association with cytokine production: IL -1(3 -511, IL -6 -174, IL -10 -1082, TNFa -308, and LTa 
+252. Genotyping was carried out on the 7900HT Sequence Detection System (Applied 
Biosystems, Warrington, UK). Primers and TaqMan probes were designed using Primer 
Express version 2.0 software (sequences and cycler conditions shown in Table 3.6.1) and 
synthesised and supplied by Applied Biosystems, UK. 10 pl PCR reactions containing 20 ng 
of DNA, 0.9 pM and 0.2 pM probes (final concentrations) were performed in 384 well plates. 
Each genotyping plate contained no DNA Template (water) controls; SDS version 2.1 
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software was used to analyse real -time and end -point fluorescence. Around 50 samples 
( -25% of the sample group) were randomly selected and included as replicates for each 
genotype tested. All replicates agreed. Only between 3 -8 samples failed to genotype for each 
SNP (96.1 -98.5% completion rate). 
Table 3.6.1 Cytokine TaqMan genotyping primer and probe sequences. (A) 
TaqMan MGB Probe Assays (Ta = 60 °C), (B) TaqMan TAMRA probe Assays (Ta = 62 °C). For 




Forward Primer: 5'- CCAAAAGAAATGGAGGCAATAGGTT -3' 
Reverse Primer: 5'- GGACCCTGGAGGCTGAAC -3' 
G allele Specific Probe: 5'- CCCGTCCcCATGCC -3 (VIC- labelled) 
A allele Specific Probe: 5'- CCCGTCCtCATGCC -3' (FAM- labelled) 
LTa+252 
Forward Primer: 5 '- CAGTCTCATTGTCTCTGTCACACATT -3' 
Reverse Primer: 5'- ACAGAGAGAGACAGGAAGGGAACA -3' 
G allele Specific Probe: 5'- CCATGgTTCCTCTC -3' (FAM) 
A allele Specific Probe: 5'- CTGCCATGaTTCC -3' (VIC) 
IL-6-174 
Forward Primer: 5'- GCTGCACTTTTCCCCCTAGTT -3' 
Reverse Primer: 5'- GCTGATTGGAAACCTTATTAAGATTGT -3' 
G allele Specific Probe: 5'- CTTTAGCATcGCAAGAC -3' (VIC) 
C allele Specific Probe: 5- CTTTAGCATgGCAAGAC -3' (FAM) 
IL-16-511 
Forward Primer: 5'- GGTCTCTACCTTGGGTGGTGTT -3' 
Reverse Primer: 5'- TCCTCAGAGGCTCCTGCAAT -3' 
C allele Specific Probe: 5'- TGCCTCgGGAGCT -3' (VIC) 







G Allele Specific Probe: 
A Allele Specific Probe: 
5' -ACA CAC AAA TCC AAG ACA ACA CTA CTA A -3' 
5' -GGA GGT CCC TTA CTT TCC TCT TAC C -3' 
5' -ATC CCT ACT TCC CCc TCC CAA AGA A -3' (VIC) 
5' -CCC TAC TTC CCC tTC CCA AAG AAG C -3' (FAM) 
7. DETECTION OF URINARY PROTEOLYSIS- INDUCING FACTOR (PIF) 
Proteolysis- inducing protein (PIF) is a tumour -derived product that has been proposed as a 
candidate cachectic factor (Todorov et al, 1996). In vitro studies have also suggested a role 
for PIF in the stimulation of pro -inflammatory cytokine production and the generation of an 
acute phase response (Watchorn et al, 2001). This thesis will therefore investigate the 
expression of PIF in patients with gastro -oesophageal cancer and relate levels of expression 
to markers of systemic inflammation, nutritional status and outcome. This topic is investigated 
in Chapter VIII. 
a) Isolation of urinary protein 
At the time of study recruitment and at each subsequent follow -up visit patients were 
requested to provide a specimen of urine. Initially, patients were asked to provide 24 -hour 
urinary samples to avoid possible problems that may relate to any unknown diurnal variation 
that may occur in PIF production. However, patients were reluctant to provide 24 -hour 
samples and owing to the often -large distances to travel to the hospital from the large 
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geographical catchment area, retrieval of samples was also difficult. Therefore, 4 -5 months 
into the study patients were asked to provide a single urinary sample at the time of clinic visit. 
Samples were collected into clean containers without preservative and specimens were 
stored at -20 °C until processing. 
As a consequence of the difficulties we had in reliably detecting urinary PIF (see 
following section), several alternative methods to isolate urinary protein were tried. 
(i) Ammonium sulphate precipitation 
This was the first method that was tried and followed exactly the method described in the 
original publications on the identification of PIF (Todorov et al, 1996; Wigmore et al, 2000). In 
addition, we followed a detailed protocol kindly provided by Professor M Tisdale (Aston 
University, Birmingham). 
After thawing, 20 ml of urine was centrifuged at 16,000g for 30 minutes at 4 °C to 
remove cellular debris. The supernatant was then transferred into a 100m1 glass beaker 
containing a magnetic follower and placed on a magnetic stirrer in a cold room at 4 °C. Over a 
period of about 6 hours aliquots of ammonium sulphate (16g; 80% w /v) was added and the 
beaker was covered with aluminium foil and left with continuous stirring overnight. The next 
morning, the sample was centrifuged at 3,000g for 30 minutes at 4 °C before transferring the 
precipitate into a 100m1 Amicon® filtration cell (Amicon, Stonehouse, UK) for washing. The 
Amicon® unit was attached to nitrogen for pressure filtration at 60 psi and each sample was 
washed four times with distilled water. A membrane filter with a molecular weight cut -off of 
10,000 was used in each case. The protein was collected from the membrane using a pipette 
and the samples were then concentrated to around 200 pl using another Amicon® unit. 
(ii) Ammonium sulphate method modification 
Samples were prepared as described above for the addition of ammonium sulphate (80% 
w /v). After continuous stirring overnight at 4 °C, samples were centrifuged using a centrifugal 
filtration device (Centriplus ®spin columns, Millipore, Watford, UK) instead of Amicon® filtration 
units to wash and concentrate the samples. The columns were chosen withl0 kDa MW cut -off 
filtration membranes. This method of protein isolation has been the preferred technique in 
95 
recent PIF studies owing to the increased ease of use compared with the Amicon® filtration 
units (Williams et al, 2004). 
The 20m1 urine sample was divided between two filtration devices, which were 
centrifuged at 3,000g for 60 minutes at 4 °C. The filtrate was removed and this cycle was 
repeated once more. This process usually yielded approximately 500 pl of retentate. Care 
was taken not to spin the tubes to dryness. 
(iii) Acetone precipitation 
This method was tried as an alternative to the ammonium sulphate precipitation method and 
has been used previously with success for the isolation of urinary proteins (Thongkoonkerd et 
al, 2002). 
Urine was spun as before to remove cellular debris. 10m1 of urine was mixed with 20 
ml of cold acetone containing 20mM dithioreitol (DTT). Samples were stored at -20 °C 
overnight then spun at 13,000g for 15 minutes. The pellet was re- suspended in sodium 
dodecylsulphate (SDS) buffer. This technique was also used without the initial spin at 16,000g 
to try and preserve as as possible. 
Determination of protein concentration 
Urinary protein concentrations were determined by the Lowry method (DC Protein assay, Bio- 
Rad, Hemel Hempstead, UK) (Lowry et al, 1951). Samples were diluted 1 in 10 and 5 pl of 
each sample was added into the wells of a 96 -well microtiter plate (Costar). Standards were 
prepared similarly following 1 in 2 serial dilutions of a known concentration of bovine serum 
albumin (Bio -Rad, Hemel Hempstead, UK). All test samples were performed in duplicate. 20 
pl of Reagent S (SDS) was mixed with 1 ml of Reagent A (sodium hydroxide) and 25 pl of this 
mixture was added to the samples in each well. 200 pl of Reagent B (Folin reagent) was then 
added to each well. The microtiter plate was placed on a gentle shaking device for 15 minutes 
before absorbance was read at 750 nm (Dynatech MR5000, Billinghurst, UK). 
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b) Western blotting 
Identification of urinary PIF was initially attempted by Western blot. Once again, owing to the 
difficulty in achieving reliable and consistent results several modifications of the method were 
tried. An outline of the general methodology that was used is described below: 
Identification of urinary PIF was attempted by sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS- PAGE). Gel electrophoresis was performed using materials and 
equipment obtained from Bio -Rad Laboratories (Hemel Hempstead, UK). 4% stacking gels 
and 12.5% resolving gels were used in each run (see Appendix D for gel recipes). Urinary 
proteins were isolated by ammonium sulphate precipitation, or by one of the other methods 
described above. The proteins were denatured prior to blotting by heating to 95 °C for 5 
minutes. 5 pg of protein was loaded onto each blot with loading dye and molecular weight 
markers. Electrophoresis was performed at 200v for approximately 40 minutes before the 
proteins were transferred onto nitrocellulose membranes (Hoefer Scientific Instruments, San 
Francisco, USA). Effective transfer was confirmed by staining the membranes with Ponceau 
S solution (0.1 % (w /v) in 5% acetic acid (v /v); Sigma -Aldrich, Gillingham, UK) and the lanes 
and molecular weight markers were marked. Membranes were rinsed with Tris- buffered 
saline (TBS; 0.15M NaCI, 10mM TrisCI, pH 8.0) then blocked for non -specific binding with 5% 
non -fat milk powder (Marvel ®, Premier Beverages, Adbaston, UK; 1g dissolved in 20mí TBS). 
After 1 hour the Marvel® was rinsed off and the membranes were incubated at room 
temperature for a further hour with the primary antibody dissolved in TBS with 0.5% Tween 20 
(Sigma, UK) at a concentration of 10pg /ml. The main antibody used was a mouse monoclonal 
antibody from the same stock of antibody used in the original studies leading to the 
identification of PIF and was a kind gift from Professor M Tisdale (Todorov et al, 1996; 
Wigmore et al, 2000). This antibody had been purified with a protein A sepharose column 
(Sigma, UK) and biotinylated using the ECL protein biotinylation module (Amersham, Little 
Chalfont, UK) prior to use. The primary antibody was rinsed off with 3 washes of TBS -Tween 
and the membranes were then incubated for 1 hour with the secondary antibody (rabbit anti - 
mouse streptavidin- horseradish peroxidase conjugate; Amersham, UK) at a 1 in 1,500 
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dilution. The membranes were washed 3 more times with TBS -Tween before they were 
transferred to the dark room. Bands were detected with an emission chemiluminescence 
system (Amersham, UK). 
Some of the urine samples were also analysed for PIF in Professor M Tisdale's laboratory at 
Aston University, Birmingham. Samples from 51 patients with a range of weight loss were 
investigated for PIF expression by the method described above. Blots were interpreted by an 
investigator who was blinded to the weight loss data and to our own results from the same 
group of patients. 
The Western blot protocol was optimised with the following modifications: isolating urinary 
protein by the ammonium sulphate precipitation method, loading 7 -10 pg of protein onto the 
gels, blocking with 5% Marvel® for 1 hour, using the primary monoclonal antibody at a 
concentration of 10 pg /ml with 1% Marvel® and incubating with the membranes for 1 hour, 
exposing the membrane to the photographic film for 60 seconds. These modifications resulted 
in bands appearing around 28 kDa, which differs to the previously published size of PIF (24 
kDa or 66 kDa - see Chapter IX) (Figure 3.7.1). Therefore, we attempted to identify the 28 
kDa product by mass spectroscopy. 
Figure 3.7.1 Western blot of urinary protein from a patient with oesophageal cancer using 




Identification of the protein band by mass spectrometry 
Protein samples were loaded onto gels (as described above) and, following electrophoresis, 
were washed three times with ultrapure water for 15 minutes each before staining with 20 ml 
colloidal based Coumassie blue (GelCode; Pierce) for 1 hour. Gels were washed again three 
times with ultrapure water as before. The band at 28 kDa was cut out the gel and stored in an 
Eppendorf tube at -20 °C until analysis. 
Subsequent analysis was performed by Dr A Cronshaw (Institute of Structural and 
Molecular Biology, University of Edinburgh). The proteins were subjected to trypsin digestion 
prior to sequencing the protein product by matrix -assisted laser desorption /ionisation, time -of- 
flight mass spectroscopy (MALDI -TOF). 
The results of the sequencing failed to confirm the presence of PIF and identified the 28 kDa 
band as CD59. CD59 (also known as Protectin) is widely expressed molecule found on cells 
on all tissues and is essential in protecting cells through inhibition of membrane attack 
complex (MAC) formation and complement mediated cell lysis (Davies and Lachmann, 1993). 
In addition, our results for the PIF Westerns (appearance of the 28 kDa band) differed from 
those obtained for the same group of patients when performed at Aston University (see 
Chapter VIII). This suggested that our Western blot was not identifying PIF. Blots were 
repeated with fresh monoclonal antibody received from Aston and Professor V Baracos' 
Laboratory in Alberta, Canada, to exclude any problems with our own antibody, but the results 
were similar. Other antibodies were therefore tried, including the development of a new PIF 
antibody. 
A commercially available polyclonal antibody was initially tried (Alpha Diagnostic, San 
Antonio, USA). This was a rabbit polyclonal antibody raised against the core peptide 
sequence for PIF and called the 'cachectic factor antibody'. Western blotting was performed 
according to the manufacturers instructions. Urinary protein was isolated and gels were 
prepared as previously described. The primary antibody was used at a range of 
concentrations (1:100 to 1:2000). Goat anti -rabbit 2° antibody labelled with horseradish - 
peroxidase (HRP) was used with ECL detection. No bands were detected with this antibody. 
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Two other polyclonal antibodies were tested (CACI and CAC2). These antibodies were 
developed by Astra- Zeneca as part of their studies into PIF and were gifted to our Department 
by Dr I Waddell. The antibodies were raised against predicted antigenic sites within the 
peptide core. Blots were performed as described for the 'cachectic factor antibody' using a 
secondary antibody labelled with HRP. Once again no bands were detected. 
Finally, our own anti -PIF polyclonal antibody was designed against the peptide 
sequence HEASAAQKENAGEDPC, which lies within the PIF core peptide. The antigenic 
peptide and the antibody, named CAC3, were developed from immunised rabbits by Sigma - 
Aldrich, Gillingham, UK. Western blots were performed according to the methods already 
described for the other polyclonal antibodies. This antibody generated a band at 11 kDa 
(Figure 3.7.2). This band was also subjected to identification by MALDI -TOF as previously 
described and was identified as casein, presumably from the Marvel milk protein used in the 
blocking process. 
Figure 3.7.2 Western blot of urinary protein from a patient with gastric cancer using the 








In addition to analysing urinary protein, blots were also run using recombinant PIF and in vitro 
synthesised PIF. These samples were hoped to be useful as positive controls and to confirm 
the effectiveness of the PIF antibody. 
Recombinant PIF (rPIF) is a 6- His -tagged recombinant peptide from bacteria that was 
developed by Astra- Zeneca. This peptide is not glycosylated and runs as two bands of 17 
kDa and 12 kDa on SDS gels. 
In vitro translated PIF was kindly gifted by Prof SJ Wigmore. The system involved 
cloning the cDNA sequence into pcDNA 3.1 (Invitrogen) and transcription and translation 
were performed using a T7 promoter system (Promega). Peptides underwent post -translation 
processing following the addition of canine pancreatic microsomal membranes ( Promega). 
This process should produce the fully glycosylated PIF molecule. 
In this study none of the PIF antibodies generated bands when blotted with either 6- 
his -rPIF or in vitro translated PIF. 
c) Mass spectroscopy (MALDI -TOF) 
Mass spectroscopy was used as an alternative method to Western blotting for the 
identification of urinary PIF. The principle of matrix -assisted laser desorption /ionisation, time - 
of- flight mass spectroscopy (MALDI -TOF) involves converting a sample of unknown proteins 
into gaseous ions, which are accelerated by high voltage under a vacuum through a magnetic 
field (Guilhaus, 1995). A detector separates the ions according to mass, charge, signal 
intensity, and time of flight (time to travel through the machine). This generates a spectrum of 
characteristic peaks that represent the 'fingerprint' of the molecule. Specialised software 
matches the appearances of the peaks to known molecules and allows identification of the 
unknown molecule. 
Isolation of urinary protein was performed by either ammonium sulphate precipitation 
or acetone precipitation as already described. Mass spectroscopy was performed by Dr A 
Cronshaw (Proteomics Facility Manager, Institute of Structural and Molecular Biology, 
Edinburgh University). Initially, concentrated urine samples were run directly on MALDI -TOF 
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(Voyager DE -STR, Applied Biosystems). We were able to repeat the work of Choudhary et al 
but found that the 24 kDa glycoprotein factor they reported was in fact Ig kappa light chain 
(Figure 3.7.3) (Choudhary et al, 1999). A novel list of the proteins identified in urine from 
patients with gastro -oesophageal cancer and weight loss are listed in Appendix E. 
Figure 3.7.3 MALDI -TOF mass spectra generated from two different patients with 
oesophageal cancer. Protein was isolated from urine by ammonium sulphate precipitation and 
the samples were loaded into a mass spectrometer (Voyager DE -STR, Applied Biosystems) 
without tryptic digestion or deglycosylation. Patient (A) represents a normal urinary protein 
trace. Patient (B) has a large peak at 23.3 kDa, which has been previously attributed to PIF. 
Subsequent analysis has identified this peak to represent Ig kappa light chain. 
(A) 
(B) 
Voyager Spec 81= >BC= 7N11(2.00gBP - 6180.7, 287061 
66,1 
VVyaOer Spec 81s>BC67N11(2.000P> 6176 6,116341 
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Therefore, owing to the complex mix of biological compounds within the urine samples it was 
necessary to run the protein samples on 1- dimensional and 2- dimensional SDS -PAGE gels 
(15 %) before performing the mass spectrometry. The 2D gels allowed greater resolution of 
the 24 kDa peak in particular. The gel lanes were then pixelated and digested with trypsin 
(Promega). Peptides from the digested bands were then run on a liquid chromatograph mass 
spectrometer (LC -MS) and MALDI -MS instruments (Figure 3.7.4). The LC -MS consisted of a 
Famos autosampler, Switchos column switching unit and an Ultimate nanoLC (Dionex). The 
digests were loaded onto a PepMAP C18 column (3 pm particle size, 75um x 15cm) at a flow 
rate of 200 pl /min. The output was monitored at 214nm. The column was equilibrated with 
solvent A (0.1% formic acid) and eluted with a linear gradient from 0 to 70% solvent B (0.1% 
formic acid in 100% acetonitrile) over 45min. The flow was controlled by Chromelion software 
and interfaced to the MS with a PicoTip (New Objective). The LCQdeca mass spectrometer 
(ThermoFinnigan) was fitted with a nanoLC ESI source. Data dependent acquisition was 
controlled by Xcalibur software and database searching was achieved using TurboSequest. 
Aliquots of 0.5 pl digests were mixed with 0.5 pl CHCA matrix on a MALDI sample 
plate. The samples were then analysed on a Voyager DE -STR MALDI-MS (Applied 
Biosystems) and the processed spectra searched against the NCBI non -redundant database 
using Protein Prospector. 
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Figure 3.7.4 Mass spectra of urinary protein from a patient with weight loss and 
oesophageal cancer. Protein was isolated from urine by ammonium sulphate precipitation. 
The proteins were run on 2D gels and the spots at 24 kDa were selected for tryptic digestion. 
These proteins were then run on the MALDI -TOF analyser. PIF was not identified. 
00,15] 71 
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Given the high degree of glycosylation of the PIF molecule, protein samples were also de- 
glycosylated prior to analysis by mass spectrometry. N- linked de- glycosylation was performed 
using peptide N- glycosidase -F (PNGaseF) provided in kit form (GlycoProfile, Sigma). A 1D 
gel was run and the products were stained with Coomassie blue and the 24 kDa band was cut 
from the gel. 200 pl of destaining solution was added to the band in an Eppendorf tube and 
incubated for 30 minutes at 37 °C. This was repeated twice and the gel was dried. 5 units of 
PNGaseF was added to the gel and incubated for 30 minutes at 37 °C. 20 pl of ultrapure water 
was added to the tube and incubation was continued overnight. The tube was centrifuged 
briefly and the enzyme was aspirated out. 200 pl of water was added and the mix was 
incubated at room temperature for 30 minutes before briefly centrifuging and removing the 
supernatant. This was repeated three more times. The sample was then trypsinised as 
before. 
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In addition to performing mass spectrometry on patients' urine samples, we also analysed the 
recombinant PIF (rPIF) and in vitro synthesised PIF samples. In particular the rPIF sample 
was analysed with and without peptidase digestion (Figure 3.7.5). This was necessary to 
demonstrate that the methodology was indeed able to identify the PIF core peptide when 
present. MALDI -TOF was able to detect normal urine samples 'spiked' with rPIF. However, in 
vitro synthesised PIF was not identified. 
Figure 3.7.5 Mass spectra generated from running the recombinant PIF (rPIF) in the 
MALDI -TOF analyzer: (A) without tryptic digestion and (B) following tryptic digestion. These 
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Detection of urinary PIF was initially attempted by Western blot by following the published 
methodology and using the same monoclonal antibody. Using these methods bands at 28 
kDa were detected, which when sequenced were identified as CD59. Several polyclonal 
antibodies were also tried and one of these resulted in the generation of bands at 11 kDa, 
which were subsequently identified as casein. In addition, Western blot results from 
Edinburgh, Birmingham and Canada differed for the same group of patients. Mass 
spectroscopy was then tried as a more robust method of detecting urinary PIF. Spectral 
peaks at 24 kDa were found to be Ig kappa light chain. Separation of urinary proteins by 2D 
electrophoresis followed by tryptic digestion with and without deglycosylation has also so far 
failed to identify PIF in patients' urine. However, the PIF synthetic peptide core has been 
successfully detected in normal urine that has been spiked with the peptide. 
8. TISSUE STUDIES 
To investigate the contribution of the tumour tissue towards the generation of systemic 
inflammation, cytokine mRNA and protein concentrations were measured within tissue 
homogenates. PIF mRNA concentrations were also measured in the tissues. Samples of 
tumour tissue and benign tissue were collected from patients with gastro -oesophageal cancer 
for analysis. In addition, the degree of inflammatory cell infiltrate into the tissues was 
determined by histological studies. This topic is explored in detail in Chapter V. The methods 
relating to the measurement of these mediators is described in the following Section. 
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a) Isolation of RNA 
Tissue collection 
Tissue was obtained from patients at the time of surgical resection or endoscopic biopsy. A 
representative sample of tumour tissue and adjacent benign mucosa was collected from each 
patient and tissues were snap frozen in liquid nitrogen prior to storage at -80 °C until further 
analysis. The average time from tissue collection to freezing for patients who underwent 
surgical resection was 15 minutes (range 10 -25 minutes). Tissue collected at the time of 
endoscopy was immediately snap frozen. An additional 12 patients were recruited as healthy 
controls. These patients underwent endoscopy as an elective investigation and in all 
instances the result of the procedure was normal, including both macroscopic and 
microscopic assessment. 
Total RNA isolation protocol 
Laser capture microdissection was not successful at isolating RNA of sufficient quality to 
perform reliable quantitative PCR. Therefore, whole tissue samples were homogenized and 
total RNA was isolated from samples using the RNeasy kit (Qiagen, Crawley, UK). 
Approximately 30 -50 mg of frozen tissue was placed into 600 pl of buffer RLT 
(containing guanidine thiocyanate and ß- mercaptoethanol) in a glass test tube. Tissues were 
disrupted using a hand -held electric homogeniser using pulses of 10 -15 seconds. Care was 
taken to avoid tissue thawing prior to homogenisation. Once the tissue was completely 
disrupted, tubes were centrifuged at 15,000 rpm for 3 minutes at room temperature. The 
supernatant was transferred to a fresh microcentrifuge tube and 600 pl of 70% ethanol was 
mixed by pipetting. The sample was then loaded into an RNeasy mini -column and centrifuged 
at 8,000g for 15 seconds and the flow- through was discarded. The mini -columns were 
washed with 350 pl of buffer RW1 (ethanol) and tubes were spun once again at 8,000g for 15 
seconds. 80 pl of DNase I (Qiagen) was loaded into each mini -column and the tubes were 
incubated at 25 °C for 20 minutes. The columns were then washed with buffer RW1 as 
already described before transferring the columns into fresh collection tubes. 500 pl of buffer 
RPE was then added to each column and the tubes were centrifuged at 8,000g for 2 minutes. 
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The columns were then placed into fresh microcentrifuge tubes once again and the RNA was 
eluted with the addition of 30 pl of RNase -free water into the columns and spinning at 8,000g 
for 1 minute. The elution process was repeated once more. 
RNA concentration was measured by optical density (OD) readings taken at 260 nm 
and 280 nm using a spectrophotometer (Ultrospec 2000, Pharmacia Biotech, Bucks, UK). 
Typical yields were around 10 -15 pg of RNA from 50 mg of frozen tissue. 
Reverse Transcription 
Reverse transcription was performed using 1 pg of total RNA. All RNA samples were checked 
for genomic DNA contamination prior to reverse transcription using conventional polymerase 
chain reaction. 2 µ1 of total RNA was mixed with 1µl MgC12 (25mM), 2.5 pl 10x Taq DNA 
polymerase buffer with added MgCl2, 2.5 pl dNTP (10mM), 5 pl forward and reverse primers 
(10 IA), 11 µ1 DEPC treated water and 1 pl Taq DNA polymerase (5u /µ1) (all reagents 
Promega, Southampton, UK). Primers for Cytochrome b were used to detect DNA 
contamination. The forward primer sequence was GGTTCTGGAATAAGAATATAGG and the 
reverse primer sequence GACAACACAGTAAGAACCAGG, giving a product of 367 bp if 
contamination was present (Figure 3.8.1). Cycling conditions were: 94 °C for 5 minutes; 40 
cycles of 94 °C for 20 seconds, 55 °C for 20 seconds, 72 °C for 30 seconds; then 72 °C for 10 
minutes. Contaminated samples were re- treated with DNase I (as described above). 
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Figure 3.8.1 Non- RT -PCR using RNA isolated from gastro -oesophageal tumour tissues to 
exclude genomic DNA contamination. Gels consisted of 1% agarose stained with ethidium 
bromide and run at 70V for approximately 35 minutes. Cytochrome b was used for the 
reaction giving a 367 bp if DNA was present. Genomic DNA isolated from blood was used as 
the positive control. 
Reverse transcription was performed once DNA contamination had been excluded. The 
reaction mixture included the RNA (1 µg in 10 pl DEPC treated water), 4 pl MgCIZ (25 mM), 2 
gl 10 x reverse transcriptase buffer, 2 gl dNTP's (10 mM), 1 pl random hexamers (500 gg /ml), 
1.5 gl AMV reverse transcriptase (10 u /µ1), and 0.5 pl recombinant RNase inhibitor (40 u /µl) 
(all reagents Promega, Southampton, UK). Reverse transcription was performed at 42 °C for 
60 minutes followed by 95 °C for 5 minutes. 
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b) Quantitative (real -time) polymerise chain reaction 
Quantitative polymerise chain reaction (PCR) was performed using the ABI PRISM 7700 real - 
time Sequence Detection System (Applied Biosystems, Warrington, UK). This system 
contains a 96 -well thermal cycler and is able to detect fluorescence emitted during the PCR 
reaction in 'real- time'. Each reaction mixture contains a forward and reverse primer and a 
fluorogenically labelled probe. The probe is an oligonucleotide with a reporter fluorescent dye 
(FAM) attached to the 5' end and a quencher dye (TAMRA) attached to the 3' end (Figure 
3.8.2). The probe is cleaved by the DNA polymerase during the reaction separating the 
quencher from the reporter dye allowing increased fluorescence. This fluorescence is 
measured in 'real -time' during the PCR reaction and an amplification plot is generated (Figure 
3.8.3). Quantification of gene expression is then determined from this graph. 
This system was used to quantify gene expression in tissues collected from patients 
with gastro -oesophageal cancer and to compare levels of gene expression with tissue 
collected from healthy controls. The following genes were chosen for study; cytokines (IL-1p, 
IL -6, IL -8, TNFa), acute phase protein (CRP), and proteolysis- inducing factor (PIF). 
Primer design 
Primers and probes were designed using Primer Expresse software (version 2, Applied 
Biosystems). A forward primer, reverse primer and a fluorogenic- labelled probe were required 
for each gene to be studied. For optimum performance of the real -time PCR machine certain 
guidelines for the design of the primers and probes had to be followed. The primers were 
designed to be around 20 nucleotides in length with the aim of generating an amplicon 
product of 50 -150 nucleotides. The melting temperature (Tm) of each was between 58 -60 °C 
and there were fewer than two G or C residues within last 5 nucleotides at the 3' end (to 
minimise non -specific extension). The primers were chosen to lie as close to the probe as 
possible, but without overlapping. 
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Figure 3.8.2 Generation of fluorescence during real -time PCR. 1) The primers and probe 
anneal to the template cDNA. 2) The primer strand disrupts the probe allowing 3) cleavage by 
DNA polymerase. 4) The quencher is separated from the reporter dye allowing increased 
fluorescence, which is detected by the PCR machine during the reaction. An amplification plot 
is generated allowing the level of gene expression to be quantified. (Reproduced from the 
Applied Biosystems website.) 
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The probe was also designed to be 20 nucleotides in length with a Tm 10 °C higher than the 
primers (68- 70 °C). It was also a condition that the 5' end was not a G residue as this 
nucleotide may continue to quench the fluorescence despite cleavage. 
Primer and probe sequences for PIF and IL -6 were designed as described above and 
manufactured by Applied Biosystems (Table 3.8.1). BLAST searching the human genome 
with the primer /probe sequences confirmed good specificity for the gene of interest. The 
primers /probes for CRP and ZAG were designed and manufactured by Applied Biosystems 
and the sequences were not disclosed by the Company. The other cytokines were available 
as a commercially produced reaction plate (TaqMan cytokine gene expression plate 1, 
Applied Biosystems). The cytokines included on the plate were IL -1 a, IL -1p, IL -2, IL-4, IL -5, 
IL -8, IL -10, IL- 12p35, IL- 12p40, IL -15, gamma interferon (yIFN), and TNFa. 
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Ribosomal 18S RNA was used as the internal control. Therefore, within each well there were 
two reactions simultaneously undergoing PCR (multiplex PCR); the target gene of interest 
(labelled with FAM), and the 18S internal control (labelled with VIC). The two reporters 
fluoresce at different wavelengths and, therefore, can be discriminated from each other by the 
real -time machine. Ribosomal RNA was chosen as the internal control as their levels are least 
likely to vary under conditions that affect the expression of mRNA (Barbu and Dautry, 1989). 
The internal control allows the efficiency of the PCR reaction to be assessed and also 
enables comparison of levels of gene expression between different samples by normalising 
for different starting concentrations of cDNA. The primers and probe for ribosomal 18S were 
provided by Applied Biosystems. 
Table 3.8.1 Real -time primer and probe sequences for interleukin -6 and proteolysis- 
inducing factor. 
Gene Sequence Tm ( °C) 
Interleukin -6 
Forward primer 5' -AGC CCA CCG GGA ACG A -3' 60 
Reverse primer 5' -AGG CGC TTG TGG AGA AGG A -3' 60 
Probe (FAM) 5' -CTC GCC TCC AGG AGC CCA GCT ATG -3' (TAMRA) 70 
Proteolysis- inducing factor 
Forward primer 5' -CAA AAG GAA AAT GCA GGT GM GA -3' 59 
Reverse primer 5' -CTC CGT CTA GGC CTT TTT CCA -3' 59 
Probe (FAM) 5' -ACA GGC ACC W GCC AAG GAA GCA -3' (TAMRA) 69 
PCR reaction conditions 
Reactions were performed in 96 -well optical reaction plates (Applied Biosystems). Primers 
were used at an initial concentration of 25 pM and probes were used at an initial 
concentration of 5 pM. 60 µl of forward primer, 60 µl of reverse primer, and 200 .tl of probe 
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were added to 1014 pl of nuclease -free water. Following gentle mixing, 14 pl of this 
primer /probe mix was added to each well. Reactions were performed in 50 pl total volume, 
consisting of; 25 pl Taqman universal PCR master -mix (UNG x2), 14 pl primer /probe mix, 2.5 
pl ribosomal 18S primer /probe mix (all reagents Applied Biosystems), 3.5 pl DEPC treated 
water, and 5 pl cDNA. Once all the reagents were added, the plate was covered and spun for 
5 minutes in a plate spinner at 1000 rpm before being loaded into the PCR machine. 
The TaqMan cytokine gene expression plate consisted of a 96 -well optical reaction 
plate with each well pre -loaded with primers and probes for the detection of one cytokine 
cDNA target and an 18S endogenous control. Therefore, 25 pl Taqman universal PCR 
master -mix (UNG x2), 20 pl of nuclease -free water, and 5 pl of cDNA was added to each well. 
The plates were spun as above before loading into the TaqMan machine. 
The cycler conditions were 2 minutes at 50 °C, 10 minutes at 95 °C, and 40 cycles with 
15 seconds at 95 °C and 1 minute at 60 °C. Samples were analysed in duplicate and reactions 
were repeated if there were any discrepancies between the two results. 
Positive controls, negative controls and quality control 
Each plate contained negative controls (no cDNA) and positive controls. If the negative 
controls suggested contamination, all the samples on the 96 -well plate were repeated. In 
addition, approximately 5 -10 randomly selected cDNA samples from previously analysed 
reactions were run again on each plate to ensure that results were consistent between runs. 
Inter -assay variability between plates was less than 15 %. 
RNA derived from endotoxin -stimulated white blood cells was used as the positive 
control for the cytokine reactions. 10 ml of whole blood was collected from each of three 
healthy donors and mixed with equal volumes of phosphate- buffered saline (PBS). 15 ml of 
histopaque (Sigma, Dorset, UK) was pipetted into each tube to underlay the blood. The tubes 
were centrifuged at 1,000g for 20 minutes. The creamy interface was carefully pipetted from 
the 3 tubes and transferred to a single tube, which was filled with PBS and centrifuged at 
3,000g for 7 minutes. The supernatant was discarded and the pelleted cells were 
resuspended in 10 ml culture medium (RPM' supplemented with L- glutamine (2 mmol /I), 
penicillin (5 units/ml), streptomycin (50 pg /ml), (3- mercaptoethanol, and 10% fetal calf serum). 
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The cells were counted by trypan blue exclusion and additional culture medium was added to 
give a final concentration of approximately 1 x 106 cells per ml. The cells were cultured in lipo- 
polysaccharide (LPS) and Con A (Sigma, Dorset, UK) each at a concentration of 1 pg /ml for 
48 hours before isolation of the RNA. 
Total RNA was isolated using Trizol (Gibco BRL, Paisley, UK). The culture medium 
was poured off and 1 ml of trizol was added for each 10 cm2 of well surface area and 
incubated for 5 minutes. The cells were scraped off the well surface using a sterile pipette tip 
and the mixture was incubated for a further 5 minutes. The mixture was then transferred into 
microcentrifuge tubes and 200 pl of chloroform was added and the tubes were shaken 
vigorously for 15 seconds. The tubes were then centrifuged for 15 minutes at 12,000g. After 
spinning, the aqueous phase was carefully transferred to a clean tube and 500 pl of 
isopropanol was added and the tubes were left to stand at room temperature for 10 minutes, 
before centrifuging again at 12,000g for 10 minutes. The supernatant was carefully removed 
and the pellet was washed with 1 ml of 70% ethanol. After a final spin at 7,500g for 5 minutes 
the RNA pellet was resuspended in nuclease -free water. The final RNA concentration was 
210 tag /ml. The total RNA was reverse transcribed as described above and the total cDNA 
was mixed then aliquoted into separate tubes each containing 20 pl of the stock cDNA. Tubes 
were stored at -20 °C until use. Each real -time reaction used an aliquot from the stock 
solution of cDNA as a positive control. 
The MIA PaCa -2 pancreatic cancer cell line was used as a positive control for PIF 
analysis. Previous work in our Laboratory had identified that this cell line synthesised PIF 
mRNA (personal communication). The cells were obtained from the Public Health Laboratory 
Service Centre for Applied Research (Parton Down, UK). Cells were cultured in Dulbecco's 
modification of Eagle's medium (Life Technologies, Inchinan, UK) supplemented with L- 
glutamine, penicillin, streptomycin and fetal calf serum (as above) at 37 °C in 95% humidified 
air -5% CO2. RNA isolation and reverse transcription were performed as already described. 
The total RNA concentration was 1.7 pg/ pl. Once again 20 pl aliquots of cDNA were stored at 
-20 °C until use. 
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Quantification of gene expression 
Quantification of gene expression was calculated using the comparative (AACT) method, 
where samples were compared with the positive control (Bustin, 2000). The threshold cycle 
(CT) is defined as the number of cycles required for the level of fluorescence to rise 
significantly above the background level (maximum = 40) (Figure 3.8.3). Lower CT values 
represent higher initial copy numbers of the gene. The CT value is generated automatically by 
the real -time machine and two values per reaction well are given; one for FAM (target gene of 
interest) and he other for VIC (the internal control, 18S). Samples that generated cycle 
numbers above 23 for the endogenous control were discarded and the samples were 
repeated. Similarly, cycle numbers greater than 36 for the gene of interest were considered to 
have no expression of the gene. 
The level of gene expression within each sample was expressed as percentages of 
the level of gene expression within the control sample. Analysis was performed as follows; the 
average CT FAM and CT VIC values for each sample were calculated and the mean VIC CT 
values were subtracted from the mean FAM CT values (FAM CT - VIC CT = ACT). AACT was 
calculated by subtracting the ACT value of the positive control sample from the ACT value for 
each sample (ACT - ACT control = AACT). The relative level of expression, normalised to the 
endogenous control and relative to the positive control, is then calculated by the following 
formula: 2 -°°cT The level of gene expression of the positive control was assigned an 
expression value of 1 and levels of gene expression in the samples were expressed as 
percentages of the control level. 
To ensure inter -plate reproducibility, samples were repeated on different plates and 
serial dilutions of the positive control cDNA were performed. Reproducibility was between 3.7- 
15,5%. 
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Figure 3.8.3 An amplification plot generated following real -time PCR of cDNA samples 
obtained from patients with gastro -oesophageal cancer. In this example TNFa is the gene of 
interest. Each colour on the graph represents a single well on the 96 -well plate. The threshold 
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c) Tissue cytokine protein measurement 
Extraction of tissue protein 
Tissue samples were collected and stored as described previously. Sections of frozen tissue 
were cut and tissues were disrupted using a hand -held electric homogeniser. Care was taken 
to avoid tissue thawing prior to homogenisation. Tissue lysates were prepared by 
homogenising 50 mg of tissue in 400 µi tissue homogenising buffer (0.4ml 500mM Tris, 0.2 ml 
100 mM ATP, 1 ml 50 mM MgCl2, 10 µi dithiothreitol (DU), lx protease inhibitor, 8.4 ml water 
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- Sigma, Dorset, UK). Samples were heated to 95 °C for 5 minutes before centrifuging at 
13,000 rpm for 30 minutes at 4 °C. The supernatants were transferred to fresh Eppendorf 
tubes and the protein concentrations were determined by the Bradford method (Bio -Rad, 
Hemel Hempstead, UK) (Bradford, 1976). Mean protein concentrations were 17.0 mg /ml 
(S.D. =11.3 mg /ml). Samples were stored at -80 °C until further analysis. 
Determination of tissue cytokine protein concentrations 
Cytokine protein concentrations were determined using the Cytometric Bead Array System 
according to the manufacturers instructions (Human Inflammation Kit, BD Biosciences, 
Oxford, UK). This kit allows the simultaneous measurement of concentrations of the following 
cytokines; 1L-16, IL -6, IL -8, IL -10, IL- 12p70, and TNFa. The system combines flow cytometry 
and sandwich ELISA for the determination of cytokine concentrations. Advantages include 
increased sensitivity, smaller reaction volumes and simultaneous measurement of six 
cytokines during the same reaction (multiplexing). Six beads coated with cytokine antibodies 
are mixed with the protein supernatant. Each bead -coated antibody fluoresces at an individual 
wavelength, which is read by a flow cytometer (BD FACScan; BD Biosciences, UK) and 
cytokine concentrations are determined from a standard curve. 
Standards were prepared by serial dilutions according to the manufacturers 
instructions. 50 µl of neat tissue extract was added to the reaction mix containing 50 pl of the 
antibody- coated microbeads and 50 pl of the PE detection reagent. Samples were incubated 
at room temperature for 3 hours in the dark. Following incubation, 1 ml of wash buffer was 
added and tubes were centrifuged at 200g for 5 minutes. The supernatant was carefully 
aspirated and discarded and the pellet was resuspended in 100 pl of wash buffer. Cytokine 
concentrations were determined by flow cytometry (BD FACScan, Oxford, UK). Care was 
taken to gently vortex the tubes immediately prior to analysis. Results were calculated to take 
into account the total protein concentration of the tissue lysate and are expressed as pg /mg of 
total protein. Assay sensitivities, intra -assay variability, and inter -assay variability are shown 
in Table 3.8.2. 
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Table 3.8.2 Assay sensitivities, intra -assay variability, and inter -assay variability of 
rindividual cytokines using the Cytometric Bead Array System (BD Biosciences, Oxford, UK). 
Cytokine Sensitivity (pg /ml) Intra -assay variability ( %) Inter -assay variability ( %) 
IL-113 7.2 5.7 10 
IL -6 2.5 6.3 9 
IL -8 3.6 3.7 5 
IL -10 3.3 5.7 9.3 
IL -12p70 1.9 3.7 7.3 
TNFa 3.7 8.3 12 
Chapter Summary 
This Chapter has described the main materials and methods undertaken during the 
completion of this thesis. It describes the processes of patient recruitment and the timings of 
data recording and sample collection. It lists the clinical, pathological and investigative 
variables collected on each patient, including the assessment of nutritional status and 
performance status. It provides detailed methodology regarding the various laboratory 
procedures performed, such as measurement of serum cytokines and acute phase protein 
concentrations. Techniques relating to the isolation of genomic DNA and cytokine genotyping 
are described. The processes of tissue collection and measurement of tissue cytokine mRNA 
and protein concentrations are outlined. Finally, the methods used in the identification of 
tumour -derived products (PIF and PTHrP) are described as well as the difficulties 
encountered by these techniques. 
The following Chapters in his thesis describe the results of these methods and a 
discussion relating to each of these results is provided at the end of every Chapter. Firstly, the 
prevalence of systemic inflammation in the cohort of patients with gastro -oesophageal cancer 
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will be explored (Chapter IV). Investigation into the aetiology of such systemic inflammation in 
these patients will examine the contribution of the tumour tissue. Tissue cytokine 
concentrations will be measured and an assessment of host immune cell infiltrates into the 
tissues will be performed. These values will then be correlated with systemic inflammatory 
markers (Chapter V). The influence of host cytokine genotype on cytokine concentrations in 
the tumour tissue and systemic circulation will be investigated, and any additional value that 
these genotypes may have on prognosis will be explored (Chapter VI). The role of tumour - 
derived products, PTHrP and PIF, towards the generation of systemic inflammation, adverse 
nutritional status and prognosis among these patients will be investigated (Chapters VII, and 
VIII). The association between these elevated markers of systemic inflammation and adverse 
prognosis will then be investigated (Chapter IX). Changes in nutritional status in patients with 
gastro -oesophageal cancer will be documented and any association between systemic 
inflammation and cachexia will be determined. In addition, the role of cachexia as an 
aetiological factor in the link between systemic inflammation and adverse prognosis in 
patients with gastro -oesophageal cancer will be investigated (Chapter X). Finally, the 
usefulness of systemic inflammation as a prognostic indicator, and the role of cachexia as a 
contributory factor, will be used to develop a novel prognostic model to aid clinical 
management decisions for patients with gastro -oesophageal cancer (Chapter XI). 
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CHAPTER IV 
PREVALENCE OF SYSTEMIC INFLAMMATION AT DIAGNOSIS AND 




This Chapter investigated the prevalence of systemic inflammation in patients with gastro- 
oesophageal cancer. Serum cytokine and acute phase protein concentrations were measured 
as markers of systemic inflammation and their concentrations were related to numerous 
demographic, clinical, and pathological data. The effects of treatment and disease 
progression on levels of expression of these markers were also explored. 
Patients newly diagnosed with gastric or oesophageal cancer were recruited at the 
time of diagnosis. Blood was collected from patients and healthy controls for determination of 
serum cytokine (IL -16, IL -6, IL -8, IL -10, and soluble TNF receptor- sTNF -R) and serum 
acute phase protein (CRP, haptoglobin, al- antichymotrypsin, transferrin, and albumin) 
concentrations by ELISA. Serum concentrations were compared with controls and with 
various demographic, clinical and pathological data. Further samples were collected at 
different time points following initiation of treatments and later in the course of the disease. 
Two hundred and twenty patients were studied. Serum positive acute phase protein 
concentrations were significantly elevated compared with controls and at the time of diagnosis 
43% of patients with gastro -oesophageal cancer had evidence of systemic inflammation (CRP 
concentration greater than 10 mg /I). The presence of systemic inflammation was associated 
with advanced disease stage, poor performance status, increasing age, and female sex. 
Surgical resection was associated with an increase in serum CRP concentrations and pre- 
operative chemotherapy was associated with a reduction in CRP concentrations. In contrast, 
serum cytokines demonstrated little association with clinical and pathological variables or with 
serum acute phase protein concentrations, except for sTNF -R, which appears to behave like 
an acute phase reactant. IL-16 and IL -10 concentrations were generally not detectable in the 
serum of patients or healthy controls. 
This study confirms systemic inflammation is present in patients with gastro- 
oesophageal cancer. Investigation into the aetiology of systemic inflammation and the 
association between systemic inflammation and adverse prognosis in patients with gastro- 
oesophageal cancer is explored in later Chapters. 
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INTRODUCTION 
This Chapter investigated the prevalence of systemic inflammation in a cohort of patients with 
gastro -oesophageal cancer. Serum cytokine and acute phase protein concentrations were 
measured as markers of systemic inflammation in the study population at the time of 
diagnosis and later in the course of the disease. The effects of treatment and disease 
progression on the levels of expression of these markers were explored. Comparisons were 
also made between elevated markers of systemic inflammation and various clinical, 
pathological and demographic data. Such information may then be used to investigate the 
aetiology of systemic inflammation in these patients and to explore the association between 
systemic inflammation and adverse prognosis. 
Elevated serum pro -inflammatory cytokine concentrations have been identified in 
association with a number of animal tumour models (Oliff et al, 1987; Strassmann et al, 1992; 
Ghelin et al, 1991; McIntosh et al, 1989) and various cancer cell lines have also demonstrated 
an ability to produce pro -inflammatory cytokines (Wigmore et al, 2002; Wigmore et al, 2001; 
Wigmore et al, 1997). Elevated markers of systemic inflammation have also been measured 
in human cancer patients. Increased pro -inflammatory cytokine concentrations have been 
measured in sera from patients with cancer and elevated concentrations of IL-16, IL -6, IL -8 
and TNFa have repeatedly been measured in blood collected from patients with gastro- 
intestinal malignancy, including gastric and oesophageal cancers (Barber et al, 1999; Wang 
et al, 1999; Kabir and Daar, 1995). However, results and conclusions of these studies are 
often inconsistent and contradictory making meaningful conclusions difficult. Such 
inconsistent findings are likely to be related to the difficulties in reliably measuring serum 
cytokine concentrations, as previously described (Muc- Wierzgon et al, 2003). In addition, the 
end -organ effects of these systemic cytokines will depend upon binding to transport proteins, 
receptor expression and receptor affinity. These findings have raised doubt as to the 
significance of circulating concentrations of pro -inflammatory cytokines as markers of 
systemic inflammatory activity. In contrast, serum concentrations of acute phase proteins 
(APPR) demonstrate more stability within the systemic compartment and may be a more 
reliable marker for the presence of systemic inflammation in patients (Gabay and Kushner, 
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1999). Up to 50% of patients with cancer have an APPR at the time of diagnosis, including 
patients with upper gastro -intestinal malignancy (Chen et al, 1999; Alexandrakis et al, 2003; 
Barber et al, 1999; Falconer et al, 1994; Falconer et al, 1995). In patients with cancer 
circulating concentrations of IL -6 have been shown to correlate with markers of systemic 
inflammation such as CRP (Barber et al, 1999). The presence of such an acute phase 
reaction may then be used as an indirect marker of increased pro -inflammatory cytokine 
activity and serum concentrations of acute phase proteins may, therefore, be used to confirm 
the presence of systemic inflammation. 
MATERIALS AND METHODS 
Study Population 
All patients diagnosed with gastric or oesophageal cancer within the Lothian and Borders 
regions between March 2002 and June 2004 were eligible for inclusion into the study. No 
patients were excluded and subjects were recruited to the study within 2 weeks of diagnosis. 
All patients had histological confirmation of their disease following endoscopic biopsy. Data 
were prospectively collected. Patients were staged as per Department policy with a 
combination of computerised tomography (CT), endoscopic ultrasound (EUS) and 
laparoscopy /laparoscopic ultrasound (LUS) according to the International Union Against 
Cancer (UICC) (Sobin and Wittekind, 2003), and final histopathological stage (pTNM) was 
used when available. Final stage (pTNM) was only available for those patients who 
underwent surgical resection. In all other cases the final clinical stage (cTNM), as agreed at 
the unit multidisciplinary team meeting (MDT), was recorded. 
Clinical information such as duration of symptoms, smoking habit and patient age and 
sex were recorded in every case. Performance status was assessed using the Karnofsky 
index (Karnofsky and Burchenal, 1949). Pathological information was also recorded for each 
patient, including treatment modality, tumour site, histological type, and tumour grade. In 
every case documentation of the use of non -steroidal anti -inflammatory drugs (NSAIDs) and 
any other therapeutic agents that may influence the inflammatory response was recorded. 
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Twenty -two healthy controls were also recruited to the study and provided blood samples for 
determination of serum cytokine and acute phase protein concentrations. This group 
comprised 15 (68 %) males with a mean age 31 years (range 22 -56 years). 
Measurement of serum acute phase protein and cytokine concentrations 
Whole blood was collected from each patient for determination of serum acute phase protein 
concentrations and serum cytokine concentrations. C- reactive protein (CRP), haptoglobin, 
and a1- antichymotrypsin (ACT) were chosen as representatives of the positive acute phase 
response, and albumin and transferrin were selected as negative acute phase proteins. Pro - 
inflammatory cytokines IL -113, IL -6 and IL -8 were also measured. Soluble tumour necrosis 
factor receptor (60 kDa) (sTNF -R) was measured as an indirect marker of circulating TNFa 
levels (Spinas et al, 1992). IL -10 was chosen as an anti -inflammatory cytokine. Serum acute 
phase protein concentrations and serum cytokine concentrations were determined by ELISA, 
as previously described in the materials and methods Chapter (Chapter III). 
Sample collection 
Blood samples were collected within two weeks of diagnosis of cancer and before any 
treatment was commenced. All patients were free from systemic infection at the time of blood 
collection. A second serum CRP measurement was undertaken a few days later in a 
subgroup of patients at the commencement of the study to investigate the stability of CRP 
concentrations. In addition, a further blood sample was collected from patients at a later stage 
in the disease process to investigate any variation in serum acute phase protein 
concentrations that may occur due to the disease progression or treatment intervention. The 
second follow -up samples were collected in 77 (35 %) patients after a mean time interval of 95 
days (range 41 -151 days) from the time of the original measurement. Between the initial and 
follow -up measurements 48 patients had undergone surgical resection, 20 patients had 
received pre -operative chemotherapy but had not yet undergone surgery, and 9 patients had 
been palliated by non -surgical methods (for example, stenting). These measurements were 
performed a minimum of 92 days following surgery and a minimum 41 days following 
completion of pre- operative chemotherapy. 
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Statistics 
Non -parametric continuous variables were analysed by the Spearman rank test and 
independent variables were analysed by the Mann -Whitney U test or the Kruskal -Wallis test. 
Categorical data was analysed by the Chi- square test. The paired sample T -test was used to 
compare serial measurements for each patient. 
RESULTS 
1. The Study Population - Patient demographics 
Two hundred and twenty patients were recruited to the study between March 2002 and June 
2004. Patient demographics are shown in Table 4.1. The median age was 71 years (range 
26 -95 years, inter -quartile range 62 -78 years) and two- thirds of patients were male. 
Seventeen (8 %) patients were asymptomatic at the time of diagnosis and were diagnosed 
following endoscopic investigation of iron deficiency anaemia. Most patients (40 %) were 
diagnosed within 2 months of the onset of symptoms, such as dysphagia or epigastric pain. 
23 (10 %) patients had experienced symptoms for at least 6 months before a diagnosis was 
made. Reasons for diagnostic delay were mostly due to reluctance of the patient to seek 
medical help. Approximately one -third of patients had a normal performance status at the time 
of diagnosis (Karnofsky score 100) and another third of patients were able to undertake 
normal activities but with some degree of effort (Karnofsky 80 or 90). Ten (5 %) patients 
required frequent medical care or hospitalisation (Karnofsky 30 -50). 
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Table 4.1 Study patient demographics (n =220) 
Number ( %] 
Age (years) * 71 (62 -78) 
Sex Male 145 [66] 
Female 75 [34] 
Smoker Current 63 [29] 
Ex- smoker 68 [30] 
Never 89 [41] 
Symptom duration Asymptomatic 17 [8] 
<2 weeks 15 [7] 
2 -4 weeks 25 [11] 
1 -2 months 48 [22] 
2 -4 months 51 [23] 
4 -6 months 41 [19] 
>6 months 23 [10] 
Karnofsky score 30 4 [2]* 
40 1 [1] 
50 5 [2] 
60 17 [8] 
70 25 [12] 
80 36 [17] 
90 50 [24] 
100 70 [34] 
Unknown 12 
Tumour Site Oesophageal 101 [46] 
Proximal third 2 
Middle third 13 
Distal third 86 
Oesophago -gastric junction 40 [18] 




Histology Adenocarcinoma 185 [84] 
Squamous cell carcinoma 30 [14] 
Small cell 2 [1] 
Indeterminate [1] 
Grade Well differentiated 3 [2]* 
Moderately differentiated 63 [34] 
Poorly differentiated 118 [64] 
Not commented 36 
Helicobacter pylori Present 13 [12]* 
Absent 95 [88] 
Not recorded 112 
Treatment undertaken Surgery alone 70 [32] 
Pre -operative chemotherapy /Surgery 25 [11] 
Chemoradiotherapy with curative intent 7 [3] 
Palliative Chemotherapy 28 [13] 
Palliative Radiotherapy 6 [3] 
Stent/dilatation /laser /symptomatic 84 [38] 
UICC Stage 1 25 [11] 
2 34 [16] 
3 86 [39] 
4 75 [34] 
Status Alive 73 [33] 
Dead 147 [67] 
'Values are median (interquartile range). * Values are expressed as percentages of known results. 
126 
The primary tumour sites were oesophageal (n =101, 46 %), gastric (n =79, 36 %) and those 
arising from the gastro -oesophageal junction [OGJ] (n =40, 18 %). Most oesophageal tumours 
were located in the distal third, whereas the gastric tumours were equally distributed 
throughout the stomach. Approximately two- thirds (69 %) of all the cancers occurred in or 
around the gastro -oesophageal junction (distal oesophagus, OG junction, or proximal 
stomach) reflecting the increasing incidence of tumours located in this area. 
Adenocarcinoma was the commonest histological type overall (n =185; 84 %), 
including oesophageal cancers alone (70 %). Most tumours were poorly differentiated (n =118; 
64 %). The presence of Helicobacter pylori was recorded only for those patients who 
underwent surgical resection or where status was documented if the bacterium was noted on 
the biopsy specimen. Data were available for 108 patients and only 13 (12 %) patients were 
noted to be positive. Prior treatment with eradication therapy was not known. 
95 (43 %) patients underwent surgical resection (Ivor -Lewis two -stage oesophago- 
gastrectomy, left thoraco -abdominal resection, transhiatal oesophageactomy, partial 
gastrectomy, or total gastrectomy) and 25 of these received pre- operative chemotherapy. All 
patients had a potentially curative resection except 5 patients, 3 patients had unexpected 
metastatic disease identified at laparotomy and therefore did not proceed to resection and 2 
patients had residual macroscopic disease (R2 resection). Seven (3 %) patients, all of whom 
had squamous cell carcinoma of the oesophagus, received chemo- irradiation with curative 
intent. The remaining patients (n =118; 54 %) were not suitable for curative therapy and 
received palliative chemo /radiotherapy or underwent alternative palliative treatments, such as 
insertion of a stent, endoscopic dilatation, or endoscopic laser therapy. 
One -third (34 %) of patients had metastatic disease (stage IV) at the time of 
presentation and most other patients (n =86; 39 %) had locally advanced (stage Ill) disease at 
diagnosis. 
Patients were followed -up for an average 32 months (range 18 -45 months). At the 
time of censoring the data 147 (67 %) patients had died. Three patients died in the post- 
operative period and one patient died from injuries sustained following a fall. Information 
obtained from death certificates indicated that all other deaths were disease related. Overall 
median survival was 12.6 months. 
127 
2. Serum markers of systemic inflammation 
a) Serum acute phase protein concentrations 
Comparison with healthy controls 
The serum acute phase protein concentrations of patients and healthy controls are shown in 
Table 4.2. When compared with healthy controls, at the time of diagnosis cancer patients had 
significantly elevated serum concentrations of positive acute phase proteins (CRP, p <0.001; 
al- antichymotrypsin, p <0.001; and haptoglobin, p <0.001; Mann -Whitney U test), but similar 
concentrations of negative acute phase reactants (albumin, p =0.290 and transferrin, 
p= 0.477). The median CRP concentration was 7 mg /I (interquartile range 2 -25 mg /I) and at 
the time of diagnosis 95 (43 %) patients had a CRP concentration greater than 10 mg /I. This 
value is used as the definition of systemic inflammation in this thesis. 
Table 4.2 Comparison of serum acute phase protein concentrations between healthy 
controls and cancer patients at the time of diagnosis. Cancer patients had significantly 
elevated serum concentrations of positive acute phase proteins, but similar concentrations of 






CRP (mg /I) 1 (1 -2) 7 (2 -25) <0.001 
a1-Antichymotrypsin (mg/I) 245 (213 -261) 446 (359 -585) <0.001 
Haptoglobin (mg/I) 821 (627 -1157) 2264 (1518 -2950) <0.001 
Albumin (g /I) 40 (39 -42) 40 (36 -43) 0.290 
Transferrin (mg/I) 2197 (1861-2451) 2056 (1550-3138) 0.477 
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Comparison with patient demographics and clinical and pathological characteristics 
Increasing patient age at the time of diagnosis was associated with increasing serum CRP 
concentration (p= 0.009, r= 0.18; Spearman rank) and al- antichymotrypsin concentration 
(p= 0.016, r= 0.17) and with reduced serum albumin concentrations (p <0.001, r= -0.32). 
Similarly, female sex was also associated with elevated serum CRP (p= 0.062; Mann -Whitney 
U test) and al- antichymotrypsin (p= 0.005) concentrations and reduced albumin concentration 
(p= 0.022). Smoking status was not associated with serum acute phase protein 
concentrations. Karnofsky performance score was associated with serum acute phase protein 
concentrations (Figure 4.1). A reduced performance status was associated with increased 
serum CRP (p <0.001; Kruskal Wallis test) and al- antichymotrypsin (p= 0.003) concentrations, 
and reduced albumin (p <0.001) and transferrin (p= 0.005) concentrations. Acute phase protein 
concentrations were similar between those patients taking NSAID's or other therapeutic 
agents (for example, steroids) that may modify the inflammatory response and patients who 
were not (data not shown). 
Figure 4.1 Karnofsky performance score was associated with serum acute phase 
protein concentrations. A reduced performance status was associated with an elevated acute 
phase response (p <0.001; Kruskal Wallis test). 
Serum albumin conc (g /I) 
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Advanced disease stage was associated with increased concentrations of the positive acute 
phase reactants CRP (p <0.001; Kruskal Wallis test), al- antichymotrypsin (p= 0.050) and 
haptoglobin (p= 0.023), and reduced concentrations of albumin (p= 0.027), but not transferrin 
(p= 0.403). In addition, poorly differentiated tumours were associated with significantly 
elevated serum concentrations of positive acute phase proteins (CRP, p <0.001; a1- 
antichymotrypsin, p <0.001; haptoglobin, p= 0.025; Mann -Whitney U test), but not with the 
negative acute phase reactants (albumin, p= 0.151; transferrin, p= 0.141). 
The histological presence of tumour necrosis and abscess formation was 
documented in 54 resection specimens. Tumour necrosis was evident in 13 (24 %) of these 
samples and was associated with elevated serum haptoglobin concentrations (p= 0.045; 
Mann- Whitney U test) and CRP concentrations, but this did not quite reach significance 
(p =0.07) (Figure 4.2). 
Neither the site of the primary tumour (oesophageal, gastric or junctional) nor 
histological subtype (adenocarcinoma or squamous cell carcinoma) were associated with 
serum acute phase protein concentrations. Similarly, serum acute phase concentrations were 
not associated with Helicobacter pylori infection. 
Figure 4.2 Tumour necrosis was evident in 13 out of 54 (24 %) resected specimens. 
Serum haptoglobin concentrations were significantly higher in patients with histological 
evidence of necrosis present in their resected specimen (p= 0.045; Mann -Whitney U test). 







Stability of serum acute phase protein measurements 
A repeat serum CRP measurement was undertaken for the initial patients recruited to the 
study (n =12) in order to investigate the stability of CRP concentrations. This second sample 
was collected at a median time interval of 7 days (inter -quartile range 3 -16 days) following the 
collection of the first sample. All samples were collected prior to the initiation of treatment. 
There was good correlation between the two measurements (p <0.0001, r= 0.87; Spearman 
rank test) (Figure 4.3). 
Figure 4.3 A scatter plot representing the correlation between CRP concentrations 
measured a median 7 days apart (n =12) [p <0.0001, r= 0.87; Spearman rank test]. 
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Serial measurements of acute phase proteins 
A second CRP and albumin measurement was performed in 77 (35 %) patients after an 
average 95 days (range 41 -151 days) from the time of the original measurement at diagnosis. 
Between the initial and follow -up measurements 48 patients had undergone surgical 
resection, 20 patients had received pre- operative chemotherapy but had not yet undergone 
surgery, and 9 patients had been palliated by non -surgical methods (for example, stenting). 
These measurements were performed a minimum of 92 days following surgery and a 
minimum 41 days following completion of pre- operative chemotherapy. 
Over the average 95 -day time interval there was a significant increase in paired 
serum CRP concentrations among those patients who had undergone surgical resection 
[median CRP at diagnosis (pre- operative) = 3 mg /I versus median CRP 95 days later (post- 
operative) = 9 mg /I; p =0.03, 95% confidence interval -23.0 to -1.1; Paired T test] (Table 4.3). 
This was associated with a significant decrease in serum albumin concentrations [median 
albumin at diagnosis (pre- operative) = 42 g/I versus median albumin 95 days later (post- 
operative) = 38 g /I; p <0.001, 95% confidence interval 2.7 to 5.9] (Table 4.3). 
In contrast, patients who had received pre- operative chemotherapy, but who had not 
yet undergone surgery, experienced a significant reduction in paired serum CRP 
concentrations [median CRP at diagnosis (pre- chemotherapy) = 5 mg /I versus median CRP 
95 days later (post- chemotherapy) = 2 mg /I; p =0.05, 95% confidence interval 0 to 12.2]. 
However, there was no significant change in serum albumin concentrations among these 
patients [median albumin at diagnosis (pre- chemotherapy) = 44 g/I versus median albumin 95 
days later (post- chemotherapy) = 42 g /I; p =0.40, 95% confidence interval -1.3 to 3.2]. 
There were no significant changes in either CRP or albumin concentrations among 
those patients who were treated by palliative means alone (see Table 4.3). 
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Table 4.3 Serial measurements of serum CRP and albumin concentrations stratified 
according to intervening therapeutic intervention. CRP /albumin 1 = serum CRP /albumin 
concentration at diagnosis. CRP /albumin 2 = serum CRP /albumin concentration measured an 
average 95 days later and following initiation of treatment. CRP concentrations increased and 
albumin concentrations decreased in those patients who had undergone surgical resection. In 
contrast, CRP concentrations decreased in those patients who received pre- operative 
chemotherapy between CRP 1 and CRP 2, but without any significant changes in serum 
albumin concentrations. There were no significant changes in either CRP or albumin 























5 (1 -16) 2 (1 -6) 0 to 12.2 0.05 44 (40 -46) 42 (38 -46) -1.3 to 3.2 0.40 
Palliation 
(n =9) 
16 (5 -22) 7 (6 -21) -17.1 to 36.8 0.42 39 (34 -42) 41 (37 -42) -5.9 to 3.9 0.65 
Median (inter -quartile range). * Paired T -test. 
b) Serum cytokine concentrations 
Comparison with healthy controls 
The serum cytokine concentrations of patients and healthy controls are shown in Table 4.4. 
IL -10 and IL -10 were not detectable in the serum of any of the controls and were measured in 
only 4 (2 %) and 10 (5 %) patient's serum respectively. Serum concentrations of IL -6 and IL -8 
were similar between patients and controls (p =0.80 and p =0.91, respectively; Mann -Whitney 
U test). Serum soluble tumour necrosis factor receptor (sTNF -R) concentrations were 
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elevated in cancer patients compared with healthy controls, but this did not quite reach 
statistical significance (p= 0.056; Mann -Whitney U test). Given the low level of expression, IL- 
1[3 and IL -10 were excluded from subsequent analysis. 







Interleukin-113 (pg/ml) 0 (0 -0) 0 (0 -0) 
Interleukin-6 (pg/mI) 11.2 (0 -214) 8.7 (0 -88) 0.911 
Interleukin-8 (pg/ml) 0 (0 -118) 0 (0 -115) 0.799 
Interleukin-10 (pg/ml) 0 (0 -0) 0 (0 -0) 
Soluble TNF receptor (ng /ml) 2.8 (1.3 -3.6) 3.3 (1.9 -5.8) 0.056 
*Mann- Whitney U test. Values are median (inter -quartile range). 
Comparison with patient demographics and clinical and pathological characteristics 
Similar to patterns of acute phase protein expression, elevated sTNF -R concentrations 
correlated with increasing patient age (p <0.001; Spearman rank), female sex (p =0.05; Mann - 
Whitney U test), and reduced Karnofsky performance scores (p <0.001; Kruskal -Wallis test). 
In contrast to acute phase protein concentrations, sTNF -R concentrations were similar 
between patients irrespective of duration of symptoms prior to diagnosis. IL -6 and IL -8 were 
not associated with or anti -inflammatory drug consumption or any other demographic data 
(data not shown for simplicity). 
In contrast with serum acute phase protein concentrations, serum cytokine 
concentrations were not associated with stage of disease or the presence of tumour necrosis. 
However, sTNF -R concentrations were significantly elevated in patients with poorly 
differentiated tumours (p= 0.002; Mann -Whitney U test). Elevated serum sTNF -R 
concentrations were also associated with gastric tumours (p= 0.046; Kruskal -Wallis test) when 
compared with serum concentrations in patients with oesophageal or OG junctional tumours 
(Table 4.5) and elevated serum IL -6 concentrations were associated with oesophageal 
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tumours (p= 0.050). In addition, serum IL -6 concentrations were increased in patients with 
squamous cell histology [SCC median concentration = 51.6 pg /ml (inter -quartile range 1.2- 
194.4 pg /ml) versus ACC median concentration = 4.8 pg /ml (inter -quartile range 0 -69.5 
pg /ml); p= 0.005; Kruskal -Wallis test]. Serum cytokines concentrations were not associated 
with Helicobacter pylori status (data not shown). 
Table 4.5 Comparison of serum sTNF -R and IL -6 concentrations according to tumour 
site. 
Tumour site P value* 
Oesophagus OG junction Gastric 
(n =101) (n =40) (n =79) 
IL-6 (pg/ml) 23.7 (0 -114) 0 (0 -28) 8.9 (0 -83) 0.050 
sTNF-R (ng/ml) 2.9 (1.8 -5.3) 2.8 (1.4 -6.2) 4.1 (2.4 -7.8) 0.046 
* Kruskal- Wallis test. Values are median (inter -quartile range). 
c) Relationship between serum cytokine concentrations and serum 
acute phase protein concentrations 
The correlations between serum cytokine concentrations and serum acute phase protein 
concentrations are shown in Table 4.6. Concentrations of serum sTNF -R correlated with all 
the acute phase protein concentrations and IL -6 and IL -8 concentrations. Serum IL -6 
concentrations were positively correlated with serum haptoglobin (p= 0.020, r =0.16; Spearman 
rank) and were negatively correlated with serum albumin concentrations (p= 0.055, r= -013). 
IL -6 concentrations also correlated with and serum IL -8 concentrations (p <0.001, r= 0.52). 
Serum IL -8 concentrations did not correlate with any of the serum acute phase proteins. IL-16 
and IL -10 were excluded from analysis due to the low levels of expression. 
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Table 4.6 Correlations between serum cytokine concentrations and serum acute phase 
protein concentrations (r = correlation co- efficient; Spearman rank analysis). 
















IL-6 0.09 0.185 0.16 0.020 0.12 0.085 -0.13 0.055 -0.04 0.586 0.52 <0.001 0.23 0.001 
IL-8 0.05 0.513 0.08 0.217 0.04 0.566 -0.01 0.907 -0.9 0.881 - 0.16 0.019 
sTNF-R 0.41 <0.001 0.20 0.003 0.39 <0.001 -0.38 <0.001 -0.18 0.007 
CRP = C- reactive protein, ACT = al- antichymotrypsin 
DISCUSSION 
At the time of diagnosis patients with gastro -oesophageal cancer had significantly elevated 
serum concentrations of positive acute phase proteins and soluble TNF receptor 
concentrations when compared with healthy controls, but similar concentrations of negative 
acute phase proteins and serum cytokines. Forty -three percent of patients had evidence of 
systemic inflammation (CRP >10 mg /I) at diagnosis. Elevated acute phase protein and sTNF- 
R concentrations, but not cytokine concentrations, were associated with reduced Karnofsky 
performance scores, poorly differentiated tumours, and advanced disease stage. Soluble 
TNF -R concentrations correlated with serum acute phase protein concentrations, but there 
was little correlation between the other serum cytokines and acute phase proteins. Surgical 
resection was associated with an increase in CRP concentrations and pre- operative 
chemotherapy was associated with a reduction in serial serum CRP concentrations. 
Patient demographics 
The patient cohort described in this thesis is comparable to equivalent patient groups 
elsewhere in the United Kingdom and patient demographics are similar to those published in 
national statistics (Cancer Research UK, 2004). The results presented here confirm that 
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gastro -oesophageal malignancy is more common in males and with increasing patient age. 
Almost 70% of tumours were located in or around the oesophago -gastric junction and the 
majority of tumours were adenocarcinomas (84 %) [70% of oesophageal tumours were 
adenocarcinomas]. This supports the claim of the rising incidence of these tumours observed 
throughout Europe and North America and has been attributed to an increase in the incidence 
of Barrett's metaplasia (Jankowski et al, 2000; Coleman et al, 1999). As is typical in the UK, 
most patients presented with locally advanced disease (stage Ill) or metastatic disease (stage 
IV) at the time of diagnosis, with fewer than half of all patients suitable for surgical resection 
(Cancer Research UK, 2004). 
Serum acute phase protein concentrations 
Cancer patients had significantly elevated serum concentrations of positive acute phase 
proteins at the time of diagnosis. In addition, 43% of patients had systemic inflammation, 
defined as a serum CRP concentration greater than 10 mg /I. An APPR has been identified in 
association with the most malignancies and the prevalence of systemic inflammation is 
comparable with those quoted in previous studies relating to gastric and oesophageal cancers 
(range 23 -32 %) (Shimada et al, 2003; Nozoe et al, 2001; Crumley et al, 2006). 
An APPR was associated with increasing patient age and female sex. Many studies 
have recognised that healthy patients greater than 65 years of age have significantly elevated 
serum CRP concentrations when compared with younger patients (Ballou et al, 1996; Wener 
et al, 2000). It is not clear why serum acute phase protein concentrations should increase with 
aging. Some authors have suggested an association with atherosclerosis (Ballou et al, 1996), 
while others have proposed dysfunction of the cytokine regulation network (Wener et al, 
2000). This study has not controlled for cardiovascular disease. The association between 
female sex and elevation of some of the serum acute phase reactant concentrations has also 
been identified previously and is thought to be related to increased circulating oestrogen 
concentrations (Wener et al, 2000). Serum acute phase protein concentrations may also be 
influenced by race and ethnicity, however, only 2 (1 %) patients were non -Caucasian in this 
study and therefore these differences were not explored. 
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Karnofsky performance score was inversely associated with serum acute phase protein 
concentrations. This association has been well documented among patients with malignancy, 
including gastrointestinal malignancy, and may represent a clinical measure of the disease 
burden (O'Gorman et al, 2000). However, the Karnofsky score and markers of systemic 
inflammation have also been shown to be independently associated with outcome in 
malignant disease (O'Gorman et al, 2000). 
Among the pathological variables, the presence of elevated serum acute phase 
protein concentrations were associated with advanced disease stage and poor tumour grade, 
but not with histological subtype or tumour location. The presence of an elevated APPR and 
advancing disease stage has been widely documented and has been linked with the 
presence of both overt and occult metastases (Barber et al, 1999). This association may 
simply represent the generation of inflammation in response to the tumour burden in the host. 
Previously, elevated serum CRP concentrations have been associated with increased tumour 
volume in patients with oesophageal cancer (Nozoe et al, 2001). However, prognostic studies 
have shown that markers of systemic inflammation are prognostic independent of disease 
stage suggesting that the inflammatory response is more than simply a marker of disease 
bulk (Rashid et al, 1982; Shimada et al, 2003; Nozoe et al, 2001; Falconer et al, 1994). The 
absence of any association between tumour location or histological subtype is perhaps not 
surprising given that the presence of systemic inflammation has been identified in a variety of 
malignant diseases of diverse location and cellular origin. This suggests that cancer - 
associated inflammation is not cancer type specific. 
Although tumour necrosis was evident in 24% of the specimens that were studied, 
serum acute phase protein concentrations were only weakly associated with histological 
necrosis /abscess formation and many patients without tumour necrosis had significantly 
elevated serum APP concentrations. This would also suggest that cancer -associated 
systemic inflammation is more than simply a passive response to the presence of tumour 
abscess formation. 
Helicobacter pylori infection incites a chronic inflammatory response within the 
stomach that may lead to atrophic gastritis, achlorhydria and malignant transformation (El- 
Omar et al, 2000). We identified a low incidence of Helicobacter pylori infection in this study 
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(12 %), however, H pylori status was reported in fewer than half the study patients and prior 
eradication treatment was not recorded. We therefore found no association between serum 
acute phase protein concentrations and Helicobacter pylori infection. 
Serum cytokine concentrations 
IL-18 and IL -10 were not detectable in the serum of any of the controls and were infrequently 
measured in patient's serum (2% and 5 %, respectively). Only very low levels of IL-1p have 
been reported in normal serum and IL -10 is rarely detectable in healthy individuals (Paul and 
Seder, 1994). Previous work in our Department has similarly found low serum IL-113 
concentrations in pancreatic cancer patients, where only 2 out of 64 patients had measurable 
serum IL-113 levels (Barber et al, 2000). Another group, however, have identified elevated 
serum IL-113 concentrations in patients with advanced gastric cancer (Kabir and Daar, 1995). 
To our knowledge serum IL -18 levels have not been directly investigated among oesophageal 
cancer patients. Elevated serum IL -10 concentrations have been identified in a number of 
gastrointestinal (and other) malignancies and elevated concentrations have been associated 
with advanced disease and adverse outcome (De Vita et al, 1999; Fortis et al, 1996). We 
found no association between elevated serum IL -10 concentrations and advanced disease 
stage. It is possible that the serum concentrations of these cytokines were below the limit of 
sensitivity for our assay. 
Concentrations of IL -6 and IL -8 were similar among cancer patients and healthy 
controls. There is extensive documentation relating serum pro -inflammatory cytokine 
concentrations to numerous clinical and pathological endpoints with conflicting and 
inconsistent conclusions. Some of these conflicting results may relate to difficulties in reliably 
measuring serum cytokine concentrations and this has been highlighted in previous Chapters. 
In addition, there is doubt over the relevance of the systemic concentrations of cytokines 
when compared with the tissue compartment concentrations where such mediators may exert 
most of their biological effects. The significance of circulating cytokine concentrations in 
cancer patients remains unclear. However, serum IL -6 concentrations were significantly 
elevated among patients with oesophageal tumours when compared with tumours arising at 
other anatomical positions. Serum IL -6 concentrations were also positively associated with 
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squamous cell histology, which accounted for approximately one -third of the cases of 
oesophageal cancer. Squamous cell cancers have been associated with significantly higher 
serum IL -6 concentrations when compared with adenocarcinomas in lung cancer patients and 
squamous tumour cells have been shown to produce IL -6 mRNA, which has been correlated 
with elevated serum IL -6 levels in oesophageal cancer patients (Yamaguchi et al, 1998; 
Wang et al, 1999). The increased serum IL -6 concentrations identified in the oesophageal 
cancer group is, therefore, likely to be secondary to the squamous cell histology within this 
group. 
In contrast with the other serum cytokines measured, sTNF -R levels were 
significantly higher in the cancer patient group compared with healthy controls. In this respect 
sTNF -R behaves more like an acute phase reactant than a cytokine. As such, we found that 
sTNF -R concentrations were also associated with increasing patient age, female sex, 
reduced Karnofsky performance scores, and poor tumour grade, but in contrast to the acute 
phase proteins, sTNF -R concentrations were not associated with stage of disease or 
histological evidence of tumour necrosis in this study. 
Correlation between serum cytokine concentrations and acute phase protein 
concentrations. 
Soluble TNF -R concentrations correlated with all the serum acute phase protein 
concentrations and our group has previously demonstrated this association among patients 
with advanced pancreatic cancer (Barber et al, 1999). These findings are most likely due to 
the increased stability of the molecule compared with TN Fa and the consistent serum levels. 
Interleukin -6 levels correlated with two of the five acute phase reactants that were measured 
in this study. Many previous studies, including work from our own group, have identified 
correlations between serum IL -6 concentrations and serum acute phase reactants in cancer 
patients (Barber et al, 1999), however these findings are often inconsistent and relate to the 
problems already mentioned regarding the validity of measuring circulating cytokine 
concentrations. Interleukin -8 concentrations did not correlate with any of the acute phase 
proteins. 
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Effects of treatment and disease progression on markers of systemic inflammation. 
CRP concentrations at the time of diagnosis demonstrated good stability and this 
reproducibility is essential in order to develop a robust measure that may be used to define 
systemic inflammation in this patient group and later for the development of a prognostic 
model (see Chapter XI). 
A second CRP and albumin measurement was performed in a subgroup of patients 
approximately 3 months following diagnosis. Analysis of the paired values demonstrated that 
CRP concentrations increased and albumin concentrations decreased in patients who had 
undergone surgery. These measurements were performed a minimum of 92 days following 
surgery and no patient had signs of active infection or post- operative complications at the 
time of sample collection. All these patients had apparently undergone curative resection with 
removal of all the macroscopic disease. The on -going systemic inflammatory response in 
these patients may not, therefore, be directly related to the tumour, but represent subclinical 
post- operative complications driving the pro -inflammatory response. Previously, reductions in 
serum acute phase protein concentrations have been identified in gastric cancer patients who 
had undergone surgical resection and increasing concentrations were measured in those 
patients with evidence of tumour recurrence (Fujita et al, 1999; Bernacka et al, 1993). 
Similarly, in colorectal cancer patients there was a reduction in CRP values following curative 
resection (28% elevated pre -operatively versus 17% elevated post -operatively) and an 
elevated CRP post -operatively was associated with adverse outcome (McMillan et al, 2003). 
In contrast, serum CRP concentrations were significantly reduced in those patients who 
received pre -operative chemotherapy without any changes in serum albumin concentrations. 
We did not evaluate whether a reduction in CRP concentration was associated with a 
histological evidence of response to the chemotherapy and it is possible that this may be the 
case. It is also possible that the chemotherapy had an anti -inflammatory/immunosuppressant 
action resulting in reduced concentrations of serum acute phase reactants. The effect of neo- 
adjuvant chemotherapy on serum acute phase protein concentrations has not previously been 
investigated in gastro -oesophageal cancer patients. However, studies in head and neck 
cancers and lung cancer found a significant reduction in serum concentrations of acute phase 
reactants following pre- operative chemotherapy (Kolebacz et al, 1999; Endo et al, 2004). 
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There was no significant change in serum acute phase concentrations in patients who 
received palliative treatments alone. This may reflect the fewer patient numbers involved. 
Previously, an increase in CRP concentrations of 15 mg /I per month has been noted among 
patients with pancreatic cancer patients with almost all patients demonstrating a systemic 
inflammatory response towards the time of death (Barber et al, 1999). That study examined 
patients with advanced disease who were near to death and it is possible that our study would 
show a similar trend were the patients followed up for longer and closer death. 
Conclusions 
The data from this Chapter has established that 43% of patients with gastro -oesophageal 
cancer have evidence of systemic inflammation at the time of diagnosis. The presence of 
systemic inflammation is associated with advanced disease stage, poor performance status, 
increasing age, and female sex. Surgical resection is associated with an increase in serum 
CRP concentrations and pre- operative chemotherapy is associated with a reduction in CRP 
concentrations. In contrast, serum cytokines demonstrate little association with clinical and 
pathological variables or with serum acute phase protein concentrations, except for sTNF -R, 
which appears to behave like an acute phase reactant. The next Chapter investigated levels 
of cytokine expression within tumour tissue and related these concentrations to markers of 
systemic inflammation and outcome in patients with gastro -oesophageal cancer. 
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CHAPTER V 
PATTERNS OF TISSUE CYTOKINE EXPRESSION AND THEIR 
ASSOCIATION WITH AN IMMUNE CELL INFILTRATE AND MARKERS OF 
SYSTEMIC INFLAMMATION IN PATIENTS WITH GASTRO- 
OESOPHAGEAL CANCER 
Deans DAC, Wigmore SJ, Gilmour H, Paterson -Brown S, Ross JA, Fearon KCH 
Tumour tissue Interleukin -1 ß is associated with systemic inflammation -a marker of 
reduced survival in gastro- oesophageal cancer. 
British Journal of Cancer 2006; 95(11): 1568 -1575 
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ABSTRACT 
Markers of systemic inflammation were elevated in 43% of patients with gastro -oesophageal 
malignancy at the time of diagnosis. Serum cytokine concentrations demonstrated little 
correlation with markers of systemic inflammation, suggesting that circulating concentrations 
of cytokines do not represent the true levels of cytokine activity driving the systemic 
inflammatory response. This Chapter investigated the role of tumour tissue in the genesis of 
systemic inflammation. Tissue cytokine concentrations were compared with serum cytokine 
and acute phase protein concentrations. In addition, tumour tissue cytokine concentrations 
were compared with concentrations measured in tissue from healthy controls and in non - 
neoplastic tissue also collected from cancer patients. The presence of an inflammatory 
cellular infiltrate into the tumour tissue was also documented and the extent of cellular 
infiltrate was compared with levels of tissue and systemic cytokine expression. 
Tumour tissue was collected from 56 patients with gastro -oesophageal cancer at the 
time of surgery. At the same time non -neoplastic mucosal tissue adjacent to the tumour was 
also sampled from each patient. Tissue was also collected from 12 healthy controls during 
upper GI endoscopy. Tissue cytokine mRNA concentrations were measured by real -time PCR 
and tissue protein concentrations were determined by a cytometric bead array system. The 
degree of chronic inflammatory cell infiltrate into the tissues was recorded. Serum cytokine 
and acute phase protein concentrations were determined by ELISA. 
Pro -inflammatory cytokine concentrations (mRNA and protein) were significantly 
elevated in tumour tissue compared with concentrations measured in non -malignant tissue 
sampled from healthy controls. Tumour tissue IL-16 concentrations were significantly 
elevated and were positively associated with markers of systemic inflammation (p =0.05, 
r= 0.31). In addition, a chronic inflammatory cellular infiltrate was identified in 75% of tumours 
and was also associated with elevated markers of systemic inflammation (CRP; p= 0.01), but 
was not associated with elevated tissue cytokine mRNA or protein concentrations. 
A chronic inflammatory cell infiltrate and tumour tissue IL -16 over -expression are 
potential key initiators of systemic inflammation in patients with oesophagogastric cancer. 
Over- expression of IL-16 appears not to be related to the presence of a host immune cell 
infiltrate and may be host/tumour dependent. 
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INTRODUCTION 
The previous Chapter has demonstrated that patients with gastro -oesophageal cancer have 
significantly elevated concentrations of serum (positive) acute phase proteins and 43% of 
these patients have evidence of systemic inflammation at the time of diagnosis. In contrast, 
serum cytokine concentrations demonstrate little association with clinical or pathological 
variables or with serum acute phase protein concentrations (except for sTNF -R). These data 
suggest that circulating concentrations of cytokines do not represent the true levels of 
cytokine activity that are driving the systemic inflammatory response in these patients. In 
order to investigate the aetiology of systemic inflammation in these patients, this Chapter 
investigated patterns of cytokine expression within tumour tissue. Tissue cytokine 
concentrations (mRNA and protein concentrations) were compared with serum cytokine and 
acute phase protein concentrations. In addition, concentrations of cytokines measured in the 
tumour tissue were compared with concentrations measured in tissue from healthy controls 
and in non -neoplastic tissue also collected from the same cancer patients. The presence of 
an inflammatory cellular infiltrate into the tumour tissue was also documented and the extent 
of cellular infiltrate was compared with levels of tissue and systemic cytokine expression. This 
Chapter, therefore, aimed to determine the role of the tumour tissue in the generation of 
systemic inflammation in patients with gastro -oesophageal cancer. 
MATERIALS AND METHODS 
Study Patients and Controls 
Patients diagnosed with gastric or oesophageal cancer within the Lothian and Borders 
regions between March 2002 and June 2004 were invited into the study (see Chapter IV for 
further details on the patient cohort). For this study, only those patients who underwent 
surgical resection were eligible for inclusion due to the requirement for tissue sampling. 
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Therefore, patients not suitable for surgery, for example, due to advanced disease or co- 
morbidity, were excluded from this study. No patients eligible for entry refused consent and no 
patients who underwent surgery were excluded. An additional 12 patients were recruited as 
healthy controls. These patients underwent endoscopy as an elective procedure for 
investigation of dyspeptic -type symptoms. In all instances the result of the procedure was 
normal, including both macroscopic and microscopic assessment. All control subjects were 
considered healthy without established co- morbidity or taking any regular medications. 
Measurement of serum acute phase protein and cytokine concentrations 
Blood was collected from patients at the time of diagnosis and prior to any therapeutic 
intervention. Samples were simultaneously collected from 22 healthy controls for comparison. 
Analysis was performed by ELISA as previously described in the Materials and Methods 
section (Chapter III). 
Measurement of tissue cytokine mRNA and protein concentrations 
Tissue was obtained from patients at the time of surgical resection. Representative samples 
of tumour tissue and adjacent non -neoplastic mucosal tissue were cut from the specimens 
within 20 minutes of resection by a Consultant pathologist. Samples were immediately snap 
frozen in liquid nitrogen prior to storage at -80 °C until further analysis. An additional 12 
patients were recruited as healthy controls and tissue was collected at the time of endoscopy. 
Mucosal tissue (7 oesophageal and 5 gastric) samples were collected from these patients 
with biopsy forceps at the time of endoscopy and samples were snap frozen for storage. 
Tissue samples were homogenised prior to analysis. Concentrations of IL-113, IL -6, IL -8 and 
TNFa were measured in the tissue samples. Quantification of cytokine mRNA was performed 
by real -time PCR and tissue cytokine protein concentrations were measured by a cytometric 
bead array system. Both these techniques are described in detail in the Materials and 
Methods Chapter (Chapter III). 
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Histological Analysis 
Representative sections of tumour tissue from each patient were fixed with formalin and 
stained with haematoxylin and eosin. A single Consultant pathologist reviewed all the tissue 
sections and samples were classified into one of three groups according to the degree of 
chronic inflammatory cellular infiltrate present. Group 1 was defined as having a scanty 
diffuse (occasional) chronic inflammatory cell infiltrate, Group 2 samples had a diffuse chronic 
inflammatory cellular infiltrate present throughout the whole tissue, and Group 3 had focal 
lymphoid aggregates only (see Figure 5.3). In addition, the presence of Helicobacter pylori 
and tissue necrosis was also noted. The pathologist was blinded to the clinical data, serum 
acute phase protein /cytokine concentrations, tissue cytokine concentrations, and the clinical 
outcome for each patient. 
Statistical Analysis 
Comparisons between groups of continuous variables were made by the Mann -Whitney U 
test. Categorical variables were compared by Fisher's exact test. Correlations between 
continuous variables were assessed by linear regression following natural logarithmic 
transformation of the data. A P value <_ 0.05 was considered statistically significant. 
RESULTS 
Study Patients 
Patient demographics are shown in Table 5.1. Fifty -six patients were recruited to the study. 
The primary tumour sites were oesophageal (n =26, 46 %), gastric (n =17, 30 %) and those 
arising from the gastro -oesophageal junction [OGJ] (n =13, 23 %). The predominant 
histological subtype was adenocarcinoma (93 %). All patients underwent surgical resection 
and 13 (23 %) of these received pre- operative chemotherapy. At the end of the study 19 
(34 %) patients had died. 
Sub -group analysis confirmed no significant differences in either tissue mRNA or 
protein levels between patients who received pre- operative chemotherapy and those who did 
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not. Similarly, there were no differences in tissue mRNA or protein levels or serum cytokine or 
acute phase protein levels among those patients taking NSAID's or any other therapeutic 
agents that may modify the inflammatory response. Therefore, all patients were included as a 
single group for analysis. 
Table 5.1 Study patient demographics (n =56) 
Number [ %] 
Age (years) 66 (58 -75) 
Sex Male 40 [71] 
Female 16 [29] 
Tumour Site Oesophageal 26 [46] 
Oesophago -gastric junction 13 [23] 
Gastric 17 [30] 
Histology Adenocarcinoma 52 [93] 
Squamous cell carcinoma 4 [7] 
Grade Well differentiated 4 [7] 
Moderately differentiated 24 [43] 
Poorly differentiated 28 [50] 
UICC Stage 1 17 [30] 
2 13 [23] 
3 21 [38] 
4 5 [9] 
Treatment undertaken Oesophagectomy 25 [45] 
Gastrectomy 18 [32] 
Pre -operative Chemotherapy followed by surgery 13 [23] 
Status Alive 37 [66] 
Dead 19 [34] 
*Values given are median (inter -quartile range) 
Concentrations of serum cytokine and acute phase proteins 
Similar to the findings described in Chapter IV relating to the whole patient cohort, this study 
also identified significantly elevated serum concentrations of positive acute phase proteins, 
but not negative acute phase proteins, in the patient population when compared with controls. 
Ten (18 %) patients had evidence of systemic inflammation (serum CRP concentration >10 
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mg /I). Serum cytokine concentrations were not significantly different between patients and 
controls and serum cytokine concentrations did not correlate with serum acute phase protein 
concentrations (data not shown for brevity). 
Tissue cytokine mRNA and protein concentrations 
Healthy Controls 
IL -1ß, IL -6 and IL -8 mRNA were not measurable in any of the gastro -oesophageal mucosa 
samples collected from healthy controls and TNFa was only detectable at low concentrations 
(Table 5.2) (Figure 5.1A). Similarly, IL -6 protein was not detected in tissue samples from 
healthy controls and IL-1[3, IL -8, and TNFa were also only measured at low concentrations 
(Table 5.2) (Figure 5.1B). 
Table 5.2 Cytokine mRNA and cytokine protein concentrations measured in tissue from 
healthy controls compared with concentrations measured in tissue (tumour tissue and benign 
tissue) from cancer patients. 
Tissue cytokine mRNA conc 
(% of PCR control) 
Tissue cytokine protein conc 
(pg /mg total protein) 
Healthy control Cancer patient Healthy control Cancer patient 
Benign tissue Benign tissue Tumour tissue Benign tissue Benign tissue Tumour tissue 
IL -10 0 0.8 3.2 2.6 44.5 135.8 
(0.2 -12.1) (0.2 -12.1) (2.2 -4.9) (23.0 -89.2) (40.5- 424.7) 
IL -6 0 1 1.9 0 0 3 
(0 -5.4) (0.3 -13.6) (0 -6.7) (0 -45.8) 
IL -8 0 0 0.2 0 8.4 56.2 
(0 -0.1) (0.1 -1.0) (0 -7.7) (2.8 -23.7) (22.6 -1 58.6) 
TNFa 0 1.3 2.7 0 3 6.6 
(0 -2.1) (0 -7.8) (0.7 -15.6) (0 -1.0) (0 -5.8) (1.1 -25.8) 
Values are median (inter -quartile range) 
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Cancer Patients - cytokine mRNA concentrations 
Tumour tissue cytokine mRNA concentrations were detected at significantly higher 
concentrations compared with those measured in tissue from healthy subjects: IL-1p 3.2% of 
control (inter -quartile range (IQR) 0- 12.1), p <0.001; IL -6 1.9% of control (IQR 0- 13.6), 
p <0.001; IL -8 0.2% of control (IQR 0 -1), p <0.001; TNFa 2.7% of control (IQR 0- 15.6), 
p =0.006 (Table 5.2) (Figure 5.1A). Similarly, IL-1p, IL -6, and TNFa mRNA concentrations 
were also measured at significantly elevated concentrations in non -neoplastic tissue sampled 
from cancer patients when compared with tissue from healthy controls. IL -8 concentrations 
were also elevated but did not reach statistical significance (p= 0.30). Although cytokine 
mRNA concentrations were higher in tumour tissue when compared with benign tissue from 
cancer patients, only IL -8 was statistically significant (p <0.001). 
Cancer Patients - cytokine protein concentrations 
Cytokine protein concentrations were significantly higher in tumour tissue compared with 
concentrations in tissue from healthy controls: IL -1ß 136 pg per mg of total protein (IQR 41- 
425), p= 0.007; IL -6 3 pg /mg (IQR 0 -46), p <0.05; IL -8 56 pg /mg (IQR 23 -159), p= 0.007; TNFa 
7 pg /mg (IQR 1 -26), p <0.05 (Table 5.2) (Figure 5.1B). Protein concentrations measured in 
benign tissue from cancer patients were also elevated when compared with healthy controls, 
but only IL -113 reached statistical significance (p= 0.041). In addition, cytokine protein 
concentrations were significantly elevated in tumour tissue when compared with levels 
measured in non -neoplastic tissue from the same cancer patients. 
Cytokine mRNA versus cytokine protein concentrations 
There was no correlation between tissue cytokine mRNA concentrations and cytokine tissue 
protein concentrations; IL -1ß (p =0.64, r =0.07; Spearman rank), IL -6 (p =0.46, r= -0.1), IL -8 
(p =0.55, r= 0.09), TNFa (p =0.90, r= 0.02). Increased mRNA concentrations were not 
associated with elevated tissue cytokine protein concentrations. 
150 
Figure 5.1 Comparison of cytokine concentrations of (A) mRNA and (B) protein between 
tissue from healthy controls and tumour tissue from patients with gastro -oesophageal cancer. 
The lines represent the median value, bars = inter -quartile range, error bars = extreme 
values. IL -113 = Interleukin -113, TNFa = Tumour necrosis factor -a. * p <0.05, * *p <0.01, 
* * *p <0.001 (Mann -Whitney U Test) 
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Relationship between tissue cytokine concentrations and serum cytokine and 
acute phase protein concentrations 
Tumour tissue IL -1 ß protein levels were positively correlated with serum CRP concentrations 
(p =0.05, r = 0.31; linear regression) and serum sTNF -R concentrations (p =0.03, r = 0.36) 
(Figure 5.2). There was also a trend towards a correlation between tumour IL -8 protein 
concentrations and serum sTNF -R concentrations, but this did not quite reach significance 
(p =0.06, r= 0.32). Neither IL -6 nor TN Fa tissue protein concentrations were associated with 
systemic cytokine or acute phase protein concentrations. 
There was no correlation between tissue cytokine mRNA concentrations and serum 
cytokine or serum acute phase protein concentrations (data not shown). 
Figure 5.2 Tumour tissue IL-18 protein levels were positively correlated with serum CRP 
concentrations (p =0.05, r = 0.31; linear regression). 
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Slides from three patients recruited to the study could not be retrieved, therefore, 53 tumour 
sections were studied. Twenty -four (45 %) tumour samples were classified as having scanty 
diffuse or patchy chronic inflammatory cells, 16 (30 %) had a diffuse chronic inflammatory 
cellular infiltrate visible throughout the whole tumour, and the remaining 13 (25 %) tumour 
sections had focal lymphoid aggregates only (Figure 5.3). Therefore, 40 (75 %) tumours had 
evidence of an increased chronic inflammatory cell infiltrate. Tumour necrosis was evident in 
13 (25 %) samples, but there was no association between degree of inflammatory cell infiltrate 
and the presence of necrosis (p =0.92, Chi -square test). Similarly, a chronic inflammatory 
cellular infiltrate was not associated with Helicobacter pylori infection (p =0.67, Fisher's exact 
test; data not shown). 
Figure 5.3 Representative photomicrographs taken from three patients with poorly 
differentiated adenocarcinoma of the oesophagus. Patient (A) demonstrates minimal /no 
inflammatory cell reaction. Patient (B) has a patchy chronic inflammatory cell infiltrate. Patient 
(C) shows a diffuse chronic inflammatory cellular infiltrate present throughout the tumour. 






Relationship between an inflammatory cell infiltrate and markers of systemic 
inflammation 
When compared with tumour sections possessing lymphoid aggregates alone, tissues with a 
diffuse or patchy inflammatory cellular infiltrate were associated with elevated serum CRP 
and sTNF -R concentrations (p =0.01 and p =0.007 respectively, Mann -Whitney U test) (Figure 
5.4). There was no association between the presence of a chronic inflammatory cell infiltrate 
and serum cytokine concentrations. 
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Figure 5.4 A diffuse or patchy inflammatory cellular infiltrate was associated with 
elevated serum CRP concentrations (p =0.01, Mann -Whitney U test). Thick bar represents 
median, the box represents quartiles, and lines represent extreme values. 
Serum CRP (mg /I) 
I 
Focal lymphoid aggregates Patchy /diffuse cells 
Inflammatory cell infiltrate into the tumour 
*p=0.01 
Relationship between an inflammatory cell infiltrate and tissue cytokine concentrations 
There were no differences in tissue cytokine mRNA or protein concentrations between tumour 




In the previous study (Chapter IV), we have shown that patients with gastro -oesophageal 
malignancy have elevated concentrations of serum acute phase proteins but similar 
concentrations of serum cytokine concentrations compared with a control population and 43% 
of patients have evidence of systemic inflammation at the time of diagnosis. In this study, we 
have shown that pro -inflammatory cytokine concentrations (mRNA and protein) are 
significantly elevated in tumour tissue (and adjacent non -neoplastic tissue) when compared 
with concentrations measured in tissue sampled from healthy controls. Moreover, tumour 
tissue IL-16 concentrations correlate with markers of systemic inflammation (CRP). In 
addition, a chronic inflammatory cellular infiltrate was identified in 75% of tumours and was 
also associated with markers of systemic inflammation (CRP), but was not associated with 
elevated tissue cytokine mRNA and protein concentrations. 
Tissue cytokine concentrations 
The data from Chapter IV suggests that circulating cytokine concentrations are an unreliable 
marker of systemic inflammation and a poor measure of tissue cytokine activity (Barber et al, 
1999; Falconer et al, 1994). Moreover, these findings suggest that circulating cytokines may 
not be the key mediators of the acute phase response. Alternatively, local cytokine 
concentrations within target tissues may represent a better measure of systemic inflammatory 
cytokine activity. Host immune cells may become 'activated' by exposure to local mediators 
as they pass through the tumour mass. These activated peripheral blood mononuclear cells 
(PBMC's) may then release increased concentrations of pro -inflammatory cytokines within 
target tissues, for example, in the liver, thereby inducing an acute phase response. PBMC's 
from cancer patients with an elevated serum APPR demonstrate greater rates of pro - 
inflammatory cytokine (IL -6 and TN Fa) production and these cells are then capable of 
stimulating increased CRP production by hepatocytes in co- culture systems (O'Riordain et al, 
1999). The tumour itself may also be capable of constituently producing pro -inflammatory 
cytokines. Increased cytokine mRNA and protein concentrations have been measured within 
oesophageal tumour cells and CRP expression has even been detected within oesophageal 
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cancer cells (Yuan et al, 2000; Martignoni et al, 2005; Nozoe et al, 2003). In our study, pro - 
inflammatory cytokine mRNA and protein concentrations were either not detectable or found 
at very low levels in tissue collected from healthy controls. In contrast, cytokine mRNA and 
protein concentrations were measured at significantly higher concentrations in both non - 
neoplastic and tumour tissue collected from cancer patients. Moreover, concentrations of 
these cytokines were higher in the tumour tissue compared with the benign tissue sampled 
from the same patients. Why apparently normal tissue from patients with cancer should 
demonstrate increased tissue cytokine concentrations is unclear, but may represent a whole 
organ upregulation of pro -inflammatory activity where the effects of cytokines and other 
mediators may 'spill over' into adjacent tissues. Certainly other groups have identified similar 
findings. For example, Yuan and co- workers investigated IL -8 mRNA concentrations in 
tumour tissue and adjacent normal lung tissue in patients with non -small cell lung cancer and 
also found increased cytokine expression within the tumour tissue and adjacent normal tissue 
(Yuan et al, 2000). Other groups have similarly demonstrated increased tissue cytokine 
concentrations associated with progression along the metaplasia -dysplasia- carcinoma 
sequence in Barrett's oesophagus (Tselepis et al, 2002; Dvorakova et al, 2004). 
In the present study median IL -113 concentrations were 10 - 100 fold higher than IL -6 
in the tumour tissue and there was a weak but significant correlation between tumour tissue 
IL -1ß concentration and serum CRP. There was a similar trend with IL -8. Both IL -1ß and IL -8 
are recognised as important cytokines in the generation of the systemic inflammatory 
response and it is possible that high tissue concentrations of these cytokines stimulate 
PBMC's as they pass through the tumour mass, which in turn act on target organs, such as 
the liver, to induce the synthesis of acute phase proteins that are associated with systemic 
inflammation (O'Riordain et al, 1999). Moreover, Martignoni and co- workers have suggested 
that IL -6 over -expression in cachectic pancreatic cancer patients is related to the ability of 
certain IL -6 producing tumours to sensitise PBMC's and induce IL -6 expression in PBMCs 
( Martignoni et al, 2005). In the latter study screening by DNA microassay analysis followed by 
quantitative PCR identified only IL -6 mRNA expression to be significantly increased in tumour 
samples of cachectic patients compared with non -cachectic patients or pancreas samples 
from normal controls. Immunohistochemistry suggested the source of IL -6 to be tumour cells 
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rather than host cells. The results of the present study, however, identify that at least in 
patients with gastro -oesophageal cancer IL-1(3 rather than IL -6 may be important as an 
initiator of the pro -inflammatory acute phase protein response. IL -6 may form a common final 
pathway via activated PBMC's. Interestingly, in the colon -26 murine model of cancer cachexia 
associated with systemic inflammation there appears to be a complex intra- tumoural 
amplification loop between IL -1 ß and IL -6, which can be down -regulated by IL -10 (Yasumoto 
et al, 1995; Fujiki et al, 1997). 
In the present study we did not find any correlation between tissue cytokine mRNA 
concentrations and systemic cytokines or acute phase protein concentrations. Raddatz and 
co- workers did identify an association between tissue cytokine mRNA levels and systemic 
CRP protein concentrations in Crohn's disease (Raddatz et al, 2005). These differing results 
may be partly explained by the lack of correlation between tissue mRNA concentrations and 
protein concentrations in our study. While some groups have demonstrated a correlation 
between IL -1(3 and IL -6 mRNA and protein concentrations in an animal model of inflammatory 
joint disease, they also failed to show any correlation for TNFa mRNA and protein 
concentrations (Rioja et al, 2004). The difficulties of relating mRNA concentrations to protein 
concentrations has been extensively documented elsewhere, but it is also important to 
consider that real -time PCR is an exquisitely sensitive technique and that what we are 
detecting in some patients, although elevated, may have little or no functional significance as 
it may not be translated into protein. Cytokine protein concentrations are, therefore, likely to 
be a more robust measure of tissue cytokine activity than mRNA levels. 
Inflammatory cell infiltrate 
The presence of chronic inflammation (atrophic gastritis and oesophagitis) has been 
implicated in cancer development (Limburg et al, 2005). Both Barrett's metaplasia and 
Helicobacter- related gastritis are associated with a lymphocytic infiltrates (Biddlestone et al, 
1998; Sung et al, 2000). The presence of an inflammatory cell infiltrate within tumour tissue 
and its relevance to tumour biology has been the subject of extensive current research. This 
topic has been described in detail in the General Introduction (Chapter II). Tumour -associated 
macrophages (TAM's) and tumour -infiltrating lymphocytes (TIL's) are commonly identified 
159 
within tumour tissue, and up to 60% of the tumour mass may be accounted for by host 
immune cells (van Ravenswaay -Claasen et al, 1992). The natural immune functions of these 
cells may be subverted by tumour -produced mediators, including cytokines. This creates a 
local environment favouring tumour growth and progression and attaining the tumour immune 
privilege (Chiou et al, 2005; Nakagomi et al, 1993; Curiel et al, 2004). 
The present study aimed to investigate the contribution of an inflammatory cell 
infiltrate towards the generation of systemic inflammation. A chronic inflammatory cellular 
infiltrate was noted in 75% of tumour samples and was associated with elevated serum 
concentrations of CRP and sTNF -R. However, there were no differences in tissue cytokine 
concentrations (mRNA or protein) between tumours with a chronic inflammatory infiltrate and 
those without. This may suggest that the differential tissue cytokine expression is likely to be 
tumour -cell derived. Moreover, that IL-1S may be the key cytokine driving the systemic 
inflammatory response in patients with gastro -oesophageal cancer. Alternatively, these 
findings also support the theory that host immune cells are activated as they pass through the 
tumour mass and these cells then release elevated pro -inflammatory cytokine concentrations 
at the site of distant target tissues, for example inducing an APPR in the liver. In order to take 
this hypothesis further, attempts were made to measure cytokine concentrations in individual 
cell populations found within the tumour tissue, such as cancer cells, immune cells, and host 
stromal cells. To perform this task individual cell types need to be isolated. Laser capture 
microdissection (LCM) enables single cell types to be separated from multiple cell 
populations, thereby creating a 'pure' cell population for analysis (Emmert-Buck et al, 1996). 
This technique was attempted but had to be abandoned due to inconsistent results, which 
were related to poor RNA quality as a consequence of this technique. In addition, 
determination of cellular cytokine protein concentrations by the cytometric bead array system 
following LCM was not possible due to the low protein concentrations that were retrieved. 
Conclusions 
Systemic inflammation is present in 43% of patients with gastro -oesophageal cancer at the 
time of diagnosis. In this study, we have shown that pro -inflammatory cytokine concentrations 
(mRNA and protein) are significantly elevated in tumour tissue from patients with gastro- 
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oesophageal cancer when compared with concentrations measured in tissue sampled from 
healthy controls. Moreover, tumour tissue IL-113 concentrations are highly expressed and are 
positively associated with markers of systemic inflammation. In addition, a chronic 
inflammatory cellular infiltrate was identified in 75% of tumours and was also associated with 
elevated markers of systemic inflammation (CRP), but was not associated with elevated 
tissue cytokine mRNA and protein concentrations. This may suggest that the differential 
tissue cytokine expression is tumour -cell derived. Both a chronic inflammatory cell infiltrate 
and tumour tissue IL-1p over -expression are potential key initiators of systemic inflammation 
in patients with oesophagogastric cancer. Differential over -expression of IL-1p appears not to 
be related to the presence of a host cell chronic inflammatory infiltrate and may be 
host/tumour dependent. 
To explore the influence of the host on the propensity to generate systemic 
inflammation in association with cancer, the next Chapter investigated the link between host 
cytokine genotype and the presence of systemic inflammation. Cytokine genotypes were 
compared with tumour tissue cytokine concentrations, markers of systemic inflammation, and 
with outcome in patients with gastro -oesophageal cancer. 
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CHAPTER VI 
THE LINK BETWEEN HOST CYTOKINE GENOTYPE, TUMOUR TISSUE 
CYTOKINE CONCENTRATIONS, MARKERS OF SYSTEMIC 
INFLAMMATION, AND ADVERSE PROGNOSIS IN PATIENTS WITH 
GASTRO -OESOPHAGEAL CANCER 
Deans DAC, Rose -Zerilli M, Wigmore SJ, Ross JA, Howell WM, Jackson AA, 
Grimble RF, Fearon KCH 
Host cytokine genotype is related to adverse prognosis and systemic inflammation in 
gastro -oesophageal cancer. 
Annals of Surgical Oncology 2007; 14(2): 329 -339 
162 
ABSTRACT 
This Chapter examined the role of host cytokine genotype in the generation of systemic 
inflammation. The pattern of cytokine genotype expression in a cohort of patients with gastro- 
oesophageal cancer was documented and the link between host genotype, tumour tissue 
cytokine concentrations, markers of systemic inflammation, and adverse prognosis 
investigated. 
Two hundred and three patients underwent SNP genotyping by TaqMan allelic 
discrimination genotyping. A control population was also genotyped (266 healthy volunteers). 
Blood was collected from every patient for determination of serum CRP and serum cytokine 
concentrations by ELISA. Tumour tissue was collected from 53 patients at the time of surgery 
and tissue cytokine mRNA concentrations were measured by real -time PCR and tissue 
protein concentrations were determined by a cytometric bead array system. 
Distribution of the cytokine genotypes was similar between patients and controls. The 
IL -6 -174 CC and IL -10 -1082 GG genotypes were associated with elevated serum CRP 
(p =0.03, p =0.01 respectively; Mann -Whitney U test) and sTNF -R (p= 0.015, p =0.02) 
concentrations. In addition, the IL -6 -174 CC was associated with elevated IL -6, IL -10 and IL- 
12 tumour tissue concentrations. Both these genotypes were also associated with reduced 
survival duration (p= 0.004, p= 0.047; log -rank test). TNFa AA genotype was also associated 
with reduced survival duration on univariate (p= 0.020) and multivariate analysis (p= 0.006, 
Cox's multivariate model), but not with inflammatory markers. No other cytokine 
polymorphisms were associated with systemic /tissue inflammatory markers or prognosis. 
The host genotype may influence levels of pro -inflammatory cytokine production in 
host immune cells or cancer cells or both, which, in turn, may influence the generation of 
systemic inflammation in cancer patients. Furthermore, cytokine genotypes are associated 
with adverse prognosis among patients with gastro -oesophageal cancer that may act in 
association with, but not entirely with, an inflammatory mediated mechanism. 
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INTRODUCTION 
The previous Chapters identified that patients with gastro -oesophageal cancer have elevated 
concentrations of serum acute phase proteins and 43% have evidence of systemic 
inflammation at the time of diagnosis (Chapter IV). In addition, pro -inflammatory cytokine 
concentrations within tumour tissue were significantly elevated and tumour IL -1p 
concentrations correlated with systemic markers of inflammation (Chapter V). Furthermore, a 
chronic inflammatory cell infiltrate was found in 75% of tumours and this finding was also 
associated with elevated markers of systemic inflammation, but was not associated with 
differences in tumour tissue cytokine concentrations (Chapter V). Therefore, both a chronic 
inflammatory cell infiltrate and tumour tissue IL-1p over -expression are potential key initiators 
of systemic inflammation in patients with oesophagogastric cancer. 
It is unclear why some patients develop a systemic inflammatory response in 
association with cancer while others do not. Possible explanations include tumour 
characteristics, where a particular tumour phenotype may produce pro -inflammatory cytokines 
and other mediators that may incite an inflammatory response. Alternatively, the host immune 
cells may be responsible for the primary stimulus for systemic inflammation. Either way the 
interactions between host and tumour cells are crucial to the development of cancer - 
associated inflammation. This Chapter examined the role of host cytokine genotype in the 
generation of systemic inflammation. The key hypothesis being that cytokine genotype may 
influence the ability of the host to generate a systemic inflammatory reaction in association 
with cancer. In this Chapter the pattern of cytokine genotype expression in a cohort of 
patients with gastro -oesophageal cancer is documented and the potential link between host 
genotype, tumour tissue cytokine concentrations, markers of systemic inflammation, and 
adverse prognosis was investigated. 
Variations in genotype for a number of cytokines have been associated with changes in both 
serum cytokine and serum acute phase protein concentrations and prognosis among patients 
with cancer. IL -113 polymorphisms have previously been shown to influence the generation of 
systemic inflammation and survival in patients with pancreatic cancer (Barber et al, 2000). 
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The possession of the less common allele 2 was associated with increased levels of serum 
CRP concentrations, increased production of IL -16 by peripheral blood mononuclear cells, 
and reduced overall survival. 
A single nucleotide polymorphism (SNP) at the -308 position of the TNFa gene lies 
within the promoter region and the A allele has been associated with higher levels of TNFa 
production in vitro following stimulation with endotoxin (Louis et al, 1998). Variation at the - 
308 locus has been associated with conflicting levels of TNFa production both in in vitro 
studies and among patients with sepsis (Mira et al, 1999; Stuber et al, 1995). Other work, 
again on pancreatic cancer patients, found no link between genotype and serum soluble TNF 
receptor (sTNF -R) concentrations or serum CRP concentrations (Barber et al, 1999b). There 
was a trend for reduced survival duration associated with possession of the AA genotype, but 
this did not reach statistical significance (p= 0.13). Another group identified that possession of 
the A allele was associated with elevated serum sTNF -R concentrations in patients with non - 
Hodgkin's lymphoma and that was associated with reduced overall survival (Juszczynski et al, 
2002). 
A SNP at the -252 locus of the lymphotoxin a (LTa) [tumour necrosis factor f3] gene 
has also been shown to modify levels of TNF production. Septic surgical patients 
homozygous for the AA genotype had significantly higher mortality than those patients who 
were homozygous for GG (Stuber et al, 1996). In patients with cancer, homozygotes had a 
more favourable prognosis than heterozygotes in advanced lung cancer and patients 
possessing the type 1 allele were shown to have poorer survival in oesophageal cancer 
(Shimura et al, 1994; O'Mahony et al, 1998). 
A SNP at -174 in the IL -6 promoter region has been associated with increased serum 
IL -6 concentrations and worse outcome among cardiac surgery patients (Burzotta et al, 
2001). Survival data for cancer patients is conflicting. The possession of the C allele has been 
associated with earlier stage disease and better outcome (independent of stage) in women 
with ovarian cancer and breast cancer (Hefler et al, 2003; DeMichele et al, 2003). However, 
the same genotype has also been associated with adverse survival in another group of 
patients with breast cancer (lacopetta et al, 2004). 
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IL -10 is generally regarded as an anti -inflammatory cytokine important in the attenuation of 
the inflammatory response. The IL -10 gene polymorphism at position -1082 lies within the 
promoter region and the AA genotype is generally thought to be associated with reduced 
levels of IL -10 production, but this is contradicted by one study (Tagore et al, 1999; Huizinga 
et al, 2000). The high IL -10 producer genotype (GG) has been linked with more advanced 
stage among patients with gastric cancer (Wu et al, 2003). 
With a view to understanding more clearly the role of host genotype in the genesis of 
tumour -related systemic inflammation this study examined the relationship between cytokine 
polymorphisms (IL -116` -511, IL -6 -174, 1L -10 -1082, TNFa -308, and LTa +252), tumour tissue 
cytokine concentrations, markers of systemic inflammation, and adverse prognosis in patients 
with gastro -oesophageal cancer. 
MATERIALS AND METHODS 
Study Patients 
Patients diagnosed with gastric or oesophageal cancer between March 2002 and May 2004 
within Lothian and Borders regions were invited to take part in the study. This was the same 
patient cohort as previously described in Chapter IV. All patients were eligible for genotyping 
and measurement of serum inflammatory markers (serum cytokines and acute phase 
proteins). Only those patients who underwent surgical resection were eligible for 
determination of tissue cytokine concentrations (see Chapter V). Duration of survival, defined 
as time from histological diagnosis to death, was recorded for all patients. 
Cytokine Genotyping 
Study patients were genotyped by TaqMan allelic discrimination genotyping as described in 
Chapter III. In addition to the patient group, blood samples were also collected from healthy 
controls for genotyping. The control group used in this study comprised 266 British Caucasian 
bone marrow and solid organ donors, collected via the Histocompatibility & Immunogenetics 
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Laboratory, Southampton University Hospitals. The mean age of these controls (140 males, 
126 females) was 39 years at the time of blood collection (age range 3 -69). All cytokine 
genotyping results in this control group have been published previously (Howell et al, 2005; 
Smith et al, 2004). 
Determination of serum cytokine and serum CRP concentrations 
CRP concentrations were measured as a representative of the acute phase response and as 
a surrogate marker for the presence of systemic inflammation. Serum CRP and serum 
cytokine concentrations were measured by ELISA as previously described in Chapter Ill. 
Determination of tissue cytokine mRNA and protein concentrations 
Samples of tumour tissue were collected from patients at the time of surgical resection and 
tissue cytokine mRNA and protein concentrations were measured by quantitative PCR and 
cytometric bead array as described in Chapters III and V. 
Histological Analysis 
Representative sections of tumour tissue were prepared from each patient who underwent 
surgical resection. Specimens were fixed with formalin and stained with haematoxylin and 
eosin. The extent of chronic inflammatory cell infiltrate was assessed by a Consultant 
pathologist as described in Chapter V. Samples were classified as having a scanty diffuse 
chronic inflammatory cell infiltrate, a diffuse chronic inflammatory cellular infiltrate present 
throughout the whole tissue, or focal lymphoid aggregates only. 
Statistical Analysis 
Comparisons between groups of continuous variables were made by the Mann -Whitney U 
test. Categorical variables were compared by the Chi -squared test. Correlations between 
continuous variables were assessed by the Spearman rank correlation coefficient. Survival 
between groups was analysed by the log -rank test and Cox's proportional hazard's model 
was used for multivariate analysis. A P value <_ 0.05 was considered statistically significant. 
Significant P values were corrected for multiple comparisons using Bonferroni correction. 
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RESULTS 
Genotype expression and patient characteristics 
Patient demographics are shown in Table 6.1. 203 patients were genotyped. Cytokine 
genotype was not associated with patient age or sex or any other demographic 
characteristics. Neither was there any association with any pathological characteristics, such 
as tumour stage, histological subtype or tumour grade. In particular, the IL -113 polymorphism 
was not associated with an increased risk of distal gastric cancer, which has been reported 
previously (Lee et al, 2003) (data not shown). 
Table 6.1 Study patient demographics (n =203) 
Number [ %] 
Age (years) * 71 (62 -78) 
Sex Male 134 [66] 
Female 69 [34] 
Tumour Site Oesophageal 91 [45] 
Oesophago -gastric junction 37 [18] 
Gastric 75 [37] 
Histology Adenocarcinoma 172 [85] 
Squamous cell carcinoma 26 [13] 
Indeterminate 5 [2] 
Grade Well differentiated 5 [2] 
Moderately differentiated 69 [34] 
Poorly differentiated 129 [64] 
UICC Stage 1 23 [12] 
2 33 [16] 
3 76 [37] 
4 71 [35] 
Treatment undertaken Surgery with curative intent 91 [45] 
Pre -operative chemotherapy /Surgery 22 [11] 
Chemoradiotherapy with curative intent 7 [3] 
Palliative Chemotherapy 24 [12] 
Palliative Radiotherapy 6 [3] 
Stent/dilatation/laser/sym ptomatic 53 [26] 
'Values are median (interquartile range). 
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Prevalence of genotype expression 
The prevalence of cytokine genotypes is presented in Table 6.2. There was a significant 
difference between cases and controls with the IL-1[3 -511 CC (p =0.01, OR = 1.664 (95% CI = 
1.137- 2.434)) and CT (p =0.03, OR = 0.657 (95% CI = 0.453 -0.955) genotypes, but this did 
not remain so when corrected for multiple comparisons, making this finding most likely 
occurring due to chance. There were no significant differences between cancer patients and 
healthy controls in the distribution of any of the other genotypes. All genotype frequencies in 
both the patient and control groups were distributed in accordance with the Hardy -Weinberg 
equilibrium except for the IL -6 patient group (p= 0.05), the TNFa control group (p =0.04) and 
the LTa control group (p= 0.002). 
Table 6.2 Allelic distribution of cytokine genotypes among the study population. 
Significant P values were corrected for multiple comparisons using Bonferroni correction 
(values in parenthesises). 




P value* ORt (95% Cl) 
IL-113 -511 CC 89 (45.4) 87 (33.3) 0.01 (0.06) 1.664 (1.137- 2.434) 
CT 81 (41.3) 135 (51.7) 0.03 (0.15) 0.657 (0.453 -0.955) 
TT 26 (13.3) 39 (14.9) n/s Ref§ 
HWEt 0.27 0.25 
IL -6 -174 GG 71 (36.0) 79 (35.3) n/s 1.034 (0.694- 1.541) 
GC 83 (42.1) 101 (45.1) n/s 0.887 (0.603- 1.304) 
CC 43 (21.8) 44 (19.6) n/s Ref 
HWE 0.05 0.26 
IL -10 -1082 GG 54 (27.0) 57 (25.6) n/s 1.077 (0.699- 1.659) 
AG 93 (46.5) 120 (53.8) n/s 0.746 (0.509- 1.093) 
AA 53 (26.5) 46 (20.6) n/s Ref 
HWE 0.32 0.24 
TNFa -308 GG 124 (62.0) 146 (68.2) n/s 0.760 (0.507- 1.139) 
AG 61 (30.5) 56 (26.2) n/s 1.238 (0.808- 1.898) 
AA 15 (7.5) 12 (5.6) n/s Ref 
HWE 0.06 0.04 
LTa +252 AA 82 (42.1) 92 (41.8) n/s 1.010 (0.684- 1.491) 
AG 84 (43.1) 83 (37.7) n/s 1.249 (0.844- 1.850) 
GG 29 (14.9) 45 (20.5) n/s Ref 
HWE 0.33 0.002 
tOdds Ratio. $P value for Hardy -Weinberg Equilibrium (HWE) (Chi- squared test). Reference Genotype. 
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Link between cytokine genotype and markers of systemic inflammation 
Eighty -two (41 %) patients had evidence of systemic inflammation (CRP >10mg /I). The 
median serum concentration of IL -6 was 9.1pg /ml (interquartile range 0- 88pg /m1), IL -8 median 
concentration 0 pg /ml ( interquartile range 0 -118 pg /ml), and for sTNF -R the median 
concentration was 3.3ng /mI ( interquartile range 1.9- 5.8ng /m1). IL -13 and IL -10 were only 
detectable in 4 (2 %) and 10 (5 %) patient's serum respectively. 
The IL -6 CC homozygous genotype was associated with significantly elevated serum CRP 
concentrations when compared with GC and GG genotypes (median 13mg /I [range 4- 35mg /I] 
versus median 6mg /I [range 2- 22mg /I]) (p =0.03, Mann -Whitney U test) (Figure 6.1A). This 
genotype was also associated with elevated serum sTNF -R concentrations (p= 0.015; Mann - 
Whitney U test). 
The GG homozygous IL -10 genotype was also associated with elevated serum CRP 
concentrations (median 16mg /I [range 3- 34mg /I]) when compared with the AA genotype 
(median 6mg /I [range 3- 13mg /I]) (p =0.02, Mann -Whitney U test) and the AG genotype 
(median 5mg /I [range 2- 24mg /I]) (p =0.03) (Figure 6.1B). The GG genotype was also 
associated with elevated serum sTNF -R concentrations (p =0.05; Mann -Whitney U test). 
Possession of both of these genotypes (IL -6 CC and IL -10 GG) was associated with 
increasing serum CRP concentrations (p= 0.013, Chi square test) (Figure 6.2). None of the 
other cytokine genotypes were associated with serum CRP or serum cytokine concentrations. 
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Figure 6.1 Serum C- reactive protein (CRP) concentrations presented by (A) interleukin -6 
(IL -6) genotype (GG = 71 patients, GC = 83 patients, CC = 43 patients) and (B) interleukin -10 
(IL -10) genotype (AA = 53 patients, AG = 93 patients, GG = 54 patients). The lines represent 
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Figure 6.2 Possession of one or both of the following genotypes, IL -6 CC and IL -10 GG, 
was associated with increasing serum CRP concentrations (p= 0.013, Chi squared test). 
CRP (mg /I) 
Number of 1 a genotypes 2 
Cummulative genotype 
*p <0.05 
Link between cytokine genotype and markers of tissue inflammation 
(a) Tissue cytokine mRNA and protein concentrations 
The IL -6 CC genotype was associated with elevated tumour tissue IL -6 (p= 0.029; Mann - 
Whitney U test), IL -10 (p= 0.009), and IL -12 (p= 0.012) protein concentrations (Table 6.3) 
(Figure 6.3). There was also a trend for elevated tissue TNFa concentrations, but this did not 
quite reach statistical significance (p= 0.08). Additionally, the IL-113 AA genotype was linked 
with reduced tumour IL -8 concentrations when compared with the GG genotype (p= 0.021) 
and the AG genotype (p= 0.042). None of the other genotypes were associated with tissue 
cytokine protein or mRNA concentrations. 
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Table 6.3 The association between host IL -6 genotype and tumour tissue cytokine 
concentrations measured by cytometric bead array (pg /mg total protein). The IL -6 CC 
genotype was associated with elevated tumour tissue cytokine concentrations. 
Tumour Cytokine 
(pg /mg total protein) 
IL -6 -174 Genotype 






















Values are median (interquartile range). "Mann-Whitney U test. 
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Figure 6.3 The IL -6 CC genotype was associated with elevated tumour tissue cytokine 
concentrations. A) IL -6 (p= 0.029); B) IL -10 (p= 0.009); C) IL -12 (p= 0.012); and D) TNFa 



















(b) Histological analysis 
Tissue sections were available for 53 of the 203 patients genotyped (see Chapter V). 24 
(45 %) tumour samples were classified as having scanty diffuse or patchy chronic 
inflammatory cells. 16 (30 %) had a diffuse chronic inflammatory cellular infiltrate visible 
throughout the whole tumour. The remaining 13 (25 %) tumour sections had focal lymphoid 
aggregates only. There was no association between the extent of inflammatory cell infiltrate 
into the tumour tissue and any of the cytokine genotypes. 
Association between cytokine genotype and survival duration 
Survival of patients by genotype is presented in Figures 6.4 and 6.5. Possession of the CC 
genotype for IL -6 was associated with reduced survival duration when compared with GG or 
GC genotype (median survival 8.4 months versus 14.1 months) (p= 0.004; Log -rank test) 
(Figure 6.4A). The homozygous genotype GG for IL -10 was associated with reduced survival 
compared with AA/AG genotypes (median survival 10.2 months versus 12.8 months, 
p= 0.047) (Figure 6.4B). Similarly, AA homozygosity for the TNFa genotype was associated 
with adverse prognosis (median survival 6.4 months versus 13.4 months, p= 0.020) (Figure 
6.4C). Furthermore, the cumulative possession of more than one of these genotypes was 
associated with reduced survival (no alleles, median survival 16.8 months; 1 allele, median 
survival 8.5 months; 2 or 3 alleles, median survival 8.8 months; p= 0.001) (Figure 6.5). 
Genotypes for IL -113 and LTa were not associated with prognosis. 
Figure 6.4 Kaplan -Meier survival plots presented by (A) interleukin -6 (IL -6) genotype 
(CC median survival 8.4 months [heavy line], GC /GG median survival 14.1 months [light line]) 
(p= 0.004; Log -rank test) and (B) interleukin -10 (IL -10) genotype (GG median survival 10.2 
months [heavy line], AA/AG median survival 12.8 months [light line]) (p= 0.047) and (C) 
tumour necrosis factor a (TNFa) genotype (AA median survival 6.4 months [heavy line], 
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Figure 6.5 Kaplan -Meier survival plot stratified for the cumulative possession of 
interleukin -6 (IL -6) CC genotype, interleukin -10 (IL -10) GG genotype and tumour necrosis 
factor a (TNFa) AA genotype. Possession of no alleles (light line), median survival 16.8 
months; 1 allele (medium line), median survival 8.5 months; 2 or 3 alleles (heavy line), 
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Multivariate survival analysis 
Multivariate analysis identified the AA genotype for TNFa as an independent adverse 
prognostic indicator when tested with age, sex, stage of disease, grade of tumour and serum 
CRP concentration (p= 0.006, hazard ratio 2.5; Cox's proportional hazard's model) (Table 
6.4). Increasing age, male sex, advanced disease stage, elevated serum CRP concentration, 
and the TNFa AA genotype were all independently associated with poor prognosis. 
Genotypes for IL -6 and IL -10 were not independent prognostic indicators (p =0.48 and p =0.18 
respectively). 
Table 6.4 Multivariate survival analysis of 203 patients with gastro -oesophageal cancer 
using Cox's proportional hazard's model. A hazard ratio greater than 1 represents an 
increased risk of death. Increasing age, male sex, advanced disease stage, elevated serum 
CRP concentration, and the TNFa AA genotype were all independently associated with poor 
prognosis. 
Variable P value Hazard Ratio 95% Cl 
Age 0.007 1.2 1.0 -1.3 
Sex 0.04 1.8 1.0 -3.0 
Stage of disease <0.001 2.4 1.8 -3.2 
Grade of tumour 0.88 1.0 0.7 -1.6 
Serum CRP 0.002 1.1 1.0 -1.2 
TNFa AA genotype 0.006 2.5 1.3 -4.9 
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DISCUSSION 
This Chapter has investigated the influence of host cytokine genotype on serum markers of 
systemic inflammation and tumour tissue cytokine concentrations. IL -6 -174 CC and IL -10 - 
1082 GG genotypes were associated with elevated markers of systemic inflammation (serum 
CRP and sTNF -R concentrations) and the IL -6 -174 CC genotype was also associated with 
elevated tumour tissue cytokine concentrations (IL -6, IL -10 and IL -12). These two genotypes 
were also linked with adverse prognosis. In addition, the TNFa -308 AA genotype was also 
linked with adverse outcome and was identified as an independent prognostic indicator, but 
this genotype was not associated with markers of systemic inflammation. These findings 
suggest that the cytokine genotype of the host may influence the ability of the patient to 
generate a systemic inflammatory response in association with gastro -oesophageal cancer. In 
addition, cytokine genotype may influence prognosis in these patients. 
Genotype prevalence in the study population 
The distributions of genotypes were similar between cancer patients and controls in this study 
and frequencies were similar to those previously published in studies of similar populations 
(Howell et al, 2005; Smith et al, 2004). Although we did identify an association between 
gastro -oesophageal cancer and the IL -13 -511 CC genotype, this relationship lost its 
significance following correction for multiple comparisons. EI -Omar et al have proposed an 
association between IL -1 3 polymorphisms and an increased risk of gastric cancer among 
patients with Helicobacter pylori infection (El -Omar et al, 2000). We found no such 
association on sub -group analysis and other groups have similarly failed to demonstrate such 
an association (Lee et al, 2003; Kato et al, 2001). 
Cytokine genotype and serum /tissue markers of inflammation 
The IL -6 CC genotype was associated with elevated serum concentrations of CRP and sTNF- 
R. A previous study of healthy volunteers identified the presence of the -174C allele to be 
associated with higher baseline CRP levels (Westerberg et al, 2004). In cancer patients the 
rates of production of IL -6 can be linked to markers of systemic inflammation such as CRP. 
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Although our study did not identify any association between IL -6 genotype and serum IL -6 
concentrations, we did find an association with the CC genotype and tumour tissue cytokine 
concentrations (including IL -6). It is possible that the CC genotype may be associated with 
elevated IL -6 production, which acts at the tissue level to promote an acute phase response. 
The similar association between IL -6 genotype and sTNF -R may reflect the more stable 
nature of the receptor molecule compared with the other cytokines, and in this regard sTNF -R 
may behave more as a marker of systemic inflammation. The positive association between 
the IL -6 CC genotype and tumour tissue cytokine concentrations occurred without apparent 
differences in the level of chronic inflammatory cellular infiltrate into the tissues. It is therefore 
possible that this genotype is associated with elevated tumour cell production of these 
cytokines, which, in turn, can be linked with markers of systemic inflammation (CRP). 
We also found an association between the GG IL -10 genotype and elevated serum 
CRP and sTNF -R concentrations. The -1082 AA polymorphism is generally thought to be 
associated with reduced levels of IL -10 production (Tagore et al, 1999). One would therefore 
expect the GG genotype to be associated with increased levels of IL -10 production. An 
association between increased levels of an anti -inflammatory cytokine and elevated 
concentrations of acute phase proteins may initially appear contradictory, but may simply 
reflect the increased counter -regulatory activity of this important anti -inflammatory mediator in 
response to the presence of systemic inflammation. 
We found no association between IL-15, TNFa, or LTa genotypes and CRP 
concentrations. In pancreatic cancer patients an association between allele 2 IL-113 genotype 
and elevated serum CRP levels has been documented, but in the present study there was no 
such association between the SNP at position -511 and CRP levels (Barber et al, 2000). 
Similarly, there was no association between TNFa polymorphisms and CRP, a finding also in 
support of previous work on pancreatic cancer patients (Barber et al, 1999b). Data relating to 
the -308 polymorphism and levels of TNFa production remain contradictory, however 
polymorphisms at this locus do not appear to influence serum CRP levels. Serum CRP 
concentrations were measured in a group of patients who had undergone cardiac surgery and 
this study did not find any differences between CRP levels and TNFa -308 genotypes 
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(Gander et al, 2004). Another group similarly failed to demonstrate differences in CRP 
concentrations by -308 genotype among smokers (EI -Omar et al, 2000). 
This study failed to show any association between cytokine genotype and serum 
cytokine concentrations (except for sTNF -R). This lack of association between serum cytokine 
concentrations and serum acute phase protein concentrations, tissue cytokine concentrations, 
and now cytokine genotypes simply reinforces the feeling that circulating cytokines have little 
functional relevance in systemic inflammation. It would seem that local tissue cytokine 
concentrations are the key determinant. IL -1 ß genotype has been linked with levels of IL-113 
production by peripheral blood mononuclear cells (PBMC) in pancreatic cancer patients, but 
not with serum IL -1 ß concentrations (Barber et al, 2000). PBMC production of IL -113 may 
better reflect tissue IL-1[3 levels rather than circulating concentrations. 
Cytokine genotype and prognosis 
The IL -6 -174 CC and the IL -10 -1082 GG genotypes were associated with reduced survival 
duration. The association between systemic inflammation and adverse prognosis among 
cancer patients has been well documented and in this study we have shown these two 
genotypes to be associated with elevated acute phase protein (CRP) concentrations. It is 
therefore possible that the adverse prognosis associated with these polymorphisms is related 
to the presence of systemic inflammation. This is supported by multivariate analysis where 
these genotypes lost their significance as prognostic indicators when CRP was co- analysed. 
The CC IL -6 genotype has been linked with adverse prognosis among breast cancer patients, 
where possession of the CC polymorphism was associated with higher grade tumours and 
worse overall survival (lacopetta et al, 2004). The GG genotype for IL -10 -1082 has 
previously been linked with advanced stage and reduced survival in gastric cancer patients 
(Wu et al, 2003). 
We also found the AA TNFa -308 genotype to be related to adverse prognosis. In 
contrast to the IL -6 and IL -10 genotypes, we found no association between TNFa 
polymorphisms and systemic inflammation. It is therefore less likely that the reduced survival 
associated with this cytokine is related entirely to the generation of an inflammatory response. 
In addition, the AA genotype was an independent prognostic indicator on multivariate 
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analysis, independent of CRP concentration, stage and other clinico- pathological 
characteristics that have previously been associated with adverse prognosis. The AA 
genotype has previously been associated with reduced survival in pancreatic cancer patients 
and other groups have similarly found the possession of the A allele to be linked with adverse 
outcome in patients with non -Hodgkin's lymphoma (Barber et al, 1999b, Juszczynski et al, 
2002). However, the AA genotype was only identified in 8% of patients, making it less useful 
in the clinical setting. The association between systemic inflammation and prognosis will be 
explored in detail in Chapter IX. 
Conclusions 
IL -6 CC and IL -10 GG genotypes are associated with markers of systemic inflammation in 
patients with gastro -oesophageal cancer. In addition, the IL -6 CC genotype is linked with 
elevated tumour tissue cytokine concentrations, but not with an increased chronic 
inflammatory cell infiltrate. In the previous Chapter, elevated tumour tissue cytokine 
concentrations have been identified in patients with systemic inflammation and tissue 
concentrations of IL-113 have been correlated with serum CRP concentrations. It is likely that 
the host genotype may influence levels of pro -inflammatory cytokine production in host 
immune cells or cancer cells or both. These increased cytokine levels can be measured in the 
tumour tissue and are associated with elevated serum acute phase protein concentrations 
and this translates into the generation of systemic inflammation. In addition, these genotypes 
are markers of adverse outcome in patients with gastro -oesophageal malignancy, possibly 
through the association with systemic inflammation. The association between systemic 
inflammation and prognosis will be explored further in Chapter IX. 
The TNFa AA genotype was also linked with adverse prognosis and this association 
was independent of systemic inflammation. Therefore, there is a pro -inflammatory cytokine 
haplotype (IL -6 CC, IL -10 GG and TNFa AA) that is associated with adverse prognosis 
among patients with gastro -oesophageal cancer that may act in association with, but not 
entirely with, an inflammatory mediated mechanism. 
The previous Chapters have so far investigated the role of cytokines in the aetiology 
of systemic inflammation in patients with gastro -oesophageal cancer. The following two 
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Chapters (VII and VIII) will investigate the role of tumour -derived mediators in the aetiology of 
systemic inflammation in these patients. The two mediators that will be studied are 
parathyroid hormone -related peptide (PTHrP) and proteolysis- inducing factor (PIF). 
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CHAPTER VII 
SERUM PARATHYROID HORMONE -RELATED PEPTIDE (PTHrP) AS A 
POTENTIAL MEDIATOR OF SYSTEMIC INFLAMMATION AND IT'S 
RELATIONSHIP TO ADVERSE PROGNOSIS AND ADVERSE 
NUTRITIONAL STATUS IN PATIENTS WITH GASTRO- OESOPHAGEAL 
CANCER 
Deans DAC, Black J, Paterson -Brown S, Wigmore SJ, Ross JA, Fearon KCH. 
Serum parathyroid hormone -related peptide (PTHrP) contributes to systemic 
inflammation and is associated with adverse prognosis in gastro -oesophageal cancer 
Cancer 2005; 103(9): 1810 -1818 
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ABSTRACT 
Serum concentrations of parathyroid hormone -related peptide (PTHrP) have been linked with 
elevated markers of systemic inflammation, cachexia and adverse outcome in patients with 
cancer. This Chapter investigated PTHrP expression in a cohort of patients with gastro- 
oesophageal malignancy and examined the role of PTHrP as a potential mediator of systemic 
inflammation. Any relationship with adverse prognosis and adverse nutritional status in these 
patients was also investigated. 
Blood was collected from patients at the time of diagnosis for determination of PTHrP 
(radio- immunoassay), calcium, and serum cytokines and acute phase proteins (ELISA) 
concentrations. Nutritional assessment was undertaken at the same time as serum collection. 
Patients underwent routine staging and treatment and survival duration was recorded. Around 
one -third of patients had an additional serum PTHrP measured approximately three months 
following the initial measurement. 
151 patients were studied. Six (4 %) patients were hypercalcaemic. 17% patients had 
elevated serum PTHrP levels at diagnosis and 49% patients had elevated levels at three 
months, irrespective of treatments undertaken. There was no association between PTHrP and 
serum calcium concentrations. An elevated serum PTHrP concentration was associated with 
markers of systemic inflammation (elevated concentrations of serum CRP and sTNF -R and 
reduced concentrations of albumin and transferrin). Elevated PTHrP concentrations were also 
linked with reduced survival duration, but this did not reach significance on longer follow -up 
(p= 0.23). PTHrP concentrations measured later in the course of the disease (3 months) 
correlated significantly with markers of adverse nutritional status. 
These findings suggest that PTHrP may play a role in the generation of systemic 
inflammation in patients with gastro -oesophageal malignancy. Therefore, mediators other 
than pro -inflammatory cytokines, such as PTHrP, may contribute to the generation of 
systemic inflammation among some patients with cancer. The relationship between systemic 
inflammation and cachexia /decreased survival may provide a possible indirect role for PTHrP 
in these processes. 
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INTRODUCTION 
In order to investigate further the aetiology of systemic inflammation in patients with gastro- 
oesophageal cancer attention is now directed towards the potential role of tumour -derived 
factors. Both parathyroid hormone -related peptide (PTHrP) and proteolysis- inducing factor 
(PIF) have been linked with elevated markers of systemic inflammation in animal and human 
studies (Ogata, 2000; Takahashi et al, 2003; Pollock et al, 1996; Funk et al, 1997; Funk et al, 
1998). These mediators have also been associated with cachexia and adverse outcome in 
patients with cancer (Iguchi et al, 2001; Todorov et al, 1996; Wigmore et al, 2000; Cariuk et 
al, 1997; Cabal -Manzano et al, 2001). PIF was investigated in Chapter VIII. This Chapter 
investigated the role of PTHrP as a potential mediator of systemic inflammation in the cohort 
of patients with gastro -oesophageal malignancy and examined any relationship with adverse 
prognosis and adverse nutritional status in these patients. 
Parathyroid hormone -related peptide (PTHrP) 
PTHrP is a tumour -derived circulating factor that has been associated with hypercalcaemia of 
malignancy, affecting up to 20% of patients during the advanced stages of cancer (Twycross, 
1997; Suva et al, 1987). Elevated serum PTHrP has been reported in 50 -90% of 
hypercalcaemic cancer patients (Truong et al, 2003). PTHrP mimics the actions of parathyroid 
hormone on the kidneys and bone to increase serum calcium concentration. More recently, 
PTHrP has been proposed as a growth factor whose activity is thought to promote tumour 
growth, particularly aiding the formation of osteolytic bone metastases (Guise, 1997). 
Association with markers of inflammation 
PTHrP may contribute to the pro -inflammatory cytokine cascade and several studies have 
identified elevated serum PTHrP concentrations in association with elevated serum cytokine 
concentration in cancer patients (Ogata, 2000; Takahashi et al, 2003). PTHrP has been 
shown to stimulate IL -6 production from osteoblasts in vivo (Pollock et al, 1996). Funk et al 
investigated the effects of endotoxaemia on PTHrP synthesis within hepatocytes. Near -lethal 
dose of endotoxin resulted in marked induction of PTHrP mRNA levels and PTHrP protein 
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synthesis (Funk et al, 1997). In addition, administration of PTHrP to mice increased serum 
acute phase protein levels. This group also found that synovial cells from patients with 
rheumatoid arthritis produced increased levels of PTHrP, and these levels were further 
enhanced by addition of IL-16 and TNFa (Funk et al, 1998). 
PTHrP expression in gastro -oesophageal cancer 
Among patients with oesophageal cancer, elevated serum PTHrP has been described in 
association with hypercalcaemia and PTHrP mRNA and protein have also been demonstrated 
within cancer cells (Jais et al, 1997). A large series from Japan, which included 382 patients 
with oesophageal cancer identified hypercalcaemia in 1.3% of patients at the time of 
diagnosis (Tachmori et al, 1991). The incidence of hypercalcaemia increased to 38% in 
patients who were monitored within 2 months of death and this study reported a close 
association between hypercalcaemia and PTHrP levels. Similarly, elevated PTHrP production 
has been reported in association with gastric cancer (Abdeen et al, 1995; Engelich et al, 
2000). One study identified PTHrP expression within tumours cells in 71 out of 92 patients 
with gastric adenocarcinoma, none of whom had hypercalcaemia (Alipov et al, 1997). These 
authors also noted that PTHrP production was associated with poorly differentiated tumours. 
Association with cancer cachexia 
PTHrP has also been proposed as a pro -cachectic factor. PTHrP is produced by a human 
lung cancer model (HARA -B) and, when implanted into mice, results in a significant reduction 
in body weight and tissue mass, an effect that is reversed by addition of an antibody to PTHrP 
(Iguchi et al, 2001). This model was associated with elevated serum calcium levels and it is 
not clear whether the observed cachexia was due to the systemic effects induced by 
hypercalcaemia, as food intake in the weight -losing mice was lower than controls. The 
relationship of PTHrP to adverse nutritional status needs further investigation. 
Link with prognosis in cancer 
Recent interest in PTI -IrP has been directed towards its role in prognosis. A study of 76 
hypercalcaemic patients with several types of cancer with advanced stage found elevated 
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serum PTHrP in 54% (Truong et al, 2003). Increased PTHrP was an independent adverse 
prognostic indicator for patients less than 65 years of age but had no prognostic role in older 
patients. Others studies have found no association between elevated serum PTHrP and 
reduced survival (Lee et al, 1997). The detection of PTHrP within tumours themselves and its 
role in prognosis has similarly found differing conclusions. Patients with breast cancer that 
produce PTHrP were found to have a favourable prognosis in one study, but this observation 
was not corroborated by others (Henderson et al, 2001; Kissin et al, 1993). Administration of 
a PTHrP antibody to mice bearing PTHrP secreting tumours not only resulted in a reduction of 
serum calcium levels but also improved survival duration in the treated mice (Sato et al, 
1993). The role of PTHrP in determining prognosis remains unclear. 
PTHrP as a potential growth factor 
The detection of PTHrP in tumours without associated hypercalcaemia has raised the 
possibility that PTHrP may have a role in addition to calcium homeostasis, such as the 
regulation of cellular proliferation and differentiation. Epidermal growth factor (EGF) and 
transforming growth factor -ß (TGF -ß) have been implicated in the progression of gastric 
cancers and these growth factors have been found to up- regulate PTHrP gene expression in 
some cell lines (Kiriyama et al, 1993). Rats implanted with prostate cancer cells that over- 
produce PTHrP had significantly enhanced tumour growth and tumour size compared with 
controls (Dougherty et al, 1999). The gene encoding PTHrP is a downstream target for the 
proto- oncogenes K -ras and src tyrosine kinase (Li and Drucker, 1994; Kamai et al, 2001). 
While src expression is common in premalignant epithelium of Barrett's oesophagus (Kumble 
et al, 1997), c -K -ras expression is rare (Arber et al, 2000). Whether the expression of src in 
gastro -esophageal cancer correlates with increased expression of PTHrP and hypercalcemia 
is unknown but may provide a mechanism for the functional activation of tumour -derived 
PTHrP in this tumour type. Whether PTHrP expression alone is sufficient to cause 
hypercalcemia is also unclear, but a requirement for further modification might explain why 
PTHrP may be produced without associated hypercalcaemia. 
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This Chapter will, therefore, investigate the role of PTHrP as a potential mediator of systemic 
inflammation in the cohort of patients with gastro -oesophageal malignancy and examine any 
relationship with adverse prognosis and adverse nutritional status in these patients. 
MATERIALS AND METHODS 
Study population and sample collection 
The study population was the same patient cohort as described in previous Chapters. Blood 
samples were collected at the time of recruitment to the study and before any treatment was 
commenced. A second blood sample was collected from a subgroup of patients following 
initiation of treatment after a mean time interval of 95 days (range 41 -151 days) from the time 
of the first sample collection. No patients had symptoms related to possible hypercalcaemia 
and none had bone metastases identified following computerised tomography staging. None 
were receiving treatment either to supplement or reduce calcium levels. Renal function was 
assessed by measuring serum creatinine concentration and values were within the normal 
range for all patients. Clinical and pathological information was recorded for each patient, 
including treatment modality, tumour grade and histological subtype. Duration of survival, 
defined as time from histological diagnosis to death, was recorded for all patients. 
Nutritional assessment and performance status scoring 
Nutritional assessment included calculation of body mass index (BMI) and performing 
anthropometry measurements (Chapter III). Muscle wasting was not sufficiently severe to 
require correction for muscle bulk. Performance status was assessed using the Karnofsky 
index (Karnofsky and Burchenal, 1949). 
Measurement of serum PTHrP and serum calcium concentrations 
Serum cPTHrP concentrations were measured by radio -immunoassay (Daiichi, Tokyo, Japan) 
as previously described (Chapter III). Using this assay, serum PTHrP levels in healthy 
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volunteers were 13.8 - 55.3 pmol /I for males and 13.9 - 54.0 pmol /I for females (Fukunaga, 
1992). No female patients had a cPTHrP serum concentration between 54.0 - 55.3 pmol /I, 
and therefore for simplicity serum levels above 55.3 pmol /l were considered above the normal 
range for both sexes. Serum total calcium was measured by an automated analyser (Clinical 
Biochemistry Department, Edinburgh Royal Infirmary, UK). The normal range for corrected 
calcium in our laboratory is 2.12 - 2.62 mmol /I. 
Measurement of serum cytokine and serum acute phase protein concentrations 
Serum acute phase protein concentrations and serum cytokine concentrations were 
measured by ELISA as described in Chapter III. 
Statistical analysis 
Correlation between serum cPTHrP and serum calcium concentrations was tested by linear 
regression analysis. Analysis of serum cPTHrP and continuous variables was tested by the 
Mann -Whitney U test. Analysis of serum cPTHrP and categorical data was undertaken with 
chi -square test and Fisher's exact test. Log -rank analysis was used to determine prognostic 
value for univariate analysis and Cox's proportional hazard's model was used for multivariate 
analysis. A P value <_ 0.05 was considered statistically significant. 
RESULTS 
Study patient demographics 
Patient demographics are shown in Table 7.1. 151 patients were recruited to this study. Sixty 
(40 %) patients underwent surgical resection, 14 of these received pre- operative 
chemotherapy. Three patients, all of whom had squamous cell carcinoma of the oesophagus, 
received chemo -irradiation with curative intent. The remaining 88 patients received a range of 
palliative treatments, such as palliative chemotherapy, palliative radiotherapy, or insertion of a 
stent or endoscopic laser therapy. Performance status was assessed using the Karnofsky 
index. The median score was 90 (interquartile range 70 -100) and the value correlated 
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strongly with stage (p <0.0001) and mortality (p <0.0001) (data not shown). The mean follow - 
up period was 31 months (range: 22 months - 42 months). At the end of this follow -up period 
103 (68 %) patients had died. 
Table 7.1 Demographics for the whole study population (n =151). Demographics are 
also shown for the subgroup of patients who provided a second blood sample after a mean 





Number [ %] 
Age (years)' 72 (63 -78) 68 (61 -75) 
Sex Male 95 [63] 36 [71] 
Female 56 [37] 15 [29] 
Tumour Site Oesophageal 64 [42] 30 [59] 
Oesophago -gastric junction (OGJ) 28 [18] 10 [20] 
Gastric 59 [39] 11 [22] 
Histology Adenocarcinoma 132 [87] 47 [92] 
Squamous cell carcinoma 16 [11] 4 [8] 
Indeterminate 1 [1] 
Small cell carcinoma 2 [1] 
Grade Well differentiated 
Moderately differentiated 37 [25] 21 [41] 
Poorly differentiated 114 [76] 30 [59] 
UICC Stage 1 13 [9] 10 [20] 
2 24 [ 16] 11 [22] 
3 54 [36] 22 [43] 
4 60 [40] 8 [16] 
Treatment undertaken Surgery with curative intent 46 [31] 30 [59] 
Pre -operative chemotherapy + Surgery 14 [9] 13 [25] 
Chemoradiotherapy with curative intent 3 [2] 
Palliative Chemotherapy 17 [11] 
Palliative Radiotherapy 4 [3] 
Stent/dilatation /laser /symptomatic 67 [44] 8 [16] 
Survival Alive 48 [32] 32 [63] 
Dead 103 [68] 19 [37] 
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Distribution of serum cPTHrP and calcium concentrations in the study population 
The mean serum level of cPTHrP was 39.4 pmol /I (range 8.6 - 100.0 pmol /l; S.D. 17.9) 
(Figure 7.1). Twenty -six (17 %) patients had elevated cPTHrP serum levels. The mean serum 
calcium concentration was 2.29 mmol /I (range 1.67 - 2.79 mmol /I; S.D. 0.17). Twelve (8 %) 
patients were hypocalcaemic and 6 (4 %) were hypercalcaemic. There was no correlation 
between serum cPTHrP and corrected calcium levels (linear regression; r =0.03, p = 0.72) 
(Figure 7.2). Patients with elevated serum cPTHrP did not have associated elevated serum 
calcium levels (p =0.63, Mann -Whitney U Test). 
Figure 7.1 Histograms representing the distribution of serum cPTHrP concentrations 
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Figure 7.2 Scatter plot demonstrating the lack of correlation between serum calcium and 
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Association between serum PTHrP concentrations and demographic and clinical data 
cPTHrP levels and patient/tumour characteristics are outlined in Table 7.2. There was no 
association between serum cPTHrP concentration and demographic or pathological data, 
including tumour location, histology or stage. Although an association with cPTHrP and 
tumour grade did not reach significance (p= 0.24), poorly differentiated tumours were more 
likely to be associated with elevated cPTHrP levels. However, serum calcium concentrations 
were significantly higher in those patients with squamous histology (p= 0.005) and in females 
(p =0.01; both Mann -Whitney U test) (data not shown). 
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Table 7.2 Serum cPTHrP levels and patient characteristics 
Serum PTHrP (pmol /l) 
Normal Elevated 
(n =125) (n =26) 
P value 








Tumour Site Oesophageal 52 12 
Oesophago -gastric junction 24 4 0.604# 
Gastric 49 10 
Histology Adenocarcinoma 109 23 







Small cell carcinoma 2 0 
Grade Well differentiated 0 0 
Moderately differentiated 33 4 0.243# 
Poorly differentiated 92 22 








4 49 11 
Karnofsky score < 50 6 3 
60 9 4 
70 15 3 
80 20 3 0.194* 
90 33 2 
100 34 7 
Not recorded 8 4 
'Median (interquartile range). * Mann -Whitney U Test. *Chi-square test. °Fisher's exact test 
Association between serum cPTHrP concentrations and markers of systemic 
inflammation 
The relationship between serum cPTHrP concentrations and serum cytokine and acute phase 
protein concentrations are shown in Table 7.3. An elevated serum cPTHrP concentration was 
associated with elevated serum sTNF -R and CRP concentrations (p =0.008 and p =0.06, 
respectively) and with reduced concentrations of albumin and transferrin (p =0.02, p= 0.009) 
(Figure 7.3). There was no association between serum cPTHrP concentrations and serum 
cytokine concentrations. 
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Table 7.3 Comparison of serum cPTHrP concentrations with serum cytokine and acute 
phase protein concentrations. 
Serum PTHrP (pmol /I) 
Normal Elevated P value* 
CRP (mg/I) 
6.5 (2.3 -23.8) 17 (4.5 -60.8) 0.06 
Transferrin (mg/I) 
1.8 (1.4 -2.2) 1.5 (1.1 -1.8) 0.009 
Haptoglobín (mg/I) 
2094 (1521 -2829) 2205 (1113 -2639) 0.46 
Albumin (g/I) 
40.0 (36.0 -43.0) 37.0 (34.0 -40.5) 0.02 
al-Antichymotrypsin (mg/I) 
402 (337 -520) 451 (326 -601) 0.47 
IL-113 (pg/ml) 
0 0 0.34 
IL-6 (pg/ml) 
8.9 (0 -86.6) 0 (0 -51.6) 0.46 
IL-8 (pg/ml) 
0 (0- 147.0) 0 (0- 126.2) 0.81 
IL-10 (pg/ml) 
o 0 0.54 
sTNF-R (ng/ml) 
3.2 (1.9 -4.9) 5.3 (2.9 -1 0.4) 0.008 
CRP= C- reactive protein. sTNF -R= soluble tumour necrosis factor receptor. Median (interquartile range) 
*Mann- Whitney U Test. 
Figure 7.3 A scatter plot demonstrating the correlation between serum cPTHrP 
concentrations and serum soluble TNF receptor (sTNF -R) concentrations (p= 0.008, r= 0.26). 
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Association between serum cPTHrP concentrations and nutritional status 
Measurements of nutritional status are shown in Table 7.4. Measurements of nutritional 
variables were similar between patients with elevated serum cPTHrP concentrations and 
those with concentrations within the normal range, except for triceps skinfold measurements, 
which were higher in the group with elevated cPTHrP (p= 0.04). 
Table 7.4 Comparison of serum cPTHrP concentrations measured at the time of 
diagnosis with nutritional variables. 
Nutritional variable Serum PTHrP (pmolll) 
Normal Elevated P value* 
BMI at diagnosis 
24.1 (21.2 -28.0) 25.3 (22.3 -28.8) 0.53 
Weight loss ( %) 
7.6 (1.9 -14.9) 6.7 (1.9 -12.9) 0.73 
Mid -arm circumference (cm) 
27.0 (24 -30) 28.0 (26.5 -32.0) 0.14 
Triceps skinfold (mm) 
11.5 (8.0 -15.0) 14.5 (9.0 -18.0) 0.04 
Arm muscle circumference (cm) 
23.4 (20.8 -25.2) 23.9 (21.7 -26.2) 0.42 
BMI = body mass index. Median (interquartile range). "Mann-Whitney U Test 
Association between serum cPTHrP concentrations and survival duration 
Initial analysis of the data after a mean follow -up period of 12 months identified an elevated 
serum cPTHrP concentration at the time of diagnosis to be associated with adverse 
prognosis. Twelve out of 26 (46 %) patients with elevated cPTHrP had died at the time the 
survival data was censored compared with 39 out of 125 (31%) patients with normal cPTHrP 
levels (p= 0.038, log -rank test). However, on multivariate survival analysis, when age, sex, 
stage and grade of tumour were included in Cox's proportional hazards model, in addition to 
serum cPTHrP, elevated cPTHrP was not an independent predictor of survival (p= 0.45). 
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These results were published in the original description in Cancer. Subsequent survival 
analysis with a longer duration of follow -up (mean follow -up 31 months) only identifies a trend 
between an elevated serum cPTHrP concentration and adverse outcome (p =0.23, log -rank 
test) (Figure 7.4). 
Figure 7.4 Kaplan -Meier curve comparing survival between patients with normal serum 
cPTHrP concentrations (light line) and elevated serum cPTHrP concentrations (heavy line). 
Initial analysis at 12 months follow -up identified an elevated serum cPTHrP concentration as 
an adverse prognostic variable. However, after a longer period of follow -up (31 months) the 
survival difference between the two groups was no longer significant (p =0.23; log -rank test). 
% Alive 
I I I 
0.0 10.0 20.0 30.0 
Survival Duration (months) 
40.0 
Number at risk: 
Normal PTHrP 125 72 44 24 0 
Elevated PTHrP 26 11 9 2 0 
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Longitudinal study of serum cPTHrP concentrations 
A second blood sample was collected from 51 patients after a mean time interval of 95 days 
(range 41 -151 days) from the time of the first measurement (see Table 7.1). Between the first 
and second measurements 30 (59 %) patients had undergone surgical resection, 13 (25 %) 
patients had received pre- operative chemotherapy but had not yet undergone surgery, and 8 
(16 %) patients had been palliated by non -surgical methods (for example, stenting). These 
measurements were performed a minimum of 92 days following surgery and a minimum 41 
days following completion of pre- operative chemotherapy. 
The median serum PTHrP 2 concentration was 54.9 pmol /I (inter -quartile range 47.7- 
64.9 pmol /I) (Table 7.5). 25 (49 %) patients had an elevated cPTHrP concentration at the 
second measurement compared with 17% of patients who had an elevated cPTHrP 
concentration at the time of diagnosis. The mean serum calcium concentration was 2.29 
mmol /I (range 1.82 - 2.68 mmol /l; S.D. 0.15). As before, there was no correlation between 
serum cPTHrP and serum calcium concentrations (p =0.97; linear regression). Only 1 (2 %) 
patient had hypercalcaemia at 3 months (and this patient had a normal cPTHrP 
concentration). 
Table 7.5 Serial measurements of serum cPTHrP concentrations stratified according to 
intervening therapeutic intervention. PTHrP 1 = serum PTHrP concentration at diagnosis. 















13.4 to 32.3 <0.001 
Pre -op chemo 35.3 48.2 
1.0 to 25.9 0.066 
(n =13) (29.9 -45.8) (38.9 -58.8) 
Palliative 30.4 55.9 
3.2 to 41.6 0.028 
(n =8) (19.4 -48.7) (42.7 -76.3) 
Whole group 35.3 54.9 
13.7 to 27.2 <0.001 
(n =51) (28.2 -48.1) (47.7 -64.9) 
% Elevated^ 17 49 
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Figure 7.5 Changes in serum PTHrP concentrations over approximately 3 months for 
individual patients with gastro -oesophageal cancer (n =51) [p <0.001, 95% Cl 13.7 to 27.2; 
















Median serum PTHrP concentrations increased in all three treatment groups between 
measurement 1 and measurement 2 (Table 7.5) (Figure 7.5). The greatest increase was seen 
in patients who had undergone surgical resection (p <0.001; Paired T test) or who had been 
treated by palliative modalities alone (p= 0.028). A similar, but non -significant, increase in 
serum PTHrP concentrations also occurred in patients who received pre- operative 
chemotherapy (p= 0.066). 
Association between serum PTHrP 2 concentrations and markers of systemic 
inflammation and survival duration 
Blood was collected for determination of CRP and albumin concentrations at the same time 
that measurements of PTHrP 2 were undertaken. In contrast, to elevated concentrations of 
cPTHrP measured at the time of diagnosis, elevated serum PTHrP 2 concentrations were not 
associated with increased serum CRP concentrations (p =0.89; Mann -Whitney U test) or 
reduced serum albumin concentrations (p= 0.66). There was no association between serum 
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PTHrP 2 concentrations and any demographic or clinical data. Similarly, there was no 
association between PTHrP 2 concentration and survival duration (p =0.81; log rank test). 
Association between serum cPTHrP 2 concentrations and nutritional status 
Serum cPTHrP concentrations measured after approximately 3 months (PTHrP 2) were 
associated with adverse nutritional status, but those measured at the time of diagnosis were 
not (Table 7.6). Elevated serum cPTHrP 2 concentrations were associated with increased 
rates of weight loss (p= 0.043; Mann -Whitney U test), reduced mid -arm circumference 
measurements (p= 0.015), reduced arm -muscle measurements (p= 0.031), and lower BMI 
(p= 0.005). There were no differences in dysphagia scores (p =0.16; chi -square), serum 
calcium concentrations (p =0.61; Mann -Whitney U test), or dietary intake (p =0.14; chi square) 
between the groups. 
Table 7.6 Nutritional variables and serum cPTHrP levels measured at the time of 
diagnosis and after an approximate time interval of 3 months in the same cohort of patients. 
PTHrP 1 = serum concentration at the time of diagnosis, PTHrP 2 = serum concentration 3 
months following diagnosis. 
Nutritional variable 





Normal Elevated P value* Normal Elevated P value* 
(80 %) (20 %) (51%) (49 %) 
27.5 25.8 27.6 23.1 
BMI 0.84 0.005 
(22.6 -31.2) (23.3 -29.7) (23.8 -31.0) (19.4 -26.3) 





(0.1 -11.0) (0 -4.5) (2.9 -12.4) (8.5 -20.2) 
Mid -arm circumference 30.0 29.3 28.5 25.8 
0.84 0.015 
(cm) (26.0 -31.4) (25.8 -32.0) (25.0 -31.1) (23.5 -28.0) 





(9.0-17.0) (10.3 -22.5) (8.0-19.0) (7.3 -15.9) 
Arm muscle 24.7 25.0 24.7 22.2 
0.40 0.031 
circumference (cm) (21.9 -27.2) (20.0 -26.3) (21.0 -26.4) (20.2 -24.6) 
202 
DISCUSSION 
In this study 17% of patients with gastro -oesophageal malignancy demonstrated elevated 
serum PTHrP concentrations at the time of diagnosis without evidence of hypercalcaemia. An 
elevated serum PTHrP concentration was associated with markers of systemic inflammation 
(elevated concentrations of serum CRP and sTNF -R and reduced concentrations of albumin 
and transferrin). There was also a trend of association between elevated PTHrP 
concentrations and adverse prognosis. Serum PTHrP concentrations increased with 
progression of disease and after a mean time interval of three months following diagnosis an 
elevated PTHrP concentration was detected in 49% of patients. Increased PTHrP 
concentrations occurred irrespsectve of treatment modality and without evidence of 
hypercalcaemia. Furthermore, these follow -up measurements were linked with markers of 
adverse nutritional status. 
In the present study only 6 (4 %) patients were hypercalcaemic and this is in 
agreement with a large Japanese study where 1.3% of oesophageal cancer patients had 
elevated serum calcium at the time of diagnosis (Tachimori et al, 1991). Patients with gastric 
or oesophageal cancers experience hypercalcaemia infrequently and bone metastases are 
uncommon. Despite normal plasma calcium levels, 26 (17 %) patients in the present study 
had elevated serum cPTHrP at the time of diagnosis. Increased levels of cPTHrP were 
equally likely irrespective of tumour origin or histological type. Similarly, in there was no 
association between advanced stage and elevated cPTHrP levels, an observation previously 
reported in other studies. Although not statistically significant in this series, the present data 
did suggest a trend between increased cPTHrP production and poor tumour differentiation. A 
study involving a much larger series of patients would be required to explore this potential 
association. A possible link between tumour grade and over production of cPTHrP has been 
reported (Alipov et al, 1997). 
We also noted that serum PTHrP concentrations appear to increase with disease 
progression. At the time of diagnosis 17% of patients had elevated serum PTHrP compared 
with 49% of patients 3 months later. This apparent increase in serum PTHrP concentration 
appears not to be influenced by therapeutic interventions, occurring with equal likelihood 
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among patients who have had potentially curative surgery and those who have received 
palliative treatments alone The rise in serum concentrations may represent residual disease 
in these patients', however; we found no association between an elevated serum PTHrP 2 
concentration and prognosis. 
Forty -four percent of patients studied demonstrated an elevated systemic acute 
phase protein response at diagnosis. Concentrations of CRP and sTNF -R were higher whilst 
albumin and transferrin (both negative acute phase reactants) were lower in patients with 
elevated PTHrP. These data suggest a possible further enhancement of systemic 
inflammation in association with elevated PTHrP. Plasma levels of the pro -inflammatory 
cytokines IL-18, IL -6 and IL -8 were not significantly different between the two groups. 
We found no correlation between serum calcium levels and cPTHrP. This raises the 
possibility of an additional role of cPTHrP acting as a growth factor potentiating tumour 
progression. We found no clear association between elevated cPTHrP and disease stage. 
However, those patients with elevated serum levels of cPTHrP had worse prognosis, which 
was initially significant on univariate analysis, but not on multivariate testing, and lost its' 
statistical significance with a longer period of follow -up. The association between elevated 
serum cPTHrP and systemic inflammation may contribute to the adverse prognosis noted in 
this patient group. 
Several tumour models have suggested that PTHrP is associated with adverse 
nutritional status (Iguchi et al, 2001). No differences in nutritional status were observed 
between patients with or without an elevated cPTHrP measured at diagnosis, except for 
triceps skinfold thickness. Patients with elevated cPTHrP were found to have increased 
triceps measurements compared with patients with normal serum levels of cPTHrP (p= 0.04). 
This finding is likely to represent sample error and be a consequence of the higher proportion 
of females, who have a greater triceps skinfold thickness per kilogram bodyweight than 
males, among the patients with elevated cPTHrP. The similarity in nutritional status between 
the two patient groups may be explained by the fact that the sample population had normal 
serum calcium levels. It is possible that the correlation noted elsewhere between elevated 
PTHrP and weight loss is attributable to the systemic effects of hypercalcaemia (eg anorexia). 
In patients with normal serum calcium PTHrP may not have any independent effect on 
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nutritional status. However, elevated serum PTHrP concentrations measured an average 
three months following diagnosis were associated with adverse nutritional status in the 
absence of hypercalcaemia and without apparent differences in dysphagia scores or levels of 
dietary intake. These findings support the animal studies where elevated PTHrP 
concentrations in mice were associated with a significant reduction in body weight and tissue 
mass, an effect that is reversed by addition of an antibody to PTHrP (Iguchi et al, 2001). It is 
possible that the elevated serum PTHrP concentrations are increasing serum calcium 
concentrations among these patients resulting in 'sub- clinical' hypercalcaemia, which, in turn, 
may induce anorexia and result in weight loss. 
Conclusions 
An elevated serum PTHrP concentration was identified in 17% of patients with gastro- 
oesophageal cancer at the time of diagnosis and in the absence of hypercalcaemia. Elevated 
concentrations were positively associated with markers of systemic inflammation. An elevated 
serum cPTHrP was also associated with adverse prognosis, but did not predict outcome 
independent of other covariates. PTHrP concentrations increased with disease progression 
and were not influenced by therapeutic interventions. Approximately three months following 
diagnosis an elevated serum PTHrP concentration was detected in 49% of patients, 
compared with 17% of the same patient cohort when measured at the time of diagnosis. 
These elevated PTHrP concentrations measured later in the course of the disease were 
linked with adverse nutritional status in the absence of hypercalcaemia. These findings 
suggest that PTHrP may play a role in the generation of systemic inflammation in patients 
with gastro -oesophageal malignancy. Therefore, mediators other than pro -inflammatory 
cytokines, such as PTHrP, may contribute to the generation of systemic inflammation in some 
patients with cancer. The exact mechanisms remain unclear, The relationship between 
systemic inflammation and cachexia /decreased survival may provide a possible indirect role 
for PTHrP in these processes. These associations were investigated in later Chapters 
(Chapters IX and X). The next Chapter investigated the potential role of another tumour - 
derived mediator, proteolysis- inducing factor (PIF), in the aetiology of systemic inflammation 
in patients with gastro -oesophageal cancer. 
205 
CHAPTER VIII 
PROTEOLYSIS -INDUCING FACTOR EXPRESSION IN PATIENTS WITH 
GASTRO- OESOPHAGEAL CANCER AND ITS RELATIONSHIP WITH 
SYSTEMIC INFLAMMATION, NUTRITIONAL STATUS AND PROGNOSIS 
Deans DAC, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KCH, Ross JA 
Expression of the proteolysis- inducing factor core peptide mRNA is up- regulated in 
both tumour and adjacent normal tissue in gastro -oesophageal malignancy. 
British Journal of Cancer 2006; 94(5): 731 -736 
206 
ABSTRACT 
This Chapter continues the investigation into the potential role of tumour -derived mediators in 
the aetiology of systemic inflammation in patients with gastro -oesophageal cancer. 
Proteolysis- inducing factor (PIF) is a potential tumour -derived mediator that has been 
identified in human cancer patients and may be linked with markers of systemic inflammation, 
cachexia and outcome. In this study, PIF gene expression was investigated in tumour and 
benign tissue from patients with gastro -oesophageal cancer and in biopsies from healthy 
volunteers. Urinary PIF expression was also investigated and levels of expression were 
compared with markers of systemic inflammation, nutritional status, and prognosis. 
Tumour tissue and adjacent benign tissue were collected from patients with gastro - 
oesophageal cancer (n =46). Tissue samples were also collected from healthy volunteers 
(n =11). PIF mRNA expression was quantified by real -time PCR. The presence of urinary PIF 
was determined by Western blot in 51 patients. Blood was collected for measurement of 
serum cytokine and acute phase protein concentrations by ELISA. Clinical and pathological 
information along with nutritional status was collected prospectively. 
PIF mRNA was detected in 27 (59 %) tumour samples and 31 (67 %) adjacent benign 
tissue samples. Four (36 %) gastro -oesophageal biopsies from healthy controls also 
expressed PIF mRNA. Expression was higher in tumour tissue (p= 0.031) and benign tissue 
(p= 0.022) from cancer patients compared with healthy controls. PIF mRNA concentrations did 
not correlate with weight loss, markers of systemic inflammation, or prognosis. Urinary PIF 
was detected in 26 (51 %) patients and was associated with increased weight loss (p= 0.004) 
and reduced anthropometry measurements without differences in dietary intake or dysphagia 
scores. There was a trend between detection of PIF in patients' urine and reduced serum 
concentrations of the negative acute phase protein albumin (p= 0.11). The presence of PIF in 
patients' urine was weakly associated with elevated serum CRP concentrations (p= 0.06), but 
was not associated with adverse survival. 
PIF -CP mRNA expression was up- regulated in both tumour and adjacent normal 
tissue in gastro -oesophageal malignancy, but was also detected in normal tissue from healthy 
volunteers. Levels of gene expression did not correlate with clinical variables and may not 
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reflect levels of the functional protein. In contrast, the glycosylated PIF protein detected in 
patients' urine was associated with systemic inflammation and nutritional depletion. The 
presence of this functionally active glycoprotein may, therefore, contribute in a minor way to 
the aetiology of systemic inflammation in patients with cancer as well as influencing 
cachexia /prognosis. 
INTRODUCTION 
Whilst systemic inflammation may be mainly driven by pro -inflammatory cytokines, other 
tumour -derived mediators may also contribute to the generation of systemic inflammation in 
patients with cancer. Moreover, the metabolic abnormalities associated with cancer may be 
due to other factors, which may have partial effects via systemic inflammation, or other direct 
effects, for example stimulating proteolysis. This Chapter will investigate proteolysis- inducing 
factor (PIF) expression in patients with gastro -oesophageal malignancy and compare patterns 
of expression with markers of systemic inflammation, nutritional status and prognosis. 
PIF is a potential tumour -derived mediator that has been identified in human subjects 
and may upregulate other mediators /markers of systemic inflammation. PIF may also be a 
direct mediator of muscle proteolysis and hence a major contributory factor to cachexia. 
Potential role in cancer cachexia 
Initially isolated from a murine cachexia tumour model (MAC16), a human homologue of PIF 
was subsequently identified in human urine from weight losing cancer patients, but not from 
weight -stable cancer patients or patients with weight loss secondary to benign disease 
(Todorov et al, 1996; Wigmore et al, 2000; Cariuk et al, 1997). PIF has been named as such 
because it has been shown to induce skeletal muscle proteolysis both in vitro and in vivo 
acting through the ubiquitin proteolytic pathway (Lorite et al, 1997; Lorite et al, 2001; Todorov 
et al, 1997). The molecule demonstrates a high degree of glycosylation, consisting of a 
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peptide core of 11 -14 kDa and carbohydrate residues contributing to the estimated total 
molecular size of 24 kDa (Todorov et al, 1997). The glycosylation appears essential for its 
proteolytic activities as neither the peptide core alone nor de- glycosylated native PIF have 
any affect on weight loss in mice (Todorov et al, 1996). 
Some gastrointestinal cancers and cancer cell lines have been shown to produce 
glycosylated PIF protein (Cabal -Manzano et al, 2001). Glycosylated PIF has been detected 
within tumour cells by immunohistochemistry and in the urine of the same subjects by 
Western blot. The presence of glycosylated PIF in tumour cells was also associated with 
increased weight loss among these patients. PIF protein has also been identified from the 
human melanoma cell line (G361) (Todorov et al, 1999) and the pancreatic cell line (MIA 
PaCa2) (unpublished data). 
Human -derived PIF has been designated human cachexia- associated protein 
(HCAP) by early identification of the human gene sequence (Genebank accession number 
AR053250) and patent (US 5834192) (Akerblom and Murray, 1998) and later by a group who 
investigated its expression in prostate cancer patients (Wang et al, 2003). HCAP mRNA was 
detected in 13 out of 15 radical prostatectomy specimens and 7 out of 9 bone metastases, but 
was not detectable in normal prostate or in any adjacent non -malignant prostate tissue from 
prostatectomy samples. In -situ hybridisation confirmed that HCAP mRNA was only detectable 
in cancer cells and not in surrounding stromal cells or benign prostate tissue. HCAP mRNA 
expression was also detected from prostate cancer cell lines. When two of these cell lines 
(PC -3M and LuCaP35) were implanted into mice there was a strong correlation between 
HCAP mRNA expression from the cancer cells and weight loss among the mice (Wang et al, 
2003). 
Association with markers of inflammation 
In hepatocytes glycosylated PIF has been shown to stimulate production of the cytokines IL -6 
and IL -8 and the acute phase protein CRP via induction of transcription factors NF -kB and 
STAT3 (Watchorm et al, 2001). PIF may, therefore, contribute to the inflammatory state 
observed in conjunction with cancer cachexia in addition to its proteolytic function, and could 
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conceivably also play a role in the generation of a pro -inflammatory state out -with the context 
of cancer. 
Molecular homology and possible roles in malignant disease 
A BLAST search of the human genome using the PIF -CP cDNA sequence (Genebank 
accession number AY590150) identified 3 products that arise from the single gene locus on 
12g3.1; dermcidin, neuronal survival- promoting peptide, and a candidate breast cancer 
oncogene. Dermcidin (DCD) is a novel peptide that was identified from human sweat and was 
shown to possess antimicrobial properties (Schittek et al, 2001). Unlike the PIF molecule, 
DCD appears to be unglycosylated. DCD mRNA was detected in normal skin, benign naevi 
and malignant melanoma cells by RT -PCR. Screening of adult and fetal tissue panels did not 
identify DCD mRNA in any other tissue. The authors therefore concluded that DCD was 
exclusive to skin and associated appendages. 
Another PIF homologue has been identified following its isolation from the culture 
medium of neuronal cells grown under oxidative stress (Cunningham et al, 1998). In vivo 
studies suggest that this protein confers survival benefits to hypoxìc neuronal cells and the 
molecule has been termed neuronal diffusible survival- promoting peptide (DSEP). 
The third peptide, which has been mapped to the PIF gene locus, was identified using 
SAGE in breast cancer tissue (Porter et al, 2003). The gene was only expressed in a subset 
of invasive breast carcinomas and their lymph node metastases. In -situ hybridisation studies 
located the mRNA to cancer cells only with no expression found within stromal cells. Northern 
blot analysis of 75 human adult and fetal tissues detected RNA expression only in the pons 
and paracentral gyrus of the brain. The protein was identified in 10% of invasive breast 
cancers, 2 out of 64 pancreatic cancers, and normal sweat glands. Receptors were found in 
the brain and on tumour cells that were producing the protein, suggesting an 
autocrine /paracrine mode of action. When the cDNA sequence was introduced into a breast 
cancer cell line (21 NT), these cells had accelerated growth and were more resistant to 
oxidative stress and hypoglycaemia. The authors have suggested that this gene may function 
as an oncogene in breast cancer with survival promoting properties. 
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More recently, a group of investigators probed a panel of normal human tissue cDNA for PIF- 
CP using real -time PCR and found absent or very low levels of expression (Monitto et al, 
2004). In an analysis of unpaired breast tissue samples minimal PIF expression in normal 
breast tissue was detected. However, significantly elevated PIF expression within breast 
tumours was observed. Mice implanted with tumours transfected with a PIF vector were found 
to produce increased levels of PIF mRNA and protein but the protein was not glycosylated 
and these mice did not develop wasting. However, the tumours from these mice were 
significantly larger than controls, supporting a previous hypothesis that PIF may confer cell 
survival properties (Wang et al, 2003). 
This Chapter will investigate PIF expression in urine and tumour tissue collected from patients 
with gastro -oesophageal cancer. Patterns of expression will be compared with markers of 
systemic inflammation, nutritional status and prognosis in these patients. 
MATERIALS AND METHODS 
Study population: patients and controls 
All patients diagnosed with gastric or oesophageal cancer between June 2002 and March 
2004 within Lothian and Borders regions were invited to take part in the study. No patients 
were excluded. Samples of blood and urine were collected at the time of diagnosis. 
Representative samples of tumour tissue were collected from patients who underwent 
surgical resection, as described previously. Full clinical and pathological information was 
recorded for each patient, including treatment modality undertaken. Duration of survival, 
defined as time from histological diagnosis to death, was recorded for all patients. 
Gastric or oesophageal biopsies were collected from 11 healthy volunteers at the 
time of endoscopic examination. In all instances both the macroscopic and microscopic 
assessments were considered normal (as described in Chapter V). 
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Nutritional Assessment 
All patients underwent nutritional assessment, including calculation of body mass index (BMI) 
and anthropometry measurements. Dietary intake was determined by interview based on food 
intake over the previous 3 days and a proportion of the patients completed food diaries. 
Dysphagia was scored using the system first described by Knyrim (Knyrim et al, 1993). 
Serum cytokine and acute phase protein concentrations 
Serum cytokine and acute phase protein concentrations were measured by enzyme -linked 
immunosorbent assay (ELISA) as described previously (Chapter III). 
Quantification of tissue PIF -core peptide mRNA 
Tissue was obtained from patients who underwent surgical resection. A section of tumour 
tissue and a sample of benign mucosa from the same organ were collected from each patient. 
Tissue was also collected from healthy controls. Tissue samples were homogenised and PIF- 
core peptide mRNA was quantified by real -time PCR.The methodology is described in detail 
in Chapter Ill. 
Identification of urinary PIF 
Patients provided urine samples at the time of diagnosis. Detection of urinary PIF was initially 
attempted by Western blot by following the published methodology and then by mass 
spectrometry, but we were unable to reliably detect urinary PIF by either technique (see 
Chapter III for an extensive discussion). However, urinary PIF was successfully detected in 
patient samples at Professor Tisdale's laboratory, Aston University, Birmingham. Urine 
samples from 51 patients with a range of weight loss were investigated for PIF expression by 
Western blot. Results were interpreted by an investigator who was blinded to the weight loss 
and other clinical data. 
Immunohistochemistry 
Immunohistochemistry was attempted using the monoclonal antibody that was involved in the 
original identification of PIF and also using the commercially marketed 'cachectic factor 
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antibody' (Alpha Diagnostic, San Antonio, USA). Both antibodies produced widespread non- 
specific binding, despite extensive protocol modifications. In the case of the monoclonal 
antibody the lack of specificity was considered to be due to antibody binding to carbohydrate 
moieties on other molecules, both intracellular and on the cell surface (including CD 59). The 
polyclonal antibody (Alpha Diagnostic, San Antonio, USA) prepared against the core peptide 
of PIF was not sufficiently specific for use. Therefore, immunohistochemistry provided no 
meaningful results. 
Statistical analysis 
Comparisons between groups of continuous variables were made by the Mann -Whitney U 
test. Categorical variables were compared by the Chi -squared test or Fisher's exact test. 
Comparisons between tumour tissue PIF -core peptide gene expression and benign tissue 
expression were tested by linear regression analysis following natural logarithmic 
transformation of the data. Survival between groups was analysed by the log -rank test. 
Probabilities _ <0.05 were considered significant. 
RESULTS 
Study population 
134 subjects were recruited to this study and urine and blood samples were collected from 
each patient. Tissue samples were additionally collected from 46 of these patients who 
underwent surgical resection. The demographics for those patients from whom tissue 
samples were obtained are shown in Table 8.1. 
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Table 8.1 Tissue samples were collected from 46 patients who underwent surgical 
resection. Patient demographics are outlined below. *Median (inter -quartile range). 
Number [ %] 
Age (years) 65 (58 -75) 
Sex Male 32 [70] 
Female 14 [30] 
Tumour Site Oesophageal 22 [48] 
Oesophago -gastric junction 9 [20] 
Gastric 15 [33] 
Histology Adenocarcinoma 43 [94] 
Squamous cell carcinoma 3 [6] 
Grade Well differentiated 4 [9] 
Moderately differentiated 20 [44] 
Poorly differentiated 22 [48] 
UICC Stage 1 14 [30] 
2 12 [26] 
3 15 [33] 
4 5 [11] 
Treatment undertaken Oesophagectomy alone 20 [43] 
Gastrectomy alone 15 [33] 
Pre -operative Chemotherapy + surgery 11 [24] 
Status Alive 35 [76] 
Dead 11 [24] 
1. Expression of PIF -core peptide mRNA in tissues 
Cancer cell lines 
A number of cell lines were investigated for PIF expression using conventional (non - 
quantitative) PCR. This was necessary to identify a positive control for the patient analysis 
and to confirm that our primer sequences could identify PIF gene expression. PIF mRNA 
expression was confirmed in the pancreatic cell line MIA PaCa2 and this was later used as 
the positive control for the patient studies. We also confirmed the previous finding that the 
melanoma cell line G361 produced PIF (Todorov et al, 1999) and expression was also 
identified in a number of hepatic cell lines (Table 8.2). 
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Table 8.2 PIF -core peptide mRNA expression in a number of cell lines. 
PIF mRNA detected No PIF mRNA identified 
Pancreatic Breast 
MIA PaCa2 MCF 7 
Hepatic Hepatic 




G361 THP 1 
PIF -CP mRNA expression in healthy controls 
PIF -CP mRNA was detected in gastro -esophageal biopsy tissue from 4 (36 %) healthy 
controls. Of these positive tissue samples, 3 were gastric biopsies and 1 was oesophageal 
tissue. detectable, the of expression were 
significantly lower when compared with levels of expression in tumour tissue (p= 0.031, Mann - 
Whitney U Test) and adjacent benign tissue (p= 0.022) taken from cancer patients (Figure 
8.2). 
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Figure 8.2 A comparison of relative expression of PIF -CP mRNA in tissue from healthy 
controls (normal), tumour tissue, and benign tissue collected from cancer patients (benign). 
The lines represent the median value, bars = inter -quartile range, error bars = extreme 






Normal Benign Tumour 
Tissue type 
PIF -CP mRNA expression in tissue from cancer patients 
PIF -CP mRNA was detected in 27 (59 %) tumour samples and 31 (67 %) adjacent benign 
tissue samples. In 24 (52 %) patients PIF mRNA was detected in both the tumour tissue and 
adjacent benign tissue collected from the same patient (Table 8.3). There was a strong 
correlation between paired mRNA concentrations in tumour tissue and mRNA concentrations 
in adjacent benign tissue (p <0.0001, r =0.73; linear regression) (Figure 8.3). Although levels of 
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PIF gene expression tended to be higher in tumour tissue compared with levels measured in 
non -neoplastic tissue, this did not reach statistical significance (p =0.51, Mann -Whitney U 
Test) (Figure 8.2). In 12 (26 %) patients PIF -CP mRNA was not detected in either the tumour 
or adjacent benign tissue. For the remaining 10 patients, PIF -CP mRNA was detected in 
either tumour tissue only (n =3) or adjacent benign tissue only (n =7). There was no difference 
in level of gene expression between patients who received pre- operative chemotherapy and 
those who did not (tumour tissue, p =0.58; benign tissue, p =0.72: Mann -Whitney U Test). 
Table 8.3 Tissue expression of PIF -CP mRNA in paired tumour and benign tissue. 
Paired tumour tissue and 
benign tissue expression 
Benign tissue expression only 
24 (52 %) 7 (15 %) 
Tumour tissue expression only Neither tumour tissue nor 
benign tissue expression 
3 (7 %) 12 (26 %) 
Figure 8.3 Correlation between paired tumour tissue PIF -CP mRNA concentrations and 
benign tissue PIF -CP mRNA concentrations (p <0.0001, r = 0.73; linear regression). All values 









Benign Tissue PIF -CP mRNA (log) 
8 
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Association between tissue PIF gene expression and markers of systemic 
inflammation 
Nine (20 %) of the 46 patients who provided tissue samples had evidence of systemic 
inflammation (serum CRP >10 mg /I). There was no association between levels of PIF -CP 
mRNA in either tumour tissue (p =0.89) or adjacent benign tissue (p =0.81) and elevated 
serum CRP concentrations (Mann -Whitney U test). Neither was there any association with 
any of the other acute phase protein concentrations or serum cytokine concentrations (data 
not shown). 
Association between tissue PIF gene expression and nutritional status 
Tumour tissue PIF -CP mRNA did not correlate with weight loss (p =0.37; linear regression), 
mid -arm circumference (p= 0.10), triceps skinfold thickness (p= 0.37), or arm -muscle 
circumference (p= 0.14). Similarly, benign tissue mRNA concentrations did not correlate with 
any nutritional variable. Patients in whom PIF -CP mRNA was measurable in both tumour and 
adjacent benign tissues did not have adverse nutritional status when compared with patients 
without detectable PIF -CP mRNA in either tissue type (Table 8.4). There remained no 
correlation when the data were analysed according to dysphagia scores (data not shown). 
Table 8.4 Tissue PIF -CP mRNA expression and nutritional variables. Nutritional 
variables were similar between patients in whom PIF -CP mRNA was measurable in both 
tumour tissue and benign tissue and patients who had no detectable mRNA (Mann -Whitney U 
Test). 
PIF -CP mRNA detected in both 
tumour tissue and benign 
tissue (n =24) 
PIF -CP mRNA not detectable in 
either tumour tissue or benign 
tissue (n =12) 
P value 
Weight loss 
( % *) 
3.3 (0.4 -9.5) 5.3 (0 -12.2) 0.93 
MAC 
(percentile group`) 
10 -25 (5 -50) 10 -25 (5 -50) 0.96 
Triceps 
(percentile group *) 
25 -50 (10 -50) 25 -50 (25 -50) 0.37 
AMC 
(percentile group *) 
10 -25 (5 -50) 25 -50 (5 -50) 0.96 
*Median (interquartile range). MAC = mid -arm circumference, Triceps = triceps skinfold thickness, AMC 
= arm muscle circumference 
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Association between tissue PIF gene expression and prognosis 
PIF -CP mRNA in either tumour tissue (p =0.64) or benign tissue (p =0.51) was not associated 
with adverse prognosis (Mann -Whitney U test). Similarly, those patients with detectable 
mRNA in both tumour and benign tissue did not have adverse survival compared with patients 
no detectable PIF -CP gene in either tissue type (p =0.79; Chi -square analysis). In addition, 
there was no association between mRNA levels and age, sex, tumour position, histology, 
degree of differentiation, or stage (data not shown). 
2. Urinary PIF expression 
Urine samples were collected from 134 patients and included the 46 patients who provided 
tissue samples and who are described above. We were unable to reliably and consistently 
detect urinary PIF to our satisfaction in our laboratory (see Materials and Methods Chapter for 
a detailed discussion). However, 51 of these patients with a range of weight loss were 
investigated for PIF expression by Professor M Tisdale's team at Aston University. Blots were 
interpreted by an investigator who was blinded to weight loss and other data. 
PIF was detected in 26 (51 %) patient's urine. The presence of urinary PIF was not 
associated with patient's age (p =0.84; Mann -Whitney U test), sex (p =0.61; Chi -square test), 
tumour position (p =0.27; Chi -square test), histological type (p =0.58; Chi -square test), or stage 
of disease (p =0.79; Chi -square test). There was a weak association between poorly 
differentiated tumours and PIF detected in patient's urine but this did not reach significance in 
this study (p =0.12; Chi -square test). 
Association between urinary PIF status and markers of systemic inflammation 
The presence of urinary PIF was inversely associated with serum concentrations of the 
negative acute phase protein albumin (p= 0.011) and there was a trend towards a positive 
association between urinary PIF and elevated serum CRP concentrations (p= 0.061; Chi- 
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square test). However, urinary PIF was not associated with any other serum cytokine or acute 
phase protein concentrations (Mann- Whitney U test - data not shown). 
Association between urinary PIF status and nutritional status 
Table 8.5 compares urinary PIF status with nutritional variables. Patients who had PIF 
detected in their urine had lost a median 13.4% (inter -quartile range 7.7- 21.3 %) of their pre - 
morbid body weight by the time of diagnosis, compared with PIF negative patients; median 
weight loss 4.4% (range 1.6- 10.6 %) (p= 0.004; Mann -Whitney U test). One patient who was 
positive for PIF had lost 32.3% of their pre -illness body weight by time of diagnosis (Figure 
8.4). PIF production was also associated with reduced mid -arm circumference (p= 0.057) and 
arm muscle circumference (p= 0.016), but not triceps skinfold thickness (p= 0.433). This 
suggests a preferential loss of lean tissue. These differences in nutritional variables between 
PIF positive and PIF negative patients were independent of dysphagia scores (p= 0.29), but 
there was a weak, but non -significant, association between PIF detectable in the urine and 
reduced dietary intake (p= 0.062). 
Figure 8.4 Percentage weight loss at the time of diagnosis according to the presence 
or absence of urinary PIF. Patients who had PIF detected in their urine had lost a median 
13.4% of their pre- morbid body weight by the time of diagnosis, compared with PIF negative 
patients; median weight loss 4.4% (p= 0.004; Mann -Whitney U test). The lines represent the 
median value, bars = inter -quartile range, error bars = extreme values. 
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Table 8.5 Nutritional variables and urinary PIF status. The presence of urinary PIF was 
associated with increased total weight loss, reduction in mid -arm circumference and arm 
muscle circumference, and reduced serum albumin concentrations (Mann -Whitney U Test). 
Absolute values were normalised into percentile groups before analysis. 
PIF Positive (n =26) PIF Negative (n =25) P value+ 
Pre -illness BMI 25.3 (22.6 -32.0) 28.2 (24.7 -31.1) 0.24 
BMI at diagnosis 21.7 (18.9 -29.4) 26.7 (23.1 -29.2) 0.06 
% weight loss 13.4 (7.7 -21.3) 4.4 (1.6 -10.6) 0.004 
Mid -arm circumference 
(percentile group) 
7.5 (5 -25) 25 (5 -50) 0.06 
Triceps skinfold thickness 
(percentile group) 
25 (5 -50) 25 (25 -63) 0.43 
Arm muscle circumference 
(percentile group) 





























All values are median (inter -quartile range). BMI = Body mass Index. *Dietary intake: 1= normal, 2= reduced, 
3 =poor # Dysphagia score: 0= normal, 1 =solid dysphagia, 2= softened foods, 3= liquidized foods, 4 =total dysphagia. 
Association between urinary PIF status and prognosis 
The presence of urinary PIF was not associated with adverse survival: PIF present, median 
survival 10.6 months; PIF absent, median survival 10.4 months (p =0.35; Log -rank test). 
3. Relationship between tissue mRNA and urinary PIF expression 
Nineteen patients were investigated for both PIF mRNA tissue expression and urinary PIF 
expression. The presence of urinary PIF was not associated with elevated PIF mRNA 
221 
concentrations in either tumour tissue (p =0.59; Mann -Whitney U test) or benign tissue 
(p= 0.38). 
DISCUSSION 
This Chapter has shown that PIF gene expression is up- regulated in both tumour tissue and 
adjacent non -neoplastic tissue in patients with gastro -oesophageal malignancy. PIF mRNA 
was detected in 59% of tumour samples and 67% of benign tissues sampled from cancer 
patients, compared with 36% of tissues from healthy controls. However, the apparent 
increased rates of gene expression in these tissues may have little functional consequence 
on the host as levels of PIF mRNA are not associated with markers of systemic inflammation, 
nutritional status or prognosis. In contrast, urinary PIF protein was detected in 51% of patients 
with cancer and was associated with adverse nutritional variables and was weakly associated 
with systemic inflammation (reduced serum albumin concentrations and elevated CRP 
concentrations). There was no correlation between PIF mRNA expression in the tissues and 
detection of PIF protein in the urine. 
Previous studies have suggested that PIF -CP mRNA is absent or expressed at only 
minimal levels in normal human tissues and found at significantly elevated levels in some 
tumours and various cancer cell lines. However, we have detected PIF -CP mRNA in benign 
tissue in the majority of patients with gastro -oesophageal cancer (67 %), and these levels are 
equivalent to levels detected within adjacent tumour tissues. In addition, we detected PIF -CP 
mRNA in biopsy tissue from healthy controls, although at significantly lower levels of 
expression and also in a number of cell lines. In a previous study PIF -CP (HCAP) mRNA 
appeared to be limited to cancer cells and their metastases (Wang et al, 2003). The data in 
the present thesis suggests that PIF -CP gene expression is not limited to neoplastic tissue 
and that the PIF -CP gene may also be active in normal tissues. Furthermore, the level of 
gene expression appears to be similar in tumour tissue and adjacent benign tissue, but lower 
in normal tissue from healthy patients. Therefore, in some individuals with cancer there may 
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be up- regulation of the PIF -CP gene not only in tumour tissue but also within the whole organ 
or even in distant tissues. 
The relevance of PIF -CP gene up- regulation remains obscure. Although PIF -CP has 
been identified as a putative cell survival factor we found no association between gene 
expression and prognosis, stage or grade of tumour. Therefore, the present study is unable to 
confirm a tumour survival- promoting role for this gene in our study. However, there was a 
weak association between urinary PIF and poor tumour grade, but not with advanced disease 
stage or prognosis. Mice implanted with a tumour carrying the PIF -CP gene demonstrated 
increased rate of tumour growth compared with controls (Monitto et al, 2004). The present 
study did not evaluate tumour volume, but we did not identify any differences in tumour stage 
or grade between patients with elevated mRNA levels and those with undetectable mRNA 
levels. 
Urinary PIF was detected in 51% of patients and was associated with increased rates 
of total body weight loss (13% versus 4 %) and reduced mid -arm circumference and arm 
muscle circumference values, but not triceps skin -fold thickness measurements. This 
suggests a preferential loss of lean body mass. These differences in nutritional assessment 
occurred independently of dysphagia scores and without a significantly reduced level of food 
intake. Previously, we have found an association between weight loss and urinary PIF among 
pancreatic cancer patients (Todorov et al, 1996; Wigmore et al, 2000; Cariuk et al, 1997). 
However, another group have recently investigated urinary PIF expression in patients with 
metastatic gastro -oesophageal cancer and found similar levels of expression (56 %), but they 
found no association with weight loss (Jatoi et al, 2006). They concluded that no association 
was apparent due to widespread weight loss secondary to the mechanical effects of the 
tumour. However, in that study almost half the patients were weight stable or had lost less 
than 5% body weight making that explanation less likely. It is also possible, given the 
difficulties experienced in this study, that what was identified as PIF was in fact another 
molecule, perhaps CD59. 
Tissue PIF -CP mRNA expression was not associated with weight loss or any adverse 
nutritional variable. In the detection of urinary PIF we are of course identifying the 
glycosylated PIF protein, whereas in the tissue study we have measured mRNA for the core 
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peptide and so this finding is perhaps unsurprising. Only a small fraction of the total peptide 
core would be expected to be glycosylated, and since PIF is only present at 1 part in 108 of 
the total protein, expression of the peptide core would not be expected to be rate -limiting for 
PIF formation, rather the expression of the glycosidases, their rate of catalysis and substrate 
availability (Todorov et al, 1996). Whether variation in glycosylation of PIF occurs and 
whether this influences biological activity is unknown. Antibodies raised against the core 
peptide do not reliably detect urinary PIF. 
Systemic inflammation was identified in 20% of patients recruited to the tissue study 
and was not associated with PIF -core tissue mRNA concentrations. However, urinary PIF was 
associated with reduced serum albumin concentrations and was weakly associated with 
elevated serum CRP concentrations. In vitro work has demonstrated that hepatocytes 
produce increased levels of IL -6, IL -8 and CRP in response to PIF stimulation, thought to be 
mediated through transcription factors NFKB and STAT3 (Watchorn et al, 2001). PIF may play 
only a minor role in the complex interaction between pro -inflammatory mediators and a direct 
relationship between PIF and acute phase proteins may not be identified out -with the in vitro 
cell model. 
It has been suggested that PIF is an important protein during embryological 
development and becomes quiescent during adult life (Watchorn et al, 2001). Neoplastic 
transformation would then allow the re- expression of the gene in adulthood (similar to 
carcinoembryonic antigen). We have found PIF -CP mRNA expression in normal healthy 
tissue albeit at reduced levels compared with tumour tissue and benign tissue from cancer 
patients and so this explanation is perhaps implausible for PIF -CP but may be important in re- 
expression of the glycosyltransferases. It is also important to consider that real -time PCR is 
an exquisitely sensitive technique and that what we are detecting in some patients, although 
elevated, may have little or no functional significance as it may not be translated into protein. 
It is possible that the gene for the PIF -CP may confer a survival advantage to a 
tumour, promoting tumour growth and spread, although this study was unable to confirm this. 
Neither tissue mRNA expression nor urinary PIF were linked with adverse prognosis. 
Alternatively, the PIF -CP gene may be expressed to some degree in all tissue types and its 
diverse functions are due to post -transcriptional and post -translational modifications. The high 
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degree of glycosylation of the PIF molecule may be due to aberrant glycosylation by tumour 
cells and this glycosylation may confer the proteolytic activity associated with PIF (Todorov et 
al, 1997). This aberrantly processed molecule could not be distinguished from any 
conventional versions by determination of the mRNA expression or indeed perhaps by the 
currently used monoclonal antibody. 
There was no association between levels of PIF core peptide mRNA expression and 
PIF glycoprotein detectable in the urine. The difficulties of relating mRNA concentrations to 
protein concentrations has been extensively documented elsewhere, and it is also important 
to consider that real -time PCR is an exquisitely sensitive technique and that what we are 
detecting in some patients, although elevated, may have little or no functional significance as 
it may not be translated into protein. In addition, what we are detecting in the urine is a 
carbohydrate moiety bound to the peptide core. Detection of urinary PIF therefore is utterly 
dependent upon appropriate glycosylation of the peptide. 
In our laboratory we were unable to identify urinary PIF with certainty. We were able 
to demonstrate using mass spectrometry that the monoclonal antibody may bind non- 
specifically to carbohydrate moieties bound to molecules other than PIF (for example, CD 59). 
In addition, our results were inconsistent and not reproducible. Subsequent attempts to 
identify the PIF molecule from immuno- precipitates generated by the antibody have so far 
been unsuccessful even using deglycosylation strategies and mass spectrometry/MALDI- 
TOF. This topic is discussed in detail in Chapter III. The urinary PIF data presented in this 
study was performed by Professor Tisdale's team at Aston University. This group has a 
longstanding experience in performing this assay with consistent and reproducible results, 
which were interpreted by an investigator who was blinded to the clinical data. Nevertheless, 
given the non -specific binding observed in our immunohistochemistry studies questions 
remain as to what exactly the antibody is binding to within patients' urine. 
Conclusions 
PIF mRNA is expressed in healthy tissue and is found at significantly elevated levels within 
tumour tissue and adjacent benign tissue from cancer patients. However, measuring mRNA 
expression is unreliable as an indicator of glycosylated PIF protein expression and, therefore, 
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has limited value in determining its role in the aetiology of systemic inflammation and outcome 
in patients with cancer. Post -translational modification of PIF may be a key step in 
determining the biological role of PIF in patients with cancer. In contrast, urinary PIF 
expression is associated with adverse nutritional status and is weakly associated with 
markers of systemic inflammation. The association between urinary PIF expression and 
adverse nutritional status may be mediated through the concurrent association with systemic 
inflammation. Alternatively, PIF may affect the nutritional status of the host via more direct 
pathways, such as stimulating skeletal muscle proteolysis through up- regulation of the 
ubiquitin proteolytic pathway. However, there are difficulties in reliably detecting PIF in urine 
and attention needs to be directed at developing robust and reproducible quantitative 
assessments of glycosylated PIF protein. 
PIF gene expression is up- regulated in tissues from cancer patients, but levels of 
expression do not relate to levels of the glycosylated peptide by Western blot in patients' 
urine. In contrast, urinary PIF is associated with markers of systemic inflammation and 
adverse nutritional status. Once more, this association may be a consequence of the clinical 
sequelae of systemic inflammation or may be mediated through more direct mechanisms 
relating to other actions of these tumour -derived mediators. 
Systemic inflammation is commonly identified in patients with gastro -oesophageal cancer. 
Pro -inflammatory cytokines are key in the development of systemic inflammation and tumour 
tissue cytokine concentrations (especially IL -1p) and the presence of a chronic inflammatory 
cell infiltrate have been identified as important mediators in this process. Cytokine genotype 
also influences the ability of the host to generate a systemic inflammatory response in these 
circumstances. In addition to cytokines, other tumour -derived factors, such as PTHrP and 
PIF, are also involved in the aetiology of systemic inflammation and may also have additional 
direct effects on nutritional status and prognosis in patients with cancer. The next two 
Chapters investigated the association between systemic inflammation and adverse prognosis 
in patients with gastro -oesophageal cancer and explored the role of cachexia as an 
aetiological factor in the link between systemic inflammation and adverse prognosis. 
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CHAPTER IX 
THE CLINICAL SIGNIFICANCE OF THE ASSOCIATION BETWEEN 
SYSTEMIC INFLAMMATION AND ADVERSE PROGNOSIS IN PATIENTS 
WITH GASTRO- OESOPHAGEAL CANCER: 
A DETAILED ANALYSIS OF PATIENT OUTCOME AT DIFFERENT STAGES OF 
DISEASE AND UNDERGOING DIFFERENT TREATMENT OPTIONS 
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ABSTRACT 
The thesis thus far has investigated the aetiology of systemic inflammation in patients with 
gastro -oesophageal malignancy. This Chapter examined the association between systemic 
inflammation and adverse prognosis in these patients. The link between serum cytokine and 
serum acute phase protein concentrations and survival duration was investigated in a cohort 
of patients with gastro -oesophageal cancer. This association was tested in a multivariate 
survival model against established prognostic variables. In addition, the prognostic value of 
tumour tissue cytokine concentrations and a chronic inflammatory cell infiltrate was 
determined. 
A consecutive series of 220 patients with gastro -oesophageal cancer were recruited 
at the time of diagnosis. Demographic, clinical and pathological information was collected 
propectively. Blood was collected for determination of serum cytokine and serum acute phase 
protein concentrations by ELISA. Cytokine concentrations were also measured in tumour 
tissue collected from patients undergoing surgical resection and the degree of chronic 
inflammatory cellular infiltrate was assessed in the specimens. Survival duration was 
recorded for each patient. 
Patients were followed -up for an average 32 months (range 18 -45 months) and at the 
time of censoring the data 147 (67 %) patients had died. Serum acute phase protein 
concentrations, but not serum cytokine concentrations, were associated with survival duration 
at diagnosis. CRP concentrations were identified as the best individual marker of adverse 
outcome. The magnitude of the systemic inflammatory response also had prognostic value. 
An increase in serum CRP concentration from a value of 1 mg /I to 10 mg /I was associated 
with an almost 50% increase in likelihood of death. Conversely, CRP concentration measured 
after initiation of treatment was not associated with prognosis. Patient age, Karnofsky 
performance score, stage of disease, and tumour grade were also identified as prognostic 
indicators on univariate analysis. Multivariate analysis identified stage of disease (p <0.001), 
Karnofsky score (p <0.001) and serum CRP concentrations (p= 0.012) as independent 
prognostic indicators. Tumour tissue cytokine concentrations were not associated with 
prognosis. However, a chronic inflammatory cell infiltrate into the tumour tissue was linked 
with adverse survival. 
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The presence of systemic inflammation is an ominous prognostic marker in patients with 
gastro -oesophageal cancer. The precise links between systemic inflammation and adverse 
prognosis are not clear. The generation of a systemic inflammatory response may reflect 
either tumour phenotype with increased malignant potential or a host response that leaves the 
individual susceptible to metastatic spread. Equally there may be an indirect link via cachexia. 
INTRODUCTION 
The previous Chapters in this thesis have investigated the aetiology of systemic inflammation 
in patients with gastro -oesophageal malignancy. In Chapter IV the prevalence of systemic 
inflammation in patients with gastro -oesophageal cancer was investigated. This Chapter 
examined the clinical significance of the association between systemic inflammation and 
adverse prognosis in these patients. 
The relationship between serum cytokine concentrations and prognosis in cancer 
patients remains unclear. Elevated serum cytokine concentrations are generally regarded as 
markers of poor prognosis, but conflicting results have been found in pancreatic cancer, lung 
cancer and many other (Falconer et al, 1994; Martignoni et al, 2005; Songur et a1,2004; Tas 
et al, 2005). This may be due to the poor correlation between serum cytokine concentrations 
and markers of systemic inflammation (see Chapter IV). The prognostic value of serum 
cytokine concentrations in gastric and oesophageal cancer remains equally contradictory. 
In contrast, concentrations of serum acute phase proteins demonstrate more stability 
within the systemic compartment. Concentrations of serum positive acute phase proteins are 
elevated in patients with gastro -oesophageal cancer and systemic inflammation is evident in 
43% of patients at the time of diagnosis (Chapter IV). Concentrations of acute phase proteins 
have been linked with reduced quality of life scores, reduced performance status, and 
reduced response rates to chemo /radiotherapy, and overall worse outcomes in patients with 
cancer (Gabay and Kushner, 1999; DeWys et al, 1980; Barber et al, 1999). An APPR has 
been shown to be an independent adverse prognostic indicator in the majority of cancers, 
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including pancreatic, lung, breast, melanoma, lymphoma, ovarian, renal, and gastrointestinal 
tumours (Rashid et al, 1982; Nozoe et al, 2001; Falconer et al, 1995; Alexandrakis et al, 
2003). In patients with gastric cancer the presence of systemic inflammation has been 
associated with a markedly reduced median survival (9 versus 53 weeks, p <0.001) (Rashid et 
al, 1982). Similarly, two Japanese studies have identified a shortened survival in oesophageal 
cancer patients with an elevated serum C- reactive protein (CRP) at the time of diagnosis 
(Nozoe et al, 2001; Shimada et al, 2003). More recently a group from the UK has similarly 
identified elevated serum CRP and reduced serum albumin concentrations as independent 
prognostic indicators among patients with inoperable gastro -oesophageal cancer (Crumley et 
al, 2006). Detection of CRP within oesophageal cancer cells themselves has also been 
identified as an independent prognostic indicator on multivariate analysis (Nozoe et al, 2003). 
In addition, a large study of patients with colorectal, breast, gastric and bronchogenic cancers 
demonstrated a negative relationship between the magnitude of the systemic inflammatory 
response and survival duration (McMillan et al, 2001). Serum concentrations of acute phase 
proteins have also been linked with disease progression and the development of recurrent 
disease (Falconer et al, 1995; Barber et al, 1999; McMillan et al, 2003; Fujita et al, 1999; 
Jamieson et al, 2005). 
The presence of an inflammatory infiltrate within tumours and its relevance to 
prognosis has been investigated in a number of cancer types. Tumour -associated 
macrophages (TAM's) have been associated with reduced disease -free survival among lung, 
head and neck, and endometrial cancer (Ohno et al, 2004; Marcus et al, 2004; Chen et al, 
2005). In contrast, increased numbers of TAM's, eosinophils, mast cells and lymphocytes 
have been linked with improved survival in colorectal cancer (Svennevig et al, 1984; Jass, 
1986; Nielsen et al, 1999). The prognostic significance of tumour -associated inflammatory 
cells is less clear in gastro -oesophageal cancer. An increased TAM infiltrate was associated 
with more advanced disease stage in patients with gastric cancer in one study, whereas other 
studies have suggested a more favourable prognosis associated with a more pronounced 
macrophage infiltration (Heidi et al, 1987; Ohno et al, 2003; Tsujitani et al, 1987). Similarly, 
increasing tumour -infiltrating lymphocyte (TIL's) count has been linked with decreased risk of 
death from gastric cancer in one study, but associated with an adverse prognosis in another 
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(Grogg et al, 2003; Setala et al, 1996). Studies relating to oesophageal cancer are equally 
contradictory (Koide et al, 2004; Ma et al, 1999). Adverse outcome relating to an apparent 
increased immune response to the tumour may at first appear contradictory, however, 
possible explanations for adverse outcome may include increased recruitment of 
inflammatory cells by the tumour to aid tumour progression. Tumour -infiltrating immune cells 
are influenced by locally produced tumour -derived mediators. Immune cells may produce free 
radicals and other mediators, such as degradation enzymes, in response to these mediators 
that may contribute to DNA damage and regulate cellular proliferation and invasion (Harrison 
et al, 2000; Kim et al, 2000; Kaiser et al, 1999; Ernst, 1999). In addition, these TAM's and 
TIL's may contribute to the generation of systemic inflammation in patients with cancer and 
the systemic sequelae that follow, for example, alterations in metabolism and wasting, may 
contribute to accelerated demise. 
This Chapter investigated the clinical significance of the association between systemic 
inflammation and adverse prognosis in patients with gastro -oesophageal cancer. A detailed 
analysis of patients' outcome at different stages of disease and undergoing different treatment 
options was performed. 
MATERIAL AND METHODS 
Study population 
The sample population was the same as that studied in Chapter IV. In summary, patients 
diagnosed with gastric or oesophageal cancer within the Lothian and Borders regions 
between March 2002 and June 2004 were eligible for inclusion into the study. No patients 
were excluded and subjects were recruited to the study within two weeks of diagnosis. 
Patients were staged as per Department policy and underwent treatments following 
discussion at the multidisciplinary team meeting (MDT). Demographic, clinical, and 
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pathological data were prospectively collected on each patient. Performance status was 
assessed using the Karnofsky index (Karnofsky and Burchenal, 1949). Survival duration, 
defined as the time from tissue diagnosis to death, was recorded for every patient. 
Measurement of serum acute phase protein and cytokine concentrations 
Blood was collected from every patient at the time of diagnosis and following initiation of 
treatments. Serum cytokine and acute phase protein concentrations were determined by 
ELISA, as previously described in Chapters III and IV. 
Measurement of tissue inflammation 
Sections of tumour tissue were collected from patients who underwent surgical resection. 
Cytokine concentrations were measured by cytometric bead array in homogenised tissue 
samples. The degree of chronic inflammatory cell infiltrate into the tissues was assessed by a 
Consultant Pathologist. Both these methodologies are described in Chapters III and V. 
Statistical 
The prognostic significance of continuous variables was tested using Cox's univariate 
analysis and categorical data was analysed by the log -rank test. Survival curves were plotted 
using the Kaplan -Meier method. Multivariate survival analysis was performed using Cox's 
proportional hazards model. The accuracy of variables at predicting death was determined by 
receiver operating characteristics (ROC) curves. 
RESULTS 
Study patients 
The patient population was the same as that studied in Chapter IV. Group demographics are 
presented in Table 4.1 (Chapter IV). In summary, 220 patients were studied and were 
followed -up for an average 32 months and minimum of 18 months (range 18 -45 months). At 
the time of censoring the data 147 (67 %) patients had died. Three patients died in the post- 
operative period and 1 patient died from injuries sustained following a fall. Information 
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obtained from death certificates indicated that all other deaths were disease related. Overall 
median survival was 12.6 months. 
1. Association between clinical /pathological variables and prognosis 
Patient demographics and clinical variables 
The relationship between clinical and pathological variables and prognosis are shown in 
Table 9.1. Increasing age at the time of diagnosis (p= 0.015; Cox's univariate analysis) and 
reduced Karnofsky performance scores (p <0.001; Cox's univariate analysis) were associated 
with reduced prognosis. Neither sex (p= 0.909; log -rank test) nor smoking status (p= 0.310; 
log -rank test) were associated with survival duration. Results of sub -group analysis by tumour 
position (oesophageal versus OG junction versus gastric) gave similar results and, therefore, 
only results for the whole patient group are shown. 
Table 9.1 Relationship of clinical and pathological variables with prognosis. 
NUMBER [%] P VALUE 






























Tumour Site Oesophageal 







Squamous cell carcinoma 


























'Values are median (interquartile range). 9 Cox's univariate analysis.' Log -rank test. 
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Pathological characteristics 
Stage of disease was associated with survival duration (Figure 9.1). Stage I was associated 
with a median survival >40 months, stage II: median survival >40 months, stage III: median 
survival 15.7 months, and stage IV: median survival 6.3 months (p <0.001; log -rank test). 
Tumour grade also influenced survival; moderately differentiated tumours had a median 
survival of 21.5 months versus poorly differentiated tumours, median survival 10.4 months 
(p= 0.009; log -rank test). Overall prognosis was similar irrespective of the site of the primary 
tumour (oesophageal versus OG junction versus gastric) (p= 0.595; log -rank test). Similarly, 
survival duration was not associated with tumour histology (p =0.771 for the whole patient 
group and p =0.675 for the oesophageal cancer group alone) or Helicobacter pylori status 
(p =0.687 for the whole patient group and p =0.623 for the gastric cancer group alone). 
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Figure 9.1 Kaplan -Meier survival curve analysing survival duration according to final 
disease stage. Stage I [light line]: median survival >40 months, stage II [medium line]: median 
survival >40 months, stage III [heavy line]: median survival 15.7 months, stage IV [heaviest 








0.0 10.0 20.0 30.0 40.0 
Survival duration (months) 
Number at risk: 
Stage I 25 23 17 7 0 
Stage II 34 30 21 8 2 
Stage III 86 58 36 14 2 
Stage IV 75 19 6 2 0 
235 
2. Association between markers of systemic inflammation and prognosis 
Serum cytokine and acute phase protein concentrations and survival duration 
Serum concentrations of positive acute phase proteins were negatively associated with 
survival duration: CRP (p <0.001, Cox's univariate analysis) and a1- antichymotrypsin 
(p <0.001) (Table 9.2). Conversely, concentrations of negative acute phase reactants were 
positively associated with survival duration: albumin (p <0.001) and transferrin (p= 0.004). 
Serum haptoglobin concentrations were linked with reduced survival, but this association did 
not reach statistical significance (p= 0.062). Serum sTNF -R concentrations were also 
negatively associated with survival duration (p= 0.001), but none of the other serum cytokines 
were associated with prognosis: IL -6 (p= 0.876) and IL -8 (p= 0.415). 
Serum CRP concentrations were identified as the best predictors of prognosis among 
all the acute phase proteins and cytokines measured, as determined by receiver operating 
characteristics (ROC) curves [area under the curve = 0.67, p <0.001] (Table 9.2) (Figure 9.2). 
Table 9.2 Relationship between serum concentrations of acute phase proteins and 
cytokines with survival duration. 
Cox's univariate analysis 
Receiver Operating Characteristics 
(ROC) curve 
HR 95% Cl P value AUC 95% Cl P value 
CRP 1.01 1.00 -1.01 <0.001 0.67 0.59 -0.74 <0.001 
ACT 1.00 1.00 -1.00 <0.001 0.57 0.48 -0.65 0.123 
Haptoglobin 1.00 1.00 -1.00 0.062 0.57 0.48 -0.66 0.104 
Albumin 0.94 0.91 -0.97 <0.001 0.60 0.52 -0.67 0.021 
Transferrin 1.00 1.00 -1.00 0.004 0.65 0.58 -0.73 0.001 
IL -6 1.00 1.00 -1.00 0.876 0.51 0.42 -0.59 0.883 
IL -8 1.00 1.00 -1.00 0.415 0.55 0.46 -0.63 0.310 
sTNF -R 1.04 1.02 -1.06 0.001 0.64 0.56 -0.72 0.002 
HR = Hazard ratio, AUC = Area under the curve 
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Figure 9.2 Serum CRP concentrations were identified as the best predictors of 
prognosis, as determined by receiver operating characteristics (ROC) curves [area under the 
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Magnitude of markers of systemic inflammation and survival duration 
Increasing serum CRP concentrations were associated with significantly reduced survival 
duration (Figure 9.3). When analysed by tertiles, the lowest CRP group had a median serum 
concentration of 2 mg /I (inter -quartile range 1 -2 mg /I) and a median survival of 26.5 months, 
the mid -tertile group had a median serum concentration of 7 mg /I (inter -quartile range 5 -11 
mg /I) and a median survival of 13.4 months, and the highest group had a median serum 
concentration of 43 mg /I (inter -quartile range 25 -80 mg /I) and a median survival of 5.3 months 
[p <0.001, log -rank test]. 
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Figure 9.3 Kaplan -Meier survival curve analysing survival duration according to CRP by 
tertile group. Tertile 1 [light line]: median CRP concentration = 2 mg /I (median survival 26.5 
months), tertile 2 [medium line]: median CRP concentration = 7 mg /I (median survival 13.4 
months), tertile 3 [heavy line]: median CRP concentration = 43 mg /I (median survival 5.3 
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Number at risk: 
Tertile 1 73 57 39 14 2 
Tertile 2 73 47 27 12 1 
Tertile 3 72 24 13 5 0 
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Serum CRP concentrations were able to discriminate between patients within the same 
treatment groups (Figure 9.4). Patients who underwent surgical resection and whose serum 
CRP concentrations were in the lowest tertile had a median survival >40 months versus those 
patients who underwent surgery and who had a CRP concentration in the highest tertile, 
median survival 25.9 months (p= 0.043; log -rank test). Similarly, for patients who were 
palliated, those with a CRP concentration in the lowest tertile had a median survival of 9.2 
months compared with those with a CRP concentration in the highest tertile, median survival 
3.5 months (p= 0.0007). 
Serum CRP concentrations were also able to discriminate survival duration between 
patients within some of the same stage groupings (Table 9.3). Patients who were stage I or Il 
and who had a CRP concentration within the lowest tertile had a median survival >40 months 
compared with those with a CRP concentration in the highest tertile who had a median 
survival of 16.7 months (p= 0.002; log -rank test). Patients with stage IV disease and a low 
serum CRP concentration had a median survival of 7.3 months versus those with a high CRP 
concentration who had a median survival of 3.5 months (p= 0.031). Serum CRP 
concentrations were not able to discriminate between patients with stage III disease overall 
(p= 0.199), however, those patients with a CRP concentration in the lowest tertile had a 
median survival of 20.4 months compared with those whose CRP concentration was in the 
highest tertile and who had a median survival of 7.9 months, suggesting that CRP 
concentrations may predict early death rather than long term survival. 
Table 9.3 
test 
Survival duration analysed by stage group and serum CRP tertile. *Log -rank 
CRP Tertile Median survival (months) P value* 
Stage I /II Low CRP (n =31) >40 
0.002 
High CRP (n =11) 16.7 
Stage Ill Low CRP (n =24) 20.4 
0.199 
High CRP (n =22) 7.9 
Stage IV Low CRP (n =18) 7.3 
0.031 
High CRP (n =39) 3.5 
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Figure 9.4 Kaplan -Meier survival curve analysing survival duration according to 
treatment intervention and CRP concentration. Light line = lowest CRP tertile and surgery 
(median survival >40 months), medium line = highest CRP tertile and surgery (median 
survival 25.9 months), heavy line = lowest CRP tertile and palliation (median survival 9.2 
months), and heaviest line = highest CRP tertile and palliation (median survival 3.5 months) 
[p <0.001; log -rank test]. 
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0.0 10.0 20.0 30.0 40.0 
Number at risk: 
Surgery, low CRP 35 33 22 9 1 
Surgery, high CRP 11 7 5 2 0 
Palliation, low CRP 24 12 7 3 0 
Palliation, high CRP 52 10 3 2 0 
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Longitudinal study of markers of systemic inflammation and survival duration 
A second CRP and albumin measurement was performed in 77 (35 %) patients after an 
average 95 days (range 41 -151 days) from the time of the original measurement at diagnosis. 
Between the initial and follow -up measurements 48 patients had undergone surgical 
resection, 20 patients had received pre- operative chemotherapy but had not yet undergone 
surgery, and 9 patients had been palliated by non -surgical methods (for example, stenting). 
These measurements were performed a minimum of 92 days following surgery and a 
minimum 41 days following completion of pre- operative chemotherapy. 
Changes in serum CRP and albumin concentrations between the first and second 
measurements are described in Chapter IV. An increase in serum CRP concentration 
between the initial measurement and those taken at the second or third time interval were not 
associated with reduced survival duration for the whole patient group (p =0.84; Mann -Whitney 
U test), or for each sub -group divided by treatment intervention; surgery (p= 0.52), pre- 
operative chemotherapy (p= 0.22), or palliative treatments (p= 0.99). In addition, neither CRP 
nor albumin concentrations measured at the second time point were associated with 
prognosis (p =0.760 and p= 0.130, respectively; Cox's univariate analysis). 
3. Association between tumour tissue inflammation and prognosis 
Relationship between tissue cytokine concentrations and survival duration 
Tissue cytokine mRNA and protein concentrations were analysed by tertiles for patient 
survival. Neither mRNA nor tissue protein concentrations in benign or malignant tissue were 
associated with prognosis among these patients. 
Relationship between the degree of chronic inflammatory cellular infiltrate and survival 
duration 
A chronic inflammatory cell infiltrate was recorded in 75% of tumour tissues. The presence of 
an inflammatory response was associated with reduced prognosis (p =0.05, log rank test) 
(Figure 9.5). 
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Figure 9.5 Kaplan -Meier survival plot presented by the presence or absence of a chronic 
inflammatory cellular infiltrate within the tumour. The heavy line represents the presence of a 
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4. Multivariate survival analysis 
Patient age at diagnosis, Karnofsky performance score, stage of disease, tumour grade and 
serum CRP concentrations were all identified as prognostic indicators on univariate analysis. 
Multivariate analysis was performed to identify which of these variables were independently 
associated with prognosis using Cox's proportional hazards model (Table 9.4). Advanced 
disease stage [hazard ratio 2.36 (95% Cl 1.77- 3.13), p <0.001], reduced performance scores 
[hazard ratio 0.97 (95% Cl 0.95 -0.98), p <0.001], and increased serum CRP concentrations 
[hazard ratio 1.21 (95% Cl 1.04- 1.41), p= 0.012] were all identified as independent prognostic 
indicators for gastro -oesophageal cancer. Therefore, the likelihood of death increases by 21% 
for every logarithmic increase in serum CRP concentration. This means that an increase in 
serum CRP concentration from a value of 1 mg /I to 10 mg /I is associated with an almost 50% 
increase in likelihood of death. 
Table 9.4 Multivariate survival analysis using Cox's proportional hazards model to 
identify independent prognostic indictors for gastro -oesophageal cancer (forward stepwise 
conditional method). Advanced disease stage (p <0.001), reduced performance scores 
(p <0.001), and increased serum CRP concentrations (p= 0.012) were all identified as 
independent prognostic indicators for gastro- oesophageal cancer. 
Hazard Ratio 95% Cl P value 
Age (Ln) 0.68 0.23 -1.98 0.478 
Karnofsky score 0.97 0.95 -0.98 <0.001 
Stage of disease 2.36 1.77 -3.13 <0.001 
Tumour grade 0.95 0.61 -1.49 0.829 
CRP conc (Ln) 1.21 1.04 -1.41 0.012 
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DISCUSSION 
Concentrations of serum acute phase proteins and sTNF -R, but not concentrations of serum 
cytokines, are associated with survival duration. Serum CRP concentration was identified as 
the best individual prognosticator. Patient age, Karnofsky performance score, stage of 
disease, and tumour grade were also identified as prognostic indicators on univariate 
analysis. Multivariate analysis identified stage of disease, Karnofsky score and serum CRP 
concentrations as independent prognostic indicators for gastro -oesophageal cancer. The 
presence of a chronic inflammatory cell infiltrate into the tumour tissue was also associated 
with reduced survival duration. 
Elevated concentrations of the positive acute phase proteins and reduced 
concentrations of the negative acute phase reactants were associated with reduced survival 
duration. Most acute phase proteins have been linked with survival duration but this study has 
identified CRP concentrations as the best predictor of prognosis. Previously serum CRP 
concentrations have been identified as an independent predictor of survival duration among 
patients with advanced pancreatic cancer and other groups have found CRP to be similarly 
discriminating (Rashid et al, 1982; Nozoe et al, 2001; Falconer et al, 1995; Alexandrakis et al, 
2003). Repeat CRP measurements at the time of diagnosis in the same group of cancer 
patients have demonstrated good reproducibility (see Chapter IV) and CRP concentrations in 
different patient groups with similar disease processes have also demonstrated similar 
reproducibility. These findings suggest serum CRP concentrations are robust measure of 
systemic inflammation. In addition, CRP determination is a routinely performed laboratory 
investigation, familiar to most and is generally widely available without the need of specialist 
laboratory equipment. Some groups have combined CRP concentrations with albumin 
concentrations to develop a prognostic scoring system (Crumley et al, 2006). However, serum 
albumin concentrations may be influenced by malnutrition, hydration status, and trans - 
capillary escape, as well as the presence of an inflammatory response and therefore this 
study has investigated only single inflammatory variables (Fleck et al, 1985). 
Serum IL -6 and IL -8 concentrations were not associated with prognosis and levels of 
IL -18 and IL -10 were generally not measurable in patients' serum (Chapter IV). Although 
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many researchers have found an association between serum cytokine concentrations and 
adverse prognosis, many have not, and the relationship between serum cytokine levels and 
measures of outcome in advanced cancer are unclear. The difficulties in reliably measuring 
circulating cytokine concentrations and their relevance have already been discussed 
elsewhere. In contrast, sTNF -R levels were negatively associated with survival duration and 
this probably reflects the increased stability of this molecule and its ability to behave like an 
acute phase protein (Spinas et al, 1992) (see Chapter IV). 
The magnitude of the systemic inflammatory response was negatively associated 
with survival and this has been reported elsewhere in patients with colorectal, gastric, breast 
and lung malignancies (McMillan et al, 2001). Those patients with CRP concentrations in the 
highest tertile had significantly reduced survival duration compared with those with values in 
the lowest tertile. It is, therefore, not only the presence of systemic inflammation that has 
prognostic value, but also the magnitude of the response. This has clear implications when 
deciding on treatment strategies for individual patients and the CRP cut -off that is selected 
will depend on the survival end -point that is chosen (see Chapter XI). 
Among pancreatic cancer patients serial CRP concentrations 
increase in individual patients as their disease progresses and the incidence of elevated 
inflammatory markers increases (Falconer et al, 1995; Barber et al, 1999b). In this study CRP 
concentrations increased in those patients who underwent surgical resection, decreased in 
those who received pre- operative chemotherapy, and remained the same for those who 
underwent palliative treatments alone (Chapter IV). We found no association between repeat 
CRP concentrations and survival duration, either for the whole group or when analysed by 
treatment sub -group. Given the high degree of reproducibility of CRP concentrations at the 
time of diagnosis, the change in CRP concentrations are likely to be influenced by treatment 
modality, and, therefore, may lose predictive value. The absence of any significant change in 
CRP concentrations among those patients who received palliative treatments alone may 
reflect the small number of subjects involved (n =9). An elevated post -operative CRP 
concentration has been linked with early disease recurrence in colorectal, pancreatic and 
gastric cancers (McMillan et al, 2003; Fujita et al, 1999; Jamieson et al, 2005). There was no 
association between an elevated post- operative CRP concentration and survival duration for 
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the 48 patients who had undergone surgery in this study. However, it must be acknowledged 
that this sub -analysis involved smaller numbers of patients with relatively few events and, 
therefore, the value of post- operative CRP measurements in predicting outcome in patients 
with gastro -oesophageal malignancy remains unclear. 
Patient age at the time of diagnosis, Karnofsky performance score, stage of disease, 
and tumour grade were all identified as additional prognostic indicators on univariate analysis. 
All these variables are well established as prognostic indicators for malignant disease. Overall 
median survival by stage was: stage I /II >40 months, stage Ill 15.7 months and stage IV 6.3 
months. These results are comparable with those previously published on equivalent patient 
populations (Dressner, 2000). There were no significant differences in survival duration by 
stage between oesophageal and gastric cancers. This supports the theory that cancer arising 
around the gastro -oesophageal junction have similar biological behaviour and may be 
justifiably analysed as a single group (Jankowski et al, 2000). 
Within each treatment and stage grouping, serum CRP concentrations were able to 
discriminate between patients' survival duration. The median survival of patients who 
underwent surgical resection and had a CRP concentration in the lowest tertile was almost 
twice that of patients with a CRP concentration in the highest tertile. This was also true for 
patients who received palliative treatments. In addition, CRP concentrations were able to 
stratify patients in stages I, Il and IV. Although differences in survival duration between CRP 
tertiles for stage Ill patients was not statistically significant, an elevated serum CRP was 
associated with a marked reduction in median survival (8 months versus 20 months). This 
clearly has clinical applications given that those patients who fail to survive longer than 12 -18 
months following surgery are better managed by alternative palliative methods (Blazeby et al, 
2000). Measurement of pre- operative serum CRP concentrations may therefore aid the 
prospective identification of such patients. 
Multivariate analysis identified stage of disease, Karnofsky score and serum CRP 
concentrations as independent prognostic indicators. Serum CRP concentrations were 
positively associated with disease stage suggesting an association between markers of 
systemic inflammation and tumour burden, however, multivariate analysis identified CRP as 
an independent prognostic variable making this explanation unlikely. Nozoe and Shimada and 
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co- workers have previously shown CRP as an independent prognostic variable in 
oesophageal cancer (Nozoe et al, 2001; Shimada et al, 2003). However, these studies from 
Japan included only patients suitable for surgical resection and patients generally had earlier 
stage disease and almost all tumours were of squamous cell subtype. It is recognised that 
Western populations differ significantly not only in histology and stage of disease at 
presentation, but also in outcomes when compared with their Eastern counterparts (Griffin, 
2005). This study has shown that CRP has a prognostic value that is relevant to Western 
patients. In patients with gastric cancer elevated serum CRP and other acute phase protein 
concentrations have been linked with adverse outcomes (Rashid et al, 1982; Ogoshi et al, 
1988) and early disease recurrence (Jamieson et al, 2005), but no study has determined 
whether markers of systemic inflammation are independently prognostic of stage and other 
pathological variables. Crumley et al devised an inflammatory scoring system to aid 
determination of prognosis among patients with gastro -oesophageal malignancy (Crumley et 
al, 2006). This system utilises serum CRP and albumin concentrations and these authors 
have shown these scores to be independently prognostic for patients with inoperable disease. 
Conclusions 
Serum acute phase protein concentrations are associated with survival duration in patients 
with gastro -oesophageal cancer. CRP concentrations are identified as the best individual 
marker of adverse outcome and serum CRP concentration is an independent prognostic 
indicator on multivariate survival analysis. It is not only the presence of systemic inflammation 
that has prognostic value, but also the magnitude of the response. An increase in serum CRP 
concentration from a value of 1 mg /I to 10 mg /I is associated with an almost 50% increase in 
likelihood of death. In contrast, neither serum cytokine concentrations nor tumour tissue 
cytokine concentrations are associated with prognosis. However, a chronic inflammatory cell 
infiltrate into the tumour tissue is linked with adverse survival. 
The presence of a systemic inflammation is an ominous prognostic marker that 
reflects either a tumour phenotype with increased malignant potential or a host response that 
leaves the individual susceptible to metastatic spread. The next Chapter examines the role of 
cachexia as an aetiological factor in the link between systemic inflammation and adverse 
prognosis in patients with gastro- oesophageal malignancy. 
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CHAPTER X 
CACHEXIA IS AN AETIOLOGICAL FACTOR IN THE LINK BETWEEN 
SYSTEMIC INFLAMMATION AND ADVERSE PROGNOSIS IN PATIENTS 
WITH GASTRO -OESOPHAGEAL CANCER 
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ABSTRACT 
Cachexia is an important cause of morbidity and mortality among cancer patients. The 
syndrome is associated with reduced quality of life scores, lower response rates to 
chemotherapy, and overall poorer outcomes. The clinical sequelae of systemic inflammation 
may lead to the development of SIMS /cachexia and this association may account for the link 
between systemic inflammation and adverse prognosis in patients with gastro -oesophageal 
cancer. In this Chapter the changes in nutritional status in a cohort of patients with gastro- 
oesophageal cancer are described and the association between nutritional variables and 
markers of systemic inflammation and prognosis in these patients were examined. 
Patients (n =220) newly diagnosed with gastro -oesophageal cancer were recruited at 
the time of diagnosis. Each patient underwent a nutritional assessment consisting of 
calculation of body mass index (BMI), measurement of total weight loss and rate of weight 
loss, anthropometry measurements, dysphagia scoring and estimation of dietary intake. 
Serum concentrations of acute phase proteins and cytokines were determined by ELISA. 
Clinical and pathological information was collected and survival duration was recorded. 
At diagnosis, 83% of patients had lost weight with a median loss of 7% body weight 
(2.5% body weight loss per month) and reduced anthropometry measurements. At three 
months following diagnosis, 92% of patients had lost weight and patients had lost significantly 
more weight than measured at the time of diagnosis. Furthermore, weight loss occurred in 
these patients irrespective of treatment modality undertaken. Increased weight loss was 
associated with serum acute phase protein concentrations and sTNF -r and IL -8 
concentrations, but not with serum IL -6 concentrations. The best predictor of the fastest rate 
of weight loss was CRP. Weight loss was also associated with poor performance status and 
advanced stage of disease stage. Multiple regression analysis identified level of dietary intake 
(estimate of size of effect 38 %), serum CRP concentrations (estimate of size of effect 34 %), 
and stage of disease (estimate of size of effect 28 %) as independent variables in determining 
degree of weight loss. There was a highly significant negative association between the 
magnitude of weight loss and survival duration. 
Nutritional depletion is common among patients with gastro -oesophageal cancer and 
processes other than reduced dietary intake or mechanical obstruction by the tumour are 
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involved in the nutritional decline. The clinical sequelae of systemic inflammation may 
contribute to the weight loss observed in these patients and weight loss may provide the 
mechanism by which systemic inflammation contributes to adverse prognosis. 
INTRODUCTION 
The previous Chapter has demonstrated an association between elevated serum markers of 
systemic inflammation and adverse outcome in patients with gastro -oesophageal cancer. This 
Chapter investigated the factors that might provide the link between systemic inflammation 
and adverse prognosis. The clinical sequelae of systemic inflammation include alterations in 
protein and fat metabolism, changes in energy expenditure and alterations in patterns of 
hormonal secretion (see General Introduction for a detailed description - Chapter II). This 
may lead to a collection of symptoms collectively known as 'systemic immune -metabolic 
syndrome' (SIMS) (Cerchetti et al, 2004). These metabolic changes are also associated with 
the syndrome of cachexia and the mechanisms underlying the metabolic changes 
accompanying SIMS and cachexia may follow common pathways, for example, through 
increased pro -inflammatory cytokine activity. Therefore, in patients with systemic 
inflammation, the clinical sequelae may lead to the development of SIMS /cachexia and this 
association may account for the link between systemic inflammation and adverse prognosis in 
patients with gastro -oesophageal cancer. In this Chapter, therefore, the changes in nutritional 
status in a cohort of patients with gastro -oesophageal cancer were described and the 
association between markers of systemic inflammation, nutritional status, and prognosis in 
these patients was examined. 
Cachexia remains an important cause of morbidity and mortality among cancer patients, 
affecting up to 85% of patients with gastrointestinal malignancy at the time of diagnosis 
(DeWys et al, 1980). Cancer cachexia is associated with reduced quality of life scores, 
reduced performance status scores, lower response rates to chemotherapy, and overall 
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poorer outcomes (DeWys et al, 1980; Barber et al, 1999b). Around 20% of deaths from 
cancer may be directly related to cachexia (Studley, 1936; Inagaki et al, 1974). In a large 
study of patients with oesophageal cancer, weight loss greater than 10% premorbid weight 
was the only significant predictor of death in patients undergoing surgical resection (Kelson et 
al, 1998). 
The metabolic similarities underlying SIMS and cachexia suggest that pro - 
inflammatory cytokines may also play a role in the aetiology of cachexia. Circulating 
concentrations of IL-1P, IL -6 and TNFa and other cytokines have been associated with 
anorexia and weight loss in rodent tumour models and in human subjects (Ghelin et al, 1991; 
Strassmann et al, 1993). More recently, IL -6 over -expression in the serum and in tumour 
specimens of pancreatic cancer patients have been linked with accelerated weight loss 
(Martignoni et al, 2005). Markers of systemic inflammation have also been linked with 
cachexia. Elevated serum CRP concentrations have been correlated positively with weight 
loss in human cancer patients (Falconer et al, 1995; Wigmore et al, 1997; O'Gorman et al, 
1999). An APPR in pancreatic cancer patients is associated with elevated resting energy 
(REE) and with reduced energy intake (Falconer et al, 1994; Wigmore et al, 
1997). In patients with cancer, therefore, an APPR has been associated with 
hypermetabolism, anorexia, increased weight loss, and adverse prognosis (Argiles et al, 
1997). 
MATERIALS AND METHODS 
Study population 
The same patient cohort was studied as described in Chapter IV. In summary, all patients 
diagnosed with gastric or oesophageal cancer within the Lothian and Borders regions 
between March 2002 and June 2004 were eligible for inclusion into the study. No patients 
were excluded and patients were recruited to the study within two weeks of diagnosis. Blood 
was collected from each patient at the time of recruitment for determination of serum cytokine 
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and acute phase protein concentrations. All patients underwent an assessment of their 
nutritional status (see below). Patients were staged and underwent various treatments 
following discussion at the multidisciplinary team meeting. Duration of survival, defined from 
time of histological diagnosis to death, was recorded for each patient. 
Nutritional assessment 
All patients underwent an assessment of their nutritional status at the time of diagnosis. An 
additional assessment was performed in a subgroup of patients later in the progression of 
their disease and following initiation of treatment. A description of the nutritional assessment 
undertaken and methods employed are detailed in the Materials and Methods section 
(Chapter III). Briefly, body mass index (BMI) was calculated following height and weight 
measurements. Pre -morbid patient weight was recalled by the patient and confirmed where 
possible from the medical notes. Total body weight loss was calculated and expressed as a 
percentage of weight lost from the pre -illness stable weight. Rates of weight loss were 
calculated by dividing the total weight lost by the number of months where symptoms were 
experienced. Anthropometry was undertaken on each patient and included measurement of 
mid -arm circumference (MAC) and triceps skin -fold thickness. Mid -arm muscle circumference 
(AMC) was calculated by means of Jelliffe's equation (Jelliffe, 1966). Measurements were 
corrected for age and sex and were normalised using standardised reference tables (Bishop 
et al, 1981). The severity of dysphagia was scored according to Knyrim et al ( Knyrim et al, 
1993). Dietary intake was estimated by all patients and scored as normal, reduced or 
poor /minimal. A small group of randomly selected patients provided detailed 3 -day food 
diaries for comparison. Patients were instructed to record all food and drink consumed over a 
3 -day period, which included a weekend day and the data were analysed by a senior dietician 
who provided information on the level of intake of macronutrients using computer software 
(CompEat ®, Nutrition Systems, Grantham, UK). Comparisons were made to dietary reference 
values issued by the Department of Health (Department of Health, 1991). Body composition 
analysis was also performed on this patient subgroup. Lean body mass was calculated from 
total body water assuming a hydration coefficient of 0.732 (Hannan et al, 1995). 
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Statistical analysis 
Non -parametric analysis was performed in all instances. Correlations were investigated by 
Spearman's rank test. Independent variables were analysed by the Mann -Whitney U or the 
Kruskal -Wallis tests. Categorical data was analysed by the Chi -square test. The paired 
sample T -test was used to compare serial measurements for each patient. Receiver operator 
characteristics (ROC) curves were used to evaluate the ability of serum acute phase protein 
concentrations to identify patients with the fastest rate of weight loss. Multiple regression 
modelling was used to identify which variables were independently associated with weight 
loss and to calculate the estimates of effect size. Survival analysis was analysed by Log -rank 
test and Cox's multivariate model. 
RESULTS 
Study Patients 
Group demographics are presented in Table 4.1 (Chapter IV). In summary, 220 patients were 
studied over a 28 -month period. Ninety -five (43 %) patients underwent surgical resection and 
25 of these received pre- operative chemotherapy. The remaining patients (n =118; 54 %) were 
not suitable for curative therapy and received palliative treatments. One -third (34 %) of 
patients had metastatic disease (stage IV) at the time of presentation and most other patients 
(n =86; 39 %) had locally advanced (stage Ill) disease at diagnosis. Approximately one -quarter 
(n =59; 27 %) of patients had early stage disease (stage I /II). 
Patients were followed -up for an average 32 months and minimum of 18 months 
(range 18 -45 months). At the time of censoring the data 147 (67 %) patients had died. Overall 
median survival was 13 months. 
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1. Description of nutritional status 
Weight loss and anthropometry measurements 
The nutritional variables for the patient group measured at the time of diagnosis are shown in 
Table 10.1. Patients had lost a median of 7.1°/o (inter -quartile range 1.2- 14.2 %) total body 
weight at the time of diagnosis compared with their pre- morbid stable body weight. This was 
equivalent to a median rate of weight loss of 2.5% total body weight per month of illness 
(inter -quartile range 0.3 -6.5% per month) [defined from the onset of symptoms]. Only 38 
(17 %) patients remained weight steady at the time of diagnosis, while 85 (39 %) patients had 
lost more than 10% body weight. Anthropometry values were reduced for MAC, median 
percentile group = 10 (inter -quartile range 1 -25 percentile); triceps skinfold, median percentile 
group = 25 (inter -quartile range 10 -50 percentile); and AMC, median percentile group = 10 
(inter -quartile range 1 -25 percentile). Lean body mass was calculated from total body water 
values obtained by electrical bioimpedence in a random subgroup of patients (n =17). All 
subjects were male. Median values were 43.0 kg (inter -quartile range 39.4 -47.8 kg) [normal 
values for males = 43.9 kg]. 
Assessment of dietary intake 
Eighty -five (39 %) patients described their dietary intake as normal, 103 (47 %) patients 
described their intake as reduced compared to normal, and 32 (14 %) patients had a poor or 
minimal food intake at diagnosis. Detailed 3 -day food diaries were collected from 22 (10 %) 
patients. When normalised to the estimated average requirement (EAR), total energy intake 
was below recommendations; median 87% of EAR kcal (inter -quartile range 68 -93 %), 
however, levels of protein intake (g /day) were above the reference nutritional intake (RNI) 
value; median 142% (inter -quartile range 109 -170 %). Actual food intake was compared with 
perceived food intake for those patients who completed food diaries. Eleven (50 %) patients 
described their intake as normal, 9 (41%) said their intake was reduced, and 2 (9 %) patients 
had a poor or minimal intake. Patient perception of reduced food intake was associated with 
reduced total calorie intake; 'normal' intake median 90% EAR kcal (inter -quartile range 81- 
105) versus 'reduced /poor' intake median 76% EAR kcal (inter -quartile range 56 -89) 
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Table 10.1 Nutritional variables for the patient group measured at the time of diagnosis. 
Pre -illness BMI 
BMI at diagnosis 
Total body weight loss ( %) 
Rate of weight loss (% per month) 
Mid -arm circumference (percentile group) 
Triceps skinfold thickness (percentile group) 
Arm -muscle circumference (percentile group) 
Lean body mass# 
26.4 (24.1 -30.1) 
24.6 (21.4 -28.0)` 
7.1 (1.2 -14.2) 
2.5 (0.3 -6.5) 
10 (1 -25) 
25 (10 -50) 
10 (1 -25) 
43.0 (39.4 -47.8) 
Dietary intake 
Normal 85 [39] 
Reduced 103 [47] 
Poor /minimal 32 [14] 
Food diary intake¶ 
Energy kcal (% of EAR) 
Protein (% of RNI) 
87 (68 -93) 
142 (109 -170) 
Dysphagia score 
0 89 [40] 
1 52 [24] 
2 43 [19] 
3 32 [15] 
4 4 [2] 
#Calculated from a subgroup of 17 patients. ¶ Calculated from a subgroup of 22 patients. EAR = estimated average 
requirement. RNI = reference nutritional intake. Values are median (inter -quartile range). [ %]. 
[p= 0.040; Mann -Whitney U test], and reduced protein intake; 'normal' intake median 170% 
RNI g /day (inter -quartile range 133 -197) versus 'reduced /poor' intake median 113% RNI 
g /day (inter -quartile range 99 -148) [p= 0.003] (Figure 10.1). However, there was no 
association between reduced calorie or protein intake and degree of weight loss, rate of 
weight loss, adverse anthropometry measurements, reduced lean body mass, or increased 
dysphagia scores for this subgroup of patients (data not shown). 
Analysis of the whole patient group, however, identified reduced dietary intake as 
perceived by the patient to be associated with a lower BMI at diagnosis (p= 0.007, Kruskal- 
Wallis test), increased percentage total body weight loss (p <0.001), increased rate of weight 
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kcal intake 
(multiple of EAR) 
loss (p <0.001), and reduced anthropometry measurements, although only triceps skin -fold 
thickness reached statistical significance (triceps p= 0.025, MAC p =0.08, AMC p= 0.11). In 
addition, reduced food intake was associated with reduced Karnofsky performance scores 
(p <0.001, Kruskal -Wallis test) and increased dysphagia scores (p <0.001, chi -square test). 
Eighty -nine (40 %) patients had no dysphagia at diagnosis, 95 (43 %) were able to 
swallow solids or semi -solid foods, 32 (15 %) were able to swallow liquids only, and 4 (2 %) 
patients had total dysphagia. As a consequence of the association between dysphagia scores 
and reduced dietary intake, advancing dysphagia was also linked with adverse nutritional 
status. 
Figure 10.1 Patient perception of reduced food intake was associated with reduced total 
calorie intake; 'normal' intake median 90% EAR kcal (inter -quartile range 81 -105) versus 
'reduced /poor' intake median 76% EAR kcal (inter -quartile range 56 -89) [p= 0.040; Mann - 
Whitney U test], and reduced protein intake; 'normal' intake median 170% RNI g /day (inter - 
range 133 -197) versus 'reduced /poor' intake median 113% RNI g /day (inter -quartile 
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Longitudinal study of nutritional status 
Seventy -seven (35 %) patients underwent a second nutritional assessment after an average 
95 days (range 41 -151 days) from the time of the original measurement at diagnosis. 
Between the initial and follow -up measurements 48 patients had undergone surgical 
resection, 20 patients had received pre- operative chemotherapy but had not yet undergone 
surgery, and 9 patients had been palliated by non -surgical methods (for example, stenting). 
These measurements were performed a minimum of 92 days following surgery and a 
minimum 41 days following completion of pre- operative chemotherapy. 
A comparison of nutritional variables measured at the time of diagnosis and those 
measured approximately 3 months later are shown in Table 10.2. Seventy -one (92 %) patients 
had lost weight at three months following diagnosis compared with 83% at the time of 
diagnosis. Compared with the measurements taken at the time of diagnosis there was a 
significant decrease in BMI (p <0.001, Paired T test), increase in total body weight loss 
(p <0.001), increased rate of weight loss (p <0.001), and reduction in anthropometry 
measurements [MAC (p <0.001), triceps skin -fold thickness (p <0.001), and AMC (p <0.001)] at 
the follow -up assessment. There was a significant improvement in dysphagia scores between 
the two time points (p <0.001, chi -square test), but despite this food intake was significantly 
reduced (p <0.001, chi -squared test). 
Effect of treatment on nutritional status 
Sub -group analysis was performed to investigate any effect of treatment modality on 
nutritional status. There was no difference in total weight loss or rates of weight loss between 
patients who had undergone surgical resection, pre- operative chemotherapy, or palliative 
treatments alone (data not shown). Patients who had undergone surgery had significantly 
improved dysphagia scores compared with those who received pre- operative chemotherapy 
or who were palliated (p <0.001, chi -square test), but conversely the surgical patient group 
had significantly reduced dietary intake compared with the other two patient groups (p= 0.018, 
chi -square test). 
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Table 10.2 Comparison of nutritional variables calculated at the time of diagnosis with 
those measured approximately 3 months later (n =77). 
1st assessment 2nd assessment Paired T test 
P value Mean change 95% Cl 
BMI at diagnosis 
25.8 (22.6 -29.0) 24.0 (20.4 -27.2) <0.001 -1.8 -2.2 to -1.4 
Total body weight loss 
( %) 
3.2 (0 -9.2) 10.3 (6.1 -16.8) <0.001 6.8 5.4 to 8.1 
Rate of weight loss 
(% per month) 
0.6 (0 -3.1) 3.3 (2.0 -5.4) <0.001 1.9 1.3 to 2.5 
Mid -arm circumference 
(percentile group) 
10 (5 -25) 5 (1 -17.5) <0.001 -8.3 -11.5 to -5.2 
Triceps skinfold thickness 
(percentile group) 
25 (21.3 -50) 25 (10 -50) <0.001 -5.6 -8.3 to -2.9 
Arm -muscle circumference 
(percentile group) 





























Values are median (inter -quartile range). *Chi- squared test. [ %]. 
2. Association between nutritional status and patient demographics 
Clinical characteristics 
Female sex was associated with reduced triceps skin -fold thickness (p <0.001, Mann -Whitney 
U test) and reduced dietary intake (p <0.001, chi -square test). In contrast male sex was 
associated with reduced MAC (p <0.001, Mann -Whitney U test) and AMC (p <0.001) 
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measurements. Despite these differences in anthropometry measurements and dietary intake 
there were no differences in amount of weight loss (p =0.68, Mann -Whitney U test) or BMI 
(p =0.28) between the sexes. Increasing patient age was associated with reduced triceps skin - 
fold thickness (p =0.03, Mann -Whitney U test), but age was not associated with any other 
nutritional variable. Reduced performance status was associated with reduced oral intake 
(p <0.001, chi -square test), increased dysphagia scores (p <0.001, chi -square test), increased 
weight loss (p <0.001, Kruskal -Wallis test), and reduced anthropometry values, although these 
did not quite reach statistical significance (MAC p =0.07, Triceps p =0.07, AMC p =0.08; 
Kruskal -Wallis test). 
Pathological characteristics 
Oesophageal tumours were associated with higher dysphagia scores (p <0.001, chi -square 
test), but not with reduced dietary intake (p =0.61) or increased weight loss (p =0.34, Kruskal- 
Wallis test). Total body weight loss was similar between the different histological subtypes 
(p= 0.20). Advanced disease stage at the time of diagnosis was associated with greater 
percentage body weight loss (p <0.001), increased dysphagia scores (p= 0.002), and reduced 
dietary intake (p= 0.005), but with similar anthropometry measurements. Patients with stage Ill 
and stage IV disease had lost a median 9.5% of their total body weight by the time of 
diagnosis. 
3. Relationship between markers of systemic inflammation and nutritional 
variables 
a) Serum acute phase protein concentrations 
Serum acute phase protein concentrations were associated with nutritional variables as 
shown in Table 10.3. Elevated concentrations of the positive acute phase proteins (CRP, a1- 
antichymotrypsin, and haptoglobin) were associated with increased total weight loss and 
increased rates of weight loss at the time of diagnosis, whereas the converse was true for the 
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negative acute phase reactants (albumin and transferrin) (Figure 10.2). Low serum albumin 
concentrations were also correlated with reduced anthropometry measurements; MAC 
(p <0.001, r =0.25) and AMC (p <0.001, r= 0.31), but not triceps skin -fold thickness (p= 0.624, 
r= 0.03). Patients were grouped into tertiles according to rate of weight loss; lowest tertile 
median rate of weight loss = 0 % per month (inter -quartile range 0 -0.3 % per month); middle 
tertile median rate of weight loss = 2.4 % per month (inter -quartile range 1.5 -3.3 % per 
month); highest tertile median rate of weight loss = 7.6 % per month (inter -quartile range 6.4- 
14.5 % per month). Increasing tertile was associated with elevated serum concentrations of 
CRP (p <0.001; Kruskal -Wallis test), al- antichymotrypsin (p <0.001), and sTNF -R (p= 0.002) 
and with reduced concentrations of albumin (p <0.001) and transferrin (p= 0.003) (Table 10.4). 
Elevated serum haptoglobin concentrations were associated with increased rates of weight 
loss but did not quite reach significance (p= 0.079). 
Table 10.3 Relationship between serum concentrations of acute phase proteins and 
cytokines with markers of nutritional status at the time of diagnosis. 
Wt loss Rate of wt loss BMI MAC Triceps AMC 
r P r P r P P r P r P 
CRP 0.30 <0.001 0.36 <0.001 -0.04 0.546 -0.03 0.627 0.10 0.168 -0.13 0.065 
ACT 0.23 0.001 0.27 <0.001 -0.05 0.486 -0.05 0.506 0.07 0.333 -0.14 0.058 
Haptoglobin 0.15 0.038 0.16 0.020 0.01 0.915 0.02 0.734 0.05 0.452 -0.01 0.927 
Albumin -0.31 <0.001 -0.35 <0.001 0.24 <0.001 0.25 <0.001 0.03 0.624 0.31 <0.001 
Transferrin -0.30 <0.001 -0.26 <0.001 0.15 0.035 0.12 0.105 0.01 0.970 0.13 0.074 
IL -6 0.08 0.294 0.08 0.260 -0.02 0.17 -0.12 0.099 -0.02 0.833 -0.12 0.108 
IL -8 0.17 0.020 0.09 0.203 -0.15 0.040 -0.12 0.100 -0.02 0.773 -0.11 0.152 
sTNF -R 0.10 0.155 0.15 0.041 0.09 0.188 0.08 0.293 0.09 0.190 -0.01 0.973 
Spearman rank analysis; r = correlation coefficient 
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Figure 10.2 Scatter plot illustrating the positive correlation between elevated serum CRP 
concentrations at diagnosis and subsequent increased rate of weight loss (p <0.001, r =0.36; 
Spearman rank analysis). 
Serum CRP cone [Ln] 
o.00 
2.00 3.00 4.00 5.00 
Rate of weight loss (% /month) [Ln] 
6.00 
Table 10.4 Association between rate of body weight loss and serum acute phase protein 
and cytokine concentrations at diagnosis. 
Rate of weight loss (% body weight lost per month) 
Lowest tertile Mid tertile Highest tertile P value* 
CRP 4 (2 -14) 4 (2 -18) 18 (7 -47) <0.001 
ACT 424 (323 -518) 412 (351 -520) 572 (399 -645) <0.001 
Haptoglobin 1965 (1224 -2850) 2120 (1573 -2853) 2460 (2020 -3101) 0.079 
Albumin 42 (38 -44) 40 (37 -42) 37 (33 -41) <0.001 
Transferrin 2263 (1911 -3353) 1852 (1594 -2618) 1691 (1385 -2913) 0.003 
IL -6 0 (0 -65.4) 17 (0- 108.7) 11.3 (0 -85.9) 0.223 
IL -8 0 (0 -0) 0 (0- 148.8) 0 (0- 240.1) 0.249 
sTNF-R 3.4 (1.9 -5.1) 2.4 (1.7 -4.3) 4.4 (2.6 -8.9) 0.002 
Values are median (inter -quartile range). *Kruskal- Wallis test. 
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Serum CRP concentration was the best predictor of the fastest rate of weight loss, as 
identified by a receiver operating characteristics (ROC) curve [area under the curve = 0.72 
(p <0.001; 95% confidence interval 0.65 -0.79)] (Table 10.5). 
Table 10.5 Areas under the receiver operating characteristics (ROC) curve for the ability 
of serum acute phase proteins and sTNF -R to predict the group of patients with the fastest 
rate of weight loss (AUC = area under the curve). 
AUC 95% CI P value 
CRP 0.72 0.65 -0.79 <0.001 
ACT 0.68 0.60 -0.77 <0.001 
Albumin 0.70 0.63 -0.79 <0.001 
Transferrin 0.61 0.52 -0.70 0.015 
sTNF -R 0.63 0.55 -0.71 0.003 
b) Serum cytokine concentrations 
Elevated serum IL -8 concentrations were correlated with increased total weight loss (p= 0.020, 
r =0.17; Spearman rank analysis), reduced BMI (p= 0.040, r= -0.15), and were associated with 
reduced dietary intake (p= 0.071) (Table 10.3). Serum sTNF -R concentrations were positively 
correlated with rate of weight loss (p= 0.041, r= 0.15). In contrast, serum IL -6 concentrations 
were not associated with any nutritional variable. 
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4. Multivariate nutritional analysis 
Levels of dietary intake, dysphagia score, karnofsky performance score, stage of disease, 
and serum CRP concentrations were all associated with degree of weight loss among the 
patient group. Multiple regression analysis was performed to identify which variables were 
independently associated with weight loss. Dysphagia score and performance score are 
clearly confounding variables and are therefore excluded from the multivariate analysis. 
Dietary intake (r = 0.28, p <0.001), stage of disease (r = 0.17, p= 0.013), and serum CRP 
concentrations (r = 0.17, p= 0.017) all retained independent association in determining extent 
of weight loss (Table 10.6). A multivariate general linear model was then used to calculate the 
estimates of size of effect size on degree of weight loss for each variable (Table 10.6). These 
data suggested that 38% of weight loss was determined by level of dietary intake, 34% by 
serum CRP concentrations (systemic inflammation), and 28% was attributable to stage of 
disease. 
Table 10.6 Multiple regression analysis of variables associated with increased weight 
loss. Dietary intake, stage of disease, and serum CRP concentrations all retained 
independent association in determining degree of weight loss. A multivariate general linear 
model was then used to calculate the estimates of size of effect on degree of weight loss for 
each variable. 
Regression 





effect size ( %) 
Dietary intake 0.28 1.80 to 5.09 1.9 38 <0.001 
Stage of disease 0.17 0.31 to 2.62 0.9 28 0.013 
CRP conc (In) 0.17 0.18 to 1.77 1.3 34 0.017 
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5. Relationship between nutritional status and prognosis 
Increased total weight loss and increased rates of weight loss at diagnosis were associated 
with adverse prognosis [HR 1.44; p <0.001 and HR 1.42; p <0.001, respectively] (Table 10.7). 
Median survival duration was compared between patients who were weight stable (33.0 
months; n =38, 17 %), those patients who had lost up to 10% of their body weight (14.7 
months; n =97, 44 %), and those who had lost greater than 10% body weight (7.4 months; 
n =85, 39 %) (Figure 10.3). Increasing magnitude of weight loss was associated with a 
corresponding reduction in survival duration (p <0.001; log -rank test). In addition, reduced 
dietary intake (p <0.001; log -rank test) and increasing dysphagia scores were also associated 
with reduced survival duration (p <0.001). In contrast, anthropometry measurements were not 
associated with prognosis and neither were lean body mass nor energy or protein intake as 
determined from food diaries, however, these groups involved smaller numbers (n =17 and 
n =22, respectively) and may have been subject to type Il error. 
Table 10.7 Relationship between nutritional variables and prognosis. Cox's hazard's 
model was used in univariate mode for the analysis of continuous variables and the log -rank 
test was used for categorical data. 
Cox' univariate analysis 
Hazard ratio 95% Cl P value 
BMI at diagnosis 0.95 0.92 -99 0.005 
Total body weight loss ( %) [Ln] 1.44 1.20 -1.73 <0.001 
Rate of weight loss (% per month) [Ln] 1.42 1.23 -1.63 <0.001 
Mid -arm circumference (percentile group) 0.99 0.99 -1.00 0.130 
Triceps skinfold thickness (percentile group) 1.00 0.99 -1.00 0.414 
Arm -muscle circumference (percentile group) 1.00 0.99 -1.01 0.532 
Lean body mass 1.06 0.94 -1.19 0.367 
Energy kcal (% of EAR) 0.44 0.04 -4.88 0.501 
Protein (% of RNI) 1.16 0.42 -3.15 0.778 
Log -rank test 
Median survival (months) P value 



















Figure 10.3 Increased weight loss at the time of diagnosis was associated with reduced 
survival duration; weight stable median survival 33.0 months (light line) versus 0 -10% weight 
loss median survival 14.7 months (medium line) versus greater than 10% weight loss median 










0.0 10.0 20.0 
Survival Duration (months) 
30.0 40.0 
Number at risk: 
Weight stable 38 30 21 6 2 
0 -10% weight loss 97 64 38 19 2 
>10% weight loss 85 37 22 6 0 
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DISCUSSION 
This Chapter has described the changes in nutritional status in a cohort of patients with 
gastro -oesophageal cancer and has investigated the association between these nutritional 
variables and markers of systemic inflammation and outcome. At the time of diagnosis, 
patients with gastro -oesophageal cancer demonstrate a median loss of 7% body weight 
(2.5% body weight loss per month) and reduced anthropometry measurements. 83% of 
patients had lost weight at the time of diagnosis. At three months following diagnosis, 92% of 
patients had lost weight and patients had lost significantly more weight than measured at the 
time of diagnosis. Furthermore, weight loss occurred in these patients irrespective of 
treatment modality undertaken. Increased weight loss was associated with serum acute 
phase protein concentrations and sTNF -r and IL -8 concentrations, but not serum IL -6 
concentrations. Weight loss was also associated with poor performance status and advanced 
stage of disease stage. Multiple regression analysis identified level of dietary intake (estimate 
of effect of size 38 %), serum CRP concentrations (estimate of effect of size 34 %), and stage 
of disease (estimate of effect of size 28 %) as independent variables in determining degree of 
weight loss. There was a highly significant negative association between the magnitude of 
weight loss and survival duration. 
Weight loss is common among cancer patients, particularly in patients with gastro- 
intestinal malignancy where up to 85% of patients may be affected during their illness (DeWys 
et al, 1980). One hundred and eighty -three (83 %) patients in our study had lost weight at the 
time of diagnosis with almost half of these patients losing 10% or more of their pre -illness 
body weight. The median rate of weight loss was 2.5% body weight per month (approximately 
1.9 kg /month) and compares with previous work relating to patients with pancreatic cancer 
where the mean rate of weight loss was 2.3 kg /month (Barber et al, 1999b; Fearon et al, 
2003). Pancreatic cancer is notorious for its association with marked weight loss (DeWys, 
1986; Galizia et al, 2002). In the present study we also found reduced anthropometry 
measurements: MAC and AMC median values in the10 
th centile and triceps skin -fold 
thickness in the 25th centile. Values below the 15th centile are generally representative of 
some degree of nutritional depletion and these data may suggest a preferential loss of lean 
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body mass rather than fat mass as is characteristic of the cachexia syndrome (Bishop et al, 
1981). However, we found no reduction in lean body mass as measured by bioimpedence 
analysis. The limitations of measuring lean body mass by electrical bioimpedence is 
documented elsewhere and better estimations could be made using either dual energy X -ray 
absorptiometry or magnetic resonance imaging. 
One hundred and thirty -four (61 %) patients described their level of dietary intake as 
reduced or poor compared with their normal levels of intake, and energy intake values were 
below national averages for those patients who completed food diaries (median 87% of 
estimated average requirement, approximately equal to 1920 kcal /day). Levels of protein 
intake exceeded minimum recommendations (142% reference nutritional intake); however, 
the average protein intake in the UK is 88g /day for men and 64g /day for females (Department 
of Health, 1991). Despite levels of protein intake in excess of reference recommendations the 
actual levels of protein intake were below the national average for both sexes (males 82g /day 
average; females 51g/day average). 1920 kcal /day may be insufficient to maintain constant 
weight even accounting for reductions in level of physical activity. Reduced dietary intake was 
associated with increased total weight loss, increased rate of weight loss, and reduced 
anthropometry measurements. 
In this study we found that patients' perception of their level of dietary intake was 
associated with actual levels of energy and protein intake as determined from detailed food 
diaries. Diet diaries have been shown previously to reflect usual daily food intake (Bingham et 
al, 1982; Gibson, 1990) and it would appear that a patient's perception of their level of food 
intake may also reflect actual levels of dietary intake. 
One hundred and thirty -two (60 %) patients had symptomatic dysphagia at the time of 
diagnosis. Increasing dysphagia scores were associated with increased total weight loss, 
increased rate of weight loss, and reduced anthropometry measurements. Additionally, 
dysphagia was also associated with reduced levels of food intake. Patients with gastro- 
oesophageal malignancy are not only subjected to the systemic effects of the disease on their 
nutritional status (for example, anorexia, hypermetabolism, and altered protein metabolism), 
but also affected by the local effects of the tumour on the upper digestive tract. However, 
patients without dysphagia (and who had a 'normal' level of food intake) had still lost a 
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median 4.4% of their total body weight by the time of diagnosis (rate 1.5% per month) and 
therefore the systemic influences of the cancer on nutritional status remain important among 
these patients. 
Patient performance status was strongly associated with reduced dietary intake and 
increased weight loss. In addition, reduced Karnofsky scores were linked with reduced 
anthropometry measurements, although these did not quite reach statistical significance. 
Performance score has previously been identified as an independent variable for weight loss 
in patients with advanced pancreatic cancer and similar findings have been reported 
elsewhere (Wigmore et al, 1997; O'Gorman et al, 1999). Clearly the functional status of the 
patient will influence appetite and desire and ability to eat. Likewise, nutritional depletion and 
cachexia will negatively influence performance status. It is therefore not surprising that 
performance status is adversely associated with nutritional variables. 
A subgroup of 77 patients (35 %) underwent a second nutritional assessment after a 
mean time interval of 95 days following diagnosis. These patients experienced on -going 
nutritional depletion and at an accelerated rate. Patients with unresectable pancreatic cancer 
demonstrate a similar inexorable progressive weight loss in an almost linear fashion as these 
patients approach death (Wigmore et al, 1997). In the present study, patients continued to 
lose weight irrespective of treatment intervention and despite improvements in the dysphagia 
scores of those patients who underwent surgery. In the case of those patients who underwent 
surgery the continued weight loss may reflect the catabolic response to the surgical insult and 
impaired muscle maintenance may continue for longer than 30 days following surgery 
(Petersson et al, 1990). A longer follow -up period would determine whether their nutritional 
status improves with recovery. However, certainly in the palliative treatment cohort, the 
general trend is for on -going nutritional decline among these patients. 
Serum acute phase protein concentrations correlated with total weight loss and rate 
of weight loss and serum albumin concentrations also correlated with anthropometry 
measurements. Previously, a similar association between elevated serum CRP 
concentrations and increased weight loss in pancreatic cancer patients has been identified 
and other groups have found similar associations in other cancer types (Scott et al, 2003; 
O'Gorman et al, 1999; Barber et al, 1999b; Falconer et al, 1995). In addition, resting energy 
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expenditure (REE) in cancer patients is increased compared with controls and those patients 
with an APPR have greater REE compared with cancer patients without an APPR (Falconer 
et al, 1994). Cancer patients with an APPR have been shown to have elevated fibrinogen 
synthesis rates in both the fed and fasting states and it is this reprioritisation of protein 
metabolism that accompanies the APPR that may also contribute to the wasting observed in 
cancer cachexia (Preston et al, 1998; Barber et al, 2000). In this study CRP and albumin 
concentrations were identified as the best predictors of rate of weight loss by ROC curves. 
However, serum albumin concentrations may be influenced by malnutrition, hydration status, 
and trans -capillary escape, as well as the presence of an inflammatory response (Fleck et al, 
1985) and therefore serum CRP concentrations were chosen for entry into the multivariate 
analysis. 
Serum cytokine concentrations were generally not associated with any nutritional 
variable. IL -8 concentrations were correlated with increased total weight loss, but not rate of 
weight loss or any other nutritional variable and it is most likely that this result is due to 
multiple statistical testing. Although many other groups have demonstrated associations 
between serum cytokine concentrations and markers of nutritional depletion we have found 
no such association in this study or previously in a study of pancreatic cancer patients 
(Falconer et al, 1994). The difficulties in reliably measuring circulating cytokine concentrations 
has already been discussed in the Introduction (Chapter II), and the relevance of such 
measurements must also be considered. Local tissue cytokine production by inflammatory 
cells (or tumour cells) is likely to be a better indicator of cytokine activity in cancer cachexia 
(Falconer et al, 1994; Martignoni et al, 2005). However, circulating acute phase proteins (for 
example, CRP) remain robust indices of systemic pro -inflammatory status. 
Increased total weight loss, increased rate of weight loss, reduced BMI, increased 
dysphagia scores, and reduced dietary intake were all associated with adverse prognosis. 
Moreover, the magnitude of weight loss was inversely associated with survival duration. The 
value of weight loss as a prognostic indicator will be investigated in a multivariate model in the 
following Chapter (Chapter XI). 
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Conclusions 
Weight loss and reduced measures of nutritional status are common in patients with gastro- 
oesophageal malignancy. 83% of patients exhibit weight loss at the time of diagnosis and 
92% of patients have lost weight three months later and at an accelerated rate. Weight loss 
appears to occur irrespective of treatment modality and independently of dysphagia score and 
dietary intake. These findings suggest that processes other than reduced intake or 
mechanical obstruction by the tumour are involved in the nutritional decline. Serum markers 
of systemic inflammation (acute phase protein concentrations and IL -8 and sTNF -R 
concentrations) are significantly associated with degree of weight loss and the presence of 
systemic inflammation (CRP concentrations) may account for 34% of this association. 
Therefore, the clinical sequelae of systemic inflammation may contribute to the weight loss 
observed in these patients. In addition, there is a highly significant negative association 
between degree of weight loss and survival duration. The association between systemic 
inflammation and adverse outcome in patients with gastro -oesophageal cancer has been 
investigated in the previous Chapter (Chapter IX). Accelerated weight loss may provide one of 
the mechanisms whereby systemic inflammation acts to reduce survival duration. 
In Chapter IX the association between systemic inflammation and outcome in patients with 
gastro -oesophageal cancer was investigated. Concentrations of serum acute phase proteins 
were associated with survival duration and serum CRP concentration was identified as an 
independent prognostic indicator on multivariate survival analysis. In the present Chapter, a 
significant negative association between weight loss and survival duration was identified. The 
next Chapter will investigate the value of systemic inflammation and adverse nutritional status 
in improving prognostic accuracy for patients with gastro -oesophageal cancer. Various clinical 
and investigative factors, including markers of systemic inflammation and cachexia, predictive 
of death from gastro -oesophageal cancer will be determined with the aim of constructing a 
novel risk prediction mode! that may improve prognostic accuracy. This model may then be 
used to assist in the prospective prognostic evaluation of patients with gastro -oesophageal 
malignancy and assist in the clinical decision making for these patients. 
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CHAPTER XI 
A CLINICAL PROGNOSTIC SCORING SYSTEM TO AID MANAGEMENT 
DECISION -MAKING FOR PATIENTS WITH GASTRO- OESOPHAGEAL 
CANCER 
Deans DAC, Wigmore S, Ross JA, de Beaux A, Paterson -Brown S, Fearon KCH 
A clinical prognostic scoring system to aid management decision -making for patients 
with gastro -oesophageal cancer. 
British Journal of Surgery 2007; 94(12): 1501 -1508 
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ABSTRACT 
Despite advances in pre- operative staging accurate prognostication for patients with gastro- 
oesophageal malignancy remains challenging, particularly in the identification of patients who 
are likely to benefit from surgical resection. Markers of systemic inflammation and adverse 
nutritional status have been linked with adverse outcome in these patients (Chapters IX and 
X). This Chapter investigated the usefulness of systemic inflammation and cachexia as 
prognostic indicators. Various clinical and investigative factors, including markers of systemic 
inflammation and cachexia, predictive of death from gastro -oesophageal cancer were 
determined with the aim of constructing a novel risk prediction model. This model may then 
be used to assist in the prospective prognostic evaluation of patients with gastro -oesophageal 
malignancy and assist in the clinical decision making for these patients. 
All patients newly diagnosed with gastro -oesophageal cancer over a 2 -year period 
were studied prospectively. Patients were staged as per unit policy and underwent treatments 
following discussion at the multi -disciplinary meeting. Clinical and investigative variables were 
collected and included markers of systemic inflammation and a nutritional assessment. Death 
within 12 and 24 months following diagnosis were the primary end -points. 
Two hundred and twenty patients were studied with an overall median survival of 12.6 
months. Advanced clinical stage (cTNM) (p <0.001), reduced Karnofsky performance score 
(p <0.001), weight loss >_ 6% body weight (p= 0.026), and serum CRP concentration >5 mg /I 
(p= 0.031) were identified as independent prognostic indicators on multivariate analysis. A 
prognostic risk score was constructed using these four variables to estimate the probability of 
death. Applying the model gave an area under the receiver operating characteristic curve of 
0.84 (p <0.001) to predict death at 12 months and an area of 0.85 (p <0.001) to predict death 
at 24 months. 
The addition of biological (systemic inflammation - serum CRP concentration) and 
host -related (weight loss and performance score) factors to conventional anatomical -based 
clinical staging modalities can improve prognostic accuracy for individual patients with gastro- 
oesophageal cancer. The risk score is able to accurately estimate the probability of death 
within 12 and 24 months of diagnosis and may be used prospectively to guide management 
decisions and provide quality assurance in the MDT decision -making process. 
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INTRODUCTION 
This thesis has so far described some of the mediators involved in the generation and 
progression of systemic inflammation in patients with gastro -oesophageal cancer. The clinical 
and nutritional sequelae of systemic inflammation in these patients have also been described. 
In addition, markers of systemic inflammation and adverse nutritional status have been linked 
with adverse outcome in these patients (Chapters IX and X). This Chapter investigated the 
usefulness of systemic inflammation and cachexia as prognostic indicators. Various clinical 
and investigative factors, including markers of systemic inflammation and cachexia, predictive 
of death from gastro -oesophageal cancer were determined with the aim of constructing a 
novel risk prediction model. This model may then be used to assist in the prospective 
prognostic evaluation of patients with gastro -oesophageal malignancy and assist in the 
clinical decision making for these patients. 
Despite advances in surgical care and improvements in staging accuracy overall survival for 
patients with gastro -oesophageal malignancy remains poor (Dressner and Griffin, 2000). 
Even for patients undergoing surgical resection 5 -year survival rates are in the order of 30% 
and for patients presenting with locally advanced disease, who represent approximately two 
thirds of patients suitable for resection, the survival rates are only in the order of 10% 
(Dressner and Griffin, 2000). Around half of these patients are dead within 18 months and do 
not achieve any benefit from surgery in terms of quality of life improvements or survival gain 
(Blazeby et al, 2000). The problem lies in prospectively identifying such patients. If clinicians 
could identify which patients are unlikely to survive 18 months following surgery then these 
patients could be offered more appropriate palliative treatments and avoid the considerable 
morbidity that may be associated with surgical resection. In addition, improved understanding 
of the factors important in determining outcome in these patients, such as the presence of 
systemic inflammation and cachexia, may assist in the identification of novel therapeutic 
targets and help guide individualised patient directed therapy, for example, anti -cachexia 
treatments. 
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Several prognostic models have been proposed in an attempt to improve prognostic accuracy 
in patients with gastro -oesophageal cancer. Some of these models are designed to predict 
operative risk and mortality (Tekkis et al, 2004; Bartels et al, 1998) and most studies that 
have proposed prognostic scores have utilised pathological variables in their scoring systems 
(Kologlu et al, 2000; Novotny et al, 2006). Other models have utilised complex computer 
models, such as artificial neural networks, to predict long -term survivors following surgical 
resection (Sato et al, 2005; Mofidi et al, 2006). Although these models have demonstrated 
improved survival predictions when compared with TNM staging alone, these models rely on 
the input of many variables including pathological information only available after resection 
and therefore may not be used prospectively. Relatively few studies have attempted to 
prospectively identify patients who are 'curable' using clinical /pre- operative staging modalities 
alone. Crumley et al studied patients with inoperable oesophago -gastric cancer and devised 
an inflammation -based prognostic scoring system (Crumley et al, 2006). A score was accrued 
depending on the presence of a CRP concentration >10 mg /I and /or an albumin concentration 
<35 g /I. Survival duration was significantly reduced with an increasing score, independent of 
disease stage. A group of Japanese researchers have similarly identified clinical stage 
(cTNM), weight loss (more than 2% body weight), and serum CRP concentrations (greater 
than 0.5 mg /dl) to be independently associated with survival on multivariate analysis for 
patients with oesophageal malignancy (Ikeda et al, 2003). Patients scored one point 
according to the presence of stage Ill or IV disease, CRP concentration >0.5 mg /dl, and 
weight loss >2% and the total score (0 to 3) was superior to the conventional cTNM staging 
at determining prognosis. 
This Chapter will determine the clinical and investigative factors, including markers of 
systemic inflammation and cachexia, predictive of death from gastro -oesophageal cancer with 
the aim of constructing a novel risk prediction model that may be applied to these patients to 
assist in clinical decision -making. This model will aim to determine the likelihood of death 
within 12 and 24 months from diagnosis. 
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MATERIALS AND METHODS 
Study population 
The same cohort of patients as those studied throughout this thesis was investigated (see 
Chapter IV for a detailed description). No patients were excluded and no patients refused 
consent. Data were prospectively collected. Patient performance status was assessed at the 
time of diagnosis using the scoring system devised by Karnofsky (Karnofsky and Burchenal, 
1949). In all instances a final clinical stage (cTNM) was agreed at the unit multidisciplinary 
team meeting (MDT) and management strategies were decided. Patients without evidence of 
metastatic disease (stages I -III) and who were medically fit were offered surgical resection. 
Those patients staged as T3 NO or T2/3 N1 were considered for pre -operative chemotherapy. 
The remaining patients received a variety of palliative treatments, either in combination or 
alone. Survival duration, defined as time from histological confirmation of disease until death, 
was recorded in each case. 
Variables that could not be used prospectively, such as number of lymph nodes with 
metastatic involvement, degree of chronic inflammatory cell infiltrate into the tumour tissue 
and final histopathological stage, were excluded from prognostic modelling. Serum cPTHrP 
concentrations were also excluded form the analysis as longer follow -up duration has 
subsequently shown that these concentrations are no longer directly prognostic. 
Measurement of markers of systemic inflammation 
Blood was collected from each patient at the time of diagnosis and before initiation of 
treatment. Serum cytokine and serum acute phase protein concentrations were determined 
by ELISA as described in previous Chapters. 
Nutritional assessment 
All patients underwent an assessment of their nutritional status at the time of diagnosis as 
described in Chapter X. Briefly, BMI was calculated and total weight loss and rate of weight 
loss per month were recorded. Anthropometry measurements were corrected for age and sex 
and were normalised using standardised reference tables (Bishop et al, 1981). The severity of 
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dysphagia was scored according to Knyrim et al (Knyrim et al, 1993). Dietary intake was 
estimated by all patients and described as normal, reduced, or poor. 
Statistical analysis 
Cox's proportional hazards model was used to determine the effects of clinical and 
investigative variables on survival duration and probability of death within 12 and 24 months 
following diagnosis in both univariate and multivariate analysis. Stepwise regression (using an 
entry value p <_0.050 and a removal value p?0.100) was used to determine the factors 
predictive of death. Models were developed separately for clinical and investigative variables 
and then for a combination of the two sets of variables. Receiver operating characteristic 
(ROC) curves were used to select cut -off values for continuous variables. Values with the 
best combination of sensitivity and specificity were chosen. The performance of the 
prognostic model was assessed by determining the area under the ROC curve. The estimates 
of probability of death at 12 and 24 months were calculated from survival tables. 
RESULTS 
Study patients 
Two hundred and twenty patients were recruited to the study between March 2002 and June 
2004. Patient demographics are shown in Table 11.1. Ninety -five (43 %) patients underwent 
surgical resection and 25 of these received pre- operative chemotherapy. Ninety (95 %) 
patients had a potentially curative resection. Of the remaining five patients, three patients had 
unexpected metastatic disease identified at laparotomy and therefore did not proceed to 
resection and two patients had residual macroscopic disease (R2 resection). Seven (3 %) 
patients, all of whom had squamous cell carcinoma of the oesophagus, received chemo- 
irradiation with curative intent. The remaining 118 patients (54 %) were not suitable for 
curative therapy and received palliative chemo /radiotherapy or underwent alternative 
palliative treatments, such as insertion of a stent, endoscopic dilatation, or endoscopic laser 
therapy. 
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Seventy -five (34 %) patients had metastatic disease (stage IV) at the time of presentation and 
86 (39 %) patients had locally advanced (stage Ill) disease. Approximately one -quarter (n =59; 
27 %) of patients had early stage disease (stage I /II). 
Table 11.1 Study patient demographics (n =220) 
Number [ %] 
Age (years)* 71 (62 -78) 
Sex Male 145 [66] 
Female 75 [34] 
Karnofsky score 30 4 [2]* 
40 1 [1] 
50 5 [2] 
60 17 [8] 
70 25 [12] 
80 36 [17] 
90 50 [24] 
100 70 [34] 
Unknown 12 
Tumour Site Oesophageal 101 [46] 
Proximal third 2 
Middle third 13 
Distal third 86 
Oesophago- gastric junction 40 [18] 




Histology Adenocarcinoma 185 [84] 
Squamous cell carcinoma 30 [14] 
Small cell 2 [1] 
Indeterminate 3 [1] 
Grade Well differentiated 3 [2]* 
Moderately differentiated 63 [34] 
Poorly differentiated 118 [64] 
Not commented 36 
Treatment undertaken Surgery alone 70 [32] 
Pre -operative chemotherapy + surgery 25 [11] 
Chemoradiotherapy with curative intent 7 [3] 
Palliative Chemotherapy 28 [13] 
Palliative Radiotherapy 6 [3] 
Stent /dilatation /laser /symptomatic 84 [38] 
UICC Stage 1 25 [11] 
2 34 [16] 
3 86 [39] 
4 75 [34] 
Status Alive 73 [33] 
Dead 147 [67] 
`Values are median (interquartile range). * Values are expressed as percentages of known results. 
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Survival duration 
Patients were followed -up for an average 32 months and a minimum of 18 months (range 18- 
45 months). At the time of censoring the data 147 (67 %) patients had died. Three patients 
died in the post- operative period and 1 patient died from injuries sustained following a fall. 
Information obtained from death certificates indicated that all other deaths were disease 
related. One hundred and eight (49 %) patients had died within 12 months of diagnosis and 
136 (136 of 194 patients followed -up for at least 24 months; 70 %) patients had died within 24 
months. Overall median survival was 12.6 months. 
Performance status 
Seventy (34 %) patients had a normal performance status at the time of diagnosis (Karnofsky 
score 100). The remaining 150 patients had some degree of impaired performance status 
(Table 11.1). Ten (5 %) patients required considerable assistance and frequent medical care 
or hospitalisation (Karnofsky 30 -50). 
Nutritional status 
The nutritional variables for the patient group measured at the time of diagnosis are the same 
as those data previously presented in Chapter X and are shown again in Table 11.2. Patients 
had lost a median of 7.1% (inter -quartile range 1.2- 14.2 %) total body weight at the time of 
diagnosis, equivalent to a median rate of weight loss of 2.5% total body weight per month of 
illness. Ninety -seven (44 %) patients had lost up to 10% of their total body weight and 85 
(39 %) patients had lost more than 10% body weight. Only 38 (17 %) patients remained weight 
steady at the time of diagnosis. Anthropometry values were globally reduced compared with 
reference values. 135 (61%) patients had a reduced dietary intake and 131 (60 %) patients 
had some degree of dysphagia to the time of diagnosis. 
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Table 11.2 Nutritional variables for the patient group measured at the time of diagnosis. 
Pre -illness BMI 26.4 (24.1 -30.1) 
BMI at diagnosis 24.6 (21.4 -28.0) 
Total body weight loss ( %) 7.1 (1.2 -14.2) 
Rate of weight loss (% per month) 2.5 (0.3 -6.5) 
Mid -arm circumference 
(percentile group) 
10 (1 -25) 
Triceps skinfold thickness 
(percentile group) 
25 (10 -50) 
Arm -muscle circumference 
(percentile group) 
10 (1 -25) 
Dietary intake Normal 85 [39] 
Reduced 103 [47] 
Poor /minimal 32 [14] 
Dysphagia score 0 89 [40] 
1 52 [24] 
2 43 [19] 
3 32 [15] 
4 4 [2] 
Values are median (inter -quartile range) [ %] 
Concentrations of serum markers of systemic inflammation 
Concentrations of serum acute phase proteins and sTNF -R, but not concentrations of serum 
cytokines, are associated with survival duration (Chapter IX). Serum CRP concentrations 
were identified as the best predictors of prognosis among all the acute phase proteins and 
cytokines measured, as determined by receiver operating characteristics (ROC) curves [area 
under the curve = 0.67, p <0.001] (see Table 9.2; Chapter IX). The median serum CRP 
concentration for the patient group was 7 mg /I (inter -quartile range 2 -25 mg /I). One hundred 
and twenty -one (55 %) patients had a CRP concentration greater than 5 mg /I at the time of 
diagnosis. 
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Identification of prognostic variables 
Table 11.3 shows the risk of death form gastro -oesophageal cancer associated with baseline 
clinical characteristics and results of investigations. Patient age, body mass index at the time 
of diagnosis, total body weight loss at diagnosis, rate of weight loss, Karnofsky performance 
score, serum CRP concentration, dysphagia score, level of dietary intake, tumour grade, and 
clinical stage were all associated with outcome for the whole patient group. Variables that 
could not be used prospectively to aid management decision making, such as number of 
lymph nodes with metastatic involvement and the presence of a chronic inflammatory cellular 
infiltrate into the tumour, were excluded from the prognostic modelling. 
Table 11.3 Hazard ratio of death associated with baseline clinical characteristics and 
results of investigations for the whole patient group with gastro -oesophageal cancer (Cox's 
univariate analysis). 
Variable Hazard ratio (95% CI) P value 
Age (years) 1.00 -1.04 0.015 
BMI at diagnosis 0.92 -0.99 0.005 
Total weight loss at diagnosis ( %) [Ln] 1.20 -1.73 <0.001 
Rate of weight loss (% per month) [Ln] 1.20 -1.71 <0.001 
Dysphagia score 1.10 -1.49 0.002 
Dietary intake 1.38 -2.31 <0.001 
Karnofsky score 0.95 -0.97 <0.001 
CRP (mg /I) [Ln] 1.25 -1.56 <0.001 
Tumour grade 1.14 -2.51 0.009 
Stage of disease (cTNM) 2.01 -3.29 <0.001 
Determination of end -points 
Twelve and 24 months were selected as end -points for prognostic analysis. Receiver 
operating characteristic (ROC) curves were used to identify cut -off values with the best 
discrimination power for each continuous variable. Values with the best combination of 
280 
sensitivity and specificity were chosen (Figure 11.1). The following discrimination points were 
selected: age greater or equal to 70 years, body mass index less than or equal to 25, weight 
loss greater or equal to 6 %, rate of weight loss greater than 2.75% per month, Karnofsky 
score less than or equal to 80, and CRP concentration greater than 5 mg /I. The risk of death 
for the new cut -off points selected for each variable are shown in Table 11.4. 
Figure 11.1 Line graph depicting the sensitivity and specificity of increasing serum CRP 
concentrations on predicting 12 month survival. A CRP cut -off value greater than 5 mg /I had 
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Table 11.4 Hazard ratio for risk of death for each new cut -off point chosen following 
discrimination analysis by ROC curves [Cox's univariate analysis]. 
Variable Hazard ratio 95% Cl P value 
Age (z 70 years) 1.6 1.15 -2.24 0.005 
BMI (5 25) 1.5 1.04 -2.02 0.028 
Weight loss (z 6 %) 2.6 1.79 -3.60 <0.001 
Rate of weight loss ( >2.75% per month) 2.5 1.86 -3.75 <0.001 
Dysphagia score 
1 versus no dysphagia 0.7 0.42 -1.11 
2 versus no dysphagia 1.5 0.95 -2.30 <0.001 
3 versus no dysphagia 1.7 1.03 -2.75 
4 versus no dysphagia 28.9 8.19 -101.84 
Dietary intake 
Reduced versus normal 1.6 1.08 -2.34 <0.001 
Poor versus normal 3.6 2.21 -6.00 
Karnofsky score 
80 -90 versus normal 1.5 0.96 -2.29 
<0.001 
60 -70 versus normal 4.4 2.73 -6.99 
5 50 versus normal 9.2 4.53 -18.83 
CRP ( >5 mg /I) 2.6 1.83 -3.64 <0.001 
Clinical stage of disease (cTNM) 
Stage Il versus stage I 1.9 0.63 -5.57 
<0.001 
Stage Ill versus stage I 3.0 1.11 -8.35 
Stage IV versus stage I 11.2 4.02 -30.96 
Tumour grade 
Poorly differentiated versus moderate 1.7 1.12 -2.46 0.012 
Multivariate survival analysis 
Due to the relatively large number of prognostic variables multivariate analysis of clinical 
variables and investigative variables were initially analysed separately. Total weight loss and 
Karnofsky score were identified as independent prognostic variables from the analysis of the 
clinical variables. Serum CRP concentration and clinical stage were identified as 
independently prognostic from the analysis of investigative variables. These four variables 
were then analysed together and each retained independent prognostic value (Table 11.5). 
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Table 11.5 Clinical and investigative variables independently predictive of death, 
determined by using stepwise selection procedures in a general population of patients with 
gastro -oesophageal cancer. [Forward, conditional method of Cox's proportional hazards 
model.] 
Variable Hazard ratio 95% Cl P value 
CRP (> 5mg /I) 1.6 1.04 -2.34 0.031 
Total weight loss 
1.6 1.05 -2.28 0.026 
{z 6% /month) 
Karnofsky score 
80 -90 versus normal 1.0 0.64 -1.56 0.996 
60 -70 versus normal 2.1 1.30 -3.54 0.003 
<_ 50 versus normal 4.8 2.23 -10.16 <0.001 
Clinical stage of disease (cTNM) 
Stage Il versus stage I 2.0 0.57 -6.96 0.277 
Stage Ill versus stage I 2.9 0.89 -9.36 0.076 
Stage IV versus stage I 8.8 2.68 -28.60 <0.001 
Development of a prognostic risk score for patients with gastro -oesophageal cancer 
Serum CRP concentration greater than 5 mg /I, weight loss greater or equal to 6% body 
weight per month, reduced Karnofsky performance score, and increasing clinical stage were 
all identified as independent adverse prognostic variables. A prognostic scoring system was 
devised by logarithmically transforming the hazard ratio and multiplying by 100 (Daly et al, 
2006). Therefore, for each patient a cumulative risk score may be calculated based upon the 
four prognostic variables (maximum score 202) (Table 11.6). The prognostic risk score could 
then be used to estimate the probability of death within 12 and 24 months (Table 11.7) 
(Figure 11.2). Applying the model developed on 75% of the patient population to the 
remaining 25% of the population gave an area under the receiver operating characteristic 
curve of 0.84 (p <0.001) to predict death at 12 months and an area of 0.85 (p <0.001) to predict 
death at 24 months (Figure 11.3). 
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Table 11.6 Risk score based on four prognostic variables. 
Variable Risk score* 











80 -100 0 
60 -70 32 
5 50 68 
Clinical stage of disease (cTNM) 
Stage I 0 
Stage II 30 
Stage III 46 
Stage IV 94 
*Log [hazard ratio] multiplied by 100. 
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Table 11.7 Estimated probability of death from time of diagnosis to 12 months and 24 
months stratified by prognostic risk score. 
Risk score Probability of death at 12 months ( %) Probability of death at 24 months ( %) 
0 0 0 
20 0 0.5 
30 0.5 2.7 
40 1.0 3.3 
46 2.7 9.1 
50 4.5 11.6 
66 11.5 21.3 
70 13.8 24.1 
72 14.6 24.8 
78 16.1 26.2 
82 16.8 26.9 
86 23.0 35.4 
94 27.5 40.7 
98 28.4 43.0 
102 29.3 44.5 
114 42.7 55.1 
118 51.6 63.8 
134 66.3 77.5 
138 67.5 78.3 
146 73.5 82.5 
154 74.8 84.1 
166 90.7 94.2 
182 92.0 95.0 
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Figure 11.3 Receiver operating characteristic curves illustrating the predictive ability of 
the prognostic risk score to predict death at (A) 12 months [area under the curve = 0.84 
(p <0.001)] and (B) 24 months [area under the curve = 0.85 (p <0.001)]. 
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Subgroup analysis 
Applying the risk score to the cancer subsites gave areas under the ROC curves for 12 and 
24 months survival as: 0.84 and 0.89 for oesophageal cancer, 0.86 and 0.89 for gastric 
cancer, and 0.78 and 0.67 for tumours at the OGJ. The score was valid for adenocarcinoma 
at 12 and 24 months (area under ROC curve 0.86 and 0.87) and squamous cell carcinoma 
(0.78 and 0.68). Analysis by treatment type gave areas under the curve of 0.78 and 0.79 for 
12 and 24 months survival in patients who underwent surgery with curative intent, and 0.77 
and 0.79 for those treated by palliative methods alone. 
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DISCUSSION 
This study has identified clinical disease stage, Karnofsky performance score, weight loss, 
and serum CRP concentrations as independent prognostic indicators on multivariate analysis 
for patients with gastro -oesophageal cancer. The development of a risk prediction score 
based on these four variables allows improved prognostic accuracy and risk prediction of 
death within 12 and 24 months from diagnosis. 
Recent improvements in clinical staging accuracies have occurred due to advances in 
technology as well as increasing expertise in their use and the formation of special interest 
radiologists /gastroenterologists. Despite these advances such modalities are still failing to 
adequately stratify patients. Current staging strategies are directed at determining the 
anatomical spread of disease. Clearly, not all tumours within the same UICC anatomical 
stage group behave in the same way and, therefore, clinical staging and estimation of 
prognosis should additionally assess tumour biological behaviour. 
Both the presence of systemic inflammation and nutritional depletion (cachexia) can 
be used as indirect measures of tumour biological activity. Systemic inflammation has been 
found in association with most epithelial malignancies and has been linked with adverse 
outcome (Rashid et al, 1982; Nozoe et al, 2001; Shimada et al, 2003; Crumley et al, 2006; 
Alexandrakis et al, 2003; Falconer et al, 1995; Cooper, 1988; Caspers et al, 1984; Forrest et 
al, 2003; McMillan et al, 2001; Masuda et al, 1998; Kodama et al, 1999; Elahi et al, 2005; 
McMillan et al, 2003; Fujita et al, 1999; Jamieson et al, 2005). In Chapter IX, an elevated 
serum CRP concentration was associated with reduced survival duration, independent of 
stage of disease, in our cohort of patients with gastro -oesophageal cancer. The present study 
has confirmed this finding, where a serum CRP concentration greater than 5mg /I was 
associated with adverse outcome on multivariate survival analysis. The source of the pro - 
inflammatory stimulus in advanced cancer remains unclear, but it is likely that both the host 
immune cells and the tumour cells contribute to the generation of the systemic inflammatory 
response. Both the presence of a host chronic inflammatory cell infiltrate and tumour tissue 
cytokine concentrations have been associated with markers of systemic inflammation in 
previous studies (Chapters V). In addition, other tumour -derived mediators, such as PTHrP 
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(Chapter VII) and PIF (Chapter VIII), are also linked with elevated serum markers of systemic 
inflammation. The presence of systemic inflammation in association with malignant disease 
may, therefore, indicate a tumour with increased growth /metastatic potential. 
Weight loss is common among patients with gastro -oesophageal cancer. In Chapter 
X, 83% of patients experienced some degree of weight loss at the time of diagnosis and 
weight loss was negatively associated with survival duration. Weight loss was also associated 
with advanced stage of disease and with markers of systemic inflammation, however, the 
current study has shown that rate of weight loss retains prognostic significance even when 
systemic inflammation and disease stage are co- analysed in a multivariate model. Weight 
loss greater than 10% total body weight has been associated with adverse outcome on 
multivariate analysis among patients with oesophageal cancer who had undergone surgical 
resection and chemo- irradiation (Kelson et al, 1998). The present study has identified weight 
loss greater than 6% as a more discriminating cut -off value in our patient cohort. These data 
suggest that weight loss and nutritional depletion reflects adverse tumour behaviour by 
additional unknown mechanisms, but may be linked with the production of pro -inflammatory 
cytokines or other tumour derived mediators, for example PTHrP and PIF. 
The relevance of performance status to prognosis is well documented and is an 
important assessment tool in the selection of patients for chemo /radiotherapy. Among 
patients with gastro -oesophageal malignancy, performance status was identified as an 
independent prognosticator on multivariate analysis of over 1000 patients, along with the 
presence of metastatic disease and an elevated serum alkaline phosphatase concentration 
(Chau et al, 2004). Increased fatigue and reduced physical function have been associated 
with increased probability of death in the first 6 months following surgical resection of gastro- 
oesophageal cancer (Blazeby et al, 2001; Blazeby et al, 2005). A multicentre study of 1080 
patients with locally advanced or metastatic gastro -oesophageal cancer treated with 
chemotherapy identified performance status, serum alkaline phosphatase concentration, and 
the presence of liver or peritoneal metastases as independent prognostic indicators on 
multivariate analysis (Chau et al, 2004). However, clinical stage was not co- analysed in the 
multivariate analysis. A Swedish study of oesophageal cancer patients also treated by 
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chemoradiotherapy similarly identified performance status, in addition to clinical stage, as 
independent prognostic variables (Bergqvist et al, 2004). 
A number of prognostic scoring systems have been proposed for patients with gastro- 
oesophageal cancer. Most of these studies include pathological information gained from 
tumour resection and these data cannot be used at the time of diagnosis to prospectively 
stratify patients. Other prognostic studies have used sophisticated novel molecular 
techniques, such as DNA microarray, to prognosticate patients (Inoue et al, 2002) or have 
involved the development of complex computer models, for example, artificial neural 
networks, where extensive clinical, investigative, and pathological information is required to 
estimate patients' prognosis (Mofidi et al, 2006). Crumley et al studied patients with 
inoperable oesophago -gastric cancer and devised an inflammation -based prognostic scoring 
system (Crumley et al, 2006). A score was accrued depending on the presence of a CRP 
concentration >10 mg /I and /or an albumin concentration <35 g /I. Survival duration was 
significantly reduced with an increasing score. A group of Japanese researchers have 
similarly identified clinical stage (cTNM), weight loss (more than 2% body weight), and serum 
CRP concentrations (greater than 0.5 mg /dl) to be independently associated with survival on 
multivariate analysis for patients with gastro -oesophageal malignancy (Ikeda et al, 2003). 
Patients scored one point according to the presence of stage Ill or IV disease, CRP 
concentration >0.5 mg /dl, and weight loss >2% and the total score (0 to 3) was associated 
with significantly reduced survival duration. 
The scoring system developed in this study allows accurate estimation of the 
probability of death within 12 and 24 months for individual patients. Clearly, the score 
selected as the cut -off, will influence the probability of survival beyond 12 or 24 months. A 
higher score would have better specificity, but some patients would still be offered surgery 
without much prospect of longer survival. Selection of a lower score would perhaps deny the 
opportunity of surgery to some patients who may benefit from resection. We believe that it is 
better to select a higher score and accept that a few patients may have been overtreated. The 
final cut -off is likely to depend on future validation studies and individual preferences. 
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Conclusions 
This study has shown that the addition of biological (systemic inflammation - serum CRP 
concentration) and host -related (weight loss and performance score) factors to conventional 
anatomical -based clinical staging modalities can improve prognostic accuracy for individual 
patients. The novel prognostic scoring system may be used for patients with oesophageal, 
junctional and gastric tumours with similar accuracy and different histological tumour types. 
The risk score is based on four measurements that are widely available, reproducible, 
inexpensive and easy to perform. The score may be used prospectively to guide management 
decisions at the time of diagnosis and provide more realistic prognostic information for 
patients and their families. In addition, the risk model can be used to provide quality 
assurance in the MDT decision -making process. The model requires prospective validation in 
other centres before widespread introduction into clinical practice. 
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CHA PIE \YZ 
GENERAL DISCUSSDO 
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The aetiology and significance of systemic inflammation in patients with cancer is complex 
and incompletely understood. Whereas much is known about the innate immune system in 
cancer biology in general, the factors that activate this system in human subjects with specific 
types of tumour are not known. The present thesis has examined patients with gastro- 
oesophageal cancer in detail. 
Prevalence of systemic inflammation in patients with gastro -oesophageal cancer 
In the present study 43% of patients at diagnosis had evidence of systemic inflammation and 
the prevalence of systemic inflammation was comparable with those quoted in previous 
studies relating to gastric and oesophageal malignancy (range 23 -32 %) [Chapter IV] (Crumley 
et al, 2006; Rashid et al, 1982; Nozoe et al, 2001; Shimada et al, 2003). In addition, CRP 
concentrations demonstrated excellent reproducibility for measurements undertaken at the 
time of diagnosis. However, follow -up CRP concentrations were influenced by intervening 
treatments. Surgical resection was associated with a significant rise in serum CRP 
concentrations in the post- operative period. This may be explained by an ongoing metabolic 
response to surgical trauma or may represent subclinical complications during the post- 
operative period. In contrast, pre- operative chemotherapy was linked with a reduction in 
serum CRP concentrations and may occur secondary to generalised immunosuppression. 
Such findings are important to consider if markers of systemic inflammation are to be used to 
estimate prognosis or influence treatment decisions. 
In contrast, in the present thesis, serum cytokine concentrations determined at 
diagnosis were not significantly different to those measured in healthy controls and 
demonstrated poor reproducibility [Chapter IV]. The similarities in serum cytokine 
concentrations measured in patients and healthy controls are likely to be related to the 
difficulties in reliably measuring circulating cytokine concentrations owing to variations in 
plasma concentrations and short half -lives (May et al, 1992). In addition, the end -organ 
effects of these cytokines will depend upon binding to transport molecules, receptor 
expression, receptor affinity, and local cytokine concentrations within target tissues (Lantz et 
al, 1990). 
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The conclusions of these studies are that serum positive acute phase protein concentrations 
(especially CRP concentrations) are robust markers of systemic inflammation when measured 
at the time of diagnosis and before initiation of treatment, whereas serum cytokine 
concentrations are not representative of true levels of systemic inflammatory activity. It is 
more likely that local cytokine concentrations within target tissues are a more accurate 
determinant of systemic inflammatory activity. 
The aetiology of systemic inflammation in patients with gastro -oesophageal cancer 
One of the key hypotheses in this thesis was that tumour cells not only produce pro - 
inflammatory cytokines but other mediators (for example, PTHrP and PIF), which may induce 
systemic inflammation in patients with cancer. The close relationship between tumourigenesis 
and host immunology has been described in detail in the introduction and it is likely that the 
interaction between host and tumour cell populations is key to the generation of systemic 
inflammation. Tumour escape and subversion of host immunosurveillance are facilitated by 
the creation of a local environment within the tumour (Seliger et al, 2001; Garrido and Algarra, 
2001). Such a milieu consists of a mix of mediators, including pro -inflammatory cytokines, 
enabling the complex interaction between the host cells and tumour cells (Almand et al, 
2001). Postulated outcomes of this interaction include carcinogenesis and tumour growth and 
metastasis ( Dalgleish and O'Byrne, 2002; O'Byrne and Dalgleish, 2001; Sharma et al, 2003; 
Bottazzi et al, 1990). The generation of systemic inflammation may occur secondary to these 
locally produced mediators (Raddatz et al, 2005). 
In this thesis pro -inflammatory cytokine (mRNA and protein) concentrations were 
significantly elevated in tumour tissue from patients with gastro -oesophageal cancer when 
compared with concentrations measured in tissue samples from healthy controls [Chapter V]. 
Although all cytokine concentrations were elevated, tumour tissue IL-16 was particularly 
highly expressed and protein concentrations correlated with markers of systemic inflammation 
(CRP). Previously, IL -6 over -expression has been associated with a pancreatic cancer 
phenotype linked with inflammation and cachexia (Martignoni et al, 2005). IL -13 is an 
important pro -inflammatory cytokine and it is the conclusion of the work in this thesis that in 
294 
patients with gastro -oesophageal malignancy, IL -1ß is an important candidate mediator 
involved in the aetiology of systemic inflammation. 
In this thesis, the extent of host immune cell infiltrate into the tumour tissue was also 
assessed [Chapter V]. Tumour tissue is commonly infiltrated by immune cells and up to 60% 
of the tumour mass may be accounted for by macrophages and lymphocytes (van 
Ravenswaay et al, 1992). Tumour cells are thought to regulate immune cell numbers through 
production of chemotactic factors (Koide et al, 2004). It is postulated that tumour cells 
produce mediators such as IL -4 and IL -10, which lead to alternative macrophage activation 
favouring the tumour (O'Byrne and Dalgleish, 2001). These host immune cells may also 
contribute to the generation of systemic inflammation (O'Riordain et al, 1999). In this thesis a 
chronic inflammatory cell (lymphocyte) infiltrate (TIL's) was noted in 75% of tumours and was 
associated with markers of systemic inflammation (CRP), but not with elevated tissue 
cytokine concentrations. TIL's may become activated as they pass through the tumour tissue 
by locally produced mediators (cytokines). These lymphocytes may interact locally with 
macrophages within the tumour (TAM's). Macrophages are then free to circulate in the 
bloodstream and release cytokines locally within target tissues, thereby conveying the 
systemic effects of inflammation, without increasing local cytokine concentrations within the 
tumour tissue itself. Previously, circulating PBMC's from patients with pancreatic cancer and 
an APPR demonstrated greater rates of pro -inflammatory cytokine (IL -6 and TNFa) 
production when compared with those without a systemic inflammatory response (O'Riordain 
et al, 1999). These cells are then capable of stimulating increased CRP production by 
hepatocytes (O'Riordain et al, 1999). Other groups have also identified the ability of certain 
tumours to sensitise PBMC's and induce IL -6 expression from these cells (Martignoni et al, 
2005). Rates of pro -inflammatory cytokine production by PBMC's from patients with gastro- 
oesophageal cancer were not measured in this thesis, but it is feasible that these cells would 
demonstrate increased cytokine activity. This may explain the association between TIL's and 
the presence of systemic inflammation in the present study. 
The studies in this thesis were performed on homogenised tissue samples and total 
cytokine mRNA and protein concentrations within the tumour mass were measured. As stated 
previously, up to 60% of the tumour mass may be host immune cells and other cell types, 
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such as stromal cells and vascular endothelium (van Ravenswaay et al, 1992). Laser capture 
miscroscopy was used in an attempt to separate out these different cell populations in order 
to determine which of these cell types had undergone up- regulation of pro -inflammatory 
cytokines. Unfortunately, due to poor quality of isolated RNA this technique was not 
successful in this thesis. Alternative techniques to localise the main cell populations producing 
the pro -inflammatory cytokines would include insitu hybridisation or immunohistochemistry. 
These techniques may form the basis of future work. However, the studies described in this 
thesis show that pro -inflammatory cytokine protein concentrations (especially IL-1p) within the 
tumour mass are linked with the generation of systemic inflammation in the host (irrespective 
of the cell population that produced them). 
The generation of a systemic inflammatory response in patients with gastro- 
oesophageal cancer is also influenced by host cytokine genotype. IL -6 and IL -10 genotypes 
were associated with markers of systemic inflammation and the IL -6 genotype was also 
associated with tumour tissue cytokine concentrations [Chapter VI]. These data suggest that 
cytokine polymorphisms are linked with differential levels of cytokine expression, which may 
then modify the systemic inflammatory response. These studies suggest that host factors are 
important determinants in the generation of systemic inflammation in patients with cancer, in 
addition to the tumour phenotype. 
Mediators other than pro -inflammatory cytokines are involved in the generation of 
systemic inflammation in patients with gastro -oesophageal cancer 
The role of two potential tumour -derived mediators, PTHrP and PIF, were investigated in this 
thesis. Elevated serum PTHrP concentrations were identified in 17% of patients with gastro- 
oesophageal cancer at the time of diagnosis without evidence of hypercalcaemia [Chapter 
VII]. Elevated concentrations were associated with markers of systemic inflammation. PTHrP 
expression has been linked previously with elevated serum cytokine and acute phase protein 
concentrations in cancer patients (Ogata, 2000; Takahashi et al, 2003; Funk et al, 1997). 
These data suggest a possible further enhancement of systemic inflammation in patients with 
cancer in association with elevated PTHrP. 
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Three months following diagnosis elevated serum PTHrP concentrations were measured in 
49% of patients and elevated concentrations were associated with adverse nutritional status 
[Chapter VII]. This association occurred in the absence of hypercalcaemia and without 
apparent differences in dysphagia scores or levels of dietary intake. These findings support 
animal studies where elevated PTHrP concentrations in mice were associated with a 
significant reduction in body weight and tissue mass, an effect that was reversed by addition 
of an antibody to PTHrP (Iguchi et al, 2001). It is possible that the elevated serum PTHrP 
concentrations induce a 'sub- clinical' hypercalcaemia in these patients, which may promote 
anorexia and result in weight loss. Clinical trials involving administration of PTHrP antibodies 
to human subjects would provide additional valuable information on the role of PTHrP in 
cancer cachexia and may represent a valuable novel therapeutic agent for these patients. 
In the present thesis, PIF protein was detected in the urine of approximately half the 
oesophagogastric cancer patients and was associated with adverse nutritional variables and 
demonstrated a trend towards elevated markers of systemic inflammation [Chapter VIII]. 
Urinary PIF has previously been linked with weight loss in patients with cancer (Todorov et al, 
1996, Wigmore et al, 2000; Cariuk et al, 1997; Cabal -Manzano et al, 2001). This association 
may be mediated through increased skeletal muscle loss via activation of the ubiquitin- 
proteolytic pathway (Lorite et al, 1997; Lorite et al, 2001; Todorov et al, 1997). PIF has been 
shown to stimulate production of pro -inflammatory cytokines (IL -6 and IL -8) in vitro and in the 
present study a trend was observed between the presence of PIF in urine and elevated serum 
CRP concentrations and reduced serum albumin concentrations (Watchorn et al, 2001). PIF 
may, therefore, also contribute to the systemic inflammatory response in patients with cancer. 
PIF mRNA expression was significantly elevated in tumour tissue when compared 
with levels measured in tissue from healthy controls, but patterns of expression did not 
correlate with markers of systemic inflammation or nutritional status or indeed with urinary PIF 
protein [Chapter VIII]. PIF is highly glycosylated and the carbohydrate component is essential 
for its proteolytic function (Todorov et al, 1996). Levels of core peptide mRNA, therefore, have 
little relevance to the concentration of functionally active glycosylated PIF. In addition, the 
relatively high prevalence of PIF mRNA detected in tissue from healthy controls (36 %), albeit 
at low levels, was unexpected as previous studies have suggested that PIF mRNA is not 
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expressed in normal tissues. The findings in this study may reflect the high sensitivity of real - 
time PCR. Alternatively, the primers may have lacked sufficient specificity for the PIF 
sequence and what was detected may not have been the PIF gene. Sequencing the PCR 
product may have helped resolve this issue. In addition, questions remain over the issue of 
whether indeed there is a human homologue of PIF. The apparent lack of specificity of the 
only antibody available for the purification of PIF and the low abundance of PIF makes this a 
very difficult issue to resolve at present. 
Therefore, in addition to pro -inflammatory cytokines, other tumour -derived mediators 
may play a role in the generation of systemic inflammation in patients with gastro- 
oesophageal cancer. These mediators may also have additional direct effects on the host, 
outwith the context of systemic inflammation, such as weight loss and cachexia. Further 
research is required to resolve these issues. 
Is nutritional status (cachexia) a key factor linking systemic inflammation with adverse 
prognosis in patients with gastro -oesophageal cancer? 
In the present thesis, elevated serum acute phase protein concentrations at the time of 
diagnosis of oesophagogastric cancer were associated with reduced overall survival duration 
[Chapter IX]. CRP concentrations were identified as the best marker of prognosis in these 
patients and the magnitude of serum CRP concentrations were negatively linked with survival 
duration. An increase in serum CRP concentration from a normal value of 1 mg /I to 10 mg /I 
was associated with an almost 50% increase in likelihood of death within two years of 
diagnosis. CRP concentrations were also able to discriminate survival duration between 
patients within the same stage group and within the same treatment group. However, there 
was no association between post- operative CRP concentrations and survival duration in 
patients who had undergone surgical resection. As already stated, the effect of treatment or 
even disease progression may influence CRP concentrations and this reduces the value of 
CRP as a prognostic indicator. The data from this thesis suggests that CRP measured at the 
time of diagnosis, and before commencement of treatment, is a robust and reliable marker of 
systemic inflammation and is an independent predictor of outcome for patients with gastro- 
oesophageal malignancy. 
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The mechanisms linking systemic inflammation with adverse prognosis remain obsure. 
However, the metabolic changes associated with systemic inflammation, such as increased 
rates of skeletal muscle proteolysis and elevated resting energy expenditure, may lead to 
nutritional depletion and the cachexia syndrome has been linked with adverse outcome in 
patients with cancer (Falconer et al, 1994; DeWys et al, 1980; Barber et al, 1999b; Studley, 
1936). In the present study, 83% of patients had lost body weight at the time of diagnosis 
(median weight loss 7 %) and by three months 92% of patients had lost weight (median weight 
loss 10 %) [Chapter X]. Increasing weight loss was associated with reduced survival duration. 
Weight loss in patients with gastro -oesophageal cancer has commonly been associated with 
reduced food intake due to dysphagia /early satiety. In the present thesis, although dietary 
intake was a significant contributor to weight loss (size of effect 38 %), on multivariate analysis 
systemic inflammation was also identified as a significant independent contributory factor 
(size of effect 34 %). These data emphasises the potential inflammation driven metabolic 
contribution to weight loss and cachexia in these patients and may provide the link between 
systemic inflammation and adverse prognosis. Therefore, therapeutic strategies should 
address the systemic inflammatory component, in addition to the quantity of dietary intake, in 
cancer patients with weight loss. 
Multivariate survival analysis identified increased weight loss, elevated serum CRP 
concentration at the time of diagnosis, reduced performance status, and advanced stage of 
disease as independent predictors of survival duration [Chapter XI]. A risk prediction model 
was constructed from these variables to devise a novel model with improved prognostic 
accuracy to aid clinical decision- making. It is anticipated that this model will be used to help 
inform treatment decisions for individual patients and provide quality assurance for the MDT 
process. 
Conclusions and future directions 
A diagrammatic overview of the main conclusions drawn from this thesis is shown in Figure 
12.1. Systemic inflammation is common in patients with gastro -oesophageal cancer with 43% 
of patients demonstrating a systemic inflammatory response at the time of diagnosis. Serum 
acute phase protein concentrations (especially CRP), but not serum cytokine concentrations, 
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are robust measures of systemic inflammatory activity when measured at the time of 
diagnosis. Pro -inflammatory cytokines produced from the tumour tissue are important 
mediators involved in the generation of systemic inflammation in patients with cancer. IL -1ß in 
particular is over -expressed in tumour tissue and may be a key determinant of systemic 
inflammation in patients with gastro -oesophageal malignancy. Cancer cells or host immune 
cells or a combination of the two cell types are likely to be the main source of these pro - 
inflammatory cytokines. Future studies employing techniques such as insitu hybridisation or 
immunohistochemistry may help determine which cell populations are the main cytokine 
producers driving the systemic inflammatory response. Transgenic murine models with 
inducible cell activation may also help resolve some of these issues. 
Cytokine genotype also influences the genesis of systemic inflammation in patients 
with gastro -oesophageal cancer. Host genotype and tumour phenotype are both implicated in 
the generation of a systemic inflammatory response. Allelic association studies are, however, 
prone to a high false positive rate as a result of small sample size. The observations in the 
present thesis require to be confirmed in a separate population. Moreover, many other 
candidate genes need to be explored. 
Additional factors, such as PTHrP and PIF, are potential tumour -derived mediators 
that may also play a role in the generation of systemic inflammation in patients with cancer. 
Both PTHrP and PIF are linked with markers of systemic inflammation and these factors may 
also have additional effects on the host, such as potentiating weight loss and cachexia. 
However, there are many questions querying the existence of PIF in human subjects and the 
outcome of ongoing work with mass spectroscopy is awaited. 
Weight loss is common in patients with gastro -oesophageal cancer and is linked with 
the presence of systemic inflammation and adverse outcome. In addition to reduced levels of 
dietary intake, metabolic mechanisms, including systemic inflammation, are key processes 
involved in weight loss progression. Cachexia may be an aetiological factor involved in the 
link between systemic inflammation and adverse prognosis. Future clinical studies involving 
monoclonal antibodies against cytokines (such as anti-IL-1[3) or PTHrP may provide valuable 
new information relating to tumour immunology and may represent much needed novel 
therapeutic strategies. Modification of the systemic inflammatory response in these patients 
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may reduce progression of rates of weight loss, improve performance status and function, 
and perhaps influence prognosis. 
Systemic inflammation, weight loss, performance status, and stage of disease are the 
main determinants of outcome in patients with gastro -oesophageal cancer. These four 
prognostic factors were used to devise a model to improve prognostic accuracy for these 
patients. Currently this novel prognostic scoring system is undergoing prospective validation 
as part of the MDT process. It is hoped that the use of this model will improve treatment 
decisions for patients with gastro -oesophageal malignancy and thereby provide better care for 
individual patients. 
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Figure 12.1 A diagrammatic representation of the main conclusions drawn from this 
thesis. 
Genotype Inflammatory Pro -inflammatory 
infiltrate t cytokines 
(IL-113) 
Systemic Inflammation 
(acute phase protein concentrations) 
f 
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(eg metastatic potential) 
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Appendix A 
Patient Information Sheet 
THE CAUSES OF INFLAMMATION IN CANCER AND ITS LINK WITH 
OUTCOME IN OESOPHAGEAL /STOMACH CANCER 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please ask if there 
is anything that is not clear or if you would like more information. 
In the treatment of patients with oesophageal (gullet) or stomach cancer there are a variety of 
treatments available. These depend on the extent of the tumour and also the general fitness 
of the patient. At the present time estimating a patient's response to these different treatment 
options is difficult and often inaccurate. Improving this process will help both doctors and 
patients in choosing the most appropriate treatment options. We think that detecting the 
presence of inflammation in the body may help to improve this process. 
Over the next two years we plan to study around 250 patients who develop oesophageal or 
stomach cancer in our region. If you decide to take part in the study we will require a single 
blood test (about a tablespoon) and a single urine test. As these samples will be taken at the 
time of your other tests you will not require an additional needle prick. If you go on to have 
surgery we would use some of the cancer cells taken out during the operation to study in the 
laboratory. In addition, we would take a small sample of muscle from your tummy wall (about 
a pea size). This will not affect you in any way after the operation. 
Taking part in the study will not affect the treatment you will receive. All patients, whether 
involved in the study or not, will receive the same follow up in the outpatient clinic. 
It is up to you to decide whether or not to take part in the study. If you decide to take part you 
will be asked to sign a consent form and you should keep this information sheet. If you decide 
to take part you are still free to withdraw at any time and without giving a reason. A decision 
to withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. 
You may contact myself (the main researcher) directly by telephoning 0131 536 3821 for 
further information at any time. Alternatively, you may contact Mr Rowan Parks (Senior 
Lecturer in the Department of Surgery) who is acting as an independent advisor - contact 
0131 536 3820. 
Thank you for your time. 
Mr Chris Deans 
Department of Surgery 
Royal Infirmary of Edinburgh March 2002 
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Consent Form 
THE AETIOLOGY OF SYSTEMIC INFLAMMATION AND ITS LINK WITH 
PROGNOSIS IN GASTRO- OESOPHAGEAL CANCER 
I agree to take part in the above titled study 
I confirm that I have read and understand the information sheet dated 
March 2002 for the above study and have had the opportunity to ask 
questions 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason, without my medical care 
or legal rights being affected 
RESEARCHER 
Name Mr Chris Deans Date 
Signature 
PATIENT 




Research Data Collection Sheet 
Patient Details 
Name /Addressograph 
Date of Diagnosis - 
Duration of symptoms - 
Co- morbidity /PMH - 
Date 
Sex 
Age at diagnosis 
Current Health (eg URTI) - Smoker 




ASA Pre -illness stable weight 




Tumour Site Oesophageal /Gastric 
Tumour Position Proximal /middle /distal /O -G Junction /etc 
Histology ACC!SCC /Other 
Differentiation Poorly /moderately /well 
Other Prognostic Features Inflammatory infiltrate 
Signet cells 
Other 
Staging Investigations - CT T N M 
- EUS T N M 
- Lap /LUS T N M 
- CXR 
Final Stage: 
- Other (eg peritoneal washings) 
Clinical T N M 
Pathological T N M 
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INVESTIGATIONS 






















Source (eg theatre, UGIE) - 
lschaemic time - Time from stomach transected to freezing 
Time from oesophagus transected to freezing 
Skeletal muscle taken Y/N 




Surgery Yes /No 
Operation - 
Date - 
Neoadjuvant chemotherapy - Y / N 







Date of Recurrence - 
Date of death - 
Cause of death - 
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KARNOFSKY INDEX 
Normal, no complaints 100 
Able to carry out normal activities, minor signs of disease 90 
Normal activity but with effort 80 
Self- caring but unable to carry out normal activity or work 70 
Requires occasional assistance but able to care for most needs 60 
Requires considerable assistance and frequent medical care 50 
Disabled, requires special care and assistance 40 
Severely disabled, hospitalisation indicated although death not imminent 30 









able to eat normal diet / no dysphagia. 
able to swallow some solid foods 
able to swallow only semi solid foods 
able to swallow liquids only 
unable to swallow anything / total dysphagia 
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Appendix C 
Reagent recipes for ELISA's 
Acute Phase Protein ELISA Reagents 




Tween 20 1m1 
dH2O to 1000m1 




dH2O to 1000m1 
Substrate Buffer: OPD tablets 4 
H2O 12 ml 
30% H2O2 5p1 
Cytokine ELISA Reagents 
Assay Buffer Bovine serum albumin 5g 





dH2O to 1000m1 
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Appendix D 
Western Blotting Reagents 
Gel Preparation - for 2 gels: 
4% Stacking gel 
12.5% Resolving gel 
0.5M Tris -HCI (pH 6.8) 2.5ml 
10% SDS 100p1 
Acrylamide /bis (30 %) 1.3ml 
dH2O 6.1m1 
10% ammonium persulphate 50 pl 
TEMED (added last) 20 pl 
1.5M Tris -HCI (pH 8.8) 2.5ml 
10% SDS 100pI 
Acrylamide /bis (30 %) 4.17m1 
dH2O 3.12m1 
10% ammonium persulphate 100 pl 
TEMED (added last) 10 pl 
332 
British Journal of Cancer (2006) 95, 1568- 1575 
© 2006 Cancer Research UK All rights reserved 0007- 0920/06 $30.00 
www.bjcancer.com 
Elevated tumour interleukin - I ß is associated with systemic 
' inflammation: a marker of reduced survival in gastro -oesophageal 
cancer 
DAC Deans', SJ Wigmore', H Gilmour', S Paterson-Brown', JA Ross' and KCH Fearon " 
Tissue Injury and Repair Group, Department of Clinical and Surgical Sciences, MRC Centre for Inflammation Research, The Chancellor's Building, 
Edinburgh University, 49 Little France Crescent, Edinburgh EH 16 4SB, UK 
Systemic inflammation is associated with adverse prognosis cancer but its aetiology remains unclear. We investigated the expression 
of proinflammatory cytokines within normal mucosa from healthy controls and tumour tissue in cancer patients and related these 
levels with markers of systemic inflammation and with the presence of a tumour inflammatory infiltrate. Tissue was collected from 56 
patients with gastro- oesophageal cancer and from 12 healthy controls. Tissue cytokine mRNA concentrations were measured by 
real -time PCR and tissue protein concentrations by cytometric bead array. The degree of chronic inflammatory cell infiltrate was 
recorded. Serum cytokine and acute phase protein concentrations (including C- reactive protein (CRP)) were measured by enzyme - 
linked immunosorbent assay. Proinflammatory cytokines were significantly overexpressed (interleukin (IL)-1ß, IL -6, IL -8 and tumour 
necrosis factor -a) both at mRNA and protein levels in the cancer specimens compared with mucosa from controls. Interleukin- I ß 
was expressed in greatest (I 0-100-fold) concentration and protein levels correlated significantly with systemic inflammation (CRP) 
(P = 0.05, r= 0.3 I ). A chronic inflammatory infiltrate was observed in 75% of the cancer specimens and was associated with systemic 
inflammation (CRP: P = 0.0 I ). However, the presence of chronic inflammation per se was not associated with altered cytokine 
expression within the tumour. Both a chronic inflammatory infiltrate and systemic inflammation (CRP) were associated with reduced 
survival (P = 0.05 and P = 0.03, respectively). Tumour chronic inflammatory infiltrate and tumour tissue IL-1# overexpression are 
potential independent factors influencing systemic inflammation in oesophagogastric cancer patients. 
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Systemic inflammation has been found in association with the 
majority of advanced solid epithelial malignancies and at the time 
of diagnosis up to 50% of patients may have an elevated acute 
phase protein response (APPR) (Falconer et al, 1995). The 
presence of an APPR has been associated with weight loss, the 
presence of hypermetabolism and anorexia, extent of disease, 
the development of recurrence in advanced cancer, and adverse 
prognosis (independent of stage of disease) (Rashid et al, 1982; 
Kodama et al, 1999; McMillan et al, 2001, 2003; Nozoe et al, 2001; 
Forrest et al, 2003). In patients with gastric cancer, the presence of 
systemic inflammation has been associated with a markedly 
reduced median survival (9 vs 53 weeks, P <0.001) (Rashid et al, 
1982). Similarly, a study from Japan has identified a shortened 
survival in oesophageal cancer patients with an elevated serum C- 
reactive protein (CRP) at the time of diagnosis (Nozoe et al, 2001). 
More recently, a group from the UK has identified elevated serum 
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CRP and reduced serum albumin concentrations as independent 
prognostic indicators among patients with inoperable gastro- 
oesophageal cancer (Crumley et al, 2006). The systemic inflam- 
matory response is highly complex and is modulated, in part, by 
the interaction of pro- and anti -inflammatory cytokines. However, 
the precise origin of systemic inflammation among cancer patients 
remains obscure. 
Human cancer cell lines have been shown to produce 
proinflammatory cytokines (Gelin et al, 1991; Strassmann et al, 
1993a, b; Wigmore et al, 2002). However, such proinflammatory 
cytokines are not reliably detected in the circulation and probably 
act locally to promote inflammation and activate host inflamma- 
tory cells (e.g. peripheral blood mononuclear cells: PBMCs) 
passing through the tumour (Falconer et al, 1994; O'Riordain 
et al, 1999). Such cells can re -enter the circulation and release 
cytokines at distant target organs (e.g. the liver). More recently, 
Martignoni et al (2005) have suggested that interleukin (IL) -6 
overexpression in pancreatic cancer patients is related to the 
ability of certain IL -6 producing tumours to sensitise PBMC and 
induce IL -6 expression in PBMCs. The main cytokines influencing 
the APPR in humans are thought to include IL -6, IL -1ß, and 
tumour necrosis factor -a (TNF -a) (O'Riordain et al, 1999). 
Interleukin -6 is the main inducer of the APPR in human 
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hepatocytes and both IL -lß and TNF -a are capable of inducing 
IL -6 production from both tumour and host cells (Strassmann et al, 
1993a,b). In cancer patients, the rates of production of IL -6 from 
isolated PBMCs can be linked to markers of systemic inflammation 
such as CRP (O'Riordain et al, 1999). The presence of such an acute 
phase reaction may then be used as an indirect marker of 
proinflammatory cytokine activity (IL -lß, IL -6, and TNF -a). 
The source of the proinflammatory stimulus in advanced cancer 
remains unclear. It has been hypothesised that in patients with 
cancer, either the tumour cells or the host cells or a combination of 
the two are responsible for the production of the proinflammatory 
cytokines that induce the APPR. With a view to modulation of 
systemic inflammation in cancer, we hypothesise that dominant 
cytokines within tumour tissue drive the systemic inflammatory 
response and that these might be considered as targets for specific 
therapy. To investigate the role of tumour tissue in the genesis of 
systemic inflammation in cancer patients, we measured cytokine 
(IL -lß, IL -6, IL -8, and TNF -a) mRNA and protein concentrations 
in tumour tissue collected from patients with gastro -oesophageal 
cancer and tissue from healthy controls and related these 
measurements to systemic concentrations of cytokines and acute 
phase proteins (APPs). We also investigated the significance of a 
chronic inflammatory cellular infiltrate within these tissues and 
related these findings to tissue cytokine concentrations and to 
clinical outcome. 
PATIENTS AND METHODS 
Study patients 
Patients diagnosed with gastric or oesophageal cancer within the 
Lothian and Borders regions between June 2002 and March 2004 
were eligible for inclusion into the study. Patients were recruited at 
the time of diagnosis and all subjects provided written informed 
consent and the study received ethical permission from the 
Lothian Research Ethics Committee. All patients who had surgery 
were eligible and were studied. No patients were excluded or 
refused consent. Patients not suitable for surgical resection 
(advanced disease stage or comorbidity) were excluded from the 
study. Patients were staged according to the International Union 
Against Cancer (UICC), and final histopathological stage (pTNM) 
was used in all cases (Sobin and Wittekind, 2003). Tumours 
located around the oesophago - gastric junction were classified 
according to Siewert and those classified as types I and II were 
staged as oesophageal tumours and type III as gastric cancers 
(Siewert and Stein, 1998). All clinical and pathological information 
was collected prospectively, including documentation of the use 
of nonsteroidal anti -inflammatory drugs (NSAIDs) and any other 
therapeutic agents that may influence the inflammatory response. 
Determination of serum APP and cytokine concentrations 
A random blood was collected from patients at the time of 
diagnosis and before any therapeutic intervention. All patients 
were free from infection at the time of blood collection. Samples 
were collected simultaneously from 22 healthy controls for 
comparison. Serum was obtained by collecting whole blood into 
lithium -heparinised tubes and centrifuging at 2000 r.p.m. for 
10min at 10 °C (Mistral 3000i, Thermo Life Sciences, Basingstoke, 
UK). Aliquots were stored at -80 °C until batch analysis. 
C- reactive protein was determined using an immunoturbidi- 
metric assay (Abbott TDX, Abbott Laboratories, Maidenhead, UK). 
A level above 10 mgr.' defined the presence of an APPR. Serum 
albumin concentrations were measured by an automated bromo- 
cresol green dye- binding technique. The remaining APPs were 
determined by sandwich enzyme- linked immunosorbent assay as 
described previously (Wigmore et al, 2002). Briefly, 96 -well plates 
were coated with 100 it primary antibody (concentration 10 mgt -') 
and incubated overnight at 4 °C (Dako, Ely, UK). The plates were 
washed with 0.1% Tween and diluted sera (100 µl) was added to the 
coated wells and incubated at room temperature for 2 h. Plates 
were washed as before and a secondary antibody conjugated with 
peroxidase was added to each well and incubated for 1 h (Dako, 
Ely, UK). The substrate used was OPD (Dako, Ely, UK) and the 
reaction was stopped with 0.5 M sulphuric acid. Plates were read 
at 490 nm using a Dynatech MR5000 automated plate reader. 
Standard curves were generated using standard APPs supplied by 
the manufacturer (Dako, Ely, UK). 
Serum cytokines were analysed with module kits and performed 
according to the manufacturers instructions (Caltag, Bender 
MedSystems, Towcester, UK). The lower limit of sensitivity for 
each assay was; <1 pgml -' IL -lß, 1.4 pg m1 -1 IL -6, 11 pg ml -1 
IL -8, 0.8 pg ml -1 IL -10, and 5.8 pg ml TNF soluble receptor 
(sTNF -R). 
Tissue cytokine mRNA and protein measurement 
Tissue collection Tissue was obtained from 56 patients at the time 
of surgical resection. A representative sample of tumour tissue was 
collected from each patient and tissues were snap frozen in liquid 
nitrogen before storage at -80 °C until further analysis. An 
additional 12 patients were recruited as healthy controls. These 
patients underwent endoscopy as an elective procedure for 
investigation of dyspeptic -type symptoms. In all instances, the 
result of the procedure was normal, including both macroscopic 
and microscopic assessment. Mucosal tissue (seven oesophageal 
and five gastric) samples were collected from these patients with 
biopsy forceps at the time of endoscopy. All control subjects were 
considered healthy without established comorbidity or taking 
regular medications. 
Quantitative reverse transcription - polymerase chain 
reaction (Q -RT -PCR) 
RNA isolation and RT Total RNA was isolated from tissue 
samples using the RNeasy kit (Qiagen Inc., Crawley, UK). RNA 
quality and integrity was assessed using an Agilent 2100 
bioanalyser (Agilent Technologies Ltd, Chesire, UK) in five 
randomly selected samples. For the remaining samples, purity 
and concentration were determined using spectrophotometry 
(Ultrospec 2000, Pharmacia Biotech, Bucks, UK). Reverse tran- 
scription was performed using 1 µg of total RNA following DNase 
treatment (Qiagen Inc., UK). All RNA samples were checked for 
genomic DNA contamination before RT using conventional RT - 
PCR. Two microlitres of total RNA was mixed with 1 µl MgCl 
(25 mM), 2.5 µl 10 x Taq DNA polymerase buffer with added MgCl, 
2.5µl dNTP (10 mM), 5µl forward and reverse primers (10µM), 
11 µl DEPC- treated water and 1 µl Taq DNA polymerase (5 U µl -') 
(all reagents Promega, Southampton, UK). Primers for cytochrome 
b were used to detect DNA contamination. The forward primer 
sequence was GGTTCTGGAATAAGAATATAGG and the reverse 
primer sequence GACAACACAGTAAGAACCAGG, giving a pro- 
duct of 367 bp if contamination was present. 
Reverse transcription was performed once DNA contamination 
had been excluded. The reaction mixture included the RNA (1µg 
in 10 µl DEPC- treated water), 4 µl MgC1 (25 mM), 2 µl 10 x reverse 
transcriptase buffer, 2µl dNTPs (10 mm), 1 p random hexamers 
(500 µg ml -1), 1.5µl AMV reverse transcriptase (10 U p1-1), and 
0.5 µl recombinant RNase inhibitor (40 U µl -') (all reagents 
Promega, Southampton, UK). Reverse transcription was performed 
at 42 °C for 60 min followed by 95 °C for 5 min. 
Real -time PCR Quantitative PCR was performed using the ABI 
PRISM 770 real -time Sequence Detection System (Applied 
Biosystems, Warrington, UK). Reactions were performed in 50µl 
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total volume, consisting of; 25 pl Taqman universal PCR master - 
mix (UNG x 2), 14µl primer /probe mix, 2.5 pl ribosomal 18S 
primer /probe mix (all reagents Applied Biosystems, UK), 3.5 pl 
DEPC- treated water, and 5pl cDNA. Each sample was analysed in 
duplicate. The reaction conditions were 2 min at 50 °C, 10 min at 
95 °C, and 40 cycles with 15 s at 95 °C and 1 min at 60 °C. Genes 
studied included IL -1ß, IL -6, IL -8, and TNF -a. The primers and 
probes were designed by Applied Biosystems, UK. 
Quantification of gene expression was calculated using the 
comparative (ALCT) method, where samples were compared with 
the positive control (Bustin, 2000). The level of gene expression 
within each sample was adjusted to an internal control (human 
ribosomal 18S) before expression was calculated as a percentage of 
the level of gene expression by the control sample. Samples that 
generated cycle numbers above 23 for the endogenous control 
(18S) were discarded and the samples were repeated. 
Positive control Whole blood was collected from healthy donors 
and the white cells were isolated using histopaque (Sigma, Dorset, 
UK). The cells were cultured in lipo- polysaccharide (Sigma, 
Dorset, UK) for 48 h before isolation of the RNA. Total RNA was 
reverse transcribed as described above. Each real -time reaction 
used an aliquot from the stock solution of cDNA as a positive 
control. 
Extraction of tissue protein Tissue lysates were prepared by 
homogenising 50 mg of tissue in 400 pl tissue homogenising buffer 
(0.4 ml 500 mm Tris, 0.2 ml 100 mm ATP, 1 ml 50 mm MgC12, 10µl 
dithiothreitol, 1 x protease inhibitor, 8.4 ml water - Sigma, Dorset, 
UK). Samples were heated to 95 °C for 5 min before centrifuging at 
13 000 r.p.m. for 30 min. Protein concentration of the supernatants 
was determined by the Bradford method (Bio -Rad, Hemel 
Hempstead, UK) (Bradford, 1976). Samples were stored at -80 °C 
until analysis. 
Determination of tissue cytokine concentrations 
Cytokine protein concentrations were determined using the 
Cytometric Bead Array System according to manufacturer's 
instructions (Human Inflammation Kit, BD Biosciences, Oxford, 
UK). This kit allows the measurement of cytokines IL -1ß, IL -6, IL- 
8, IL -10, IL- 12p70, and TNF -a. Briefly, 50 pl of tissue extract was 
added to the reaction mix containing antibody- coated microbeads 
and incubated at room temperature for 3 h. Cytokine concentra- 
tions were determined by flow cytometry (BD FACScan, Oxford, 
UK). Results were calculated to take into account the total protein 
concentration of the tissue lysate and are expressed as pgmg -1 of 
total protein. Intra -assay variability ranged between 2 and 10% and 
interassay variability was 4 -15 %. 
Histological analysis 
Representative sections of tumour tissue were fixed with formalin 
and stained with haematoxylin and eosin. A single Consultant 
pathologist (HG) reviewed all the tissue sections and the extent of a 
chronic inflammatory cellular infiltrate was recorded. Sections 
were classified as either diffuse scanty (occasional) chronic 
inflammatory cells present, focal lymphoid aggregates only, diffuse 
chronic inflammatory cellular infiltrate present throughout the 
tissue, or patchy chronic inflammatory cells present (Figure 1). HG 
was blinded to the clinical data, serum APP /cytokine concentra- 
tions, and tissue cytokine concentrations relating to each patient. 
Statistical analysis 
Comparisons between groups of continuous variables were made 
by the Mann - Whitney U -test. Categorical variables were com- 
pared by Fisher's exact test. Correlations between continuous 
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Figure I Representative photomicrographs taken from three patients 
with poorly differentiated adenocarcinoma of the oesophagus. Patient (A) 
demonstrates minimal /no inflammatory cell reaction, Patient (B) has a 
patchy chronic inflammatory cell infiltrate. Patient (C) shows a diffuse 
chronic inflammatory cellular infiltrate present throughout the tumour. 
Sections of tumour tissue were fixed with formalin and stained with 
haematoxylin and eosin (magnification x 100). 
variables were assessed by Spearman's rank correlation coefficient. 
Survival between groups was analysed by the log -rank test and 
Cox's proportional hazards model. A P -value 0.05 was 
considered statistically significant. 
RESULTS 
Study patients 
Patient demographics are shown in Table 1. Subgroup analysis 
confirmed no significant differences in either tissue mRNA or 
© 2006 Cancer Research UK 
Table I Study patient demographics (n = 56) 
Number ( %) 
Age (years)a 66 (58 -75) 
Sex 
Male 40 (71) 
Female 16 (29) 
Tumour site 
Oesophageal 26 (46) 
Oesophago -gastric junction 13 (23) 
Gastric 17 (30) 
Histology 
Adenocarcinoma 52 (93) 
Squamous cell carcinoma 4 (7) 
Grade 
Well differentiated 4 (7) 
Moderately differentiated 24 (43) 
Poorly differentiated 28 (50) 
UICC stage 
1 17 (30) 
2 13 (23) 
3 21 (38) 
4 5 (9) 
Treatment undertaken 
Oesophagectomy 25 (45) 
Gastrectomy 18 (32) 
Preoperative chemotherapy followed by surgery 13 (23) 
Status 
Alive 37 (66) 
Dead 19 (34) 
'Values given are median ( interquartile range). 
protein levels between patients who received preoperative 
chemotherapy and those who did not (data not shown). Similarly, 
there were no differences in tissue mRNA or protein levels or 
serum cytokine or APP levels among those patients taking NSAIDs 
or any other therapeutic agents that may modify the inflammatory 
response (data not shown). Therefore, all patients were included as 
a single group for analysis. 
Serum cytokine and APP concentrations 
Serum APP concentrations for the study patients and healthy 
controls are shown in Table 2. The patient group had significantly 
elevated concentrations of positive APPs compared with the 
control population; CRP (P < 0.001, Mann - Whitney U- test), 
haptoglobin (P <0.001), and al- antichymotrypsin (P <0.001). 
There was no difference in concentrations of the negative acute 
phase reactants; albumin (P = 0.242) or transferrin (P = 0.346). 
Ten (18%) patients had a serum CRP concentration > 10 mg l -', 
which was associated with reduced survival duration (P = 0.031, 
log -rank test) (Figure 2). C- reactive protein concentration 
remained an independent prognostic indicator on multivariate 
analysis when analysed with stage, age, sex, and grade (P= 0.048, 
hazard ratio 2.7 (1.1 -7.3 95% CI); Cox's proportional hazards 
model). 
Serum cytokine concentrations were similar between the healthy 
controls and cancer patients (Table 2). Serum cytokine concentra- 
tions did not correlate with serum APP concentrations (linear 
regression, data not shown) and patients with CRP levels greater 
than 10 mgr' did not have significantly elevated serum cytokine 
concentrations. 
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Table 2 Serum concentrations of acute phase proteins and cytokines for 
the patient group (n = 56) and healthy controls (n = 22) 
Patient group (n = 56)Control group (n =22)P-value 
CRP (mg /I) 4 (2-16) I (1-3) <0.001 
Haptoglobin (mg/I) 1869 (1421-2651) 821 (627-1157) <0.001 
ACT (mg/I) 409 (326-502) 245 (213-261) <0.001 
Albumin (g/l) 42 (39-44) 42 (39-45) 0.227 
Transferrìn (mg/I) 2076 (1565-2648) 2197 (1861 -2451) 0.478 
IL-1/3 (pg/m1) Ob 0 - 
IL -6 (pg/ml) 0 (0-91) 11 (0-214) 0.412 
IL -8 (pg/ml) 0 (0-57) 0 (0- I 18) 0.683 
IL -10 (pg /ml) 0` 0 - 
sTNF -R (ng/ml) 2.6 (1.3-4.1) 2.8 (1.3-3.6) 0.559 
ACT = a I -antichymotrypsin; CRP = C- reactive protein; IL = interleukin; sTNF- 
R = soluble tumour necrosis factor receptor (p55). Positive acute phase protein 
concentrations were elevated in the patient group compared with the control group. 
There were no differences between concentrations of the negative acute phase 
reactants or serum cytokines. 'Mann-Whitney U -test. °Only two patients had 
measurable serum IL- I ß concentrations. `Only Four patients had measurable IL -10 
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Figure 2 Kaplan -Meier survival plot presented by serum CRP 
concentration. Heavy line CRP > I 0 mg I-1 (median survival 509 days) vs 
light line CRP < 10 mg I- I (median survival > 900 days); P = 0.031. log -rank 
test. 
Tissue cytokine mRNA and protein concentrations 
Interleukin -6 and IL -8 mRNA were not measurable in any of the 
gastro -oesophageal mucosa samples collected from healthy con- 
trols and IL -1ß and TNF -cc were only detectable at very low 
concentrations (Figure 3A). In contrast, mRNA for IL -lß, IL -6, 
IL -8, and TNF -a were detected in tumour tissue at significantly 
elevated concentrations: IL -lß P< 0.001; IL -6 P <0.001; IL -8 
P <0.001; TNF -a P =0.006 (see Figure 3A). 
Similarly, IL -6 protein was not detected in mucosal tissue 
samples from healthy controls and IL -lß, IL -8, and TNF -a were 
only measured at low concentrations (median concentrations; 
IL -lß 2.6 pg mg -' total protein, IL -8 0.2 pg mg -' total protein, 
TNF-cc 0.1 pg mg -' total protein). However, cytokine protein con- 
centrations were significantly elevated in the tumour tissue: IL -lß 
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Figure 3 Comparison of cytokine levels of (A) mRNA and (B) protein between tissue from healthy controls and tumour tissue from patients with gastro- 
oesophageal cancer. The lines represent the median value, bars = inter-quartile range, error bars = extreme values. IL- I ß = interleukin- I ß, TNF -a = tumour 
necrosis factor -a. *P <0.05, * *P<0.01, * * *P<0.00I (Mann- Whitney U- test). 
136pgmg -1 of total protein (IQR 41 -425), P= 0.007; IL -6 
3 pg mg (IQR 0 -46), P<0.05; IL -8 56 pg mg -1 (IQR 23-159), 
P= 0.007; TNF -a 7pgmg 1 (IQR 1 -26), P <0.05 (Figure 3B). Of 
note, IL -lß concentrations were found at appreciably higher 
concentrations compared with the other cytokines (10-100-fold 
increase). 
There was no correlation between tissue cytokine mRNA 
concentrations and cytokine tissue protein concentrations; IL -lß 
(P= 0.64, r = 0.07; Spearman's rank), IL -6 (P = 0.46, r = -0.1), 
IL -8 (P = 0.55, r = 0.09), TNF -a (P= 0.90, r = 0.02). Increased 
mRNA concentrations were not associated with elevated tissue 
cytokine protein concentrations. 
Tissue cytokine mRNA concentrations did not correlate with 
serum cytokine concentrations or serum APP concentrations (data 
not shown). However, tumour tissue IL -1ß protein levels were 
positively correlated with serum CRP concentrations (P = 0.05, 
r= 0.31; linear regression) (Figure 4). Although TNF -a protein 
levels did not correlate with serum cytokine /APP concentrations 
there was a significant correlation between sTNF -R and serum 
CRP concentrations (P = 0.03, r = 0.36). There was no correlation 
between tumour tissue IL -6 and either circulating IL -6 or APP 
concentrations. There was also a trend towards a correlation 
between tumour IL -8 protein concentrations and serum sTNF -R 
concentrations, but this did not quite reach statistical significance 
(P =0.06, r= 0.32). 
Histological analysis 
Histology from three patients recruited to the study could not be 
traced; therefore, 53 tumour sections were studied. Twenty-four 
(45 %) tumour samples were classified as having scanty diffuse or 
patchy chronic inflammatory cells. Sixteen (30 %) tumour samples 
had a diffuse chronic inflammatory cellular infiltrate visible 
throughout the whole tumour. The remaining 13 (25 %) tumour 
sections had focal lymphoid aggregates only. When compared with 
tumour sections possessing lymphoid aggregates alone, tissues 
with a diffuse or patchy inflammatory cellular infiltrate were 
0.00 2.00 4.00 6.00 8.00 
Tumour tissue IL-1ß protein conc. (log) 
Figure 4 A scatter plot illustrating the relationship between serum CRP 
concentrations and tumour tissue 1L-Iß protein concentrations (P=0.05. 
r= 0.3 I ; linear regression). 
associated with elevated serum CRP and sTNF -R concentrations 
(P = 0.01 and P= 0.007, respectively, Mann - Whitney U -test) 
(Figure 5). In addition, a chronic inflammatory cellular response 
was associated with reduced prognosis (P = 0.05, log -rank test) 
(Figure 6). A chronic inflammatory infiltrate remained an 
independent prognostic indicator on multivariate analysis when 
analysed with stage, age, sex, tumour grade, and serum CRP 
concentrations (P = 0.013, hazard ratio 7.7 (1.5-38.0 95% CI); 
Cox's proportional hazards model). 





Focal lymphoid aggregates Patchy /diffuse cells 
Inflammatory cell infiltrate into the tumour 
Figure 5 A diffuse or patchy inflammatory cellular infiltrate was 
associated with elevated serum CRP concentrations (P =0.01, Mann - 
Whitney U- test). Thick bar represents median, the box represents quartiles, 
and lines represent extreme values. 
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Figure 6 Kaplan -Meier survival plot presented by the presence or 
absence of a chronic inflammatory cellular infiltrate within the tumour. The 
heavy line represents the presence of a chronic inflammatory infiltrate vs 
focal lymphoid aggregates alone, light line (P = 0.05; log -rank test). 
There was no correlation between the presence of a chronic 
inflammatory cell infiltrate and serum cytokine concentrations. 
Six (11%) patients had histological evidence of Helicobacter 
pylori on the resected specimens. A chronic inflammatory cellular 
infiltrate was not associated with H. pylori infection (P = 0.67, 
Fisher's exact test). 
Tumour necrosis was evident in 13 (25%) samples, including 
four samples collected from patients who received preoperative 
chemotherapy, but there was no association between treatment 
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modality and the presence of tumour necrosis (P = 0.92, a test). 
The presence of tumour necrosis was associated with elevated 
serum haptoglobin but not CRP concentrations (P =0.045 and 
P=0.07, respectively, Mann - Whitney U- test). Tumour necrosis 
was not associated with differences in tissue cytokine concentra- 
tions or survival (P= 0.62, log -rank test). 
Tissue cytokine (IL -lß, IL -6, IL -8, and TNF -a) mRNA and 
protein levels were found at similar concentrations within tumour 
tissues with a chronic inflammatory cell infiltrate and tumour 
samples with lymphoid aggregates alone. 
DISCUSSION 
In this study, we have shown that patients with gastro -oesophageal 
malignancy have elevated serum concentrations of APPs but 
similar serum proinflammatory cytokine concentrations compared 
with a control population. A range of proinflammatory cytokine 
concentrations (mRNA and protein) were significantly elevated in 
tumour tissue compared with tissue sampled from healthy 
controls. However, only IL -lß correlated with markers of systemic 
inflammation (CRP). In addition, a chronic inflammatory cellular 
infiltrate within the tumour was associated with elevated serum 
APP concentrations and reduced survival, but was not associated 
with elevated tissue cytokine mRNA and protein concentrations. 
An APPR has been well documented among patients with 
cancer, including gastric and oesophageal malignancies, and an 
elevated serum CRP has been identified as an adverse prognostic 
indicator, independent of stage of disease, among these patients 
(Rashid et al, 1982; Falconer et al, 1995; Kodama et al, 1999; 
McMillan et al, 2001, 2003; Nozoe et al, 2001; Forrest et al, 2003). 
The present study has confirmed these findings. Patients with 
gastro -oesophageal cancer had significantly elevated serum con- 
centrations of positive APPs compared with healthy controls. 
Moreover, the 10 (18 %) patients with a CRP concentration above 
10 mg l-1 at diagnosis had a reduced survival interval, which was 
independent of disease stage. Our study did not demonstrate any 
differences in serum cytokine concentrations between cancer 
patients and controls. Although some studies have shown an 
association between serum cytokines and APPs (Martignoni et al, 
2005) several have failed to demonstrate such a link and 
determination of serum cytokines remains an unreliable measure 
of tissue cytokine activity (Falconer et al, 1994; Barber et al, 1999). 
Moreover, these findings suggest that circulating cytokines may 
not be the key mediators of the APPR. 
Proinflammatory cytokine mRNA and protein concentrations 
were either not detectable or found at low levels in tissue collected 
from healthy controls. In contrast, mRNA and cytokine protein 
concentrations were measured at significantly higher concentra- 
tions in tumour tissue. In all instances, tissue cytokine concentra- 
tions were significantly elevated in tumour tissue compared with 
tissue from healthy controls. These findings are supported by Yuan 
et al (2000) who investigated IL -8 mRNA concentrations in tumour 
tissue and adjacent normal lung tissue among patients with non - 
small -cell lung cancer and also found increased cytokine expres- 
sion within the tumour tissue. Other groups have similarly 
demonstrated increased tissue cytokine concentrations associated 
with progression along the metaplasia - dysplasia - carcinoma 
sequence in Barrett's oesophagus (Tselepis et al, 2002; Dvorakova 
et al, 2004). 
In the present study, median IL -lß concentrations were 10-100 - 
fold higher than IL -6 in the tumour tissue and there was a weak but 
significant correlation between tumour tissue IL -lß concentration 
and serum CRP. There was a similar trend with IL -8. Both IL -lß 
and IL -8 are recognised as important cytokines in the generation 
of the systemic inflammatory response and it is possible that high 
tissue concentrations of these cytokines stimulate PBMCs as they 
pass through the tumour mass, which in turn act on target organs, 
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such as the liver, to induce the synthesis of APPs that are 
associated with systemic inflammation. Previously, we have 
demonstrated that PBMC from weight -losing pancreatic cancer 
patients control the hepatic APPR by a primarily IL -6- dependent 
mechanism (O'Riordain et al, 1999). Moreover, Martignoni et al 
(2005) have suggested that IL -6 overexpression in cachectic 
pancreatic cancer patients is related to the ability of certain IL -6 
producing tumours to sensitise PBMC and induce IL -6 expression 
in PBMCs. In the latter study, screening by DNA microassay 
analysis followed by quantitative PCR identified only IL -6 mRNA 
expression to be significantly increased in tumour samples of 
cachectic patients compared with noncachectic patients or 
pancreas samples from normal controls. Immunohistochemistry 
suggested the source of IL -6 to be tumour cells rather than host 
cells. The results of the present study, however, identify that at 
least in patients with gastro -oesophageal cancer IL -lß rather than 
IL -6 may be important as an initiator of the proinflammatory 
APPR. Interleukin -6 may form a common final pathway via 
activated PBMCs. Interestingly, in the colon -26 murine model of 
cancer cachexia associated with systemic inflammation there 
appears to be a complex intratumoural amplification loop between 
IL -lß and IL -6, which can be downregulated by IL -10 (Yasumoto 
et al, 1995; Fujiki et al, 1997). 
In this study, we did not find any correlation between tissue 
cytokine mRNA concentrations and systemic cytokines or APP 
concentrations. Raddatz et al (2005) did identify an association 
between tissue cytokine mRNA levels and systemic CRP concen- 
trations in Crohn's disease. These differing results may be partly 
explained by the lack of correlation between tissue mRNA 
concentrations and protein concentrations in this study. Although 
some groups have demonstrated a correlation between IL -lß and 
IL -6 mRNA and protein concentrations in an animal model of 
inflammatory joint disease, they also failed to show any correlation 
for TNF -a mRNA and protein concentrations (Rioja et al, 2004). 
The difficulties of relating mRNA concentrations to protein 
concentrations has been extensively documented elsewhere, but 
it is also important to consider that real -time PCR is an exquisitely 
sensitive technique and that what we are detecting in some 
patients, although elevated, may have little or no functional 
significance as it may not be translated into protein. Cytokine 
protein concentrations are, therefore, likely to be a more robust 
measure of tissue cytokine activity than mRNA levels. 
A chronic inflammatory cellular infiltrate was noted in 40 (75 %) 
tumour samples and was associated with elevated levels of serum 
CRP and sTNF -R. In addition, a chronic inflammatory infiltrate 
was associated with reduced survival. The presence of an 
inflammatory infiltrate within tumours and its relevance to 
prognosis has been investigated in a number of cancer types. 
Tumour -associated macrophages have been associated with 
reduced disease -free survival among lung, head and neck, and 
endometrial cancer (Marcus et al, 2004; Ohno et al, 2004; Chen 
et al, 2005). In contrast, increased numbers of tumour -associated 
macrophages, eosinophils, mast cells, and lymphocytes have been 
linked with improved survival in colorectal cancer (Svennevig 
et al, 1984; Jass, 1986; Nielsen et al, 1999). The prognostic 
significance of tumour- associated inflammatory cells is less clear 
in gastro- oesophageal cancer. An increased macrophage infiltrate 
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Host Cytokine Genotype is Related to Adverse Prognosis and 
Systemic Inflammation in Gastro -Oesophageal Cancer 
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Background: Systemic inflammation has been linked with reduced survival in cancer, 
however, the role of the host cytokine genotype versus tumour phenotype in the generation of 
this response is not clearly established. This study examined the relationship between cytokine 
polymorphisms (IL -1(1 511, IL -6 174, IL -l0 1082, TNFa 308 and LTa +252) and serum 
cytokine concentrations, serum CRP concentration and survival duration in patients with 
gastro- oesophageal malignancy. 
Methods: Two hundred and three newly diagnosed patients with gastric or oesophageal 
cancer had serum CRP and cytokine concentrations determined by ELISA. SNP genotyping 
was performed by Taqman allelic discrimination genotyping and compared with the genotype 
observed in 266 healthy volunteers. Clinico- pathological information was collected prospec- 
tively and survival duration was recorded. 
Results: Distribution of the cytokine genotypes was similar between patients and controls. 
The IL -6 174 CC and IL -10 1082 GG genotypes were associated with elevated serum CRP 
(P = .03, P = .01, respectively; Mann Whitney U test) and sTNF -R (P = .015, P = .02) 
concentrations. These genotypes were also associated with reduced survival duration 
(P = .01, P = .047; log -rank test). TNFa AA genotype was also associated with reduced 
survival duration on univariate (P = .032) and multivariate analysis (P = .006, multivariate 
model), but not with inflammatory markers. No other cytokine polymorphisms were associ- 
ated with systemic inflammatory markers or prognosis. 
Conclusions: There is a pro- inflammatory cytokine haplotype (IL -6 CC, IL -10 GG, TNFa 
AA) that is associated with adverse prognosis that may act, at least in part, through an 
inflammatory mediated mechanism. Determining patients' cytokine haplotype may improve 
prognostication and allow stratification for intervention studies. 
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Malignant tumours arising around the oesophago- 
gastric junction have the fastest increase in incidence 
of any solid tumour in Europe and North America.l'2 
Together gastric and oesophageal malignancy are the 
third leading cause of cancer -related death in the 
UK.3 Despite advances in both staging techniques 
and treatments, 5- year -survival rarely exceeds 30 %.4 
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Systemic inflammation has been associated with a 
number of malignant diseases, including gastric and 
oesophageal cancer, and is associated with adverse 
outcome.' -15 Among patients with gastric cancer the 
presence of systemic inflammation has been associ- 
ated with a markedly reduced median survival (53 vs. 
9 weeks, P < .001).14 Similarly, a recent Japanese 
study has identified a shortened survival in oesoph- 
ageal cancer patients with an elevated serum C- 
reactive protein (CRP) at the time of diagnosis.15 The 
systemic inflammatory response is modulated by the 
complex interaction of many pro- and anti- inflam- 
matory cytokines. Although the production of these 
mediators is partly responsive to environmental 
influences, the origin of systemic inflammation 
among cancer patients remains obscure and may be 
influenced by host cytokine genotype. Variations in 
genotype for a number of cytokines have been asso- 
ciated with changes in both serum cytokine and ser- 
um acute phase protein concentrations and prognosis 
among cancer patients. 
Tumour necrosis factor a (TNFa), interleukin -lß 
(IL -lß), and IL -6 are key pro -inflammatory cytokines 
involved in the generation of the inflammatory re- 
sponse. Increased production of these cytokines has 
been shown to contribute to adverse outcome in pa- 
tients with sepsis, infections and inflammatory dis- 
eases, such as inflammatory bowel disease and 
rheumatoid arthritis.16 -19 Our group has previously 
investigated the influence of IL-1I3 polymorphisms on 
systemic inflammation and survival in patients with 
pancreatic cancer.2° The possession of the less corn - 
mon allele 2 was associated with increased levels of 
serum CRP concentrations, increased production of 
IL -lß by peripheral blood mononuclear cells 
(PBMC), and reduced overall survival. In contrast, 
another group failed to identify an association be- 
tween IL-1I3 polymorphisms and outcome for pa- 
tients with ovarian cancer.21 
A single nucleotide polymorphism (SNP) at the 308 
position of the TNFa gene lies within the promoter 
region and the A allele has been associated with 
higher levels of TNFa production in vitro following 
stimulation with endotoxin.72 Variation at the 308 
locus has been associated with conflicting levels of 
TNFa production both in in vitro studies and among 
patients with sepsis.23'24 Our own work, again on 
pancreatic cancer patients, found no link between 
genotype and serum soluble TNF receptor (sTNF -R) 
concentrations or serum CRP concentrations.25 
There was a trend for reduced survival duration 
associated with possession of the AA genotype, but 
this did not reach statistical significance (P = .13). 
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Another group identified that possession of the A 
allele was associated with elevated serum sTNF -R 
concentrations in patients with non -Hodgkin's lym- 
phoma and was associated with reduced overall sur- 
vival.2" 
A SNP at the 252 locus of the lymphotoxin a (LTa) 
(tumour necrosis factor ß) gene has also been shown 
to modify levels of TNF production. Septic surgical 
patients homozygous for the AA genotype had sig- 
nificantly higher mortality than those patients who 
were homozygous for GG.27 Among cancer patients, 
homozygotes had a more favourable prognosis than 
heterozygotes in advanced lung cancer and patients 
possessing the type 1 allele were shown to have 
poorer survival in oesophageal cancer.28'29 
A SNP at 174 in the IL -6 promoter region has been 
associated with increased serum IL -6 concentrations 
and worse outcome among cardiac surgery patients.30 
Survival data for cancer patients is conflicting. The 
possession of the C allele has been associated with 
earlier stage disease and better outcome (independent 
of stage) in women with ovarian cancer and breast 
cancer.31'32 However, the same genotype has also 
been associated with adverse survival in another 
group of patients with breast cancer.' 
Interleukin -10 (IL -10) is generally regarded as an 
anti -inflammatory cytokine important in the attenu- 
ation of the inflammatory response. The IL -10 gene 
polymorphism at position 1082 lies within the pro- 
moter region and the AA genotype is generally 
thought to be associated with reduced levels of IL -10 
production, but this is contradicted by one study.3435 
The high IL -10 producer genotype (GG) has been 
linked with more advanced stage among patients with 
gastric cancer.36 
With a view to understanding more clearly the role 
of host genotype in the genesis of tumour -related 
systemic inflammation this study examined the rela- 
tionship between cytokine polymorphisms (IL -1 )8 
511, IL -6 174, IL -10 1082, TNFa 308 and LTa + 252) 
and serum cytokine concentrations, serum CRP 
concentrations and survival duration among newly 
diagnosed patients with gastro -oesophageal cancer. 
MATERIALS AND METHODS 
Study Patients and Controls 
Patients diagnosed with gastric or oesophageal 
cancer between March 2002 and May 2004 within 
Lothian and Borders regions were invited to take part 
in the study. All patients provided written informed 
r 
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consent and the study received ethical permission 
from the Lothian Research Ethics Committee. His- 
tological confirmation of disease was established in 
all cases following endoscopic biopsy. Patients were 
staged with a combination of computerised tomog- 
raphy (CT), endoscopic ultrasound (EUS) and lapa- 
roscopy /laparoscopic ultrasound (LUS) according to 
the International Union Against Cancer (UICC).' 
Final histopathological stage (pTNM) was only 
available for those patients who underwent surgical 
resection. In all other cases the final clinical stage 
(cTNM), as agreed at the unit multidisciplinary team 
meeting (MDT), was recorded. Tumours around the 
oesophago -gastric junction were classified according 
to Siewert and those classified as type I and II were 
staged as oesophageal and type III were staged as 
gastric." For the purposes of analysis the cTNM 
stage was used for all patients. Separate subgroup 
analysis of those patients with final histopathological 
(pTNM) stage gave identical results. Clinical and 
pathological information was recorded prospectively 
for each patient, including treatment modality, tu- 
mour grade and histological subtype. Duration of 
survival, defined as time from histological diagnosis 
to death, was recorded for all patients. 
In addition to the patient group, blood samples 
were also collected from healthy controls for geno- 
typing. The control group used in this study com- 
prised 266 British Caucasian bone marrow and solid 
organ donors, collected via the Histocompatibility 
and Immunogenetics Laboratory, Southampton 
University Hospitals. The mean age of these controls 
(140 males, 126 females) was 39.2 years at the time of 
blood collection (age range 3 -69). All cytokine 
genotyping results in this control group have been 
published previously.39'4° 
Serum Cytokine and CRP Measurement 
Whole blood was collected from each patient at the 
time of diagnosis. Samples were collected from pa- 
tients without evidence of infection and at least 
2 weeks following any invasive investigation to avoid 
artificial induction of an acute phase systemic re- 
sponse. CRP was determined using an automated 
immunoturbidimetric assay (Abbott TDX, Abbott 
Laboratories, Maidenhead, UK). A level above 
10 mg /1 was considered evidence of an acute phase 
response. 
Cytokine concentrations were determined by 
sandwich enzyme -linked immunosorbent assay 
(ELISA) using module kits and performed according 
to the manufacturers instructions (Caltag, Bender 
MedSystems, Towcester, UK) as described previ- 
ously.41 The lower limit of sensitivity for each assay 
was: < 1 pg /ml IL -lß, 1.4 pg /ml IL -6, .8 pg /ml IL -10 
and 5.8 pg /mI sTNF -R. 
Cytokine Genotyping 
Genomic DNA was extracted from samples of 
lithium -heparinised blood using the Wizard Genomic 
DNA purification kit (Promega, Southampton, UK). 
The following SNPs were selected for genotyping due 
to their documented but variable association with 
cytokine production: IL -lß 511, IL -6 174, IL -10 
1082, TNFa 308 and LTa + 252. Genotyping was 
carried out by TaqMan allelic discrimination geno- 
typing on the 7900HT Sequence Detection System 
(Applied Biosystems, Warrington, UK). Primers and 
TaqMan probes were designed using Primer Express 
version 2.0 software (sequences shown in Table 1) 
and synthesised and supplied by Applied Biosystems 
UK. Ten microlitre PCR reactions containing 20 ng 
of DNA, .9 and .2 .tM probes (final concentrations) 
were performed in 384 well plates. Each genotyping 
plate contained no DNA Template (water) controls; 
SDS version 2.1 software was used to analyse real - 
time and end -point fluorescence. Around 50 samples 
( -p25% of the sample group) were randomly selected 
and included as replicates for each genotype tested. 
All replicates agreed. Only between 3 -8 samples 
failed to genotype for each SNP (96.1- 98.5% com- 
pletion rate). 
Statistical Analysis 
Comparisons between groups of continuous vari- 
ables were made by the Mann -Whitney U test. Cat- 
egorical variables were compared by the Chi -squared 
test. Correlations between continuous variables were 
assessed by the Spearman rank correlation coeffi- 
cient. Survival between groups was analysed by the 
log -rank test and Cox's proportional hazard's model 
was used for multivariate analysis. A P value <_ .05 
was considered statistically significant. Significant P 
values were corrected for multiple comparisons using 
Bonferroni correction. 
RESULTS 
Study Patients and Genotype Distributions 
Patient demographics are outlined in Table 2. Two 
hundred and three patients were genotyped. The 
Ann. Snrg. Oncol. Vol. 14, No. 2. 2007 
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TABLE 1. Cytokine TaqMan genotyping primer and probe sequences 
SNP Sequence 




G allele specific probe 
A allele specific probe 
LTa + 252 
Forward primer 
Reverse primer 
G allele specific probe 
A allele specific probe 
IL -6 174 
Forward primer 
Reverse primer 
G allele specific probe 
C allele specific probe 
IL -lß 511 
Forward primer 
Reverse primer 
C allele specific probe 
T allele specific probe 
(B) TaqMan TAMRA probe assays (Ta = 62 °C) 
IL -10 1082 
Forward primer 
Reverse primer 
G allele specific probe 
A allele specific probe 
5'- CCAAAAGAAATGGAGGCAATAGGTT -3' 
5'- GGACCCTGGAGGCTGAAC -3' 
5'- CCCGTCCcCATGCC -3' (VIC- labelled) 













5' -ACA CAC AAA TCC AAG ACA ACA CTA CTA A -3' 
5' -GGA GGT CCC TTA CTT TCC TCT TAC C -3' 
5' -ATC CCT ACT TCC CCc TCC CAA AGA A -3' (VIC) 
5' -CCC TAC TTC CCC TTC CCA AAG AAG C -3' (FAM) 
For each probe, the position of SNP is marked in lower case. 
median age was 71 years (interquartile range 62 -78) 
and 66% of patients were male. The primary tumour 
sites were oesophageal (n = 91, 45 %), gastric 
(n = 75, 37 %) and those arising from the gastro- 
oesophageal junction (OGJ) (n = 37, 18 %). Histo- 
logical confirmation of disease was obtained in all 
cases and the predominant histological subtype was 
adenocarcinoma (85 %). 113 (56 %) patients underwent 
surgical resection, 22 of these received pre- operative 
chemotherapy. Seven (3 %) patients, all of whom had 
squamous cell carcinoma of the oesophagus, received 
chemo- irradiation with curative intent. The remaining 
patients (n = 90) were not suitable for curative 
therapy and received palliative chemo /radiotherapy 
or underwent alternative palliative treatments, such as 
insertion of a stent or endoscopic laser therapy. 
The prevalence of cytokine genotypes are presented 
in Table 3. There was a significant difference between 
cases and controls with the IL -Iß 511 cc [P = .01, 
OR = 1.664 (95% CI = 1.137- 2.434)] and ct 
[P = .03, OR = .657 (95% CI = .453 -.955)] geno- 
types, but it did not remain so when corrected for 
multiple comparisons, making this finding most likely 
occurring due to chance. There were no significant 
differences between cancer patients and healthy 
controls in the distribution of any of the other 
genotypes. All genotype frequencies in both the 
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patient and control groups were distributed in 
accordance with the Hardy -Weinberg equilibrium 
except for the IL -6 patient group (P = .05), the 
TNFa control group (P = .04) and the LTa control 
group (P = .002). 
Serum Cytokine and CRP Concentrations 
The median serum concentration of IL -6 was 
9.1 pg /ml (interquartile range 0-88 pg /ml) and for 
sTNF -R the median concentration was 3.3 ng /ml 
(interquartile range 1.9 -5.8 ng /ml). IL -lß and IL -10 
were only detectable in 4 (2 %) and 10 (5 %) patient's 
serum, respectively. 82 (41 %) patients had an elevated 
acute phase protein response (CRP > 10 mg /1). 
Serum sTNF -R concentration correlated with ser- 
um CRP concentration (r = .38, P < .001; spear - 
man rank test), but there was no significant 
relationship between the other serum cytokine con- 
centrations and CRP level. 
Link between Genotype and Mediators /Markers of 
Systemic Inflammation 
The IL -6 CC genotype was associated with ele- 
vated serum sTNF -R concentrations when compared 
with the GC genotype (P = .015; Mann -Whitney U 
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TABLE 2. Study patient demographics (n = 203) 
Number ( %) 
Age (years)+ 71 (62 -78) 
Sex 
Male 134 (66) 
Female 69 (34) 
Tumour site 
Oesophageal 91 (45) 
Oesophago- gastric junction 37 (18) 
Gastric 75 (37) 
Histology 
Adenocarcinoma 172 (85) 
Squamous cell carcinoma 26 (13) 
Indeterminate 5 (2) 
Grade 
Well differentiated 5 (2) 
Moderately differentiated 69 (34) 
Poorly differentiated 129 (64) 
UICC stage 
1 23 (12) 
2 33 (16) 
3 76 (37) 
4 71 (35) 
Treatment undertaken 
Surgery with curative intent 91 (45) 
Pre -operative chemotherapy /surgery 22 (11) 
Chemoradiotherapy with curative intent 7 (3) 
Palliative chemotherapy 24 (12) 
Palliative radiotherapy 6 (3) 
Stent /dilatation /laser /symptomatic 53 (26) 
+ values are median (interquartile range). 
test), but not when compared with the GG genotype 
(P = .14). Similarly, the IL -10 GG genotype was 
also associated with elevated sTNF -R concentrations 
when compared with the AG genotype (P = .05), 
but not when compared with the AA allele (P = .22). 
There was no association between any other serum 
cytokine concentrations and IL -6 or IL -10 genotypes. 
In addition, there was no association between any IL- 
1#, TNFa or LTa genotypes and serum cytokine 
concentrations. 
The IL -6 CC homozygous status was associated 
with significantly elevated serum CRP concentrations 
when compared with GC and GG genotypes [median 
13 mg /1 (range 4-35 mg /1) versus median 6 mg /1 
(range 2 -22 mg /1)] (P = .03, Mann -Whitney U test) 
the GG IL -10 genotype was also associated with ele- 
vated serum CRP levels [median 16 mg /1 (range 3- 
34 mg /1)] when compared with the AA genotype 
[median 6 mg /1 (range 3 -13 mg /1)] (P = .02, Mann - 
Whitney U test) and the AG genotype [median 5 mg /1 
(range 2 -24 mg /1)] (P = .03). The GG homozygous 
genotype was associated with elevated serum CRP 
levels (P = .01). None of the other cytokine genotypes 
were associated with serum CRP concentrations. 
Possession of one or more of the following geno- 
types, IL -6 CC, IL -10 GG or TNFa AA, was associ- 
ated with increasing serum CRP concentrations 
(P = .013, Chi square test) (Fig. 1). Moreover, 
multivariate analysis demonstrated that this positive 
association was independent of both treatment 
modality undertaken and stage of disease [regression 
coefficient = .16 (95% CI .05 -.64), P = .021; linear 
regression analysis]. 
Survival Analysis 
Survival of patients by genotype is presented in 
Figs. 2 and 3. Possession of the CC genotype for IL -6 
was associated with reduced survival duration when 
compared with GG or GC genotype (median survival 
256 vs. 431 days) (P = .010; log -rank test) (Fig. 2A). 
The homozygous genotype GG for IL -10 was associ- 
ated with reduced survival compared with AA /AG 
genotypes (median survival 310 vs. 389 days, 
P = .047) (Fig. 2B). Similarly, AA homozygosity for 
the TNFa genotype was associated with adverse 
prognosis (median survival 194 vs. 409 days, 
P = .032) (Fig. 2C). Furthermore, the possession of 
more than one of these genotypes was associated with 
reduced survival (no alleles, median survival 512 days; 
1 allele, median survival 269 days; 2 or 3 alleles, med- 
ian survival 258 days; P = .004) (Fig. 3). Genotypes 
for IL -1ß and LTa were not associated with prognosis. 
Multivariate testing identified the AA genotype for 
TNFa as an independent adverse prognostic indicator 
when tested with age, sex, stage of disease, grade of 
tumour and serum CRP concentration (P = .006, 
hazard ratio 2.5; Cox's proportional hazard's model) 
(Table 4). Increasing age, male sex, advanced disease 
stage, elevated serum CRP concentration, and the 
TNFa AA genotype were all independently associated 
with poor prognosis. Genotypes for IL -6 and IL -10 
were not independent prognostic indicators (P = .48 
and P = .18, respectively). 
Eighty -two (41 %) patients had an elevated acute 
phase protein response (CRP > 10 mg /1) at the time 
of diagnosis and this was associated with a signifi- 
cantly reduced survival duration; CRP < 10 mg /1 
median survival 550 days versus CRP > 10 mg /I 
median survival 217 days (P < .001; log -rank test) 
(Fig. 4). Moreover, multivariate testing also identi- 
fied CRP as an independent prognostic indicator 
(P = .002, hazard ratio 1.1; Cox's proportional 
hazard's model) (Table 4). 
DISCUSSION 
In the present study the IL -6 174 CC and IL -10 
1082 GG genotypes were associated with elevated 
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TABLE 3. Allelic distribution of cytokine genotypes among the study population 
Cytokine Allele Study patients n (%) Controls n ( %) P value* ORt (95% CL) 
IL-lß 511 CC 89 (45.4) 87 (33.3) .01 (.06) 1.664 (1.137- 2.434) 
CT 81 (41.3) 135 (51.7) .03 (.15) .657 (.453 -.955) 
TT 26 (13.3) 39 (14.9) NS Ref§ 
HWEt .27 .25 
IL-6 174 GG 71 (36.0) 79 (35.3) NS 1.034 (.694 -1.541) 
GC 83 (42.1) 101 (45.1) NS .887 (.603 -1.304) 
CC 43 (21.8) 44 (19.6) NS Ref 
HWE .05 .26 
IL-10 1082 GG 54 (27.0) 57 (25.6) NS 1.077 (.699 -1.659) 
AG 93 (46.5) 120 (53.8) NS .746 (.509- 1.093) 
AA 53 (26.5) 46 (20.6) NS Ref 
HWE .32 .24 
TNFa 308 GG 124 (62.0) 146 (68.2) NS .760 (.507- 1.139) 
AG 61 (30.5) 56 (26.2) NS 1.238 (.808- 1.898) 
AA 15 (7.5) 12 (5.6) NS Ref 
HWE .06 .04 
LTa + 252 AA 82 (42.1) 92 (41.8) NS 1.010 (.684 -1.491) 
AG 84 (43.1) 83 (37.7) NS 1.249 (.844- 1.850) 
GG 29 (14.9) 45 (20.5) NS Ref 
HWE .33 .002 
* P values were considered statistically significant when P <_ .05. Significant P values were corrected for multiple comparisons using 
Bonferroni correction (values in parenthesises). 
t Odds ratio. 
t P value for Hardy -Weinberg equilibrium (HWE) (Chi- squared test). 
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FIG. 1. Possession of one or more of the following genotypes, IL -6 
CC, IL -10 GG or TNFa AA, was associated with increasing serum 
CRP concentrations (P = .013, Chi squared test). 
markers of systemic inflammation (CRP and sTNF -R 
concentrations) and were associated with reduced 
survival duration. In addition, the TNFa 308 AA 
genotype was not associated with systemic inflam- 
mation, but was identified as an independent adverse 
prognostic marker. Therefore, there is a pro- inflam- 
matory cytokine haplotype that is associated with 
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adverse prognosis among patients with gastro- 
oesophageal cancer that may act in association with, 
but not entirely with, an inflammatory mediated 
mechanism. 
IL -1ß and IL -10 are not routinely measurable in 
the serum of healthy controls or cancer patients. In 
this study IL -lß and IL-10 were only detectable in 4 
(2 %) and 10 (5 %) patient's serum, respectively. We, 
therefore, did not find an association between geno- 
type and serum concentrations of these cytokines. We 
have, however, previously shown an association be- 
tween IL -1ß genotype and IL -lß production by 
PBMC in pancreatic cancer patients, but not with 
serum IL -lß concentrations.20 PBMC production of 
IL -lß may better reflect tissue IL -Iß levels rather 
than circulating serum concentrations and perhaps is 
a more accurate determinant of IL-113 activity. 
TNFa is also rarely detected in the serum, however, 
soluble TNF receptors (sTNF -R) are shed in re- 
sponse to TNFa release and may be used as an 
indirect measure of TNFa concentration.Q2 Serum 
sTNF -R concentrations were higher among those 
patients with elevated serum CRP concentrations. 
We found a significant correlation between serum 
sTNF -R and serum CRP concentrations (r = .38, 
P < .001) and we have shown a similar association 
among patients with pancreatic cancer.43 There was 
no association between TNF genotype and serum 
sTNF -R concentrations either in this study or our 












I I I t 
0 200 400 600 800 1000 
Survival duration (Days) 
Number at risk (Genotype): Number at risk (Genotype): 
CC 43 25 13 6 5 












I I I I I 
200 400 600 800 1000 





0 GG 54 33 21 13 6 1 







I II 111111 t 
1 I I I 1 I 
0 200 400 600 800 1000 
Survival duration (Days) 
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FIG. 2. Kaplan -Meier survival plots presented by (A) interleukin -6 (IL -6) genotype [CC median survival 256 days (heavy line), GC /GG 
median survival 431 days (light line)] (P = .010; Log -rank test); (B) interleukin -10 (IL -10) genotype [GG median survival 310 days (heavy 
line), AA /AG median survival 389 days (light line)] (P = .047) and (C) tumour necrosis factor a (TNFa) genotype [AA median survival 
194 days (heavy line), AG /GG median survival 409 days (light line)] (P = .032). 
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Survival duration (Days) 
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Number at risk (Genotype): 
0 Alleles 103 81 59 27 14 
1 Allele 70 44 27 15 8 
2/3 Alleles 19 10 5 3 2 o 
FIG. 3. Kaplan -Meier survival plot stratified for possession of 
interleukin -6 (IL -6) CC genotype, interleukin -10 (IL -10) GG 
genotype and tumour necrosis factor a (TNFa) AA genotype. 
Possession of no alleles (light line), median survival 512 days; 1 
allele (medium line), median survival 269 days; 2 or 3 alleles (heavy 
line), median survival 258 days (P = .004; Log -rank test). 
TABLE 4. Multivariate survival analysis of 203 patients 
with gastro- oesophageal cancer using Cox's proportional 
hazard's model 
Variable P value Hazard ratio 95% CI 
Age .007 1.2 1.0 -1.3 
Sex .04 1.8 1.0 -3.0 
Stage of disease < .001 2.4 1.8 -3.2 
Grade of tumour .88 1.0 .7 -1.6 
Serum CRP .002 1.1 1.0 -1.2 
TNFa AA genotype .006 2.5 1.3 -4.9 
A hazard ratio greater than 1 represents an increased risk of 
death. Increasing age, male sex, advanced disease stage, elevated 
serum CRP concentration, and the TNFa AA genotype were all 
independently associated with poor prognosis. 
and genotype appears contradictory and at present 
there is no clear evidence relating TNFa genotype to 
circulating TNFa levels. However, tissue levels of 
TNFa may be a more relevant measure of TNF 
activity rather than systemic concentrations, which 
was not measured in the present study. 
Forty -one percent of patients had an elevated acute 
phase response (CRP > 10 mg /1). Systemic inflam- 
mation has been found in association with the 
majority of solid epithelial malignancies and around 
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FIG. 4. Kaplan -Meier survival plot according to the presence or 
absence of systemic inflammation. CRP < 10 mg /1 median sur- 
vival = 550 days (light line) versus CRP > 10 mg /I median sur- 
vival 217 days (heavy line) (P < .001; Log -rank test). 
50% of patients may have an acute phase response 
(APPR) at the time of diagnosis.43 The presence of an 
elevated CRP has been associated with adverse 
prognosis in a number of types of cancer, indepen- 
dent of stage of disease.5 -I5 We have similarly iden- 
tified an elevated serum CRP concentration as an 
adverse prognostic indicator among patients with 
gastro -oesophageal cancer, also independent of stage 
of disease. The presence of systemic inflammation in 
malignant disease is an important marker of tumour 
behaviour and clearly has clinical relevance in 
assisting management decision making as well as 
emphasising the therapeutic potential of targeted 
anti -inflammatory strategies in advanced cancer. 
IL -6 and IL -10 genotypes were associated with 
serum CRP concentrations in this study. The IL -6 
CC genotype was associated with elevated serum 
concentrations of CRP and sTNF -R. A study of 
healthy volunteers identified the presence of the 174C 
allele to be associated with higher baseline CRP lev- 
e1s.44 In cancer patients the rates of production of IL- 
6 can be linked to markers of systemic inflammation 
such as CRP. Although our study did not identify 
any association between IL -6 genotype and serum IL- 
6 concentrations, it is possible that the CC genotype 
may be associated with elevated IL -6 production, 
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which acts at the tissue level to promote an acute 
phase response. The similar association between IL -6 
genotype and sTNF -R may reflect the more stable 
nature of the receptor molecule compared with the 
other cytokines, and in this regard sTNF -R may be- 
have more as a marker of systemic inflammation. 
We also found the GG IL -10 genotype to be asso- 
ciated with elevated serum CRP and sTNF -R con- 
centrations. The 1082 AA polymorphism is generally 
thought to be associated with reduced levels of IL -10 
production.34 One would therefore expect the GG 
genotype to be associated with increased levels of IL- 
10 production. An association between increased 
levels of an anti -inflammatory cytokine and elevated 
concentrations of acute phase proteins may initially 
appear contradictory, but may simply reflect the in- 
creased counter -regulatory activity of this important 
anti- inflammatory mediator in response to the pres- 
ence of systemic inflammation. 
We found no association between IL-1#, TNFa or 
LTa genotypes and CRP concentrations. In pancre- 
atic cancer patients we previously demonstrated an 
association between allele 2 IL-1f3 genotype and ele- 
vated serum CRP levels, but in the present study there 
was no such association between the SNP at position 
511 and CRP levels.20 Similarly, there was no associ- 
ation between TNFa polymorphisms and CRP, a 
finding also in support of our previous work on 
pancreatic cancer patients.25 Data relating to the 308 
polymorphism and levels of TNFa production remain 
contradictory, however polymorphisms at this locus 
do not appear to influence serum CRP levels. Serum 
CRP concentrations were measured in a group of 
patients who had undergone cardiac surgery and this 
study did not find any differences between CRP levels 
and TNFa 308 genotypes.45 Another group similarly 
failed to demonstrate differences in CRP concentra- 
tions by 308 genotype among smokers.46 
The IL -6 174 CC and the IL -10 1082 GG geno- 
types were associated with reduced survival duration. 
The association between systemic inflammation and 
adverse prognosis among cancer patients has been 
well documented and in this study we have shown 
these two genotypes to be associated with elevated 
acute phase protein (CRP) concentrations. It is 
therefore possible that the adverse prognosis associ- 
ated with these polymorphisms is related to the 
presence of systemic inflammation. This is supported 
by multivariate analysis where these genotypes lost 
their significance as prognostic indicators when CRP 
was co- analysed. The CC IL -6 genotype has been 
linked with adverse prognosis among breast cancer 
patients, where possession of the CC polymorphism 
was associated with higher grade tumours and worse 
overall survival." The GG genotype for IL -10 1082 
has previously been associated with advanced stage in 
gastric cancer patients and associated reduced sur- 
vival.36 
We also found the AA TNFa 308 genotype to be 
related to adverse prognosis. In contrast to the IL -6 
and IL -10 genotypes, we found no association be- 
tween TNFa polymorphisms and systemic inflam- 
mation. It is therefore less likely that the reduced 
survival associated with this cytokine is related en- 
tirely to the generation of an inflammatory response. 
In addition, the AA genotype was an independent 
prognostic indicator on multivariate analysis, inde- 
pendent of CRP concentration, stage and other cli- 
nico- pathological characteristics that have previously 
been associated with adverse prognosis. We previ- 
ously identified an association between the AA 
genotype and reduced survival in pancreatic cancer 
patients and another group similarly found the pos- 
session of the A allele to be linked with adverse 
outcome in patients with non- Hodgkin's lym- 
phoma.25'26 However, the AA genotype was only 
identified in 8% of patients, making it less useful in 
the clinical setting. 
Distributions of the cytokine genotypes were sim- 
ilar between cancer patients and controls in this study 
and frequencies were similar to those previously 
published in studies of similar populations.40'4i Al- 
though we did identify an association between gastro- 
oesophageal cancer and the IL-1# 511 CC genotype, 
this relationship lost its significance following cor- 
rection for multiple comparisons. El -Omar et al. have 
proposed an association between IL-1# polymor- 
phisms and an increased risk of gastric cancer among 
patients with helicobacter pylori infection.47 We 
found no such association on sub -group analysis and 
other groups have similarly failed to demonstrate 
such an association.48.49 
In summary, the possession of more than one of 
these genotypes (IL -6 CC, IL -10 GG and TNFa AA) 
resulted in a cumulative reduction in survival dura- 
tion. This may relate to an increased magnitude of 
systemic inflammatory response or to some other 
unknown mechanism, but clearly there is a cytokine 
haplotype that is associated with adverse prognosis 
among these patients. 
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BACKGROUND. Parathyroid hormone -related peptide (PTHrP) is a tumor -derived 
circulating factor that has been associated with hypercalcemia of malignancy. The 
role of PTHrP as a prognostic indicator remains unclear. Studies suggest that it may 
function as a growth factor; and, recently, the ability of PTHrP to induce cytokine 
expression has been described. PTI -IrP also has been proposed as a procachectic 
factor. In this study, the authors investigated the prognostic value of PTHrP in 
patients who had gastroesophageal carcinoma without hypercalcemia and deter- 
mined whether PTHrP was associated with systemic inflammation and adverse 
nutritional status. 
METHODS. Patients were recruited at the time of diagnosis. Serum was collected for 
determination of c- terminal fragment PTHrP (cPTHrP) levels (by radioimmunoas- 
say) and calcium levels as well as levels of serum cytokines and acute -phase 
proteins (with an enzyme -linked immunosorbent assay). Nutritional assessment of 
patients was undertaken at the same time as serum collection. Patients underwent 
routine staging, and survival duration was recorded. 
RESULTS. One hundred fifty -one patients with esophagogastric carcinoma were 
recruited. Six of 151 patients (4.0 %) patients were hypercalcemic, and 26 patients 
(17.2 %) had elevated serum cPTHrP levels. There was no association between the 
cPTHrP level and either serum calcium concentrations (P = 0.72) or adverse 
nutritional status. Elevated cPTHrP, however, was associated with significantly 
higher serum levels of soluble tumor necrosis factor receptor (P = 0.008) and with 
significantly lower levels of transferrin (P = 0.009) and albumin (P = 0.02). There 
was also a weak association with C- related protein levels (P = 0.06). Elevated 
cPTHrP levels also were associated with an adverse prognosis, as determined by 
reduced survival duration, on univariate analysis (P = 0.038), but not on multivar- 
iate analysis (P = 0.15). 
CONCLUSIONS. Elevated serum cPTHrP levels were present in approximately 17% of 
patients with gastroesophageal carcinoma in the absence of hypercalcemia and 
was associated with markers of systemic inflammation and with an adverse prog- 
nosis. Cancer 2005;103:1810 -8. © 2005 American Cancer Society. 
KEYWORDS: parathyroid hormone- related peptide, hypercalcemia, cachexia, cyto- 
kines, prognosis. 
Hypercalcemia is among the most frequent paraneoplastic syn- 
dromes, and it is estimated that hypercalcemia affects approxi- 
mately 20% of patients during the advanced stages of malignant 
disease.' Parathyroid hormone - related peptide (PTHrP) is a tumor - 
derived circulating factor that has been associated with hypercalce- 
mia of malignancy.' Elevated serum PTHrP has been reported in 
50 -90% of hypercalcemic patients with malignant disease .3 PTHrP 
© 2005 American Cancer Society 
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mimics the actions of parathyroid hormone on the 
kidneys and bone to increase serum calcium concen- 
tration. More recently, PTHrP has been proposed as a 
growth factor with activity that may promote tumor 
growth, particularly aiding in the formation of osteo- 
lytic bone metastases.' 
Recent interest in PTHrP has been directed to- 
ward its role in prognosis. In a study of 76 hypercal- 
cemic patients with various types of advanced -stage 
malignancies, elevated serum PTHrP levels were 
found in 54% of patients.3. Increased PTHrP was an 
independent, adverse prognostic indicator for patients 
age < 65 years but had no prognostic role in older 
patients. Others investigators found no association 
between elevated serum PTHrP levels and reduced 
survival.' Differing conclusions also have been 
reached regarding the detection of PTHrP within tu- 
mors themselves and its role in prognosis. Patients 
with breast carcinoma who had tumors that produced 
PTHrP had a favorable prognosis in one study, but this 
observation was not corroborated by others.''' The 
administration of a PTHrP antibody to mice bearing 
PTHrP- secreting tumors not only resulted in a reduc- 
tion of serum calcium levels but also improved sur- 
vival duration in the treated mice .8 The role of PTHrP 
in determining prognosis remains unclear. 
In addition, PTHrP has been proposed as a pro - 
cachectic factor. PTHrP is produced by a human lung 
carcinoma model (HARA -B); and, when it is implanted 
into mice, results in a significant reduction in body 
weight and tissue mass, an effect that is reversed by 
the addition of an antibody to PTHrP.9 This model was 
associated with elevated serum calcium levels, and it 
is not clear whether the observed cachexia was due to 
the systemic effects induced by hypercalcemia, be- 
cause food intake in the weight -losing mice was lower 
than controls. The relation of PTHrP to adverse nutri- 
tional status needs further investigation. 
PTHrP also may contribute to the proinflamma- 
tory cytokine cascade. Several studies identified ele- 
vated serum cytokines, in particular, interleukin -6 
(IL -6) and tumor necrosis factor (TNF), in association 
with elevated serum PTHrP.1" Another group dem- 
onstrated that PTHrP stimulates IL -6 production from 
osteoblasts in vivo.12 Funk et al. investigated the ef- 
fects of endotoxemia on PTHrP synthesis within hepa- 
tocytes: A near -lethal dose of endotoxin resulted in 
marked induction of PTHrP mRNA levels and PTHrP 
protein synthesis.13 In addition, the administration of 
PTHrP to mice increased serum acute -phase protein 
levels. Those investigators also found that synovial 
cells from patients with rheumatoid arthritis produced 
increased levels of PTHrP, and these levels were en- 
hanced further by the addition of IL -1ß and TNF -a.14 
PTHrP Expression in Gastroesophageal CA/Deans et al. 1811 
Elevated serum PTHrP has been described in as- 
sociation with hypercalcemia in esophageal carci- 
noma, and PTHrP mRNA and protein also have been 
demonstrated within tumor cells.15 In a large series 
from Japan that included 382 patients with esophageal 
carcinoma, hypercalcemia was identified in 1.3% of 
patients at the time of diagnosis." The incidence of 
hypercalcemia increased to 38% in patients who were 
monitored within 2 months of death, and the authors 
reported observing a close association between hyper - 
calcemia and PTHrP levels. Similarly, elevated PTHrP 
production has been reported in association with gastric 
carcinoma. "" In one study, PTHrP expression was 
identified within tumor cells in 71 of 92 patients with 
gastric adenocarcinoma, none of whom had hypercalce- 
mia.19 Those authors also noted that PTHrP production 
was associated with poorly differentiated tumors. 
The detection of PTHrP in tumors without asso- 
ciated hypercalcemia has raised the possibility that 
PTHrP may play a role in addition to calcium ho- 
meostasis, such as the regulation of cellular prolifera- 
tion and differentiation. Epidermal growth factor and 
transforming growth factor ß (TGF -/3) have been im- 
plicated in the progression of gastric malignancies, 
and it has been found that these growth factors up- 
regulate PTHrP gene expression in some cell lines.20 
Rats implanted with prostate carcinoma cells that 
overproduce PTHrP had significantly enhanced tumor 
growth and tumor size compared with control ani- 
mals.21 The gene encoding PTHrP is a downstream 
target for the protooncogenes K -ras and Src tyrosine 
kinase.22.23 Whereas src expression is common in pre - 
malignant epithelium of Barrett esophagus,24 c -K -ras 
expression is rare.25 Whether the expression of src in 
gastroesophageal carcinoma correlates with increased 
expression of PTHrP and hypercalcemia is unknown 
but may provide a mechanism for the functional ac- 
tivation of tumor -derived PTHrP in this tumor type. 
Whether PTHrP expression alone is sufficient to cause 
hypercalcemia also is unclear, but a requirement for 
further modification may explain why PTHrP is pro- 
duced without associated hypercalcemia. 
For the current study, we investigated serum 
PTHrP production in patients with gastroesophageal 
carcinoma and determined its association with serum 
calcium levels in addition to serum acute -phase pro- 
teins and cytokines. The link between PTHrP levels 
and nutritional status was evaluated along with the 
role of PTHrP as a prognostic marker. 
MATERIALS AND METHODS 
Patients 
Patients were recruited to the study within 2 weeks of 
diagnosis. All patients had histologic confirmation of 
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their disease after undergoing endoscopic biopsy. 
Blood samples were collected within 2 weeks of diag- 
nosis and before patients started any treatment. All 
patients were free from systemic infection at the time 
of blood collection. No patients had symptoms related 
to possible hypercalcemia, and none had bone metas- 
tases identified after computerized tomography stag- 
ing. No patients were receiving treatment either to 
supplement or to reduce calcium levels. No patients 
were taking calcium -containing "over the counter" 
medications. Renal function was assessed by measur- 
ing serum creatinine concentration, and values were 
within the normal range for all patients. Muscle wast- 
ing was not sufficiently severe to require correction for 
muscle bulk. Patients provided written informed con- 
sent, and the study received ethical permission from 
the Lothian Research Ethics Committee. Clinical in- 
formation was collected prospectively. Patients were 
staged with a combination of computerized tomogra- 
phy, endoscopic ultrasound, and laparoscopy /laparo- 
scopic ultrasound studies according to the Interna- 
tional Union Against Cancer26; and final 
histopathologic stage (pTNM) was used when avail- 
able (n = 59 patients). Final stage (pTNM) was avail- 
able only for those patients who underwent surgical 
resection. In all other patients, the final clinical stage, 
as agreed at the unit multidisciplinary team meeting, 
was recorded. Tumors around the esophagogastric 
junction were classified according to Siewart: Type I 
and II tumors were classified as esophageal tumors, 
and Type III tumors were classified as gastric carcino- 
mas.27 Clinical and pathologic information was re- 
corded for each patient, including treatment modality, 
tumor grade, and histologic subtype. Duration of sur- 
vival, which was defined as the time from histologic 
diagnosis to death, was recorded for all patients. All 
deaths were disease related, except for three patients 
who died in the postoperative period from sepsis and 
multiorgan failure. All patients were included in the 
survival analysis. 
Nutritional Assessment 
Nutritional assessment included calculation of body 
mass index from the patients' weight and height and 
measurement of midarm circumference and triceps 
skinfold thickness, as described previously.28 Midarm 
muscle circumference was calculated by means of Jel- 
liffe's equation.29 Premorbid patient weight was re- 
called by the patient and was confirmed from the 
medical notes when possible. Performance status was 
assessed using the Karnofsky index.30 
Serum PTHrP and Calcium Concentrations 
Whole blood was collected from patients at the time of 
diagnosis. Samples were centrifuged, and the serum 
was stored at - 70 °C until batch analysis. PTHrP has 
a very short half -life and is unstable unless it is stored 
in plasma with esterase inhibition. However, its break- 
down products include a c- terminal region, which is 
stable when it is stored in serum and demonstrates 
direct correlation to circulating, intact serum PTHrP 
concentrations.31 This is a direct breakdown product 
of PTHrP; therefore, its presence indicates PTHrP in 
plasma. In this study, the c- terminal fragment 
(cPTHrP) was measured by radioimmunoassay (Daii- 
chi, Tokyo, Japan). This assay has no demonstrable 
cross -reactivity with parathyroid hormone. The sensi- 
tivity of this test is 10 pmol /L, the intraassay variability 
is 4.1 %, and the interassay variability is 3.3 %. Using 
this assay, serum PTHrP levels in healthy volunteers 
were (± 2 standard deviations from the mean) 13.8- 
55.3 pmol /L for males and 13.9 -54.0 pmol /L for fe- 
males.32 No female patients had a cPTHrP serum con- 
centration between 54.0 pmol /L and 55.3 pmol /L; 
therefore, for simplicity serum levels > 55.3 pmol /L 
were considered above the normal range for both 
genders. 
Total serum calcium was measured by an auto- 
mated analyzer (Clinical Biochemistry Department, 
Edinburgh Royal Infirmary, Edinburgh, UK). Calcium 
levels were adjusted for serum albumin concentration 
using the following formula, according to Truong et 
al., 20033: 
40 - albumin concentration 
4 
X 0.1 
+ measured serum calcium concentration 
Note that the normal range for corrected calcium in 
our laboratory is 2.12 -2.62 mmol /L. 
Acute -Phase Proteins and Cytokines 
C- reactive protein (CRP) levels were determined using 
an immunoturbidimetric assay (Abbott TDX; Abbott 
Laboratories, Maidenhead, UK). A CRP level > 10 
mg /L represents the presence of an acute -phase re- 
sponse. Levels of the remaining acute -phase proteins 
and cytokines were determined by sandwich enzyme - 
linked immunoadsorbent assay, as described previ- 
ously.33 Serum cytokines were analyzed with module 
kits according to the manufacturer's instructions 
(Caltag; Bender MedSystems, Towcester, UK). The 
lower limit of sensitivity for each assay was < 1 pg /mL 
for IL -10, 1.4 pg /mL for: IL -6, 11 pg /mL for IL -8, 0.8 
pg /mL for IL -10, and 5.8 pg /mL for soluble TNF re- 
ceptor (sTNF -R). 
Acute -phase protein concentrations were deter- 
mined using primary and secondary antibodies sup- 
plied by Dako (Ely, UK).33 Briefly, 96 -well plates were 
coated with 100 µL primary antibody (concentration, 
10 mg /L) and incubated overnight at 4 °C. The plates 
were washed with 0.1 %n Tween, diluted serum (100 µL) 
was added to the coated wells, and the plates were 
incubated at room temperature for 2 hours. The plates 
were washed as described above, a secondary anti- 
body conjugated with peroxidase was added to each 
well, and the plates were incubated for an additional 
hour. The substrate used was OPD (Dako), and the 
reaction was stopped with 0.5 M sulphuric acid. Plates 
were read at 490 nanometers using a Dynatech 
MR5000 automated plate reader (Dynatech, Billing - 
hurst, UK). Standard curves were generated using 
standard acute -phase proteins supplied by the man- 
ufacturer (Dako). 
Statistical Analysis 
Correlations between serum cPTHrP and serum cal- 
cium concentrations were tested by linear regression 
analysis. Analysis of serum cPTHrP and continuous 
variables was tested by the Mann -Whitney U test. 
Analysis of serum cPTHrP and categoric data was un- 
dertaken with the chi -square and Fisher exact tests. 
Log -rank analysis was used to determine prognostic 
values for the univariate analysis, and a Cox propor- 
tional hazards model was used for the multivariate 




Patient demographics are outlined in Table 1. One 
hundred fifty -one patients were recruited to the study. 
Their median age was 72 years (range, 26 -95 years), 
and 63% of patients were male. The primary tumor 
sites were esophageal (n = 64 patients; 42 %), gastric (n 
= 59 patients; 39 %), and tumors arising from the gas - 
troesophageal junction (n = 28 patients; 19 %). Histo- 
logic confirmation of disease was obtained in all tu- 
mors, and the predominant histologic subtype was 
adenocarcinoma (87 %). There were no well differen- 
tiated tumors. Sixty patients (40 %) underwent surgical 
resection, and 14 of those patients received preoper- 
ative chemotherapy. Three patients, all of whom had 
squamous cell carcinoma of the esophagus, received 
chemoirradiation with curative intent. Seventeen pa- 
tients (11 %) received palliative chemotherapy, and 4 
patients (3 %) received palliative radiotherapy. Sixty - 
seven patients (44 %) were not suitable for curative 
therapy or palliative chemoradiotherapy and under- 
went alternative palliative treatments, such as inser- 




Characteristic No. of patients ( %) 
Age (yrs)' 72 (63 -78) 
Gender 
Male 95 (62.9) 
Female 56 (37.1) 
Tumor site 
Esophageal 64 (42.4) 
Esophagogastric junction 28 (18.5) 
Gastric 59 (39.1) 
Histology 
Adenocarcinoma 132 (87.4) 
Squamous cell carcinoma 16 (10.6) 
Indeterminate 1 (0.7) 
Small cell carcinoma 2 (1.3) 
Grade 
Well differentiated 0 (0.0) 
Moderately differentiated 37 (24.5) 
Poorly differentiated 114 (75.5) 
UICC stage 
Stage I 13 (8.6) 
Stage II 24 (15.9) 
Stage III 54 (35.8) 
Stage IV 60 (39.7) 
Treatment undertaken 
Surgery with curative intent 46 (30.5) 
Preoperative chemotherapy /surgery 14 (9.3) 
Chemoradiotherapy with curative intent 3 (2.0) 
Palliative chemotherapy 17 (11.3) 
Palliative radiotherapy 4 (2.6) 
Stent /dilatation /laserlsymptomatic 67 (44.4) 
Karnofsky score 
30 3 (2.0) 
40 1 (0.7) 
50 5 (3.3) 
60 13 (8.6) 
70 18 (11.9) 
80 23 (15.2) 
90 35 (23.2) 
100 41 (27.2) 
Not recorded 12 (7.9) 
Survival 
Alive 100 (66.2) 
Dead 51 (33.8) 
Follow -up (days)° 379 (207-510) 
UICC: International Union Against Cancer. 
o Median (interquartile range). 
tion of a stent or endoscopic laser therapy, according 
to their symptoms. 
Performance status was assessed using the 
Karnofsky index. The median score was 90 (interquar- 
tile range, 70 -100), and the score was correlated 
strongly with disease stage (P < 0.0001) and mortality 
(P < 0.0001; data not shown). The median follow -up 
was 379 days (interquartile range, 207 -510 days); and, 
at the time the data were censored, 51 patients (34 %) 
had died. 
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FIGURE 1. These graphs illustrate the distribution of serum levels of the (A) 
c- terminal fragment of parathyroid hormone -related (PTHrP) and (B) serum 
calcium within the study population. 
Serum PTHrP and Calcium Concentrations 
The mean ± standard deviation serum level of cPTHrP 
was 39.4 -!- 17.9 pmol /L (range, 8.6 -100.0 pmol /L) 
(Fig. 1A). Twenty -six patients (17 %) had elevated se- 
rum cPTHrP levels. The mean ± standard deviation 
serum calcium concentration was 2.29 ± 0.17 mmol /L 
(range, 1.67 -2.79 mmol /L) (Fig. 1B). Twelve patients 
(8 %) were hypocalcemic, and 6 patients (4 %) were 
hypercalcemic. 
There was no correlation between serum 
cPTHrP levels and corrected calcium levels (linear 
regression; r = 0.03; P = 0.72) (Fig. 2). Patients with 
elevated serum cPTHrP levels did not have associ- 
ated elevated serum calcium levels (P = 0.63; Mann - 
Whitney U test). 
Serum PTHrP (pmol/i) 
FIGURE 2. This graph illustrates the correlation between serum calcium and 
serum parathyroid hormone -related peptide (PTHrP) concentrations (correlation 
coefficient = 0.03; P = 0.72). 
Serum PTHrP Concentrations Correlated with Patient 
Characteristics, Tumor Type, Disease Stage, and Tumor 
Grade 
PTHrP levels and patient /tumor characteristics are 
outlined in Table 2. There was no association between 
serum cPTHrP concentration and diagnosis and 
pathologic data, including tumor location, histology, 
or stage. Although an association with cPTHrP and 
tumor grade did not reach significance (P = 0.24), 
poorly differentiated tumors were more likely to be 
associated with elevated cPTHrP levels. Serum cal- 
cium concentrations were significantly higher in pa- 
tients who had squamous histology (P = 0.005; Mann - 
Whitney U test) and in females (P = 0.01; Mann - 
Whitney U test) (Fig. 3). 
Serum PTHrP Concentration and Survival 
Twelve of 26 patients (46 %) who had elevated cPTHrP 
levels had died at the time the survival data were 
censored compared with 39 of 125 patients (31 %) who 
had normal cPTHrP levels. Figure 4 shows a Kaplan - 
Meier survival curve that compares patients with nor- 
mal serum PTHrP (n = 125 patients) and elevated 
serum PTHrP (n = 26 patients). Those patients who 
had elevated serum cPTHrP levels had a significantly 
reduced survival duration compared with patients 
who had normal serum levels (P = 0.038; log -rank 
analysis). However, when age, gender, disease stage, 
and tumor grade were included in the Cox propor- 
tional hazards model, in addition to serum cPTHrP, 
elevated cPTHrP was not an independent predictor of 
survival (P = 0.45). 
TABLE 2 
Serum Parathyroid Hormone -Related Peptide Levels and Patient 
Characteristics 
Characteristic 
Serum PTHrP (pmol /L) 
P value 
Normal 
(n = 125) 
Elevated 
(n = 26) 
Age (yrs) 
Median 72 75 
Interquartile range 63 -78 62-83 0.264' 
Gender 
Male 80 15 
Female 45 11 0.702h 
Tumor site 
Esophageal 52 12 
Esophagogastric junction 24 4 
Gastric 49 10 0.604b 
Histology 
Adenocarcinoma 109 23 
Squamous cell 
carcinoma 13 3 
Indeterminate 1 0 
Small cell carcinoma 2 0 1.00` 
Grade 
Well differentiated 0 0 
Moderately differentiated 33 2 
Poorly differentiated 92 22 0.243" 
UICC stage 
Stage I 12 1 
Stage Il 20 4 
Stage Ill 44 10 
Stage N 49 11 0.949` 
Kamofsky score 
30 1 2 
40 1 0 
50 4 1 
60 9 4 
70 15 3 
80 20 3 
90 33 2 
100 34 7 
Not recorded 8 4 0.1948 
PTHrP: parathyroid hormone-related peptide; UICC: International Union Against Cancer. 
'Mann-Whitney U test 
b Chi-square test. 
Fisher exact test. 
Serum PTHrP Concentration and Nutritional Status 
Nutritional status is shown in Table 3. There were no 
significant differences in the nutritional variables 
measured between patients with or without elevated 
serum cPTHrP concentrations, except for triceps skin - 
fold measurements, which were higher in the group 
with elevated cPTHrP (P = 0.04). Patients with ele- 
vated serum cPTHrP had lower serum albumin levels 
compared with patients who had albumin levels 
within the normal range (P = 0.02). 









Sex of patient 
Female 
FIGURE 3. These graphs illustrate the mean serum calcium concentration 
stratified according to (A) tumor histology (P = 0.005; Mann - Whitney U test) 
and (B) gender (P = 0.01). Error bars indicate 95% confidence intervals. ACC: 
adenocarcinoma; SCC: squamous cell carcinoma. 
Serum PTHrP Concentrations and Serum Acute -Phase 
Proteins and Cytokines 
The correlation between cPTHrP and serum acute - 
phase proteins and cytokines is shown in Table 4. The 
median serum CRP and haptoglobin concentrations 
for patients who had elevated serum cPTHrP levels 
were above the normal ranges. Patients who had ele- 
vated serum cPTHrP levels had higher serum CRP 
levels compared with patients who had normal 
cPTHrP levels (P = 0.06). There was no difference in 
serum haptoglobin levels between patients with or 
without an elevated serum cPTHrP levels (P = 0.46). 
Patients who had elevated PTHrP levels had signifi- 
candy lower serum transferrin levels compared with 
patients who had normal PTHrP levels (P = 0.009) 
(Fig. 5A). a -1- Antichymotrypsin levels were within the 
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FIGURE 4. These Kaplan -Meier curves were constructed by comparing the 
survival of patients with normal levels of the c- terminal fragment of serum 
parathyroid hormone -related peptide (cPTHrP) (solid line) and patients with 
elevated serum cPTHrP (dashed line) (log -rank analysis; P = 0.038). 
TABLE 3 
Serum Parathyroid Hormone -Related Peptide Levels and Nutritional 
Variables 
Nutritional parameter 
Serum PTHrP (pmol /L)° 
P 
value" Normal Elevated 
BMI at diagnosis (kg /m2) 24.1 (21.2-28.0) 25.3 (22.3 -28.8) 0.53 
Weight loss ( %) 7.6 (1.9 -14.9) 6.7 (1.9-12,9) 0.73 
Midarm circumference (cm) 27.0 (24.0 -30.0) 28.0 (26.5 -32.0) 0.14 
Triceps skinfold (mm) 11.5 (8.0 -15.0) 14.5 (9.0 -18.0) 0.04 
Arm muscle circumference (cm) 23.4 (20.8 -252) 23.9 (21.7 -26.2) 0.42 
Albumin (g /L) 40.0 (36.0 -43.0) 37,0 (34.0 -40.5) 0.02 
PTHrP: parathyroid hormone- related peptide; BMI: body mass index. 
a Median (interquartile range). 
Mann -Whitney U test. 
normal range for patients with or without elevated 
serum cPTHrP levels, and there was no difference 
between the 2 groups (P = 0.47). 
IL -lß levels were not significantly different be- 
tween the groups (P = 0.34) and were within the 
normal range, as were levels of IL -6 (P = 0.46), IL -8 (P 
= 0.81), and IL -10 (P = 0.54). However, patients who 
had elevated PTHrP levels had significantly elevated 
sTNF -R levels compared with patients who had serum 
cPTHrP levels within the normal range (P = 0.008) 
(Fig. 5B). 
DISCUSSION 
In the current study, only 6 patients (4%) were hyper - 
calcemic, a proportion that is in agreement with the 
TABLE 4 
Serum Parathyroid Hormone -Related Peptide and the Acute Phase 
Proteins and Cytokines 
Variable 
Serum PTHrP (pmol/L)" 
P 
values Normal Elevated 
CRP (mg/L) 6.5 (2.3 -23.8) 17 (4.5 -60.8) 0.06 
Transferrin (mg/L) 1.8 (1.4 -2.2) 1.5 (1.1 -1.8) 0.009 
Haptoglobin (mg/L) 2094 (1521-2829) 2205 (1113-2639) 0.46 
al-Antichymotrypsin (mg/L) 402 (337-520) 451 (326-601) 0.47 
H: lß (pg/mL) 0 0 0.34 
IL-6 (pg/mL) 8.9 (0.0 -86.6) 0 (0.0 -51.6) 0.46 
IL-8 (pg/mL) 0 (0.0- 147.0) 0 (0.0- 126.2) 0.81 
IL-10 (pg/mL) 0 0 0.54 
sTNF-R (ng/mL) 3.2 (1.9 -4.9) 5.3 (2.9 -10.4) 0.008 
PTHrP: parathyroid hormone -related peptide; CRP: C- reactive protein; Il: Iß: interleukin tß; sTNF -R: 
soluble tumor necrosis factor receptor. 
a Median (interquartile range). 
n Mann -Whitney U test. 
findings in a large Japanese study in which 1.3% of 
patients with esophageal carcinoma had elevated se- 
rum calcium levels at the time of diagnosis.1e Patients 
with gastric or esophageal carcinomas experience hy- 
percalcemia infrequently, and bone metastases are 
uncommon. Despite normal plasma calcium levels, 26 
patients (17%) in the current study had elevated se- 
rum cPTHrP levels. Increased levels of cPTHrP were 
likely irrespective of tumor origin or histologic type. 
Similarly, there was no association between advanced 
disease stage and elevated cPTHrP levels, an observa- 
tion that was reported previously in other studies. 
Although not statistically significant in the current 
series, the current data did suggest a trend toward a 
correlation between increased cPTHrP production 
and poor tumor differentiation. A study involving a 
much larger series of patients would be required to 
explore this potential association. A possible link be- 
tween tumor grade and the overproduction of cPTHrP 
has been reported.19 
Several tumor models have suggested that PTHrP 
is associated with adverse nutritional status.° No dif- 
ferences in nutritional status were observed between 
patients with or without an elevated cPTHrP, except 
for triceps skinfold thickness. Patients who had ele- 
vated cPTHrP levels had increased triceps measure- 
ments compared with patients who had normal serum 
levels of cPTHrP (P = 0.04). This finding likely repre- 
sents sample error and may be a consequence of the 
higher proportion of females, who have a greater tri- 
ceps skinfold thickness per kilogram of body weight 
compared with males, among the patients with ele- 
vated cPTHrP. The similarity in nutritional status be- 




FIGURE 5. These graphs illustrate the correlations between (A) serum 
concentrations of the c- terminal fragment of parathyroid hormone -related 
peptide (PTHrP) with serum concentrations of transferrin (P = 0.007; r = 0.24; 
linear regression) and (B) with serum concentrations of soluble tumor necrosis 
factor (TNF) receptor (P = 0.002; r = 0.26). 
fact that the sample population had normal serum 
calcium levels. It is possible that the correlation noted 
elsewhere between elevated PTHrP and weight loss is 
attributable to the systemic effects of hypercalcemia 
(e.g., anorexia). In patients with normal serum cal- 
cium levels, PTHrP may not have any independent 
effect on nutritional status. 
Forty -four percent of the patients studied demon- 
strated an elevated, systemic, acute -phase protein re- 
sponse. The association between systemic inflamma- 
tion and malignant disease has been documented well 
in the literature and is supported by the current data. 
Levels of CRP (which is a positive, acute -phase reac- 
tant) were higher, whereas levels of albumin and 
transferrin (both of which are negative, acute -phase 
PTHrP Expression in Gastroesophageal CA/Deans et aI. 1817 
reactants) were lower in patients who had elevated 
levels of PTHrP. These data suggest a possible further 
enhancement of systemic inflammation in association 
with elevated PTHrP. Plasma levels of the proinflam- 
matory cytokines IL -16, IL -6, and IL -8 did not differ 
significantly between the 2 groups. However, the cor- 
relations between serum cytokine levels and tissue 
inflammation or measures of outcome in patients with 
advanced carcinoma remain unclear. In contrast, 
sTNF -R levels were significantly higher in the group 
with elevated PTHrP levels. Again, this is consistent 
with a greater level of systemic inflammation. It is 
believed that plasma sTNF -R levels are a robust, indi- 
rect index of TNF -a production in tissue compart- 
ments.34 
We found no correlation between serum calcium 
levels and cPTHrP levels. This raises the possibility of 
an additional role for cPTHrP as a growth factor that 
potentiates tumor progression. We found no clear as- 
sociation between elevated cPTHrP levels and disease 
stage. However, patients who had elevated serum lev- 
els of cPTHrP had a worse prognosis, which was sig- 
nificant on univariate analysis, but not on multivariate 
testing. The association between elevated serum 
cPTHrP and systemic inflammation may contribute to 
the adverse prognosis noted in this patient group. 
Elevated serum cPTHrP levels were found to be 
associated with gastroesophageal carcinoma in the 
absence of hypercalcemia. Although serum proinflam- 
matory cytokines (and, in particular, IL -6) were not 
higher in patients who had elevated levels of cPTHrP, 
overall, markers of systemic inflammation (as indi- 
cated by levels of acute -phase proteins and sTNF -R) 
were associated with elevated cPTHrP. Elevated serum 
cPTHrP also was associated with an adverse progno- 
sis, but it did not predict outcome independent of 
other covariates. Circulating PTHrP levels were not 
associated with adverse nutritional status. However, 
given the strong correlation between systemic inflam- 
mation and cachexia /decreased survival, there is a 
possible indirect role for cPTHrP in these processes. 
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Expression of the proteolysis- inducing factor core peptide mRNA 
is upregulated in both tumour and adjacent normal tissue in 
gastro -oesophageal malignancy 
DAC Deans', SJ Wigmore', H Gilmour2, MJ Tisdale3, KCH Fearonr and JA Ross" 
Department of Clinical and Surgical Sciences, Cell Injury and Apoptosis Section, Tissue Injury and Repair Group, MRC Centre for Inflammation Research, 
Edinburgh University, The Chancellor's Building, (SU227) 49 Little France Crescent Edinburgh EH I 6 4SB, UK Department of Pathology, Royal Infirmary, 
51 Little France Crescent Old Dalkeith Road, Edinburgh EH 16 4SA, UK 3Department of Pharmaceutical Sciences, Aston University, Birmingham, UK 
Gastro- oesophageal cancer is associated with a high incidence of cachexia. Proteolysis- inducing factor (PIF) has been identified as a 
possible cachectic factor and studies suggest that PIF is produced exclusively by tumour cells. We investigated PIF core peptide (PIF - 
CP) mRNA expression in tumour and benign tissue from patients with gastro- oesophageal cancer and in gastro- oesophageal biopsies 
for healthy volunteers. Tumour tissue and adjacent benign tissue were collected from patients with gastric and oesophageal cancer 
(n = 46) and from benign tissue only in healthy controls (n = I I ). Expression of PIF -CP mRNA was quantified by real -time PCR. 
Clinical and pathological information along with nutritional status was collected prospectively. In the cancer patients. PIF -CP mRNA 
was detected in 27 (59 %) tumour samples and 31 (67 %) adjacent benign tissue samples. Four (36 %) gastro- oesophageal biopsies 
from healthy controls also expressed PIF -CP mRNA. Expression was higher in tumour tissue (P = 0.03 I) and benign tissue 
(P = 0.022) from cancer patients compared with healthy controls. In the cancer patients, tumour and adjacent benign tissue PIF -CP 
mRNA concentrations were correlated with each other (P <0.0001, r =0.73) but did not correlate with weight loss or prognosis. 
Although PIF -CP mRNA expression is upregulated in both tumour and adjacent normal tissue in gastro- oesophageal malignancy, 
expression does not relate to prognosis or cachexia. Post -translational modification of PIF may be a key step in determining the 
biological role of PIF in the patient with advanced cancer and cachexia. 
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Although cachexia is a major cause of morbidity and mortality 
among cancer patients, the mechanisms remain unclear. Proteo- 
lysis- inducing factor (PIF) has been identified as a possible 
cachectic factor (Todorov et al, 1996). Initially isolated from a 
murine tumour model (MAC16), a human homologue of PIF was 
subsequently identified in human urine from weight losing cancer 
patients (Todorov et al, 1996; Cariuk et al, 1997; Wigmore et al, 
2000). Proteolysis- inducing factor has been named as such because 
it has been shown to induce skeletal muscle proteolysis both in 
vitro and in vivo (Lorite et al, 1997, 2001; Watchorn et al, 2001). 
The molecule demonstrates a high degree of glycosylation, 
consisting of a peptide core of 4 kDa and carbohydrate residues 
contributing to the estimated total molecular size of 24 kDa 
(Todorov et al, 1997). The glycosylation appears essential for its 
proteolytic activities, as neither the peptide core alone nor de- 
glycosylated native PIF has any effect on weight loss in mice 
(Todorov et al, 1996). 
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In hepatocytes, glycosylated PIF has been shown to stimulate 
production of the cytokines interleukin -6 (IL -6) and IL -8 and the 
acute -phase protein C- reactive protein (CRP) via induction of 
transcription factors NF -xB and STAT3 (Watchorn et al, 2001). 
Therefore, PIF may contribute to the inflammatory state observed 
in conjunction with cancer cachexia in addition to its proteolytic 
function, and could conceivably also play a role in the generation 
of a proinflammatory state outwith the context of cancer. 
Some gastrointestinal cancers and cancer cell lines have been 
shown to produce glycosylated PIF protein (Cabal- Manzano et al, 
2001). Glycosylated PIF has been detected within tumour cells by 
immunohistochemistry and in the urine of the same subjects by 
Western blot. The presence of glycosylated PIF in tumour cells was 
also associated with increased weight loss among these patients. 
Proteolysis- inducing factor has also been identified from the 
human melanoma cell line (G361) (Todorov et al, 1999) and the 
pancreatic cell line (MIA PaCa2) (unpublished data). 
Human -derived PIF has been designated human cachexia- 
associated protein (HCAP) by early identification of the human 
gene sequence (GenBank accession number AR053250) and patent 
(US 5834192) (Akerblom and Murry, 1998) and later by a group, 
which investigated its expression in prostate cancer patients 
(Wang et al, 2003). mRNA of HCAP was detected in 13 out of 15 
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radical prostatectomy specimens and seven out of nine bone 
metastases, but was not detectable in normal prostate or in any 
adjacent non -malignant prostate tissue from prostatectomy 
samples. In situ hybridisation confirmed that HCAP mRNA was 
only detectable in cancer cells and not in surrounding stromal cells 
or benign prostate tissue. Expression of HCAP mRNA was also 
detected from prostate cancer cell lines. When two of these cell 
lines (PC -3M and LuCaP35) were implanted into mice, there was a 
strong correlation between HCAP mRNA expression from the 
cancer cells and weight loss among the mice (Wang et al, 2003). 
A BLAST search of the human genome using the PIF core 
peptide (PIF -CP) cDNA sequence (GenBank accession number 
AY590150) identified three products that arise from the single gene 
locus on 1283.1; dermcidin (DCD), neuronal survival- promoting 
peptide, and a candidate breast cancer oncogene. Dermcidin is a 
novel peptide that was identified from human sweat and was 
shown to possess antimicrobial properties (Schittek et al, 2001). 
Unlike the PIF molecule, DCD appears to be unglycosylated. 
Dermcidin mRNA was detected in normal skin, benign naevi, and 
malignant melanoma cells by RT -PCR. Screening of adult and 
fetal tissue panels did not identify DCD mRNA in any other tissue. 
The authors therefore concluded that DCD was exclusive to skin 
and associated appendages. 
Another PIF homologue has been identified following its 
isolation from the culture medium of neuronal cells grown under 
oxidative stress (Cunninghan et al, 1998). In vivo studies suggest 
that this protein confers survival benefits to hypoxic neuronal cells 
and the molecule has been termed neuronal diffusible survival - 
promoting peptide. 
The third peptide, which has been mapped to the PIF gene locus, 
was identified using SAGE in breast cancer tissue (Porter et al, 
2003). The gene was expressed only in a subset of invasive breast 
carcinomas and their lymph node metastases. In situ hybridisation 
studies located the mRNA to cancer cells only with no expression 
found within stromal cells. Northern blot analysis of 75 human 
adult and fetal tissues detected RNA expression only in the pons 
and paracentral gyrus of the brain. The protein was identified in 
10% of invasive breast cancers, two out of 64 pancreatic cancers, 
and normal sweat glands. Receptors were found in the brain and 
on tumour cells that were producing the protein, suggesting an 
autocrine /paracrine mode of action. When the cDNA sequence was 
introduced into a breast cancer cell line (21NT), these cells had 
accelerated growth and were more resistant to oxidative stress and 
hypoglycaemia. The authors have suggested that this gene may 
function as an oncogene in breast cancer with survival- promoting 
properties. 
More recently, a group of investigators probed a panel of normal 
human tissue cDNA for PIF -CP using real -time PCR and found 
absent or very low levels of expression (Monitto et al, 2004). In an 
analysis of unpaired breast tissue samples, minimal PIF expression 
in normal breast tissue was detected. However, significantly 
elevated PIF expression within breast tumours was observed. Mice 
implanted with tumours transfected with a PIF vector were found 
to produce increased levels of PIF mRNA and protein but the 
protein was not glycosylated and these mice did not develop 
wasting. However, the tumours from these mice were significantly 
larger than controls, supporting a previous hypothesis that PIF 
may confer cell survival properties (Cunningham et al, 1998). 
PIF mRNA and protein are not expressed in most normal tissues 
and are overexpressed by certain tumours. We investigated the 
expression of the PIF -CP gene in paired tissue samples from 
patients with gastric or oesophageal tumours and compared levels 
of expression between tumour tissue and adjacent non -neoplastic 
tissue using the PIF mRNA sequence that our group had 
previously cloned (GenBank accession number AY590150). We 
also compared levels of gene expression with nutritional status and 
investigated the possible survival- promoting role of the PIF -CP 
gene on prognosis and survival among the patient cohort. 
MATERIALS AND METHODS 
Study patients 
All patients diagnosed with gastric or oesophageal cancer between 
June 2002 and March 2004 within Lothian and Borders regions 
were invited to take part in the study. Patients who were not 
suitable for surgical resection were excluded. Patients provided 
written informed consent and the study received ethical permis- 
sion from the Lothian Research Ethics Committee. Clinical 
information was collected prospectively. Patients were staged 
according to the International Union Against Cancer (UICC) 
(Sobin and Wittekind, 2003), and final histopathological stage 
(pTNM) was used in all cases. Tumours around the oesophago- 
gastric junction were classified according to Siewert and those 
classified as type I and II were classified as oesophageal tumours, 
and type III as gastric cancers (Siewert and Stein, 1998). Full 
clinical and pathological information was recorded for each 
patient, including treatment modality. Patients provided urine 
samples at the time of recruitment and whole blood was collected 
at the same time. Duration of survival, defined as time from 
histological diagnosis to death, was recorded for all patients and all 
deaths were disease related. 
Gastric or oesophageal biopsies were collected from II 
healthy volunteers at the time of endoscopic examination. These 
patients were undergoing endoscopic investigation of gastro- 
intestinal symptoms. In all instances, both the macroscopic 
and microscopic assessments were considered normal. Those 
patients with abnormal findings were excluded as healthy 
controls. The tissue was sampled with biopsy forceps and the 
histological appearances were confirmed as normal by a consultant 
pathologist (HG). 
Nutritional assessment 
Nutritional assessment including calculation of body mass index 
from the patients' weight and height and measurement of mid -arm 
circumference (MAC) and triceps skinfold thickness (triceps) was 
performed as described previously (Wigmore et al, 2000). Mid -arm 
muscle circumference (AMC) was calculated by means of Jelliffe's 
(1966)equation. Premorbid patient weight was recalled by the 
patient and confirmed where possible from the medical notes. 
Anthropometry measurements were normalised using standar- 
dised reference tables (Bishop et al, 1981). 
Tissue collection 
Tissue was obtained from patients at the time of surgical resection. 
A section of tumour tissue and a sample of benign mucosa from 
the same organ were collected from each patient. A single 
consultant pathologist (HG) analysed tissue sections to confirm 
the presence of malignant cells in the tumour samples and the 
absence of malignant cells within the benign samples. Tissue 
samples were snap -frozen in liquid nitrogen before storage at 
-80 °C until further analysis. The average time from tissue 
collection to freezing was 15 min (range 10 - 25 min). Tumour 
tissue and benign tissue were collected from the same patient in all 
cases. Tissue biopsies collected from healthy controls were snap - 
frozen within 1 min of collection. 
Quantitative polymerase chain reaction (Q -RT -PCR) 
RNA isolation and reverse transcription Total RNA was isolated 
from tissue samples using the RNAeasy kit (Qiagen Inc., Crawley, 
UK). RNA quality and integrity was assessed using an Agilent 2100 
bioanalyser (Agilent Technologies Ltd, Chesire, UK) in five 
samples. For the remaining samples, purity and concentration 
were determined using spectrophotometry (Ultrospec 2000, 
Pharmacia Biotech, Bucks, UK). RNA samples were treated with 
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DNase (Qiagen Inc., UK) and all RNA samples were checked for 
genomic DNA contamination before reverse transcription using 
standard PCR for cytochrome b. 
Reverse transcription was performed once DNA contamination 
had been excluded. The reaction mixture included RNA (1µg in 
10µl diethyl -pyrocarbonate (DEPC)- treated water), 4 pl MgC12 
(25 mM), 2 pl 10 x reverse transcriptase buffer, 2 pl dNTPs 
(10 mM), 1µl random hexamers (500 pg ml -1), 1.5 pl AMV reverse 
transcriptase (10 U µl -1), and 0.5 pl recombinant RNase inhibitor 
(40Uµ1 -1) (all reagents Promega, Southampton, UK). Reverse 
transcription was performed at 42 °C for 60 min followed by 95 °C 
for 5 min. 
Real -time PCR Quantitative PCR was performed using the ABI 
PRISM 770 real -time Sequence Detection System (Applied 
Biosystems, Warrington, UK). Reactions were performed in 50µl 
total volume, consisting of 25 pl Taqman universal PCR master - 
mix (UNG x 2), 14 µ1 primer /probe mix, 2.5µl ribosomal 18S 
primer /probe mix (all reagents Applied Biosystems, Warrington, 
UK), 3.5 µ1 DEPC- treated water, and 5 pl cDNA. The reaction 
conditions were 2 min at 50 °C, 10 min at 95 °C, and 40 cycles with 
15 s at 95 °C and 1 min at 60 °C. The primers and probes were 
designed using Primer Express® software based on our previously 
registered sequence for PIF (GenBank accession number 
AY590150) and the sequences were checked for compatibility by 
Applied Biosystems (Warrington, UK). The primers were 5'- 
CAAAAGGAAAATGCAGGTGAAGA, 5'- TGGAAAAAGGCCTAGA 
CGGAG, and the probe 5'FAM- ACAGGCACCAAAGCCAAGGAAG 
CA- TAMRA. 
Quantification of gene expression was calculated using the 
comparative (AACT) method, where samples were compared with 
the positive control (Bustin, 2000). Human ribosomal 18S was used 
as the internal control for all PCR reactions. The values generated 
for the gene of interest (PIF -CP) were normalised to the internal 
control as follows: the average threshold cycle numbers for PIF (CT 
FAM) and for 18S (CT VIC) were calculated for each sample and 
the mean VIC CT values were subtracted from the mean FAM CT 
values (FAM CT -VIC CT =ACT). Samples that generated cycle 
numbers greater than 23 for the internal control (18S; VIC) were 
considered too dilute for accurate analysis and these samples were 
repeated. 
The level of gene expression within each sample was then 
expressed as a percentage of the total level of gene expression by 
the positive control (MIA PaCa2). Expression of PIF -CP by the 
positive control was also initially normalised to the internal 
control. Then, AACT was calculated by subtracting the ACT 
value of the positive control sample from the ACT value for 
each sample (i.e. ACT sample -ACT control = AACT). The relative 
level of expression, normalised to the endogenous control and 
relative to the positive control, was then calculated by the formula 
2 -eecT The level of gene expression of the positive control was 
assigned an arbitrary expression value of 1 and levels of gene 
expression in the samples were expressed as percentages of the 
positive control level. 
Each sample was analysed in duplicate. The variability between 
duplicates was between 0 and 4.8 %. To investigate inter -plate 
variability, between five and 10 randomly selected samples were 
repeated on different test plates and serial dilutions of the positive 
control cDNA were also performed. Inter -plate reproducibility was 
between 3.7 and 15.5 %. 
Positive control Previous work undertaken by our group has 
identified the pancreatic cancer cell line MIA PaCa2 to consistently 
produce PIF -CP mRNA. This cell line was, therefore, used as 
positive control for real -time PCR analysis. Total RNA was 
collected from cultured cells by the Trizol extraction method 
(Invitrogen, Renfrew, UK) before undergoing reverse transcription 
as described above. 
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Acute -phase proteins 
C- reactive protein was determined using an immunoturbidimetric 
assay (Abbott TDX, Abbott Laboratories, Maidenhead, UK). A 
level above 10 mg I 
-1 
represents the presence of an acute -phase 
response. The remaining acute -phase proteins (transferrin, hap - 
toglobin, and al- antichymotrypsin) were determined by enzyme - 
linked immunosorbent assay as described previously (Wigmore 
et al, 2002). 
Statistical analysis 
Differences in levels of PIF -CP mRNA expression between different 
tissue types and PIF urinary expression were analysed by the 
Mann - Whitney U -test. Survival differences were tested by the log - 
rank test. Comparisons between tumour tissue PIF -CP gene 
expression and benign tissue expression were tested by linear 
regression analysis following natural logarithmic transformation of 
the data. Stage was analysed by the y2 test. Probabilities 50.05 
were considered significant. 
RESULTS 
Study patients 
Patient demographics are shown in Table 1. Forty -six patients were 
recruited to the study, the median age was 65 years (inter -quartile 
range 58 -75) and 32 (70 %) of the patients were men. The primary 
tumour sites were oesophageal (n = 22, 48 %), gastric (n = 15, 
33 %), and those arising from the gastro- oesophageal junction 
Table I Patient demographics (n = 46) 
Number ( %) 
Age (years) 
Sex 
65 (58 -75) 
Male 32 (70) 
Female 14 (30) 
Tumour site 
Oesophageal 22 (48) 
Oesophago -gastric junction 9 (20) 
Gastric 15 (33) 
Histology 
Adenocarcinoma 43 (94) 
Squamous cell carcinoma 3 (6) 
Grade 
Well differentiated 4 (9) 
Moderately differentiated 20 (44) 
Poorly differentiated 22 (48) 
UICC stage 
14 (30) 
2 12 (26) 
3 15 (33) 










I I (24) 
35 (76) 
II (24) 
Values are median (inter -quartile range). UICC = International Union Against Cancer. 
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(n = 9, 20 %). Histological confirmation of disease was obtained in 
all cases and the predominant histological subtype was adeno- 
carcinoma (94 %). All patients underwent surgical resection and 11 
(24%) of these received preoperative chemotherapy. At the end of 
the study, 11 (24 %) patients had died. 
All the control patients were considered healthy and all were 
weight stable. These patients underwent endoscopy as an elective 
investigation and in all instances the result of the procedure was 
normal, including both macroscopic and microscopic assessment. 
Helicobacter pylori was not detected in any of these tissue samples. 
Expression of PIF -CP mRNA in tissues 
Healthy controls mRNA of PIF -CP was detected in gastro- 
oesophageal biopsy tissue from four (36 %) healthy controls. Of 
these positive tissue samples, three were gastric biopsies, and one 
was oesophageal tissue. Although PIF -CP mRNA levels were 
detectable, the levels of expression were significantly lower when 
compared with levels of expression in tumour tissue (P = 0.031, 
Mann - Whitney U -test) and adjacent benign tissue (P = 0.022) 
taken from cancer patients (Figure 1). 
Study patients PIF -CP mRNA was detected in 27 (59 %) tumour 
samples and 31 (67 %) adjacent benign tissue samples. In 24 (52 %) 
patients, PIF mRNA was detected in both the tumour tissue and 
adjacent benign tissue collected from the same patient (Table 2). 
There was a strong correlation between paired mRNA concentra- 






















El P=0.022 h El P=0.51 hl 
Normal Benign Tumour 
Tissue type 
Figure I A comparison of relative expression of PIF -CP mRNA in tissue 
from healthy controls (normal), tumour tissue, and benign tissue collected 
from cancer patients (benign). The lines represent the median value, 
bars = inter-quartile range, error bars = extreme values (Mann -Whitney 
U- test). 
Table 2 Tissue expression of PIF -CP mRNA in paired tumour tissue and 
benign tissue 
Paired tumour tissue and benign tissue 
expression 
24 (52%) 
Tumour tissue expression only 
Benign tissue expression only 
7 (15%) 
Neither tumour tissue nor benign tissue 
expression 
3 (7%) I2 (26%) 
PIF -CP = proteolysis- inducing factor core peptide. 
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benign tissue (P<0.0001, r =0.73; linear regression) (Figure 2). 
However, there was no difference in the level of gene expression 
between tumour tissue and adjacent benign tissue from the cancer 
patients (P = 0.51, Mann - Whitney U -test) (Figure I). In 12 (26 %) 
patients, PIF -CP mRNA was not detected in either the tumour or 
adjacent benign tissue. For the remaining 10 patients, PIF -CP 
mRNA was detected in either tumour tissue only (n = 3) or 
adjacent benign tissue only (n = 7). There was no difference in the 
level of gene expression between patients who received preopera- 
tive chemotherapy and those who did not (tumour tissue, P = 0.58; 
adjacent benign tissue, P = 0.72: Mann - Whitney U- test). 
Tissue PIF -CP mRNA expression and nutritional status 
Tumour tissue PIF -CP mRNA did not correlate with weight loss 
(P = 0.37; linear regression), MAC (P = 0.10), triceps skinfold 
thickness (P = 0.37), or AMC (P = 0.14). Similarly, benign tissue 
mRNA concentrations did not correlate with weight loss (P = 0.84) 
or any anthropometric measurements. Patients in whom PIF -CP 
mRNA was measurable in both tumour and adjacent benign 
tissues did not have adverse nutritional status when compared 
with patients without detectable PIF -CP mRNA in either tissue 
type (Table 3). There remained no correlation when the data were 
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Benign tissue PIF -CP mRNA (log) 
Figure 2 Correlation between paired tumour tissue PIF -CP mRNA 
concentrations and benign tissue PIF -CP mRNA concentrations 
(P <0.0001, r =0.73; linear regression). All values underwent natural 
logarithmic transformation. 
Table 3 Tissue PIF -CP mRNA expression and nutritional variables 
PIF -CP mRNA 
detected in both 
tumour tissue and 
benign tissue 
(n = 24) 
PIF -CP mRNA 
not detectable in 
either tumour 
tissue or benign 
tissue (n = I 2) P value 
Weight loss ( %) 3.3 (0.4 -9.5) 5.3 (0 -12.2) 0.93 
MAC (percentile group) 10 -25 (5 -50) 10 -25 (5 -50) 0.96 
Triceps (percentile group) 25 -50 (10 -50) 25 -50 (25 -50) 0.37 
AMC (percentile group) 10 -25 (5 -50) 25 -50 (5 -50) 0.96 
Nutritional variables were similar between patients in whom PIF -CP mRNA was 
measurable in both tumour tissue and benign tissue and patients who had no 
detectable mRNA (Mann - Whitney U- test). Absolute values were normalised into 
percentile groups before analysis. Values are median (inter -quartile range). PIF- 
CP = proteolysis- inducing factor core peptide, MAC = mid -arm circumference, 
triceps = triceps skinfold thickness, AMC = arm muscle circumference. 
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Tissue PIF -CP mRNA expression and systemic 
inflammation 
Nine (20ß6) patients had an elevated serum CRP ( >10mg1 -1), 
which may be used as a surrogate marker of systemic inflamma- 
tion. There was no association between levels of PIF -CP mRNA in 
either tumour tissue (P= 0.89) or adjacent benign tissue (P = 0.81) 
and elevated serum acute -phase protein concentrations (Mann - 
Whitney U- test). 
Tissue PIF -CP mRNA expression and prognosis 
PIF -CP mRNA in either tumour tissue (P = 0.64) or benign tissue 
(P =0.51) was not associated with adverse prognosis (Mann - 
Whitney U- test). Similarly, those patients with detectable mRNA in 
both tumour and benign tissue did not have adverse survival 
compared with patients with no detectable PIF -CP gene in either 
tissue type (P =0.79; X2 analysis). 
We found no association between mRNA levels and age, sex, 
tumour position, histology, degree of differentiation, or stage (data 
not shown). 
DISCUSSION 
Previous studies have suggested that PIF -CP mRNA is absent or 
expressed at only minimal levels in normal human tissues and 
found at significantly elevated levels in some tumours and various 
cancer cell lines. However, we have detected PIF -CP mRNA in 
benign tissue in the majority of patients with gastro -oesophageal 
cancer, and these levels are equivalent to levels detected within 
adjacent tumour tissues. In addition, we detected PIF -CP mRNA in 
biopsy tissue from healthy controls, although at significantly lower 
levels of expression. In a previous study, PIF -CP (HCAP) mRNA 
appeared to be limited to cancer cells and their metastases (Wang 
et al, 2003). Our data suggest that PIF -CP gene expression is not 
limited to neoplastic tissue and that the PIF -CP gene may also be 
active in normal tissues. Furthermore, the level of gene expression 
appears to be similar in tumour tissue and adjacent benign tissue. 
Therefore, in some individuals with cancer, there may be 
upregulation of the PIF -CP gene not only in tumour tissue but 
also within the whole organ or even in distant tissues. 
The relevance of PIF -CP gene upregulation remains obscure. 
Although PIF -CP has been identified as a putative cell survival 
factor we found no association between gene expression and 
prognosis, stage, or grade of tumour. Therefore, the present study 
is unable to confirm a tumour survival- promoting role for this 
gene in our study. Mice implanted with a tumour carrying the PIF- 
CP gene demonstrated increased rate of tumour growth compared 
with controls (Monitto et al, 2004). The present study did not 
evaluate tumour volume, but we did not identify any differences in 
tumour stage or grade between patients with elevated mRNA levels 
and those with undetectable mRNA levels. 
Tissue PIF -CP mRNA expression was not associated with weight 
loss or any adverse nutritional variable. Previously, we have found 
an association between weight loss and urinary PIF (Todorov et al, 
1996; Cariuk et al, 1997; Wigmore et al, 2000). In those studies, we 
detected the glycosylated PIF protein, whereas in this study, we 
have measured mRNA for the core peptide and so this finding is 
perhaps unsurprising. Only a small fraction of the total peptide 
core would be expected to be glycosylated, and as PIF is only 
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present at 1 part in 108 of the total protein, expression of the 
peptide core would not be expected to be rate limiting for PIF 
formation, rather the expression of the glycosidases, their rate of 
catalysis, and substrate availability (Todorov et al, 1996). Whether 
variation in glycosylation of PIF occurs and whether this 
influences biological activity is unknown. Antibodies raised 
against the core peptide do not reliably detect urinary PIF. 
Systemic inflammation was identified in 20ß6 of patients and 
was not associated with PIF core tissue mRNA concentrations. In 
vitro work has demonstrated that hepatocytes produce increased 
levels of IL -6, IL -8, and CRP in response to PIF stimulation 
(Watchorn et al, 2001). This is thought to be mediated through 
transcription factors NF -KB and STAT3. Proteolysis- inducing 
factor may play only a minor role in the complex interaction 
between proinflammatory mediators and a direct relationship 
between PIF and acute -phase proteins may not be identified 
outwith the in vitro cell model. 
It has been suggested that PIF is an important protein during 
embryological development and becomes quiescent during adult 
life (Watchorn et al, 2001). Neoplastic transformation would then 
allow the re- expression of the gene in adulthood (similar to 
carcinoembryonic antigen). We have found PIF -CP mRNA 
expression in normal healthy tissue albeit at reduced levels 
compared with tumour tissue and benign tissue from cancer 
patients and so this explanation is perhaps implausible for PIF -CP 
but may be important in re- expression of the glycosyltransferases. 
It is also important to consider that real -time PCR is an exquisitely 
sensitive technique and that what we are detecting in some 
patients, although elevated, may have little or no functional 
significance as it may not be translated into protein. 
It is possible that the gene for the PIF -CP may confer a survival 
advantage to a tumour, promoting tumour growth and spread, 
although this study was unable to confirm this. Alternatively, the 
PIF -CP gene may be expressed to some degree in all tissue types 
and its diverse functions are due to post -transcriptional and post - 
translational modifications. The high degree of glycosylation of the 
PIF molecule may be due to aberrant glycosylation by tumour cells 
and this glycosylation may confer the proteolytic activity 
associated with PIF (Todorov et al, 1997). This aberrantly 
processed molecule could not be distinguished from any conven- 
tional versions by determination of the mRNA expression. 
PIF -CP mRNA is expressed in healthy tissue and is found at 
significantly elevated levels within tumour tissue and adjacent 
benign tissue. However, measuring mRNA expression is unreliable 
as an indicator of glycosylated PIF protein expression and 
therefore has limited value both as a diagnostic and prognostic 
test. Attention needs to be directed at developing robust and 
reproducible quantitative assessments of glycosylated PIF protein. 
Such tests need to be able to identify PIF in complex matrices such 
as plasma or urine and must be able to identify glycosylation 
variants of the moiety. Similarly, such tests need to distinguish 
between different proteins carrying identical glycosylation motifs. 
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Background: Accurate prediction of prognosis in gastro -oesophageal cancer remains challenging. The 
aim of this study was to develop a robust model for outcome prediction. 
Methods: The study included 220 patients with gastric or oesophageal cancer newly diagnosed over a 
2 -year period. Patients were staged and underwent treatment following discussion at a multidisciplinary 
team (MDT) meeting. Clinical and investigative variables were collected, including performance and 
nutritional status, and serum C- reactive protein (CRP) level. Primary endpoints were death within 12 
and 24 months. 
Results: Overall median survival was 13 months. Advanced clinical stage (P < 0.001), reduced 
performance score (P < 0.001), weight loss exceeding 2.75 per cent per month (P = 0.026) and serum 
CRP concentration above 5 mg/1 (P = 0.031) were identified as independent prognostic indicators in 
multivariable analysis. A prognostic score was constructed using these four variables to estimate a 
probability of death. Applying the model gave an area under the receiver- operator characteristic curve 
of 0.84 and 0.85 for prediction of death at 12 and 24 months respectively (both P < 0.001). 
Conclusion: This model accurately estimated the probability of death within 12 and 24 months. This 
may aid the MDT decision -making process. 
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Introduction 
The incidence of tumours arising around the oesophago- 
gastric junction (OGJ) continues to rise, and gastric and 
oesophageal cancers together are the third leading cause 
of cancer -related death in the UK1 -3. Overall survival 
figures remain disappointing, with many patients in the 
UK presenting with locally advanced tumours and very 
few with early -stage disease. The only real prospect of 
cure lies in surgical resection. This still carries significant 
risks in terms of morbidity and mortality with or without 
preoperative chemo /radiotherapy. 
Despite advances in staging and treatment, the 5 -year 
survival rate following resection rarely exceeds 30 per cent 
and is less than 10 per cent in patients with locally advanced 
disease (stages JIb and III)4'5. Indeed in this group, which 
represents approximately two- thirds of all patients suitable 
for curative resection, around 50 per cent do not survive 
more than 18 months. One study has shown that patients 
who fail to live for 2 years after surgery do not regain 
preoperative quality of life levels. Only those who survive 
beyond this time enjoy a return to their former state of 
well- being6. 
The problem lies in identifying such patients prospec- 
tively. Improvements in preoperative staging techniques, 
including spiral computed tomography (CT), endoscopie 
ultrasonography (EUS) and laparoscopy, are likely to help, 
but additional factors that can be used to refine progno- 
sis are required. If clinicians could identify those unlikely 
to live more than 12 -18 months following radical resec- 
tion, such patients could be offered non -surgical palliative 
therapies. 
Management decisions are currently undertaken as part 
of a multidisciplinary team (MDT) process. An objective 
measure of prognosis would therefore not only improve 
stratification of patients, but also provide a measure of 
quality assurance for the MDT. The aims of this study 
were to determine the clinical and investigative factors 
predictive of death from gastro- oesophageal cancer within 
12 and 24 months of diagnosis in order to construct a risk 
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prediction model to assist in the prospective prognostic 
evaluation of patients with gastro- oesophageal malignancy. 
Methods 
All patients diagnosed with gastric or oesophageal cancer 
within the Lothian and Borders regions between March 
2002 and June 2004 were eligible for inclusion in the 
study. Patients were recruited within 2 weeks of diagnosis 
and all subjects provided written informed consent. The 
study received permission from the Lothian Research 
Ethics Committee. No patients was excluded or refused to 
give consent. All patients had histological confirmation of 
cancer following endoscopic biopsy. Data were collected 
prospectively. 
Patients were staged with a combination of CT, EUS and 
laparoscopy/laparoscopic ultrasonography according to the 
International Union Against Cancer (UICC) system7. 
Tumours located around the OGJ were classified according 
to Siewert and Steins; type I and II tumours were staged 
as oesophageal cancers and type III as gastric cancers. In 
all instances a final clinical stage (clinical tumour node 
metastasis; cTNM) was agreed at the unit MDT meeting 
and management strategies were decided. Patients with no 
evidence of metastatic disease (stages I -III) and who were 
medically fit were offered surgical resection. Those staged 
as T3 NO or T2/3 Nl were considered for preoperative 
chemotherapy. The remaining patients received various 
palliative treatments, either alone or in combination. 
Survival time, defined as the interval from histological 
confirmation of disease until death, was recorded for all 
patients. 
Performance status was assessed at the time of diagnosis 
by a single researcher using the Karnofsky scoring system. 
All patients underwent an assessment of nutritional status at 
the time of diagnosis. Body mass index (BMI) was calculated 
following height and weight measurements. Weight before 
illness was recalled by the patient and confirmed from 
medical records where possible. Total bodyweight loss was 
calculated and expressed as a percentage of stable weight 
before illness. The rate of weight loss was calculated 
by dividing the total weight lost by the number of 
months over which symptoms had been experienced. 
Anthropometry in each patient included measurement 
of mid -arm circumference and triceps skinfold thickness. 
Mid -arm muscle circumference was calculated by means 
of Jelliffe's equation10. Measurements were corrected for 
age and sex, and normalized using standardized reference 
tables11. The severity of dysphagia was scored according 
to Knyrim and colleagues12. Dietary intake was estimated 
by all patients and described as normal, reduced compared 
with normal, or poor /minimal. 
Blood was collected at the time of diagnosis and before 
initiation of treatment. C- reactive protein (CRP) was used 
as a surrogate marker of systemic inflammation13. Serum 
CRP concentrations were measured using an automated 
immunoturbidimetric assay; a concentration of 10 mg/I 
represented the upper limit of the normal range. 
Variables that could not be used prospectively to 
aid management, such as number of lymph nodes with 
metastatic involvement and final histopathological stage, 
were excluded from prognostic modelling. 
Statistical analysis 
The Cox proportional hazards model was used to 
determine the effects of clinical and investigative variables 
on survival time, and probability of death within 12 
and 24 months following diagnosis in both univariable 
and multivariable analysis. Stepwise regression (using 
an entry value of P < 0.050 and a removal value of 
P > 0.100) was used to determine the factors predictive 
of death. Models were developed separately for clinical and 
investigative variables, and then for a combination of the 
two. Receiver -operator characteristic (ROC) curves were 
used to select cut-off values for continuous variables. Values 
with the best combination of sensitivity and specificity were 
chosen. The performance of the prognostic model was 
assessed by determining the area under the ROC curve. 
The estimates of probability of death at 12 and 24 months 
were calculated from survival tables. 
Results 
Details of the 220 patients recruited between March 2002 
and June 2004 are shown in Table 1. Approximately two - 
thirds (68.6 per cent) of the cancers occurred at or close 
to the OGJ. Histological confirmation of disease was 
obtained in all cases and 70.3 per cent of oesophageal 
tumours were adenocarcinomas. Only three patients 
had well differentiated tumours and almost two- thirds 
(64.1 per cent) had poorly differentiated cancer. Seventy- 
five patients (34.1 per cent) had metastatic disease (stage 
IV) at the time of presentation and most others had locally 
advanced (stage III) disease. Only one- quarter of patients 
had early disease (stage I/1I). 
Ninety-five patients (43.2 per cent) underwent surgical 
resection. In 90 patients the resection was `curative' 
(RO resection). Three patients had unexpected metastatic 
disease identified at laparotomy and did not proceed 
to resection, and two patients had residual macroscopic 
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Table 1 Patient demographics 
Age (years)f 71 (62 -78) 
Sex 
M 145 (65.9) 
F 75 (34.1) 
Karnofsky scoret 
30 4 (1.9) 
40 1 (0.5) 
50 5(2.4) 
60 17 (8.2) 
70 25 (12.0) 





Oesophagus 101 (45.9) 
Proximal third 2 
Middle third 13 
Distal third 86 
Oesophagogastric junction 40 (18.2) 





Adenocarcinoma 185 (84.1) 
Squamous cell carcinoma 30 (13.6) 
Small cell 2 (0.9) 
Indeterminate 3 (1.4) 
Tumour gradet 
Well differentiated 3 (1.6) 
Moderately differentiated 63 (34.2) 
Poorly differentiated 118 (64.1) 
Unknown 36 
Treatment 
Surgery alone 70 (31.8) 
Preoperative chemotherapy /surgery 25 (11.4) 
Chemoradiotherapy with curative intent 7 (3-2) 
Palliative chemotherapy 28 (12.7) 
Palliative radiotherapy 6 (2.7) 





IV 75 (34.1) 
Status 
Alive 73 (33.2) 
Dead 147 (66.8) 
*Values are number of patients with percentages in parentheses unless 
indicated otherwise; tpercentages based on number of patients with 
known results; values are median (interquartile range). UICC, 
International Union Against Cancer. 
disease (R2 resection). Twenty-five of the 95 patients who 
underwent surgery received preoperative chemotherapy. 
Oesophageal and OGJ tumours were treated by Ivor Lewis 
Copyright © 2007 British Journal of Surgery Society Ltd 
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oesophagogastrectoiny (46 patients) or thoracoabdominal 
resection (16). Distal gastric tumours were resected 
by either partial (16) or total (17) gastrectomy. Seven 
patients (3.2 per cent) with squamous cell carcinoma of 
the oesophagus received only chemoradiotherapy with 
curative intent. The remaining 118 patients (53.6 per cent) 
were deemed unsuitable for curative therapy and received 
palliative chemo /radiotherapy or alternative palliative 
treatments, including endoscopic stenting, dilatation or 
laser therapy. 
Median follow -up was 32 (range 18 -45) months. At 
the time of censoring, 147 patients (66.8 per cent) had 
died. Three patients died in the postoperative period 
and one from injuries sustained following a fall several 
months after discharge. Information obtained from death 
certificates indicated that all other deaths were disease 
related. One hundred and eight patients (49.1 per cent) 
died within 12 months of diagnosis and 136 (61.8 per cent) 
died within 24 months. The median survival for patients 
who underwent surgical resection was 30 months and that 
for patients treated with palliative intent was 7 months. 
Overall median survival was 13 months. 
Seventy patients (33-7 per cent) had a normal perfor- 
mance status at the time of diagnosis (Karnofsky score 
100) and 86 (41.3 per cent) were able to undertake nor- 
mal activities but with some degree of effort (Karnofsky 
80 or 90). Forty-two patients (20.2 per cent) were unable 
to carry out normal activity or work and required occa- 
sional assistance with care (Karnofsky 60 or 70), and ten 
patients (4.8 per cent) required considerable assistance and 
frequent medical care or admission to hospital (Karnofsky 
30 -50) (Table 1). 
Median total bodyweight loss by the time of diagnosis 
was 7.1 per cent, equivalent to a median rate of weight 
loss of 2.5 per cent total bodyweight per month of illness 
(Table 2). Median BMI fell from 26.4 to 24.6 (mean 
reduction 2.4 (95 per cent confidence interval 2.0 to 
2.7) kg /m2; P < 0.001, paired t test). Only 38 patients 
(17.3 per cent) remained weight steady at the time of 
diagnosis, whereas 97 (44.1 per cent) had lost up to 
10 per cent of their total bodyweight and 85 (38.6 per cent) 
had lost more than 10 per cent. Anthropometric values 
for mid -arm circumference, triceps skinfold and arm 
muscle circumference, dietary intake and dysphagia scores 
are summarized in Table 2. Of the 166 patients with 
oesophageal, junctional or proximal gastric tumours, 75.3 
per cent had some degree of dysphagia. 
The median serum CRP concentration was 7 (interquar- 
tile range 2 -25) mg /1. One hundred and twenty-one 
patients (55.0 per cent) had a CRP level greater than 5 mg /1 
at the time of diagnosis. 
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Table 2 Nutritional variables measured at the time of diagnosis 
Body mass index (kg /m2)t 
Before illness 26.4 (24.1-30.1) 
At diagnosis 24.6 (21.4-28.0) 
Total bodyweight loss ( %)t 7.1 (1.2-14.2) 
Rate of weight loss (% per month)t 2.5 (0.3-6.5) 
Mid -arm circumference (percentile group)t 10 (1-25) 
Triceps skinfold thickness (percentile group)t 25 (10-50) 
Arm muscle circumference (percentile group)t 10 (1-25) 
Dietary intake 
Normal 85 (38.6) 
Reduced 103 (46.8) 
Poor or minimal 32 (14.6) 
Dysphagia score 
0 89 (40.5) 
1 52 (23.6) 
2 43 (195) 
3 32 (14.5) 
4 4 (1.8) 
*Values are number of patients with percentages in parentheses unless 
indicated otherwise; tvalues are median (interquartile range). 
Table 3 I- lazard ratio for risk of death associated with baseline 
clinical characteristics and results of investigations for the whole 
patient group with gastro -oesophageal cancer 
Hazard ratio P' 
Age (years) 1.02 (1 00, 1.04) 0.015 
Body mass index at diagnosis (kg /m2) 0.95 (0.92, 0.99) 0.005 
Ln total weight loss at diagnosis ( %) 1.44 (1.20, 1.73) < 0.001 
Ln rate of weight loss (% per month) 1.43 (1.20, 1.71) < 0.001 
Dysphagia score 1.28 (1.10, 1.49) 0.002 
Dietary intake 1.86 (1.38, 2.31) < 0.001 
Karnofsky score 0.96 (0.95, 0.97) < 0.001 
Ln C- reactive protein (mg /I) 1.40 (1-25,1.56) < 0.001 
Tumour grade 1.66 (1.14, 2.51) 0.009 
Stage of disease (cTNM) 2.60 (2.01, 3.29) < 0.001 
Values in parentheses are 95 per cent confidence intervals. Ln, natural 
log; cTNM, clinical tumour node metastasis. *Cox univariable analysis. 
Table 3 shows the risk of death from gastro -oesophageal 
cancer associated with baseline clinical characteristics and 
results of investigations. Age, BMI at the time of diagnosis, 
total body weight loss at diagnosis, rate of weight loss, 
Karnofsky performance score, serum CRP concentration, 
dysphagia score, level of dietary intake, tumour grade and 
clinical stage were all associated with outcome for the 
whole patient group. 
On the basis of ROC curves, cut -off values with the best 
discriminatory power for each continuous variable were: 
age at Ieast 70 years, BMI less than or equal to 25 kg/m2, 
weight loss at least 6 per cent, rate of weight loss greater 
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than 2.75 per cent per month, Karnofsky score 80 or less, 
and CRP concentration greater than 5 mg /1. The risk of 
death for the cut -off point selected for each variable is 
shown in Table 4. 
Because of the large number of prognostic vari- 
ables, clinical and investigative variables were initially 
included in separate multivariable analyses. Rate of weight 
loss and Karnofsky score were identified as indepen- 
dent prognostic clinical variables, and serum CRP con- 
centration and clinical stage as independent investiga- 
tive variables. These four variables were then analysed 
together and each retained independent prognostic value 
(Table 5). 
A prognostic scoring system was devised by logarith- 
mically transforming the hazard ratio for each of these 
variables and multiplying by 100 (Reference14). For each 
patient a cumulative risk score could be calculated (maxi- 
mum score 202) (Table 6). The prognostic risk score could 
then be used to estimate the probability of death within 12 
and 24 months (Fig. 1). Applying the model gave an area 
under the ROC curve of 0.84 and 0.85 for prediction of 
death at 12 and 24 months respectively (both P < 0.001). 
Table 4 Hazard ratio for risk of death for each new cut -off point 
chosen following discrimination analysis by use of 
receiver- operator characteristic curves 
Hazard ratio P' 
Age (? 70 years) 1.60 (1 15, 2.24) 0 -005 
Body mass index ( <25 kg /m2) 1.53 (1.04, 2.02) 0028 
Weight loss (? 6 %) 2.54 (1.79, 3.60) < 0.001 
Rate of weight loss (> 2.75% 
per month) 
2.64 (1.86, 3.75) < 0.001 
Dysphagia score < 0.001 
1 versus no dysphagia 0.68 (0.42, 1.11) 
2 versus no dysphagia 1.48 (0.95, 2.30) 
3 versus no dysphagia 1.68 (1.03, 2.75) 
4 versus no dysphagia 28.88 (8.19, 101.84) 
Dietary intake < 0.001 
Reduced versus normal 1.59 (1.08, 2.34) 
Poor versus normal 3.64 (2.21, 6.00) 
Kamofsky score < 0.001 
80 -90 versus normal 1.49 (0.96, 2-29) 
60 -70 versus normal 4.37 (2.73, 6.99) 
< 60 versus normal 9.23 (4.53, 18.83) 
C- reactive protein (> 5 mg/I) 2.58 (1.83, 3.64) <0.001 
Clinical stage of disease 
(cTNM) 
< 0.001 
Stage II versus stage I 1.87 (0.63, 5.57) 
Stage Ill versus stage I 3.04 (1.11, 8.35) 
Stage IV versus stage I 11.16 (4.02, 30.96) 
Tumour grade 
Poorly differentiated versus 
moderate 
1.66 (1.12, 2.46) 0.012 
Values in parentheses are 95 per cent confidence intervals. cTNM, 
clinical tumour node metastasis. *Cox univariable analysis. 
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Table 5 Clinical and investigative variables independently Table 6 Risk score based on four prognostic variables 
predictive of death, determined by using stepwise selection 
procedures in a general population of patients with 
gastro -oesophageal cancer 
Hazard ratio 
C- reactive protein (> 5 mg /1) 1.58 (1 04, 2.34) 0.031 
Rate of weight loss (> 2.75% per month) 1.61 (1.05, 2.28) 0.026 
Karnofsky score 
80 -90 versus normal 1.01 (0.64, 1 56) 0.996 
60 -70 versus normal 2.08 (130, 3.54) 0.003 
< 60 versus normal 4.83 (2.23, 10.16) < 0.001 
Clinical stage of disease (cTNM) 
Stage II versus stage I 2.02 (0 57, 6.96) 0.277 
Stage III versus stage I 2.88 (0.89, 936) 0.076 
Stage IV versus stage I 8.83 (2.68, 2860) <0.001 
C- reactive protein (mg /I) 
<5 
>5 











Values in parentheses are 95 per cent confidence intervals. cTNM, 
clinical tumour node metastasis. *Forward conditional method of Cox 
proportional hazards model. 
Applying the risk score to the cancer subsites gave areas 
under the ROC curves for survival at 12 and 24 months 
of 0.84 and 0.89 for oesophageal cancer, 0.86 and 0.89 
for gastric cancer, and 0-78 and 0.67 for tumours at the 
OGJ. The score was valid for adenocarcinoma at 12 and 
24 months (area under ROC curve 0.86 and 0.87) and 
squamous cell carcinoma (0.78 and 0.68). Analysis by 
treatment type gave areas under the curve of 0.78 and 
0.79 for survival at 12 and 24 months in patients who 
underwent surgery with curative intent, and 0.77 and 0.79 























*Log (hazard ratio) multiplied by 100. cTNM, clinical tumour node 
metastasis. 
Discussion 
This study identified clinical disease stage, Karnofsky 
performance score, rate of weight loss and serum CRP 
concentration as independent prognostic indicators for 
patients with gastro- oesophageal cancer. The development 
of a risk prediction score based on these four variables 
allows improved prognostic accuracy and risk prediction of 
death within 12 and 24 months after diagnosis. 
Despite advances in clinical staging accuracy, patients 
are still not stratified adequately, particularly those with 
disease involving the OGJ15 When compared with 
40 46 50 66 70 72 78 82 86 94 98 102 114 118 134 138 146 154 166 182 202 
Risk score 
Fig. 1 Plot with which to assign estimated probability of death within 12 or 24 months after diagnosis according to prognostic risk 
score. Values along the horizontal axis represent the total risk score attainable through application of the individual risk scores outlined 
in Table 6. Total scores are not linear as patients' scores may not fall between these values 
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final histopathological stage, CT has an accuracy of 
68 -86 per cent for locoregional assessment (TN stage) 
and 80 -98 per cent for detection of metastatic disease. 
Comparable rates have been found for magnetic resonance 
imaging and EUS 16 -23. In addition, not all tumours within 
the same UICC stage group behave in the same way, and 
so clinical staging and estimation of prognosis should also 
allow for biological tumour behaviour. 
Both the presence of systemic inflammation and nutri- 
tional depletion (cachexia) can be used as indirect measures 
of biological tumour activity. Systemic inflammation has 
been found in association with most epithelial malignancies 
and linked with adverse outcome13.24 -36 Up to 50 per cent 
of patients may have a raised acute -phase response at the 
time of diagnosis of cancer and an increased serum CRP 
level is an independent adverse prognostic indicator in a 
number of types of gastrointestinal cancer13. In patients 
with gastric cancer median survival is shortened from 53 
to 9 weeks in the presence of a heightened inflammatory 
response (P < 0.001)33. Similarly, shortened survival has 
been associated with a raised serum CRP level in patients 
with oesophageal cancer34 -36 
Cachexia remains an important cause of morbidity 
and mortality among patients with cancer, affecting up 
to 85 per cent of those with gastrointestinal malignancy 
at the time of diagnosis37. Weight loss of greater than 
10 per cent total bodyweight has been associated with 
adverse outcome on multivariable analysis among patients 
with oesophageal cancer who had undergone surgical 
resection and chemoradiotherapy38.39. 
The relevance of performance status to prognosis is well 
documented and performance is an important assessment 
tool in the selection of patients for chemo /radiotherapy. 
Among patients with gastro- oesophageal malignancy, 
performance status was identified as an independent 
prognosticator on multivariable analysis of over 1000 
patients, and reduced physical function has been associated 
with increased probability of death in the first 6 months 
after surgical resection of gastro- oesophageal cancer4°,41 
A number of prognostic scoring systems have been 
proposed for patients with gastro- oesophageal cancer. 
Most include pathological information gained from 
tumour resection and these data cannot be used at 
the time of diagnosis to inform management. Other 
prognostic studies have used sophisticated novel molecular 
techniques to determine prognosis, for example DNA 
microarray42, or involved the development of complex 
computer models, such as artificial neural networks, for 
which extensive clinical, investigative and pathological 
information is required to estimate prognosis43 . A study in 
patients with inoperable oesophagogastric cancer devised 
an inflammation -based prognostic scoring system36. The 
score was based on the presence of a CRP concentration 
above 10 mg /1 and/or an albumin concentration below 
35 g /l. Survival time was reduced significantly with an 
increasing score. A Japanese group similarly found that 
clinical stage (cTNM), weight loss (more than 2 per cent 
bodyweight) and serum CRP concentration (greater than 
0.5 mg /dl) were associated independently with survival in 
patients with gastro- oesophageal malignancy44. 
The scoring system developed in this study allows 
accurate estimation of the probability of death within 
12 and 24 months for individual patients. Clearly, the 
score selected as the cut -off will influence the probability 
of survival beyond 12 or 24 months. A higher score 
would have better specificity, but some patients would 
still be offered surgery without much prospect of longer 
survival. Selection of a lower score would perhaps deny the 
opportunity of surgery to some patients who may benefit 
from resection. The authors believe that it is better to 
select a higher score and accept that a few patients may 
have been overtreated. The final cut -off is likely to depend 
on future validation studies and individual preferences. 
This study has shown that the addition of biological 
(CRP) and host -related (weight loss and performance 
score) factors to conventional clinical staging modalities 
can improve prognostic accuracy for individual patients. 
The novel prognostic scoring system may be used for 
patients with oesophageal, junctional and gastric tumours 
with similar accuracy, and for different histological tumour 
types. The risk score is based on four measurements 
that are widely available, reproducible, inexpensive and 
easy to perform. The score may be used prospectively to 
guide management decisions at the time of diagnosis, and 
provide more realistic prognostic information for patients 
and their families. In addition, the risk model can be used 
to provide quality assurance in the MDT decision -making 
process. This model now requires prospective validation in 
other centres before widespread introduction into clinical 
practice. 
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